{"71a7e496ddf9c0de884c23dcb988a9977d45d7f9": [["COVID-19Coronavirus diseaseIntroductionOrigin and spread of COVID-19 in ItalyIntroductionThe first cases of COVID-19 had been reported in Central Italy, in Rome.", [["COVID-19", "DNA", 108, 116], ["COVID", "TEST", 0, 5], ["19Coronavirus diseaseIntroductionOrigin", "PROBLEM", 6, 45], ["COVID", "TEST", 60, 65], ["COVID", "TEST", 108, 113], ["19Coronavirus diseaseIntroductionOrigin", "OBSERVATION", 6, 45], ["spread", "OBSERVATION_MODIFIER", 50, 56]]], ["The first autochthonous diagnosed case, in the Italian territory, was reported on the February 20, 2020, in a 38-year-old man from the city of Codogno (Lombardy) with no travel history to known areas of viral infection or relation to a probable or confirmed COVID-19 case.", [["viral infection", "DISEASE", 203, 218], ["man", "ORGANISM", 122, 125], ["man", "SPECIES", 122, 125], ["viral infection", "PROBLEM", 203, 218], ["viral", "OBSERVATION_MODIFIER", 203, 208], ["infection", "OBSERVATION", 209, 218]]], ["After the case in Codogno, other people in Lombardy with flu-like symptoms were found positive for SARS-CoV-2, including medical staff.", [["flu-like symptoms", "DISEASE", 57, 74], ["SARS", "DISEASE", 99, 103], ["people", "ORGANISM", 33, 39], ["people", "SPECIES", 33, 39], ["SARS-CoV", "SPECIES", 99, 107], ["flu-like symptoms", "PROBLEM", 57, 74], ["SARS", "PROBLEM", 99, 103]]], ["Thereafter, the Italian COVID-19 epidemic has been mainly characterized by a local transmission.", [["the Italian COVID", "TEST", 12, 29]]], ["Geographical spread of the COVID-19 has been heterogeneous with a substantial gradient at the latitude levels with the highest spread in the Northern regions and the lowest in the Southern regions and in the main Islands.", [["COVID-19", "DNA", 27, 35], ["the COVID", "TEST", 23, 32], ["a substantial gradient at the latitude levels", "PROBLEM", 64, 109], ["spread", "OBSERVATION_MODIFIER", 13, 19], ["heterogeneous", "OBSERVATION_MODIFIER", 45, 58], ["substantial", "OBSERVATION_MODIFIER", 66, 77], ["gradient", "OBSERVATION_MODIFIER", 78, 86], ["latitude", "OBSERVATION_MODIFIER", 94, 102], ["levels", "OBSERVATION_MODIFIER", 103, 109], ["highest", "OBSERVATION_MODIFIER", 119, 126], ["spread", "OBSERVATION_MODIFIER", 127, 133], ["Northern", "ANATOMY_MODIFIER", 141, 149], ["regions", "ANATOMY_MODIFIER", 150, 157], ["lowest", "OBSERVATION_MODIFIER", 166, 172], ["Southern", "ANATOMY_MODIFIER", 180, 188], ["regions", "ANATOMY_MODIFIER", 189, 196], ["main", "OBSERVATION_MODIFIER", 208, 212], ["Islands", "OBSERVATION_MODIFIER", 213, 220]]], ["The region of Lombardy has the highest number of cases of SARS-CoV-2 and appears to be the epicenter of the Italian outbreak, unlike regions like Molise, Basilicata, and Sardinia, where the SARS-CoV-2 circulation has been encompassed (Italian National Institute of Health (ISS) and National Institute of Statistics 2020) (Fig. 1) .", [["SARS", "DISEASE", 58, 62], ["SARS", "DISEASE", 190, 194], ["SARS-CoV-2", "ORGANISM", 58, 68], ["SARS-CoV", "SPECIES", 58, 66], ["SARS-CoV", "SPECIES", 190, 198], ["SARS", "PROBLEM", 58, 62], ["the SARS", "TEST", 186, 194], ["Lombardy", "OBSERVATION", 14, 22], ["highest", "OBSERVATION_MODIFIER", 31, 38], ["number", "OBSERVATION_MODIFIER", 39, 45], ["SARS", "OBSERVATION", 58, 62], ["appears to be", "UNCERTAINTY", 73, 86], ["Sardinia", "OBSERVATION_MODIFIER", 170, 178]]], ["According to the Italian National Institute of Health (ISS), by May 4 in Italy, there were 209,254 cases of COVID-19 and 26,892 associated deaths (Italian National Institute of Health (ISS) 2020) (Fig. 2) .", [["COVID", "DISEASE", 108, 113], ["deaths", "DISEASE", 139, 145], ["COVID", "TEST", 108, 113]]], ["The last evaluation of the Imperial College COVID-19 Response Team estimated that the infected patients in Italy should be about 9% (95% CI 3.2-26) of the total population (Ferguson et al. 2020) .", [["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["The last evaluation", "TEST", 0, 19], ["CI", "TEST", 137, 139], ["infected", "OBSERVATION_MODIFIER", 86, 94]]], ["Although cases were more common among women (53.1%), mainly among the elderly population, lethality is higher in male subjects (Fig. 3) Considering only the month of March, the average national level shows an increase in deaths due to the total causes of 49.4%.", [["deaths", "DISEASE", 221, 227], ["women", "ORGANISM", 38, 43], ["women", "SPECIES", 38, 43], ["lethality", "PROBLEM", 90, 99], ["higher", "OBSERVATION_MODIFIER", 103, 109], ["increase", "OBSERVATION_MODIFIER", 209, 217]]], ["If we take as a reference the period from the first COVID-19 death reported by the COVID-19 ISS (February 20) until March 31, deaths increase although the strong concentration of the phenomenon in some areas of the country \"flatten\" the size of the impact of the COVID-19 epidemic on total mortality (Italian National Institute of Health (ISS) 2020) Specifically, 91% of the excess mortality registered at the average national level in March 2020 is concentrated in the areas of high spread of the epidemic: 37 northern provinces plus Pesaro and Urbino.", [["death", "DISEASE", 61, 66], ["deaths", "DISEASE", 126, 132], ["the phenomenon", "PROBLEM", 179, 193], ["the COVID", "TEST", 259, 268], ["the excess mortality", "PROBLEM", 371, 391], ["Pesaro and Urbino", "TREATMENT", 535, 552], ["size", "OBSERVATION_MODIFIER", 237, 241], ["concentrated", "OBSERVATION_MODIFIER", 450, 462], ["high", "OBSERVATION_MODIFIER", 479, 483], ["spread", "OBSERVATION_MODIFIER", 484, 490]]], ["In all of these provinces, deaths from all causes have more than doubled compared to the 2015-2019 average for the month of March.", [["deaths", "DISEASE", 27, 33]]], ["If we consider the period from February 20 to March 31, 52% are deaths reported by the COVID-19 ISS (Italian National Institute of Health (ISS) 2020)IntroductionIn the areas with medium spread of epidemic (35 provinces mainly located in the Center-North), death increase due to the total causes in the period from February 20 to March 31 is much more contained: 47% are attributed to COVID-19 positive deaths.", [["deaths", "DISEASE", 64, 70], ["death", "DISEASE", 256, 261], ["deaths", "DISEASE", 402, 408], ["death", "PROBLEM", 256, 261], ["COVID", "TEST", 384, 389]]], ["Finally, in the areas with a low spread of epidemic (34 provinces mostly located in the Center and in the South), Fig. 1 The \"Three Italy\" of the COVID-19 epidemic.", [["the COVID", "TEST", 142, 151], ["epidemic", "PROBLEM", 155, 163], ["low", "OBSERVATION_MODIFIER", 29, 32], ["spread", "OBSERVATION_MODIFIER", 33, 39]]], ["The highest geographical SARS-CoV-2 spread was reported in the northern regions of Italy and the lowest in the southern regions and in the main Islands.", [["SARS", "DISEASE", 25, 29], ["The highest geographical SARS", "TEST", 0, 29], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["geographical", "OBSERVATION_MODIFIER", 12, 24], ["SARS", "OBSERVATION", 25, 29], ["CoV", "OBSERVATION_MODIFIER", 30, 33], ["northern", "ANATOMY_MODIFIER", 63, 71], ["regions", "ANATOMY_MODIFIER", 72, 79], ["Italy", "ANATOMY_MODIFIER", 83, 88], ["lowest", "OBSERVATION_MODIFIER", 97, 103], ["southern", "ANATOMY_MODIFIER", 111, 119], ["regions", "ANATOMY_MODIFIER", 120, 127], ["main", "OBSERVATION_MODIFIER", 139, 143], ["Islands", "ANATOMY_MODIFIER", 144, 151]]], ["The region of Lombardy has the highest number of cases of SARS-CoV-2 and appears to be the epicenter of the Italian outbreak, unlike regions like Molise, Basilicata, and Sardinia, where the SARS-CoV-2 circulation has been encompassedTransmission, symptoms, and diagnosisInfection is transmitted from human to human and through contact with contaminated environmental surfaces.", [["SARS", "DISEASE", 58, 62], ["SARS", "DISEASE", 190, 194], ["Infection", "DISEASE", 270, 279], ["SARS-CoV-2", "ORGANISM", 58, 68], ["SARS-CoV-2", "ORGANISM", 190, 200], ["human", "ORGANISM", 300, 305], ["human", "ORGANISM", 309, 314], ["human", "SPECIES", 300, 305], ["human", "SPECIES", 309, 314], ["SARS-CoV", "SPECIES", 58, 66], ["SARS-CoV", "SPECIES", 190, 198], ["human", "SPECIES", 300, 305], ["human", "SPECIES", 309, 314], ["SARS", "PROBLEM", 58, 62], ["the SARS", "TEST", 186, 194], ["symptoms", "PROBLEM", 247, 255], ["Infection", "PROBLEM", 270, 279], ["Lombardy", "OBSERVATION", 14, 22], ["highest", "OBSERVATION_MODIFIER", 31, 38], ["number", "OBSERVATION_MODIFIER", 39, 45], ["SARS", "OBSERVATION", 58, 62], ["appears to be", "UNCERTAINTY", 73, 86], ["Sardinia", "OBSERVATION_MODIFIER", 170, 178]]], ["Respiratory droplets and contact transmission are considered to be the main transmission routes.", [["Respiratory droplets", "ANATOMY", 0, 20], ["Respiratory droplets", "PROBLEM", 0, 20], ["droplets", "OBSERVATION", 12, 20]]], ["Recent reports indicate that SARS-CoV-2 can be detected in the urine and stool of laboratory confirmed patients, implying a risk of fecal-oral transmission (General Office of National Administration of Traditional Chinese Medicine n.d.).", [["urine", "ANATOMY", 63, 68], ["oral", "ANATOMY", 138, 142], ["fecal-oral transmission", "DISEASE", 132, 155], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 29, 39], ["urine", "ORGANISM_SUBSTANCE", 63, 68], ["stool", "ORGANISM_SUBSTANCE", 73, 78], ["patients", "ORGANISM", 103, 111], ["fecal", "ORGANISM_SUBDIVISION", 132, 137], ["oral", "ORGANISM_SUBDIVISION", 138, 142], ["patients", "SPECIES", 103, 111], ["SARS-CoV", "SPECIES", 29, 37], ["SARS-CoV-2", "PROBLEM", 29, 39], ["the urine", "TEST", 59, 68], ["Traditional Chinese Medicine", "TREATMENT", 202, 230], ["SARS", "OBSERVATION", 29, 33], ["urine", "ANATOMY", 63, 68]]], ["Moreover, there is still no evidence that SARS-CoV-2 can be transmitted through aerosols or from mother to baby during pregnancy or childbirth (Yuefei et al. 2020) .", [["SARS-CoV-2", "ORGANISM", 42, 52], ["SARS-CoV", "SPECIES", 42, 50], ["SARS", "PROBLEM", 42, 46], ["no evidence", "UNCERTAINTY", 25, 36], ["SARS", "OBSERVATION", 42, 46]]], ["COVID-19 patients are the main source of infection, and severe patients are considered to be more contagious than mild ones.", [["infection", "DISEASE", 41, 50], ["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 63, 71], ["infection", "PROBLEM", 41, 50], ["main", "OBSERVATION_MODIFIER", 26, 30], ["infection", "OBSERVATION", 41, 50], ["severe", "OBSERVATION_MODIFIER", 56, 62]]], ["Asymptomatically infected persons or patients in incubation, without signs or symptoms of respiratory infection, proven to shed infectious virus, may also be potential sources of infection (Bai et al. 2020; Pan et al. 2020; Rothe et al. 2020 ).", [["respiratory", "ANATOMY", 90, 101], ["respiratory infection", "DISEASE", 90, 111], ["infection", "DISEASE", 179, 188], ["persons", "ORGANISM", 26, 33], ["patients", "ORGANISM", 37, 45], ["persons", "SPECIES", 26, 33], ["patients", "SPECIES", 37, 45], ["symptoms", "PROBLEM", 78, 86], ["respiratory infection", "PROBLEM", 90, 111], ["shed infectious virus", "PROBLEM", 123, 144], ["infection", "PROBLEM", 179, 188], ["infected", "OBSERVATION", 17, 25], ["respiratory", "ANATOMY", 90, 101], ["infection", "OBSERVATION", 102, 111], ["infectious", "OBSERVATION", 128, 138], ["infection", "OBSERVATION", 179, 188]]], ["These features may explain the sudden epidemic spreading of the virus.Transmission, symptoms, and diagnosisThe clinical spectrum of COVID-19 symptoms varies from asymptomatic/pauci-symptomatic forms to clinical conditions, characterized by severe respiratory failure, that necessitates mechanical ventilation and support in an intensive care unit, to multiorgan and systemic manifestations, characterized by sepsis, septic shock, and multiple organ dysfunction syndromes (Lupia et al. 2020 ).", [["respiratory", "ANATOMY", 247, 258], ["multiorgan", "ANATOMY", 351, 361], ["organ", "ANATOMY", 443, 448], ["COVID", "DISEASE", 132, 137], ["respiratory failure", "DISEASE", 247, 266], ["sepsis", "DISEASE", 408, 414], ["septic shock", "DISEASE", 416, 428], ["organ dysfunction syndromes", "DISEASE", 443, 470], ["organ", "ORGAN", 443, 448], ["the sudden epidemic spreading of the virus", "PROBLEM", 27, 69], ["symptoms", "PROBLEM", 84, 92], ["COVID", "TEST", 132, 137], ["symptoms", "PROBLEM", 141, 149], ["asymptomatic/pauci-symptomatic forms to clinical conditions", "PROBLEM", 162, 221], ["severe respiratory failure", "PROBLEM", 240, 266], ["mechanical ventilation", "TREATMENT", 286, 308], ["support", "TREATMENT", 313, 320], ["multiorgan and systemic manifestations", "PROBLEM", 351, 389], ["sepsis", "PROBLEM", 408, 414], ["septic shock", "PROBLEM", 416, 428], ["multiple organ dysfunction syndromes", "PROBLEM", 434, 470], ["may explain", "UNCERTAINTY", 15, 26], ["sudden", "OBSERVATION_MODIFIER", 31, 37], ["epidemic", "OBSERVATION_MODIFIER", 38, 46], ["spreading", "OBSERVATION_MODIFIER", 47, 56], ["virus", "OBSERVATION", 64, 69], ["severe", "OBSERVATION_MODIFIER", 240, 246], ["respiratory failure", "OBSERVATION", 247, 266], ["mechanical ventilation", "OBSERVATION", 286, 308], ["sepsis", "OBSERVATION", 408, 414], ["septic shock", "OBSERVATION", 416, 428], ["multiple", "OBSERVATION_MODIFIER", 434, 442], ["organ", "ANATOMY", 443, 448], ["dysfunction", "OBSERVATION", 449, 460]]], ["Pneumonia appears to be the most frequent manifestation of infection, with fever, cough, dyspnea, and bilateral infiltrates on chest imaging revealing invasive lesions in both lungs (Yang and Jin, 2020) .", [["chest", "ANATOMY", 127, 132], ["invasive lesions", "ANATOMY", 151, 167], ["lungs", "ANATOMY", 176, 181], ["Pneumonia", "DISEASE", 0, 9], ["infection", "DISEASE", 59, 68], ["fever", "DISEASE", 75, 80], ["cough", "DISEASE", 82, 87], ["dyspnea", "DISEASE", 89, 96], ["lesions", "PATHOLOGICAL_FORMATION", 160, 167], ["lungs", "ORGAN", 176, 181], ["Pneumonia", "PROBLEM", 0, 9], ["infection", "PROBLEM", 59, 68], ["fever", "PROBLEM", 75, 80], ["cough", "PROBLEM", 82, 87], ["dyspnea", "PROBLEM", 89, 96], ["bilateral infiltrates", "PROBLEM", 102, 123], ["chest imaging", "TEST", 127, 140], ["invasive lesions in both lungs", "PROBLEM", 151, 181], ["infection", "OBSERVATION", 59, 68], ["fever", "OBSERVATION_MODIFIER", 75, 80], ["cough", "OBSERVATION", 82, 87], ["bilateral", "ANATOMY_MODIFIER", 102, 111], ["infiltrates", "OBSERVATION", 112, 123], ["chest", "ANATOMY", 127, 132], ["invasive", "OBSERVATION_MODIFIER", 151, 159], ["lesions", "OBSERVATION", 160, 167], ["both", "ANATOMY_MODIFIER", 171, 175], ["lungs", "ANATOMY", 176, 181]]], ["Other common clinical manifestations included fever, cough, fatigue, sputum production, shortness of breath, sore throat, headache, and olfactory and gustative disorders (Guan et al. 2020a; Guan et al. 2020b ).", [["sputum", "ANATOMY", 69, 75], ["olfactory", "ANATOMY", 136, 145], ["fever", "DISEASE", 46, 51], ["cough", "DISEASE", 53, 58], ["fatigue", "DISEASE", 60, 67], ["shortness of breath", "DISEASE", 88, 107], ["sore throat", "DISEASE", 109, 120], ["headache", "DISEASE", 122, 130], ["olfactory and gustative disorders", "DISEASE", 136, 169], ["Other common clinical manifestations", "PROBLEM", 0, 36], ["fever", "PROBLEM", 46, 51], ["cough", "PROBLEM", 53, 58], ["fatigue", "PROBLEM", 60, 67], ["sputum production", "PROBLEM", 69, 86], ["shortness of breath", "PROBLEM", 88, 107], ["sore throat", "PROBLEM", 109, 120], ["headache", "PROBLEM", 122, 130], ["olfactory and gustative disorders", "PROBLEM", 136, 169], ["sore throat", "ANATOMY", 109, 120], ["headache", "OBSERVATION", 122, 130]]], ["In addition, a part of patients manifested gastrointestinal symptoms, with diarrhea and vomiting, and in some patients, they may be presenting complaint (Chan et al. 2020; .", [["gastrointestinal", "ANATOMY", 43, 59], ["gastrointestinal symptoms", "DISEASE", 43, 68], ["diarrhea", "DISEASE", 75, 83], ["vomiting", "DISEASE", 88, 96], ["patients", "ORGANISM", 23, 31], ["gastrointestinal", "ORGAN", 43, 59], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 110, 118], ["gastrointestinal symptoms", "PROBLEM", 43, 68], ["diarrhea", "PROBLEM", 75, 83], ["vomiting", "PROBLEM", 88, 96], ["gastrointestinal", "ANATOMY", 43, 59], ["symptoms", "OBSERVATION", 60, 68]]], ["Whether upper respiratory symptoms and gastrointestinal symptoms were rare, fever and cough represented the main symptoms, suggesting the differences in viral tropism as compared with SARS-CoV, MERS-CoV, and influenza virus (Assiri et al. 2013; Lee et al. 2003; Wang et al. 2016) .Transmission, symptoms, and diagnosisIn severe cases, elderly and subjects with underlying disorders (i.e., hypertension, chronic obstructive pulmonary disease, diabetes, cardiovascular disease) could develop acute respiratory distress syndrome (ARDS), septic shock, metabolic acidosis, and coagulation dysfunction, leading to the death (Huang et al. 2020a ).", [["respiratory", "ANATOMY", 14, 25], ["gastrointestinal", "ANATOMY", 39, 55], ["pulmonary", "ANATOMY", 423, 432], ["cardiovascular", "ANATOMY", 452, 466], ["respiratory", "ANATOMY", 496, 507], ["upper respiratory symptoms", "DISEASE", 8, 34], ["gastrointestinal symptoms", "DISEASE", 39, 64], ["fever", "DISEASE", 76, 81], ["cough", "DISEASE", 86, 91], ["SARS", "DISEASE", 184, 188], ["influenza virus", "DISEASE", 208, 223], ["hypertension", "DISEASE", 389, 401], ["chronic obstructive pulmonary disease", "DISEASE", 403, 440], ["diabetes", "DISEASE", 442, 450], ["cardiovascular disease", "DISEASE", 452, 474], ["acute respiratory distress syndrome", "DISEASE", 490, 525], ["ARDS", "DISEASE", 527, 531], ["septic shock", "DISEASE", 534, 546], ["metabolic acidosis", "DISEASE", 548, 566], ["coagulation dysfunction", "DISEASE", 572, 595], ["death", "DISEASE", 612, 617], ["upper respiratory", "ORGANISM_SUBDIVISION", 8, 25], ["gastrointestinal", "ORGAN", 39, 55], ["SARS-CoV", "ORGANISM", 184, 192], ["MERS-CoV", "ORGANISM", 194, 202], ["influenza virus", "ORGANISM", 208, 223], ["pulmonary", "ORGAN", 423, 432], ["influenza virus", "SPECIES", 208, 223], ["SARS-CoV", "SPECIES", 184, 192], ["MERS-CoV", "SPECIES", 194, 202], ["influenza virus", "SPECIES", 208, 223], ["upper respiratory symptoms", "PROBLEM", 8, 34], ["gastrointestinal symptoms", "PROBLEM", 39, 64], ["fever", "PROBLEM", 76, 81], ["cough", "PROBLEM", 86, 91], ["the main symptoms", "PROBLEM", 104, 121], ["viral tropism", "PROBLEM", 153, 166], ["SARS", "PROBLEM", 184, 188], ["CoV", "TEST", 189, 192], ["MERS", "PROBLEM", 194, 198], ["CoV", "PROBLEM", 199, 202], ["influenza virus", "PROBLEM", 208, 223], ["symptoms", "PROBLEM", 295, 303], ["diagnosisIn severe cases", "PROBLEM", 309, 333], ["underlying disorders", "PROBLEM", 361, 381], ["hypertension", "PROBLEM", 389, 401], ["chronic obstructive pulmonary disease", "PROBLEM", 403, 440], ["diabetes", "PROBLEM", 442, 450], ["cardiovascular disease", "PROBLEM", 452, 474], ["acute respiratory distress syndrome", "PROBLEM", 490, 525], ["ARDS)", "PROBLEM", 527, 532], ["septic shock", "PROBLEM", 534, 546], ["metabolic acidosis", "PROBLEM", 548, 566], ["coagulation dysfunction", "PROBLEM", 572, 595], ["the death", "PROBLEM", 608, 617], ["upper", "ANATOMY_MODIFIER", 8, 13], ["respiratory", "ANATOMY", 14, 25], ["gastrointestinal", "ANATOMY", 39, 55], ["viral tropism", "OBSERVATION", 153, 166], ["influenza virus", "OBSERVATION", 208, 223], ["hypertension", "OBSERVATION", 389, 401], ["chronic", "OBSERVATION_MODIFIER", 403, 410], ["obstructive", "OBSERVATION_MODIFIER", 411, 422], ["pulmonary", "ANATOMY", 423, 432], ["disease", "OBSERVATION", 433, 440], ["acute", "OBSERVATION_MODIFIER", 490, 495], ["respiratory distress", "OBSERVATION", 496, 516], ["ARDS", "OBSERVATION", 527, 531], ["septic shock", "OBSERVATION", 534, 546], ["metabolic acidosis", "OBSERVATION", 548, 566], ["coagulation dysfunction", "OBSERVATION", 572, 595]]], ["Molecular-based approaches are the first line of methods to confirm SARS-CoV-2-suspected infection.", [["infection", "DISEASE", 89, 98], ["SARS-CoV-2", "ORGANISM", 68, 78], ["SARS-CoV", "SPECIES", 68, 76], ["SARS", "TEST", 68, 72], ["CoV", "TEST", 73, 76], ["suspected infection", "PROBLEM", 79, 98], ["infection", "OBSERVATION", 89, 98]]], ["Specifically, reverse-transcription polymerase chain reaction (RT-PCR) is used to detect the nucleic acid of SARS-CoV-2 in sputum, throat swabs, and secretions of the lower respiratory tract samples (Lippi et al. 2020) .", [["sputum", "ANATOMY", 123, 129], ["throat swabs", "ANATOMY", 131, 143], ["secretions", "ANATOMY", 149, 159], ["lower respiratory tract samples", "ANATOMY", 167, 198], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 109, 119], ["sputum", "ORGANISM_SUBSTANCE", 123, 129], ["throat swabs", "MULTI-TISSUE_STRUCTURE", 131, 143], ["SARS-CoV", "SPECIES", 109, 117], ["reverse-transcription polymerase chain reaction", "PROBLEM", 14, 61], ["RT-PCR", "TEST", 63, 69], ["the nucleic acid", "TEST", 89, 105], ["SARS", "PROBLEM", 109, 113], ["CoV", "TEST", 114, 117], ["sputum", "TEST", 123, 129], ["throat swabs", "TEST", 131, 143], ["secretions of the lower respiratory tract samples", "PROBLEM", 149, 198], ["throat", "ANATOMY", 131, 137], ["lower", "ANATOMY_MODIFIER", 167, 172], ["respiratory tract", "ANATOMY", 173, 190]]], ["Although nucleic acid testing is the gold standard technique for laboratory diagnosis, other methods such as virus antigen or serological antibody testing are also valuable assays Meyer et al. 2014) .", [["nucleic acid", "CHEMICAL", 9, 21], ["virus antigen", "PROTEIN", 109, 122], ["nucleic acid testing", "TEST", 9, 29], ["laboratory diagnosis", "TEST", 65, 85], ["other methods", "PROBLEM", 87, 100], ["virus antigen", "TEST", 109, 122], ["serological antibody testing", "TEST", 126, 154]]], ["A positive test for SARS-CoV-2 generally confirms the diagnosis of COVID-19, although false-positive tests are possible.", [["SARS-CoV", "SPECIES", 20, 28], ["A positive test", "TEST", 0, 15], ["SARS", "TEST", 20, 24], ["CoV", "TEST", 25, 28], ["COVID", "TEST", 67, 72], ["false-positive tests", "PROBLEM", 86, 106]]], ["If initial testing is negative but the suspicion for COVID-19 remains, the WHO recommends resampling and testing from multiple respiratory tract sites(World Health Organization Coronavirus Disease (COVID-19)).", [["respiratory tract sites", "ANATOMY", 127, 150], ["respiratory tract", "ORGANISM_SUBDIVISION", 127, 144], ["initial testing", "TEST", 3, 18], ["COVID", "TEST", 53, 58], ["resampling and testing", "TEST", 90, 112], ["multiple respiratory tract sites", "PROBLEM", 118, 150], ["Coronavirus Disease", "PROBLEM", 177, 196], ["respiratory tract", "ANATOMY", 127, 144], ["Coronavirus Disease", "OBSERVATION", 177, 196]]], ["Imaging findings of chest computed tomography (CT) in patients with COVID-19 most commonly demonstrate ground-glass opacification with or without consolidative abnormalities, consistent with viral pneumonia.", [["viral pneumonia", "DISEASE", 191, 206], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["Imaging findings", "TEST", 0, 16], ["chest computed tomography", "TEST", 20, 45], ["CT", "TEST", 47, 49], ["COVID", "TEST", 68, 73], ["ground-glass opacification", "PROBLEM", 103, 129], ["consolidative abnormalities", "PROBLEM", 146, 173], ["viral pneumonia", "PROBLEM", 191, 206], ["chest", "ANATOMY", 20, 25], ["ground", "OBSERVATION", 103, 109], ["glass opacification", "OBSERVATION", 110, 129], ["without", "UNCERTAINTY", 138, 145], ["consolidative", "OBSERVATION_MODIFIER", 146, 159], ["abnormalities", "OBSERVATION", 160, 173], ["consistent with", "UNCERTAINTY", 175, 190], ["viral", "OBSERVATION_MODIFIER", 191, 196], ["pneumonia", "OBSERVATION", 197, 206]]], ["Other studies have suggested that chest CT abnormalities are more likely to be bilateral, have a peripheral distribution, and involve the lower lobes.", [["chest", "ANATOMY", 34, 39], ["lower lobes", "ANATOMY", 138, 149], ["lower lobes", "MULTI-TISSUE_STRUCTURE", 138, 149], ["Other studies", "TEST", 0, 13], ["chest CT abnormalities", "PROBLEM", 34, 56], ["chest", "ANATOMY", 34, 39], ["abnormalities", "OBSERVATION", 43, 56], ["more likely to be", "UNCERTAINTY", 61, 78], ["bilateral", "ANATOMY_MODIFIER", 79, 88], ["peripheral", "ANATOMY_MODIFIER", 97, 107], ["distribution", "OBSERVATION_MODIFIER", 108, 120], ["lower lobes", "ANATOMY", 138, 149]]], ["Fig. 3 Cases of SARS-CoV-2 infected patients in female and male gender.", [["SARS-CoV-2 infected", "DISEASE", 16, 35], ["SARS-CoV-2", "ORGANISM", 16, 26], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["SARS", "PROBLEM", 16, 20]]], ["SARS-CoV-2 was more common among women (53.1%) than among man (46.9%), although lethality is higher in male subjects Chest CT may be helpful in making the diagnosis, but no finding can completely rule in or rule out the possibility of COVID-19.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["women", "ORGANISM", 33, 38], ["man", "ORGANISM", 58, 61], ["women", "SPECIES", 33, 38], ["man", "SPECIES", 58, 61], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "TEST", 0, 8], ["lethality", "PROBLEM", 80, 89], ["Chest CT", "TEST", 117, 125], ["COVID", "TEST", 235, 240], ["higher", "OBSERVATION_MODIFIER", 93, 99], ["Chest", "ANATOMY", 117, 122]]], ["Negative RT-PCR tests on oropharyngeal swabs despite CT findings suggestive of viral pneumonia have been reported in some patients who ultimately tested positive for SARS-CoV-2.", [["oropharyngeal swabs", "ANATOMY", 25, 44], ["viral pneumonia", "DISEASE", 79, 94], ["SARS", "DISEASE", 166, 170], ["oropharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 25, 44], ["patients", "ORGANISM", 122, 130], ["SARS-CoV-2", "ORGANISM", 166, 176], ["patients", "SPECIES", 122, 130], ["SARS-CoV", "SPECIES", 166, 174], ["RT-PCR tests", "TEST", 9, 21], ["oropharyngeal swabs", "TEST", 25, 44], ["CT findings", "TEST", 53, 64], ["viral pneumonia", "PROBLEM", 79, 94], ["SARS", "PROBLEM", 166, 170], ["CoV", "TEST", 171, 174], ["oropharyngeal", "ANATOMY", 25, 38], ["suggestive of", "UNCERTAINTY", 65, 78], ["viral", "OBSERVATION_MODIFIER", 79, 84], ["pneumonia", "OBSERVATION", 85, 94]]], ["Serologic tests should be able to identify patients who have either current or previous infection but a negative PCR test (Lim et al. 2020; Ling et al. 2020) .", [["infection", "DISEASE", 88, 97], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["Serologic tests", "TEST", 0, 15], ["previous infection", "PROBLEM", 79, 97], ["PCR test", "TEST", 113, 121], ["infection", "OBSERVATION", 88, 97]]], ["Previous studies have demonstrated that the development of antibody response to infection can be host dependent and take time; in the case of SARS-CoV-2, the majority of patients seroconvert between 7 and 11 days post-exposure to the virus, although some patients may develop antibodies sooner .", [["infection", "DISEASE", 80, 89], ["SARS", "DISEASE", 142, 146], ["SARS-CoV-2", "ORGANISM", 142, 152], ["patients", "ORGANISM", 170, 178], ["patients", "ORGANISM", 255, 263], ["antibodies", "PROTEIN", 276, 286], ["patients", "SPECIES", 170, 178], ["patients", "SPECIES", 255, 263], ["SARS-CoV", "SPECIES", 142, 150], ["Previous studies", "TEST", 0, 16], ["antibody response", "PROBLEM", 59, 76], ["infection", "PROBLEM", 80, 89], ["SARS", "PROBLEM", 142, 146], ["CoV", "TEST", 147, 150], ["the virus", "PROBLEM", 230, 239], ["antibodies", "PROBLEM", 276, 286], ["antibody response", "OBSERVATION", 59, 76], ["infection", "OBSERVATION", 80, 89]]], ["As a result of this natural delay, antibody-detecting tests for SARS-CoV-2 are not useful for the diagnosis of an acute illness but might be important for understanding the diffusion of Sars-CoV-2 in symptomatic or paucisymptomatic patients.Virus and pathophysiologySARS-CoV-2, taxonomically, has been classified as Betacoronavirus (lineage B) by the WHO .", [["paucisymptomatic", "DISEASE", 215, 231], ["SARS-CoV-2", "ORGANISM", 64, 74], ["Sars-CoV-2", "ORGANISM", 186, 196], ["patients", "ORGANISM", 232, 240], ["Virus", "ORGANISM", 241, 246], ["pathophysiologySARS-CoV-2", "ORGANISM", 251, 276], ["lineage B", "CELL", 333, 342], ["patients", "SPECIES", 232, 240], ["SARS-CoV", "SPECIES", 64, 72], ["Sars-CoV", "SPECIES", 186, 194], ["this natural delay", "PROBLEM", 15, 33], ["antibody", "TEST", 35, 43], ["SARS", "PROBLEM", 64, 68], ["CoV", "TEST", 69, 72], ["an acute illness", "PROBLEM", 111, 127], ["Virus", "PROBLEM", 241, 246], ["pathophysiologySARS", "TEST", 251, 270], ["CoV", "TEST", 271, 274], ["acute", "OBSERVATION_MODIFIER", 114, 119], ["illness", "OBSERVATION", 120, 127]]], ["Genetic sequence analysis showed more than 50% homology to MERS-CoV and 80% to SARS-CoV and both originate in bats.", [["SARS", "DISEASE", 79, 83], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 59, 67], ["SARS-CoV", "ORGANISM", 79, 87], ["MERS-CoV", "DNA", 59, 67], ["MERS-CoV", "SPECIES", 59, 67], ["SARS-CoV", "SPECIES", 79, 87], ["Genetic sequence analysis", "TEST", 0, 25], ["MERS", "TEST", 59, 63], ["CoV", "TEST", 64, 67], ["SARS", "TEST", 79, 83], ["bats", "OBSERVATION", 110, 114]]], ["The differences between the sequences are mainly in the ORF1a gene and the spike gene, encoding S-protein, which is the key protein for the interaction between coronavirus and host cells Zhou et al. 2020; ).", [["cells", "ANATOMY", 181, 186], ["ORF1a", "GENE_OR_GENE_PRODUCT", 56, 61], ["S-protein", "GENE_OR_GENE_PRODUCT", 96, 105], ["coronavirus", "ORGANISM", 160, 171], ["host cells", "CELL", 176, 186], ["ORF1a gene", "DNA", 56, 66], ["spike gene", "DNA", 75, 85], ["S-protein", "PROTEIN", 96, 105], ["the sequences", "TEST", 24, 37], ["encoding S-protein", "PROBLEM", 87, 105]]], ["The coronaviruses (CoVs) family is a class of enveloped, positive-sense single-stranded RNA viruses having an extensive range of natural roots.", [["roots", "ANATOMY", 137, 142], ["coronaviruses", "ORGANISM", 4, 17], ["CoVs", "GENE_OR_GENE_PRODUCT", 19, 23], ["roots", "ORGAN", 137, 142], ["coronaviruses (CoVs) family", "PROTEIN", 4, 31], ["stranded RNA viruses", "PROBLEM", 79, 99], ["coronaviruses", "OBSERVATION", 4, 17], ["extensive", "OBSERVATION_MODIFIER", 110, 119], ["range", "OBSERVATION_MODIFIER", 120, 125], ["natural roots", "OBSERVATION", 129, 142]]], ["These viruses can cause respiratory, enteric, hepatic, and cardiovascular diseases (de Wilde et al. 2018; Weiss and Leibowitz 2011; Zheng et al. 2020 ).", [["respiratory", "ANATOMY", 24, 35], ["hepatic", "ANATOMY", 46, 53], ["cardiovascular", "ANATOMY", 59, 73], ["respiratory, enteric, hepatic, and cardiovascular diseases", "DISEASE", 24, 82], ["hepatic", "MULTI-TISSUE_STRUCTURE", 46, 53], ["respiratory, enteric, hepatic, and cardiovascular diseases", "PROBLEM", 24, 82], ["viruses", "OBSERVATION", 6, 13], ["enteric", "OBSERVATION_MODIFIER", 37, 44], ["hepatic", "ANATOMY", 46, 53], ["cardiovascular", "ANATOMY", 59, 73]]], ["SARS-CoV-2 virion presents a genome size of 29.9 kb [Available via http://nmdc.cn/coronavirus] with a n u c l e o c a p s i d c o m p o s e d o f g e n o m i c R N A a n d phosphorylated nucleocapsid (N) protein.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 187, 203], ["SARS-CoV-2 virion", "DNA", 0, 17], ["nucleocapsid (N) protein", "PROTEIN", 187, 211], ["SARS", "PROBLEM", 0, 4], ["g e", "TEST", 146, 149], ["A a n d phosphorylated nucleocapsid", "TEST", 164, 199], ["size", "OBSERVATION_MODIFIER", 36, 40]]], ["The nucleocapsid is covered by an envelope with the spike (S) glycoprotein trimmer, which exists in all CoVs, and the hemagglutininesterase (HE), only expressed from some CoVs.", [["CoVs", "GENE_OR_GENE_PRODUCT", 104, 108], ["hemagglutininesterase", "GENE_OR_GENE_PRODUCT", 118, 139], ["CoVs", "GENE_OR_GENE_PRODUCT", 171, 175], ["spike (S) glycoprotein trimmer", "PROTEIN", 52, 82], ["CoVs", "PROTEIN", 104, 108], ["hemagglutininesterase", "PROTEIN", 118, 139], ["HE", "PROTEIN", 141, 143], ["CoVs", "PROTEIN", 171, 175], ["glycoprotein trimmer", "TREATMENT", 62, 82], ["some CoVs", "PROBLEM", 166, 175], ["nucleocapsid", "OBSERVATION", 4, 16], ["some CoVs", "OBSERVATION", 166, 175]]], ["Moreover, in the viral envelope, located among the S protein, are confined the membrane (M) and the envelope (E) proteins .", [["membrane", "ANATOMY", 79, 87], ["membrane", "CELLULAR_COMPONENT", 79, 87], ["envelope (E) proteins", "GENE_OR_GENE_PRODUCT", 100, 121], ["S protein", "PROTEIN", 51, 60], ["envelope (E) proteins", "PROTEIN", 100, 121], ["the S protein", "TEST", 47, 60]]], ["The SARS-CoV-2 genome contains a variable number of open reading frames (ORFs) encoding for structural proteins, including S, M, E, N proteins and accessory proteic chains (Lei et al. 2018; Letko et al. 2020) .", [["SARS", "DISEASE", 4, 8], ["SARS-CoV-2 genome", "DNA", 4, 21], ["open reading frames", "DNA", 52, 71], ["ORFs", "DNA", 73, 77], ["structural proteins", "PROTEIN", 92, 111], ["S, M, E, N proteins", "PROTEIN", 123, 142], ["accessory proteic chains", "PROTEIN", 147, 171], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["structural proteins", "TEST", 92, 111], ["SARS", "OBSERVATION", 4, 8], ["variable", "OBSERVATION_MODIFIER", 33, 41], ["number", "OBSERVATION_MODIFIER", 42, 48], ["proteic chains", "OBSERVATION", 157, 171]]], ["To address the pathogenetic and virulence mechanisms of SARS-CoV-2, the role of structural and non-structural proteins (nsps) must be considered (Letko et al. 2020) .", [["SARS", "DISEASE", 56, 60], ["SARS-CoV-2", "ORGANISM", 56, 66], ["nsps", "GENE_OR_GENE_PRODUCT", 120, 124], ["structural and non-structural proteins", "PROTEIN", 80, 118], ["nsps", "PROTEIN", 120, 124], ["SARS-CoV", "SPECIES", 56, 64], ["SARS", "PROBLEM", 56, 60], ["CoV", "TEST", 61, 64]]], ["Four structural proteins are essential for virion assembly and infection of CoVs (Di Gennaro et al. 2020 ).", [["virion", "ANATOMY", 43, 49], ["infection", "DISEASE", 63, 72], ["virion", "CELLULAR_COMPONENT", 43, 49], ["CoVs", "PATHOLOGICAL_FORMATION", 76, 80], ["structural proteins", "PROTEIN", 5, 24], ["virion assembly", "PROBLEM", 43, 58], ["infection of CoVs", "PROBLEM", 63, 80], ["proteins", "OBSERVATION", 16, 24], ["infection", "OBSERVATION", 63, 72]]], ["S protein, present on the viral surface as a trimer, is the primary determinant of viral tropism and is responsible for receptor binding and membrane fusion (Beniac et al. 2006; Delmas and Laude 1990) .", [["surface", "ANATOMY", 32, 39], ["membrane", "ANATOMY", 141, 149], ["membrane", "CELLULAR_COMPONENT", 141, 149], ["S protein", "PROTEIN", 0, 9], ["S protein", "TEST", 0, 9], ["viral tropism", "PROBLEM", 83, 96], ["receptor binding", "PROBLEM", 120, 136], ["membrane fusion", "TREATMENT", 141, 156], ["viral tropism", "OBSERVATION", 83, 96]]], ["The M protein has three transmembrane domains.", [["transmembrane", "ANATOMY", 24, 37], ["M protein", "GENE_OR_GENE_PRODUCT", 4, 13], ["M protein", "PROTEIN", 4, 13], ["transmembrane domains", "PROTEIN", 24, 45], ["The M protein", "TEST", 0, 13]]], ["It shapes the virions, promotes the curvature of the membrane, and binds to the nucleocapsid (Nal et al., 2005; Neuman et al. 2011) .", [["virions", "ANATOMY", 14, 21], ["membrane", "ANATOMY", 53, 61], ["membrane", "CELLULAR_COMPONENT", 53, 61], ["nucleocapsid", "CELLULAR_COMPONENT", 80, 92], ["virions", "OBSERVATION", 14, 21], ["curvature", "OBSERVATION_MODIFIER", 36, 45], ["membrane", "ANATOMY", 53, 61]]], ["Regarding the E protein, it plays a role in virus assembly, release and viral pathogenesis (DeDiego et al. 2007; Nieto-Torres et al. 2014 ).", [["E protein", "GENE_OR_GENE_PRODUCT", 14, 23], ["E protein", "PROTEIN", 14, 23], ["viral pathogenesis", "PROBLEM", 72, 90]]], ["Finally, the N protein contains two domains, both of which can bind virus RNA genome via different mechanisms.", [["N protein", "PROTEIN", 13, 22], ["virus RNA genome", "DNA", 68, 84], ["the N protein", "TEST", 9, 22]]], ["It is reported that N protein can bind to nsp3 protein packaging the encapsidated genome into virions (Chang et al. 2006; Fehr and Perlman, 2015; Hurst et al. 2009 ).", [["virions", "ANATOMY", 94, 101], ["nsp3", "GENE_OR_GENE_PRODUCT", 42, 46], ["N protein", "PROTEIN", 20, 29], ["nsp3 protein", "PROTEIN", 42, 54], ["encapsidated genome", "DNA", 69, 88], ["nsp3 protein packaging", "TREATMENT", 42, 64], ["encapsidated genome", "OBSERVATION", 69, 88]]], ["Moreover, N is also an antagonist of interferon and viral encoded repressor of RNA interference, which appears to be beneficial for the viral replication (Cui et al. 2015) .", [["interferon", "GENE_OR_GENE_PRODUCT", 37, 47], ["interferon", "PROTEIN", 37, 47], ["viral encoded repressor", "PROTEIN", 52, 75], ["an antagonist of interferon", "TREATMENT", 20, 47], ["viral encoded repressor", "TREATMENT", 52, 75], ["RNA interference", "PROBLEM", 79, 95], ["the viral replication", "TREATMENT", 132, 153]]], ["Among nsps, most of these proteins, specifically nsp1 to 16, displayed a specific role in CoVs replication and in blocking the host innate immune response (Cascella et al. 2020; Guo et al. 2020 ).", [["nsps", "GENE_OR_GENE_PRODUCT", 6, 10], ["nsp1", "GENE_OR_GENE_PRODUCT", 49, 53], ["CoVs", "GENE_OR_GENE_PRODUCT", 90, 94], ["nsps", "PROTEIN", 6, 10], ["nsp1 to 16", "PROTEIN", 49, 59], ["these proteins", "TEST", 20, 34], ["nsp1", "TEST", 49, 53], ["CoVs replication", "TREATMENT", 90, 106]]], ["The pathogenic mechanism that starts with SARS-CoV-2 infection and culminates in pneumonia and heart or other extensive tissue damage seems to be particularly complex and able to produce an overreaction of the immune system associated with a pronounced cytokine storm, also known as cytokine release syndrome (CRS).", [["heart", "ANATOMY", 95, 100], ["tissue", "ANATOMY", 120, 126], ["immune system", "ANATOMY", 210, 223], ["infection", "DISEASE", 53, 62], ["pneumonia", "DISEASE", 81, 90], ["tissue damage", "DISEASE", 120, 133], ["CRS", "DISEASE", 310, 313], ["SARS-CoV-2", "ORGANISM", 42, 52], ["heart", "ORGAN", 95, 100], ["tissue", "TISSUE", 120, 126], ["cytokine", "PROTEIN", 253, 261], ["cytokine", "PROTEIN", 283, 291], ["SARS-CoV-2", "SPECIES", 42, 52], ["The pathogenic mechanism", "PROBLEM", 0, 24], ["SARS", "PROBLEM", 42, 46], ["CoV-2 infection", "PROBLEM", 47, 62], ["pneumonia", "PROBLEM", 81, 90], ["heart or other extensive tissue damage", "PROBLEM", 95, 133], ["an overreaction of the immune system", "PROBLEM", 187, 223], ["a pronounced cytokine storm", "PROBLEM", 240, 267], ["cytokine release syndrome", "PROBLEM", 283, 308], ["infection", "OBSERVATION", 53, 62], ["pneumonia", "OBSERVATION", 81, 90], ["heart", "ANATOMY", 95, 100], ["extensive", "OBSERVATION_MODIFIER", 110, 119], ["tissue", "OBSERVATION_MODIFIER", 120, 126], ["damage", "OBSERVATION", 127, 133], ["pronounced", "OBSERVATION_MODIFIER", 242, 252], ["cytokine storm", "OBSERVATION", 253, 267]]], ["Clinical features include extremely elevated cytokine levels (IL-6, IL-10, and TNF-\u03b1), lymphopenia (in CD4+ and CD8+ T cells), decreased IFN-\u03b3 expression in CD4+ T cells, and an increase in Th17 cell proportion.", [["CD4+ and CD8+ T cells", "ANATOMY", 103, 124], ["CD4+ T cells", "ANATOMY", 157, 169], ["Th17 cell", "ANATOMY", 190, 199], ["lymphopenia", "DISEASE", 87, 98], ["IL-6", "GENE_OR_GENE_PRODUCT", 62, 66], ["IL-10", "GENE_OR_GENE_PRODUCT", 68, 73], ["TNF", "GENE_OR_GENE_PRODUCT", 79, 82], ["-\u03b1", "GENE_OR_GENE_PRODUCT", 82, 84], ["CD4", "GENE_OR_GENE_PRODUCT", 103, 106], ["CD8", "GENE_OR_GENE_PRODUCT", 112, 115], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 137, 142], ["CD4", "GENE_OR_GENE_PRODUCT", 157, 160], ["Th17 cell", "CELL", 190, 199], ["cytokine", "PROTEIN", 45, 53], ["TNF", "PROTEIN", 79, 82], ["CD4", "PROTEIN", 103, 106], ["CD8", "PROTEIN", 112, 115], ["T cells", "CELL_TYPE", 117, 124], ["IFN", "PROTEIN", 137, 140], ["\u03b3", "PROTEIN", 141, 142], ["CD4", "PROTEIN", 157, 160], ["T cells", "CELL_TYPE", 162, 169], ["Clinical features", "TEST", 0, 17], ["extremely elevated cytokine levels", "PROBLEM", 26, 60], ["IL", "TEST", 62, 64], ["IL", "TEST", 68, 70], ["TNF", "TEST", 79, 82], ["lymphopenia", "PROBLEM", 87, 98], ["CD4", "TEST", 103, 106], ["CD8+ T cells", "PROBLEM", 112, 124], ["decreased IFN", "PROBLEM", 127, 140], ["CD4+ T cells", "PROBLEM", 157, 169], ["an increase in Th17 cell proportion", "PROBLEM", 175, 210], ["extremely", "OBSERVATION_MODIFIER", 26, 35], ["elevated", "OBSERVATION", 36, 44], ["lymphopenia", "OBSERVATION", 87, 98], ["increase", "OBSERVATION_MODIFIER", 178, 186], ["Th17 cell proportion", "OBSERVATION", 190, 210]]], ["Th17 cells are helper T cells differentiated from Th0 cells mainly stimulated by IL-6 and IL-23.", [["Th17 cells", "ANATOMY", 0, 10], ["helper T cells", "ANATOMY", 15, 29], ["Th0 cells", "ANATOMY", 50, 59], ["Th17 cells", "CELL", 0, 10], ["helper T cells", "CELL", 15, 29], ["Th0 cells", "CELL", 50, 59], ["IL-6", "GENE_OR_GENE_PRODUCT", 81, 85], ["IL-23", "GENE_OR_GENE_PRODUCT", 90, 95], ["Th17 cells", "CELL_TYPE", 0, 10], ["helper T cells", "CELL_TYPE", 15, 29], ["Th0 cells", "CELL_TYPE", 50, 59], ["IL-6", "PROTEIN", 81, 85], ["IL-23", "PROTEIN", 90, 95], ["Th17 cells", "TREATMENT", 0, 10], ["Th0 cells", "TEST", 50, 59], ["IL", "TEST", 81, 83], ["IL", "TEST", 90, 92], ["Th0 cells", "OBSERVATION", 50, 59]]], ["Specifically, IL-6, an important member of the cytokine network and produced by activated macrophages, plays a central role in acute inflammation with its antiinflammatory and pro-inflammatory effects.", [["macrophages", "ANATOMY", 90, 101], ["inflammation", "DISEASE", 133, 145], ["IL-6", "GENE_OR_GENE_PRODUCT", 14, 18], ["macrophages", "CELL", 90, 101], ["IL-6", "PROTEIN", 14, 18], ["cytokine network", "PROTEIN", 47, 63], ["activated macrophages", "CELL_TYPE", 80, 101], ["acute inflammation", "PROBLEM", 127, 145], ["its antiinflammatory and pro-inflammatory effects", "TREATMENT", 151, 200], ["macrophages", "OBSERVATION", 90, 101], ["central", "OBSERVATION_MODIFIER", 111, 118], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["inflammation", "OBSERVATION", 133, 145], ["antiinflammatory", "OBSERVATION_MODIFIER", 155, 171]]], ["Biologically, IL-6 promotes T cell population proliferation and activation and B cell differentiation, regulates acute phase response, and affects the hormone-like properties of vascular disease, lipid metabolism, insulin resistance, mitochondrial activity, neuroendocrine system, and neuropsychological behavior Pyle et al. 2017 ).", [["T cell", "ANATOMY", 28, 34], ["B cell", "ANATOMY", 79, 85], ["vascular", "ANATOMY", 178, 186], ["mitochondrial", "ANATOMY", 234, 247], ["neuroendocrine system", "ANATOMY", 258, 279], ["vascular disease", "DISEASE", 178, 194], ["IL-6", "GENE_OR_GENE_PRODUCT", 14, 18], ["T cell", "CELL", 28, 34], ["B cell", "CELL", 79, 85], ["vascular", "MULTI-TISSUE_STRUCTURE", 178, 186], ["lipid", "SIMPLE_CHEMICAL", 196, 201], ["insulin", "GENE_OR_GENE_PRODUCT", 214, 221], ["mitochondrial", "CELLULAR_COMPONENT", 234, 247], ["IL-6", "PROTEIN", 14, 18], ["IL", "TREATMENT", 14, 16], ["T cell population proliferation", "TREATMENT", 28, 59], ["activation and B cell differentiation", "PROBLEM", 64, 101], ["acute phase response", "PROBLEM", 113, 133], ["the hormone", "PROBLEM", 147, 158], ["vascular disease", "PROBLEM", 178, 194], ["lipid metabolism", "PROBLEM", 196, 212], ["insulin resistance", "TREATMENT", 214, 232], ["cell differentiation", "OBSERVATION", 81, 101], ["acute", "OBSERVATION_MODIFIER", 113, 118], ["vascular", "ANATOMY", 178, 186], ["disease", "OBSERVATION", 187, 194], ["insulin resistance", "OBSERVATION", 214, 232]]], ["On the other end, IL-6 increases during inflammatory and cardiovascular diseases (myocardial ischemia, coronary atherosclerosis, angina pectoris, congestive heart failure, hypertension), infections, autoimmune disorders, and some types of cancer (Bennardo et al. 2020) .", [["cardiovascular", "ANATOMY", 57, 71], ["myocardial", "ANATOMY", 82, 92], ["coronary", "ANATOMY", 103, 111], ["heart", "ANATOMY", 157, 162], ["cancer", "ANATOMY", 239, 245], ["cardiovascular diseases", "DISEASE", 57, 80], ["myocardial ischemia", "DISEASE", 82, 101], ["coronary atherosclerosis", "DISEASE", 103, 127], ["angina pectoris", "DISEASE", 129, 144], ["congestive heart failure", "DISEASE", 146, 170], ["hypertension", "DISEASE", 172, 184], ["infections", "DISEASE", 187, 197], ["autoimmune disorders", "DISEASE", 199, 219], ["cancer", "DISEASE", 239, 245], ["IL-6", "GENE_OR_GENE_PRODUCT", 18, 22], ["myocardial", "MULTI-TISSUE_STRUCTURE", 82, 92], ["coronary", "MULTI-TISSUE_STRUCTURE", 103, 111], ["heart", "ORGAN", 157, 162], ["cancer", "CANCER", 239, 245], ["IL-6", "PROTEIN", 18, 22], ["inflammatory and cardiovascular diseases", "PROBLEM", 40, 80], ["myocardial ischemia", "PROBLEM", 82, 101], ["coronary atherosclerosis", "PROBLEM", 103, 127], ["angina pectoris", "PROBLEM", 129, 144], ["congestive heart failure", "PROBLEM", 146, 170], ["hypertension", "PROBLEM", 172, 184], ["infections", "PROBLEM", 187, 197], ["autoimmune disorders", "PROBLEM", 199, 219], ["cancer", "PROBLEM", 239, 245], ["inflammatory", "OBSERVATION_MODIFIER", 40, 52], ["cardiovascular", "ANATOMY", 57, 71], ["diseases", "OBSERVATION", 72, 80], ["myocardial", "ANATOMY", 82, 92], ["ischemia", "OBSERVATION", 93, 101], ["coronary", "ANATOMY", 103, 111], ["atherosclerosis", "OBSERVATION", 112, 127], ["angina", "OBSERVATION_MODIFIER", 129, 135], ["pectoris", "OBSERVATION", 136, 144], ["congestive", "OBSERVATION_MODIFIER", 146, 156], ["heart", "ANATOMY", 157, 162], ["failure", "OBSERVATION", 163, 170], ["hypertension", "OBSERVATION", 172, 184], ["infections", "OBSERVATION", 187, 197], ["autoimmune disorders", "OBSERVATION", 199, 219], ["cancer", "OBSERVATION", 239, 245]]], ["During the spread of infection, SARS-CoV-2 could cross through the mucous membranes, especially nasal and larynx mucosa; enters the lungs through the respiratory tract (Bennardo et al. 2020; Rose-John 2018; Chen et al. 2020b) ; and could cause the aggravation of patient's condition in 7 to 14 days after onset.", [["mucous membranes", "ANATOMY", 67, 83], ["nasal", "ANATOMY", 96, 101], ["larynx mucosa", "ANATOMY", 106, 119], ["lungs", "ANATOMY", 132, 137], ["respiratory tract", "ANATOMY", 150, 167], ["infection", "DISEASE", 21, 30], ["SARS", "DISEASE", 32, 36], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 32, 42], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 67, 83], ["nasal", "ORGAN", 96, 101], ["larynx mucosa", "MULTI-TISSUE_STRUCTURE", 106, 119], ["lungs", "ORGAN", 132, 137], ["respiratory tract", "ORGANISM_SUBDIVISION", 150, 167], ["patient", "ORGANISM", 263, 270], ["patient", "SPECIES", 263, 270], ["SARS-CoV", "SPECIES", 32, 40], ["infection", "PROBLEM", 21, 30], ["SARS", "PROBLEM", 32, 36], ["nasal and larynx mucosa", "PROBLEM", 96, 119], ["the aggravation of patient's condition", "PROBLEM", 244, 282], ["spread", "OBSERVATION_MODIFIER", 11, 17], ["infection", "OBSERVATION", 21, 30], ["mucous membranes", "ANATOMY", 67, 83], ["nasal", "ANATOMY", 96, 101], ["larynx mucosa", "ANATOMY", 106, 119], ["lungs", "ANATOMY", 132, 137], ["respiratory tract", "ANATOMY", 150, 167]]], ["B lymphocyte reduction may occur early during the disease and may affect antibody production in patients.", [["B lymphocyte", "ANATOMY", 0, 12], ["B lymphocyte", "CELL", 0, 12], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["B lymphocyte reduction", "TREATMENT", 0, 22], ["the disease", "PROBLEM", 46, 57], ["antibody production", "PROBLEM", 73, 92], ["lymphocyte reduction", "OBSERVATION", 2, 22]]], ["Elevated IL-6 levels were observed in patients infected by SARS-CoV-2 and were correlated with the exacerbation of the disease around 2 to 10 days after onset (Di Gennaro et al. 2020 ).", [["SARS", "DISEASE", 59, 63], ["IL-6", "GENE_OR_GENE_PRODUCT", 9, 13], ["patients", "ORGANISM", 38, 46], ["SARS-CoV-2", "ORGANISM", 59, 69], ["IL-6", "PROTEIN", 9, 13], ["patients", "SPECIES", 38, 46], ["SARS-CoV", "SPECIES", 59, 67], ["Elevated IL", "PROBLEM", 0, 11], ["CoV", "TEST", 64, 67], ["the disease", "PROBLEM", 115, 126], ["IL", "OBSERVATION", 9, 11], ["infected", "OBSERVATION_MODIFIER", 47, 55], ["disease", "OBSERVATION", 119, 126]]], ["Excessive IL-6 signaling leads to a many of biological effects, such as maturing na\u00efve T cells into effector T cells, the induction of vascular endothelial growth factor (VEGF) expression in epithelial cells, the increase of vessel permeability, and reducing myocardium contractility, culminating in organ damage (Pathan et al. 2004; Tanaka et al. 2016) .", [["na\u00efve T cells", "ANATOMY", 81, 94], ["effector T cells", "ANATOMY", 100, 116], ["epithelial cells", "ANATOMY", 191, 207], ["vessel", "ANATOMY", 225, 231], ["myocardium", "ANATOMY", 259, 269], ["organ", "ANATOMY", 300, 305], ["organ damage", "DISEASE", 300, 312], ["IL-6", "GENE_OR_GENE_PRODUCT", 10, 14], ["na\u00efve T cells", "CELL", 81, 94], ["effector T cells", "CELL", 100, 116], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 135, 169], ["VEGF", "GENE_OR_GENE_PRODUCT", 171, 175], ["epithelial cells", "CELL", 191, 207], ["vessel", "MULTI-TISSUE_STRUCTURE", 225, 231], ["myocardium", "MULTI-TISSUE_STRUCTURE", 259, 269], ["organ", "ORGAN", 300, 305], ["IL-6", "PROTEIN", 10, 14], ["na\u00efve T cells", "CELL_TYPE", 81, 94], ["effector T cells", "CELL_TYPE", 100, 116], ["vascular endothelial growth factor", "PROTEIN", 135, 169], ["VEGF", "PROTEIN", 171, 175], ["epithelial cells", "CELL_TYPE", 191, 207], ["Excessive IL", "TREATMENT", 0, 12], ["vascular endothelial growth factor (VEGF) expression in epithelial cells", "PROBLEM", 135, 207], ["the increase of vessel permeability", "PROBLEM", 209, 244], ["reducing myocardium contractility", "PROBLEM", 250, 283], ["organ damage", "PROBLEM", 300, 312], ["vascular endothelial", "ANATOMY", 135, 155], ["epithelial cells", "OBSERVATION", 191, 207], ["increase", "OBSERVATION_MODIFIER", 213, 221], ["vessel", "ANATOMY", 225, 231], ["permeability", "OBSERVATION_MODIFIER", 232, 244], ["myocardium contractility", "OBSERVATION", 259, 283]]], ["Since elevated IL-6 levels were consistently reported during COVID-19 and were correlated with higher mortality in these patients, IL-6 might serve as a predictive biomarker for COVID-19 severity.Virus and pathophysiologyThe role of angiotensin-converting enzyme 2 (ACE2) Different organ systems are believed to participate in COVID-19 due to the wide range expression of the primary SARS-CoV-2 entry receptor, angiotensin-converting enzyme 2 (ACE2) (Fig. 4) .Virus and pathophysiologyACE2 is particularly expressed on the type II alveolar epithelial cells (Guan et al. 2020a; Guan et al. 2020b; Yang et al. 2020a; Yang et al. 2020b; Yang et al. 2020c; Zhao et al. 2020) although also the gastrointestinal tract, kidneys, heart, brain stem, vasculature, liver, and nasal and oral mucosa express these receptors, contributing to extrapulmonary manifestations .", [["organ", "ANATOMY", 282, 287], ["type II alveolar epithelial cells", "ANATOMY", 523, 556], ["gastrointestinal tract", "ANATOMY", 689, 711], ["kidneys", "ANATOMY", 713, 720], ["heart", "ANATOMY", 722, 727], ["brain stem", "ANATOMY", 729, 739], ["vasculature", "ANATOMY", 741, 752], ["liver", "ANATOMY", 754, 759], ["nasal", "ANATOMY", 765, 770], ["oral mucosa", "ANATOMY", 775, 786], ["extrapulmonary", "ANATOMY", 828, 842], ["angiotensin", "CHEMICAL", 233, 244], ["angiotensin", "CHEMICAL", 411, 422], ["COVID-19", "CHEMICAL", 61, 69], ["COVID-19", "CHEMICAL", 327, 335], ["IL-6", "GENE_OR_GENE_PRODUCT", 15, 19], ["patients", "ORGANISM", 121, 129], ["IL-6", "GENE_OR_GENE_PRODUCT", 131, 135], ["Virus", "ORGANISM", 196, 201], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 233, 264], ["ACE2", "GENE_OR_GENE_PRODUCT", 266, 270], ["organ", "ORGAN", 282, 287], ["COVID-19", "GENE_OR_GENE_PRODUCT", 327, 335], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 384, 394], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 411, 442], ["ACE2", "GENE_OR_GENE_PRODUCT", 444, 448], ["Virus", "ORGANISM", 460, 465], ["pathophysiologyACE2", "GENE_OR_GENE_PRODUCT", 470, 489], ["type II alveolar epithelial cells", "CELL", 523, 556], ["gastrointestinal tract", "ORGAN", 689, 711], ["kidneys", "ORGAN", 713, 720], ["heart", "ORGAN", 722, 727], ["brain stem", "TISSUE", 729, 739], ["vasculature", "MULTI-TISSUE_STRUCTURE", 741, 752], ["liver", "ORGAN", 754, 759], ["nasal", "ORGAN", 765, 770], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 775, 786], ["IL-6", "PROTEIN", 15, 19], ["IL-6", "PROTEIN", 131, 135], ["angiotensin-converting enzyme 2", "PROTEIN", 233, 264], ["ACE2", "PROTEIN", 266, 270], ["primary SARS-CoV-2 entry receptor", "PROTEIN", 376, 409], ["angiotensin-converting enzyme 2", "PROTEIN", 411, 442], ["ACE2", "PROTEIN", 444, 448], ["pathophysiologyACE2", "PROTEIN", 470, 489], ["type II alveolar epithelial cells", "CELL_TYPE", 523, 556], ["patients", "SPECIES", 121, 129], ["elevated IL", "TEST", 6, 17], ["COVID", "TEST", 61, 66], ["a predictive biomarker", "TEST", 151, 173], ["COVID", "TEST", 178, 183], ["Virus", "PROBLEM", 196, 201], ["angiotensin-converting enzyme", "TREATMENT", 233, 262], ["COVID", "TEST", 327, 332], ["the primary SARS", "PROBLEM", 372, 388], ["CoV", "TEST", 389, 392], ["angiotensin", "TREATMENT", 411, 422], ["Virus", "PROBLEM", 460, 465], ["pathophysiologyACE2", "TREATMENT", 470, 489], ["extrapulmonary manifestations", "PROBLEM", 828, 857], ["elevated", "OBSERVATION_MODIFIER", 6, 14], ["IL", "OBSERVATION", 15, 17], ["alveolar", "ANATOMY_MODIFIER", 531, 539], ["epithelial cells", "OBSERVATION", 540, 556], ["gastrointestinal tract", "ANATOMY", 689, 711], ["kidneys", "ANATOMY", 713, 720], ["heart", "ANATOMY", 722, 727], ["brain stem", "ANATOMY", 729, 739], ["vasculature", "ANATOMY", 741, 752], ["liver", "ANATOMY", 754, 759], ["nasal", "ANATOMY", 765, 770], ["oral mucosa", "ANATOMY", 775, 786], ["extrapulmonary", "ANATOMY", 828, 842], ["manifestations", "OBSERVATION", 843, 857]]], ["However, the different distribution of ACE2 in organs and tissue is significantly correlated to the clinical symptoms of SARS-CoV-2 infection (Nejadi Babadaei et al. 2020) (Fig. 4) .Virus and pathophysiologyIn addition to functional receptor role, physiologically, ACE2 is an important modulator of the renin-angiotensinaldosterone system (RAAS), which systemically regulates, via distinct hormones, the cardiovascular and immune systems and is involved in heart function and in the development of hypertension and diabetes mellitus.", [["organs", "ANATOMY", 47, 53], ["tissue", "ANATOMY", 58, 64], ["cardiovascular", "ANATOMY", 404, 418], ["heart", "ANATOMY", 457, 462], ["SARS-CoV-2 infection", "DISEASE", 121, 141], ["hypertension", "DISEASE", 498, 510], ["diabetes mellitus", "DISEASE", 515, 532], ["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["organs", "ORGAN", 47, 53], ["tissue", "TISSUE", 58, 64], ["CoV-2", "ORGANISM", 126, 131], ["Virus", "ORGANISM", 182, 187], ["ACE2", "GENE_OR_GENE_PRODUCT", 265, 269], ["renin", "GENE_OR_GENE_PRODUCT", 303, 308], ["angiotensinaldosterone", "GENE_OR_GENE_PRODUCT", 309, 331], ["RAAS", "GENE_OR_GENE_PRODUCT", 340, 344], ["cardiovascular", "ANATOMICAL_SYSTEM", 404, 418], ["heart", "ORGAN", 457, 462], ["ACE2", "PROTEIN", 39, 43], ["ACE2", "PROTEIN", 265, 269], ["renin", "PROTEIN", 303, 308], ["SARS-CoV-2", "SPECIES", 121, 131], ["ACE2 in organs and tissue", "PROBLEM", 39, 64], ["the clinical symptoms", "PROBLEM", 96, 117], ["SARS", "PROBLEM", 121, 125], ["CoV-2 infection", "PROBLEM", 126, 141], ["Virus", "PROBLEM", 182, 187], ["hypertension", "PROBLEM", 498, 510], ["diabetes mellitus", "PROBLEM", 515, 532], ["different", "OBSERVATION_MODIFIER", 13, 22], ["distribution", "OBSERVATION_MODIFIER", 23, 35], ["ACE2", "OBSERVATION", 39, 43], ["organs", "ANATOMY", 47, 53], ["heart", "ANATOMY", 457, 462], ["hypertension", "OBSERVATION", 498, 510], ["diabetes mellitus", "OBSERVATION", 515, 532]]], ["Briefly, the prorenin is cleaved in the kidneys, and then, the activated renin is released into the blood stream where it in turn activates angiotensinogen, which is converted into angiotensin I and finally into angiotensin II (AngII).", [["kidneys", "ANATOMY", 40, 47], ["blood stream", "ANATOMY", 100, 112], ["angiotensin", "CHEMICAL", 181, 192], ["angiotensin II", "CHEMICAL", 212, 226], ["AngII", "CHEMICAL", 228, 233], ["prorenin", "GENE_OR_GENE_PRODUCT", 13, 21], ["kidneys", "ORGAN", 40, 47], ["renin", "GENE_OR_GENE_PRODUCT", 73, 78], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["angiotensinogen", "GENE_OR_GENE_PRODUCT", 140, 155], ["angiotensin I", "GENE_OR_GENE_PRODUCT", 181, 194], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 212, 226], ["AngII", "GENE_OR_GENE_PRODUCT", 228, 233], ["prorenin", "PROTEIN", 13, 21], ["renin", "PROTEIN", 73, 78], ["angiotensinogen", "PROTEIN", 140, 155], ["angiotensin I", "PROTEIN", 181, 194], ["angiotensin II", "PROTEIN", 212, 226], ["angiotensinogen", "TEST", 140, 155], ["kidneys", "ANATOMY", 40, 47]]], ["Specific angiotensinconverting enzymes (ACEs), mainly expressed on renal and pulmonary epithelium, facilitate this activation cascade.", [["renal", "ANATOMY", 67, 72], ["pulmonary epithelium", "ANATOMY", 77, 97], ["Specific angiotensinconverting enzymes", "GENE_OR_GENE_PRODUCT", 0, 38], ["ACEs", "GENE_OR_GENE_PRODUCT", 40, 44], ["renal", "ORGAN", 67, 72], ["pulmonary epithelium", "TISSUE", 77, 97], ["angiotensinconverting enzymes", "PROTEIN", 9, 38], ["ACEs", "PROTEIN", 40, 44], ["Specific angiotensinconverting enzymes", "TEST", 0, 38], ["this activation cascade", "TREATMENT", 110, 133], ["renal", "ANATOMY", 67, 72], ["pulmonary epithelium", "ANATOMY", 77, 97]]], ["ACE2 is a well-characterized negative regulator of the RAAS system as it converts AngII into the vasodilatory fragment Ang 1-7, which simultaneously decreases the AngII concentration to facilitate the antihypertensive effect (Keidar et al. 2007; Santos et al. 2018 ).COVID-19 and cardiovascular manifestationsACE2, located also on the cell surface of cardiac systems, may help to understand those patients infected by SARS-CoV-2 that presented cardiovascular symptoms (myocardial injury, cardiac chest pain, fulminant heart failure, cardiac arrhythmias, and cardiac death), in addition to the typical respiratory symptoms during COVID-19 (Long et al. 2020) (Fig. 4) .", [["cardiovascular", "ANATOMY", 280, 294], ["cell surface", "ANATOMY", 335, 347], ["cardiac systems", "ANATOMY", 351, 366], ["cardiovascular", "ANATOMY", 444, 458], ["myocardial", "ANATOMY", 469, 479], ["cardiac", "ANATOMY", 488, 495], ["heart", "ANATOMY", 518, 523], ["cardiac", "ANATOMY", 533, 540], ["cardiac", "ANATOMY", 558, 565], ["respiratory", "ANATOMY", 601, 612], ["AngII", "CHEMICAL", 82, 87], ["Ang 1-7", "CHEMICAL", 119, 126], ["AngII", "CHEMICAL", 163, 168], ["SARS", "DISEASE", 418, 422], ["cardiovascular symptoms", "DISEASE", 444, 467], ["myocardial injury", "DISEASE", 469, 486], ["cardiac chest pain", "DISEASE", 488, 506], ["fulminant heart failure", "DISEASE", 508, 531], ["cardiac arrhythmias", "DISEASE", 533, 552], ["cardiac death", "DISEASE", 558, 571], ["respiratory symptoms", "DISEASE", 601, 621], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["RAAS", "GENE_OR_GENE_PRODUCT", 55, 59], ["AngII", "GENE_OR_GENE_PRODUCT", 82, 87], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 119, 126], ["AngII", "SIMPLE_CHEMICAL", 163, 168], ["COVID-19", "GENE_OR_GENE_PRODUCT", 267, 275], ["cardiovascular", "ANATOMICAL_SYSTEM", 280, 294], ["cell surface", "CELLULAR_COMPONENT", 335, 347], ["cardiac", "ORGAN", 351, 358], ["patients", "ORGANISM", 397, 405], ["SARS-CoV-2", "ORGANISM", 418, 428], ["cardiovascular", "ANATOMICAL_SYSTEM", 444, 458], ["myocardial", "MULTI-TISSUE_STRUCTURE", 469, 479], ["cardiac", "ORGAN", 488, 495], ["chest", "ORGANISM_SUBDIVISION", 496, 501], ["heart", "ORGAN", 518, 523], ["cardiac", "ORGAN", 533, 540], ["ACE2", "PROTEIN", 0, 4], ["COVID", "PROTEIN", 267, 272], ["patients", "SPECIES", 397, 405], ["SARS-CoV", "SPECIES", 418, 426], ["the vasodilatory fragment Ang", "TREATMENT", 93, 122], ["the AngII concentration", "TREATMENT", 159, 182], ["the antihypertensive effect", "TREATMENT", 197, 224], ["COVID", "TEST", 267, 272], ["SARS", "PROBLEM", 418, 422], ["CoV", "TEST", 423, 426], ["cardiovascular symptoms", "PROBLEM", 444, 467], ["myocardial injury", "PROBLEM", 469, 486], ["cardiac chest pain", "PROBLEM", 488, 506], ["fulminant heart failure", "PROBLEM", 508, 531], ["cardiac arrhythmias", "PROBLEM", 533, 552], ["cardiac death", "PROBLEM", 558, 571], ["the typical respiratory symptoms", "PROBLEM", 589, 621], ["COVID", "TEST", 629, 634], ["AngII", "OBSERVATION", 82, 87], ["vasodilatory fragment", "OBSERVATION", 97, 118], ["cardiac", "ANATOMY", 351, 358], ["myocardial", "ANATOMY", 469, 479], ["injury", "OBSERVATION", 480, 486], ["chest", "ANATOMY", 496, 501], ["heart", "ANATOMY", 518, 523], ["failure", "OBSERVATION", 524, 531], ["cardiac", "ANATOMY", 533, 540], ["arrhythmias", "OBSERVATION", 541, 552]]], ["The mechanism for the SARS-CoV-2 intracellular entry involves the viral S protein C-terminal domain containing a receptorbinding region that binds to the extracellular domain of ACE2 (Di Gennaro et al. 2020 ).", [["intracellular", "ANATOMY", 33, 46], ["extracellular", "ANATOMY", 154, 167], ["SARS", "DISEASE", 22, 26], ["C", "CHEMICAL", 82, 83], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 22, 32], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 33, 46], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 154, 167], ["ACE2", "GENE_OR_GENE_PRODUCT", 178, 182], ["viral S protein C-terminal domain", "PROTEIN", 66, 99], ["receptorbinding region", "PROTEIN", 113, 135], ["extracellular domain", "PROTEIN", 154, 174], ["ACE2", "PROTEIN", 178, 182], ["2020", "PROTEIN", 202, 206], ["the SARS", "TEST", 18, 26], ["CoV", "TEST", 27, 30], ["the viral S protein C-terminal domain", "PROBLEM", 62, 99], ["a receptorbinding region", "PROBLEM", 111, 135], ["viral", "OBSERVATION", 66, 71]]], ["Cleavage of the S protein by the host transmembrane serine protease 2 (TMPRSS2), to generate the S1 and S2 subunits, is a crucial step for the membrane fusion and viral internalization by endocytosis with ACE2 (Hoffmann et al. 2020) (Fig. 4) .", [["membrane", "ANATOMY", 143, 151], ["serine", "CHEMICAL", 52, 58], ["transmembrane serine protease 2", "GENE_OR_GENE_PRODUCT", 38, 69], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 71, 78], ["S1", "GENE_OR_GENE_PRODUCT", 97, 99], ["S2", "GENE_OR_GENE_PRODUCT", 104, 106], ["membrane", "CELLULAR_COMPONENT", 143, 151], ["ACE2", "GENE_OR_GENE_PRODUCT", 205, 209], ["S protein", "PROTEIN", 16, 25], ["host transmembrane serine protease 2", "PROTEIN", 33, 69], ["TMPRSS2", "PROTEIN", 71, 78], ["S1 and S2 subunits", "PROTEIN", 97, 115], ["ACE2", "PROTEIN", 205, 209], ["the S protein", "TREATMENT", 12, 25], ["the host transmembrane serine protease", "TREATMENT", 29, 67], ["the S1 and S2 subunits", "TREATMENT", 93, 115], ["a crucial step", "TREATMENT", 120, 134], ["the membrane fusion", "TREATMENT", 139, 158], ["viral internalization", "PROBLEM", 163, 184], ["membrane fusion", "OBSERVATION", 143, 158]]], ["Interestingly, the interaction between S protein with the extracellular domain of ACE2, which triggers the endocytosis of the complex, is remarkably Fig. 4 Infection mechanism and tissue distribution of ACE2 receptors in humans.", [["extracellular", "ANATOMY", 58, 71], ["tissue", "ANATOMY", 180, 186], ["S protein", "GENE_OR_GENE_PRODUCT", 39, 48], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 58, 71], ["ACE2", "GENE_OR_GENE_PRODUCT", 82, 86], ["tissue", "TISSUE", 180, 186], ["ACE2", "GENE_OR_GENE_PRODUCT", 203, 207], ["humans", "ORGANISM", 221, 227], ["S protein", "PROTEIN", 39, 48], ["extracellular domain", "PROTEIN", 58, 78], ["ACE2", "PROTEIN", 82, 86], ["ACE2 receptors", "PROTEIN", 203, 217], ["humans", "SPECIES", 221, 227], ["humans", "SPECIES", 221, 227], ["the extracellular domain of ACE2", "PROBLEM", 54, 86], ["4 Infection mechanism", "PROBLEM", 154, 175], ["ACE2 receptors in humans", "PROBLEM", 203, 227], ["Fig", "OBSERVATION_MODIFIER", 149, 152], ["Infection", "OBSERVATION", 156, 165], ["tissue", "OBSERVATION_MODIFIER", 180, 186], ["distribution", "OBSERVATION_MODIFIER", 187, 199], ["ACE2 receptors", "OBSERVATION", 203, 217]]], ["1 The mechanism of the SARS-CoV-2 intracellular entry involves the viral Spike (S) protein C-terminal domain containing a receptor-binding region that binds to the extracellular domain of angiotensin-converting enzyme 2 (ACE2).", [["intracellular", "ANATOMY", 34, 47], ["extracellular", "ANATOMY", 164, 177], ["SARS", "DISEASE", 23, 27], ["angiotensin", "CHEMICAL", 188, 199], ["C", "CHEMICAL", 91, 92], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 23, 33], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 34, 47], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 188, 219], ["ACE2", "GENE_OR_GENE_PRODUCT", 221, 225], ["viral Spike (S) protein C-terminal domain", "PROTEIN", 67, 108], ["receptor-binding region", "PROTEIN", 122, 145], ["extracellular domain", "PROTEIN", 164, 184], ["angiotensin-converting enzyme 2", "PROTEIN", 188, 219], ["ACE2", "PROTEIN", 221, 225], ["the SARS", "TEST", 19, 27], ["CoV", "TEST", 28, 31], ["the viral Spike", "TEST", 63, 78], ["protein C-terminal domain", "PROBLEM", 83, 108], ["a receptor-binding region", "TREATMENT", 120, 145], ["angiotensin", "TEST", 188, 199], ["viral Spike", "OBSERVATION", 67, 78]]], ["Cleavage of the S protein by the host transmembrane serine protease 2 (TMPRSS2) is a crucial step for the membrane fusion and viral internalization by endocytosis with ACE2.", [["membrane", "ANATOMY", 106, 114], ["serine", "CHEMICAL", 52, 58], ["transmembrane serine protease 2", "GENE_OR_GENE_PRODUCT", 38, 69], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 71, 78], ["membrane", "CELLULAR_COMPONENT", 106, 114], ["ACE2", "GENE_OR_GENE_PRODUCT", 168, 172], ["S protein", "PROTEIN", 16, 25], ["host transmembrane serine protease 2", "PROTEIN", 33, 69], ["TMPRSS2", "PROTEIN", 71, 78], ["ACE2", "PROTEIN", 168, 172], ["the S protein", "TREATMENT", 12, 25], ["the host transmembrane serine protease", "TREATMENT", 29, 67], ["a crucial step", "TREATMENT", 83, 97], ["the membrane fusion", "TREATMENT", 102, 121], ["viral internalization", "PROBLEM", 126, 147], ["ACE2", "TEST", 168, 172], ["membrane fusion", "OBSERVATION", 106, 121], ["viral internalization", "OBSERVATION", 126, 147]]], ["2 Different organs participate in COVID-19 due to the wide range expression of the primary SARS-CoV-2 entry receptor ACE2.", [["organs", "ANATOMY", 12, 18], ["COVID-19", "CHEMICAL", 34, 42], ["organs", "ORGAN", 12, 18], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 91, 101], ["ACE2", "GENE_OR_GENE_PRODUCT", 117, 121], ["primary SARS-CoV-2 entry receptor", "PROTEIN", 83, 116], ["ACE2", "PROTEIN", 117, 121], ["COVID", "TEST", 34, 39], ["organs", "ANATOMY", 12, 18]]], ["ACE2 is particularly expressed on the type II alveolar epithelial cells, heart, and brain.", [["type II alveolar epithelial cells", "ANATOMY", 38, 71], ["heart", "ANATOMY", 73, 78], ["brain", "ANATOMY", 84, 89], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["alveolar epithelial cells", "CELL", 46, 71], ["heart", "ORGAN", 73, 78], ["brain", "ORGAN", 84, 89], ["ACE2", "PROTEIN", 0, 4], ["type II alveolar epithelial cells", "CELL_TYPE", 38, 71], ["ACE2", "PROBLEM", 0, 4], ["alveolar", "ANATOMY_MODIFIER", 46, 54], ["epithelial cells", "OBSERVATION", 55, 71], ["heart", "ANATOMY", 73, 78], ["brain", "ANATOMY", 84, 89]]], ["The different distribution of ACE2 in organs and tissue is significantly correlated to the clinical symptoms of SARS-CoV-2 infection increased in patients suffering from hypertension or coronary heart disease (Svenningsen et al. 2017; Zheng et al. 2016) .", [["organs", "ANATOMY", 38, 44], ["tissue", "ANATOMY", 49, 55], ["coronary", "ANATOMY", 186, 194], ["heart", "ANATOMY", 195, 200], ["SARS", "DISEASE", 112, 116], ["infection", "DISEASE", 123, 132], ["hypertension", "DISEASE", 170, 182], ["coronary heart disease", "DISEASE", 186, 208], ["ACE2", "GENE_OR_GENE_PRODUCT", 30, 34], ["organs", "ORGAN", 38, 44], ["tissue", "TISSUE", 49, 55], ["SARS-CoV-2", "ORGANISM", 112, 122], ["patients", "ORGANISM", 146, 154], ["heart", "ORGAN", 195, 200], ["ACE2", "PROTEIN", 30, 34], ["patients", "SPECIES", 146, 154], ["SARS-CoV-2", "SPECIES", 112, 122], ["ACE2 in organs and tissue", "PROBLEM", 30, 55], ["the clinical symptoms", "PROBLEM", 87, 108], ["SARS", "PROBLEM", 112, 116], ["CoV-2 infection", "PROBLEM", 117, 132], ["hypertension", "PROBLEM", 170, 182], ["coronary heart disease", "PROBLEM", 186, 208], ["different", "OBSERVATION_MODIFIER", 4, 13], ["distribution", "OBSERVATION_MODIFIER", 14, 26], ["ACE2", "OBSERVATION", 30, 34], ["organs", "ANATOMY", 38, 44], ["infection", "OBSERVATION", 123, 132], ["increased", "OBSERVATION_MODIFIER", 133, 142], ["hypertension", "OBSERVATION", 170, 182], ["coronary heart", "ANATOMY", 186, 200], ["disease", "OBSERVATION", 201, 208]]], ["ACE2 internalization by SARS-CoV-2 results in the loss of ACE2 at the cell surface and removes a key pathway for the cell to degrade ANG II and generate the cardiovascularprotective Ang-(1-7).", [["cell surface", "ANATOMY", 70, 82], ["cell", "ANATOMY", 117, 121], ["Ang-(1-7", "CHEMICAL", 182, 190], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 24, 34], ["ACE2", "GENE_OR_GENE_PRODUCT", 58, 62], ["cell surface", "CELLULAR_COMPONENT", 70, 82], ["cell", "CELL", 117, 121], ["ANG II", "GENE_OR_GENE_PRODUCT", 133, 139], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 182, 190], ["ACE2", "PROTEIN", 0, 4], ["ACE2", "PROTEIN", 58, 62], ["ANG II", "PROTEIN", 133, 139], ["ACE2 internalization", "TREATMENT", 0, 20], ["CoV", "TEST", 29, 32], ["ACE2 at the cell surface", "TREATMENT", 58, 82], ["the cardiovascularprotective Ang", "TEST", 153, 185]]], ["Certainly, an increase in the overall ratio of ANG II/Ang-(1-7), following ACE2 internalization, may exacerbate the pulmonary tissue damage, initially caused by SARS-CoV-2 (Guan et al. 2020a; Guan et al. 2020b; Yang et al. 2020a; Yang et al. 2020b; Yang et al. 2020c) .", [["pulmonary tissue", "ANATOMY", 116, 132], ["ANG II", "CHEMICAL", 47, 53], ["Ang-(1-7", "CHEMICAL", 54, 62], ["pulmonary tissue damage", "DISEASE", 116, 139], ["ANG II", "GENE_OR_GENE_PRODUCT", 47, 53], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 54, 62], ["ACE2", "GENE_OR_GENE_PRODUCT", 75, 79], ["pulmonary tissue", "TISSUE", 116, 132], ["ANG II", "PROTEIN", 47, 53], ["ACE2", "PROTEIN", 75, 79], ["Ang", "TEST", 54, 57], ["ACE2 internalization", "TREATMENT", 75, 95], ["the pulmonary tissue damage", "PROBLEM", 112, 139], ["SARS", "PROBLEM", 161, 165], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["pulmonary tissue", "ANATOMY", 116, 132]]], ["Moreover, the down-regulation of ACE2 on the surface of infected cells might secondary imply an excessive response of the immune system and, then, the progression and the worsening of the disease in SARS-CoV-2infected patients.", [["surface", "ANATOMY", 45, 52], ["cells", "ANATOMY", 65, 70], ["immune system", "ANATOMY", 122, 135], ["SARS-CoV-2infected", "DISEASE", 199, 217], ["ACE2", "GENE_OR_GENE_PRODUCT", 33, 37], ["surface", "CELLULAR_COMPONENT", 45, 52], ["cells", "CELL", 65, 70], ["SARS-CoV-2infected", "ORGANISM", 199, 217], ["patients", "ORGANISM", 218, 226], ["ACE2", "PROTEIN", 33, 37], ["infected cells", "CELL_TYPE", 56, 70], ["patients", "SPECIES", 218, 226], ["SARS-CoV", "SPECIES", 199, 207], ["ACE2", "PROBLEM", 33, 37], ["infected cells", "PROBLEM", 56, 70], ["an excessive response of the immune system", "PROBLEM", 93, 135], ["the disease in SARS", "PROBLEM", 184, 203], ["infected cells", "OBSERVATION", 56, 70], ["excessive response", "OBSERVATION", 96, 114], ["immune system", "OBSERVATION", 122, 135], ["progression", "OBSERVATION_MODIFIER", 151, 162], ["worsening", "OBSERVATION_MODIFIER", 171, 180], ["disease", "OBSERVATION", 188, 195]]], ["Lung and heart damage is due precisely by an overreaction of the immune system associated with a pronounced cytokine storm resulting into vascular inflammation, plaque instability, myocardial inflammation, and hypercoagulable state [ (Levi et al. 2004; Prabhu 2004) ; Yang et al. 2020] .", [["Lung", "ANATOMY", 0, 4], ["heart", "ANATOMY", 9, 14], ["immune system", "ANATOMY", 65, 78], ["vascular", "ANATOMY", 138, 146], ["plaque", "ANATOMY", 161, 167], ["myocardial", "ANATOMY", 181, 191], ["Lung and heart damage", "DISEASE", 0, 21], ["inflammation", "DISEASE", 147, 159], ["plaque instability", "DISEASE", 161, 179], ["myocardial inflammation", "DISEASE", 181, 204], ["Lung", "ORGAN", 0, 4], ["heart", "ORGAN", 9, 14], ["vascular", "MULTI-TISSUE_STRUCTURE", 138, 146], ["plaque", "PATHOLOGICAL_FORMATION", 161, 167], ["myocardial", "MULTI-TISSUE_STRUCTURE", 181, 191], ["cytokine", "PROTEIN", 108, 116], ["Lung and heart damage", "PROBLEM", 0, 21], ["an overreaction of the immune system", "PROBLEM", 42, 78], ["a pronounced cytokine storm", "PROBLEM", 95, 122], ["vascular inflammation", "PROBLEM", 138, 159], ["plaque instability", "PROBLEM", 161, 179], ["myocardial inflammation", "PROBLEM", 181, 204], ["hypercoagulable state", "PROBLEM", 210, 231], ["heart", "ANATOMY", 9, 14], ["damage", "OBSERVATION", 15, 21], ["pronounced", "OBSERVATION_MODIFIER", 97, 107], ["cytokine storm", "OBSERVATION", 108, 122], ["vascular", "ANATOMY", 138, 146], ["inflammation", "OBSERVATION", 147, 159], ["plaque", "OBSERVATION_MODIFIER", 161, 167], ["myocardial", "ANATOMY", 181, 191], ["inflammation", "OBSERVATION", 192, 204], ["hypercoagulable state", "OBSERVATION", 210, 231]]], ["Clinical features include the dysregulation of T helper cells of type 1 and 2 and levels extremely elevated of IL-6 and ferritin Yang et al. 2020a; Yang et al. 2020b; Yang et al. 2020c) , which are also well-known markers for sepsis.", [["T helper cells", "ANATOMY", 47, 61], ["sepsis", "DISEASE", 226, 232], ["T helper cells", "CELL", 47, 61], ["type 1", "GENE_OR_GENE_PRODUCT", 65, 71], ["IL-6", "GENE_OR_GENE_PRODUCT", 111, 115], ["ferritin", "GENE_OR_GENE_PRODUCT", 120, 128], ["T helper cells", "CELL_TYPE", 47, 61], ["IL", "PROTEIN", 111, 113], ["the dysregulation of T helper cells", "PROBLEM", 26, 61], ["levels", "TEST", 82, 88], ["IL", "TEST", 111, 113], ["ferritin Yang", "TEST", 120, 133], ["sepsis", "PROBLEM", 226, 232], ["sepsis", "OBSERVATION", 226, 232]]], ["The cardiovascular system involvement, during severe COVID-19, is unquestioned although the specific mechanisms remain to be explored.", [["cardiovascular system", "ANATOMY", 4, 25], ["COVID-19", "CHEMICAL", 53, 61], ["cardiovascular", "ANATOMICAL_SYSTEM", 4, 18], ["severe COVID", "PROBLEM", 46, 58], ["cardiovascular system", "ANATOMY", 4, 25]]], ["One proposed mode of action is related to a direct infection of cardiomyocytes (CMCs) by SARS-CoV-2 during the critical phase that leads to the myocarditis development .", [["cardiomyocytes", "ANATOMY", 64, 78], ["CMCs", "ANATOMY", 80, 84], ["infection", "DISEASE", 51, 60], ["myocarditis", "DISEASE", 144, 155], ["cardiomyocytes", "CELL", 64, 78], ["CMCs", "CELL", 80, 84], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 89, 99], ["cardiomyocytes", "CELL_TYPE", 64, 78], ["CMCs", "CELL_TYPE", 80, 84], ["a direct infection of cardiomyocytes", "PROBLEM", 42, 78], ["CoV", "TEST", 94, 97], ["the myocarditis development", "PROBLEM", 140, 167], ["infection", "OBSERVATION", 51, 60], ["cardiomyocytes", "ANATOMY", 64, 78], ["myocarditis", "OBSERVATION", 144, 155]]], ["A second assumption is that an over-activated immune system is predominantly contributing to SARS-CoV-2-induced heart damage.", [["heart", "ANATOMY", 112, 117], ["heart damage", "DISEASE", 112, 124], ["CoV-2", "GENE_OR_GENE_PRODUCT", 98, 103], ["heart", "ORGAN", 112, 117], ["SARS-CoV", "SPECIES", 93, 101], ["an over-activated immune system", "TREATMENT", 28, 59], ["SARS", "PROBLEM", 93, 97], ["CoV", "TEST", 98, 101], ["heart damage", "PROBLEM", 112, 124], ["heart", "ANATOMY", 112, 117], ["damage", "OBSERVATION", 118, 124]]], ["Following to cardiac ischemia as an effect of pneumonia and ARDS Chen et al. 2020b; Guan et al. 2020a; Guan et al. 2020b) , CMC damage induces a range of pro-inflammatory mechanisms, which in turn escape control and further promote loss of CMCs (Mehta et al. 2020 ).", [["cardiac", "ANATOMY", 13, 20], ["CMCs", "ANATOMY", 240, 244], ["cardiac ischemia", "DISEASE", 13, 29], ["pneumonia", "DISEASE", 46, 55], ["ARDS", "DISEASE", 60, 64], ["CMC", "CHEMICAL", 124, 127], ["cardiac", "ORGAN", 13, 20], ["CMCs", "CELL", 240, 244], ["CMCs", "CELL_TYPE", 240, 244], ["cardiac ischemia", "PROBLEM", 13, 29], ["pneumonia", "PROBLEM", 46, 55], ["ARDS", "PROBLEM", 60, 64], ["CMC damage", "PROBLEM", 124, 134], ["pro-inflammatory mechanisms", "PROBLEM", 154, 181], ["escape control", "TREATMENT", 197, 211], ["cardiac", "ANATOMY", 13, 20], ["ischemia", "OBSERVATION", 21, 29], ["pneumonia", "OBSERVATION", 46, 55]]], ["Consequently, a secondary induced cardiac injury seems to be plausible.", [["cardiac", "ANATOMY", 34, 41], ["cardiac injury", "DISEASE", 34, 48], ["cardiac", "ORGAN", 34, 41], ["a secondary induced cardiac injury", "PROBLEM", 14, 48], ["cardiac", "ANATOMY", 34, 41], ["injury", "OBSERVATION", 42, 48]]], ["However, this scenario is strongly supported by previous studies investigating the SARS-CoV outbreak in 2002 or MERS-CoV-associated epidemic in 2012 (World Health Organization (WHO) 2020), where acute myocarditis and heart failure have also been reported (Alhogbani 2016) .", [["heart", "ANATOMY", 217, 222], ["SARS-CoV outbreak", "DISEASE", 83, 100], ["myocarditis", "DISEASE", 201, 212], ["heart failure", "DISEASE", 217, 230], ["SARS-CoV", "ORGANISM", 83, 91], ["MERS-CoV", "ORGANISM", 112, 120], ["heart", "ORGAN", 217, 222], ["SARS-CoV", "SPECIES", 83, 91], ["MERS-CoV", "SPECIES", 112, 120], ["previous studies", "TEST", 48, 64], ["the SARS", "PROBLEM", 79, 87], ["acute myocarditis", "PROBLEM", 195, 212], ["heart failure", "PROBLEM", 217, 230], ["acute", "OBSERVATION_MODIFIER", 195, 200], ["myocarditis", "OBSERVATION", 201, 212], ["heart", "ANATOMY", 217, 222], ["failure", "OBSERVATION", 223, 230]]], ["Considering the multiple effects on the heart, it can be assumed that previous cardiovascular diseases (CVDs) could lead to worse progression of COVID-19 and to an increased risk of mortality (Long et al. 2020) .", [["heart", "ANATOMY", 40, 45], ["cardiovascular", "ANATOMY", 79, 93], ["cardiovascular diseases", "DISEASE", 79, 102], ["CVDs", "DISEASE", 104, 108], ["COVID", "DISEASE", 145, 150], ["heart", "ORGAN", 40, 45], ["cardiovascular", "ANATOMICAL_SYSTEM", 79, 93], ["previous cardiovascular diseases", "PROBLEM", 70, 102], ["COVID", "TEST", 145, 150], ["multiple", "OBSERVATION_MODIFIER", 16, 24], ["effects", "OBSERVATION", 25, 32], ["heart", "ANATOMY", 40, 45], ["cardiovascular", "ANATOMY", 79, 93], ["diseases", "OBSERVATION", 94, 102], ["increased", "OBSERVATION_MODIFIER", 164, 173]]], ["Interestingly, the increased mortality rate in patients with preexisting or new cardiac injuries is concomitant with high levels of troponin T (TnT) serum, a common cardiac damage biomarker.", [["cardiac", "ANATOMY", 80, 87], ["serum", "ANATOMY", 149, 154], ["cardiac", "ANATOMY", 165, 172], ["cardiac injuries", "DISEASE", 80, 96], ["cardiac damage", "DISEASE", 165, 179], ["patients", "ORGANISM", 47, 55], ["cardiac", "ORGAN", 80, 87], ["troponin T", "GENE_OR_GENE_PRODUCT", 132, 142], ["TnT", "GENE_OR_GENE_PRODUCT", 144, 147], ["serum", "ORGANISM_SUBSTANCE", 149, 154], ["cardiac", "ORGAN", 165, 172], ["troponin T", "PROTEIN", 132, 142], ["TnT", "PROTEIN", 144, 147], ["patients", "SPECIES", 47, 55], ["the increased mortality rate", "PROBLEM", 15, 43], ["new cardiac injuries", "PROBLEM", 76, 96], ["high levels of troponin T (TnT) serum", "PROBLEM", 117, 154], ["a common cardiac damage biomarker", "TEST", 156, 189], ["increased", "OBSERVATION_MODIFIER", 19, 28], ["mortality", "OBSERVATION_MODIFIER", 29, 38], ["new", "OBSERVATION_MODIFIER", 76, 79], ["cardiac", "ANATOMY", 80, 87], ["injuries", "OBSERVATION", 88, 96], ["cardiac", "ANATOMY", 165, 172], ["damage", "OBSERVATION", 173, 179]]], ["To support this hypothesis, the study of Guo and colleagues reported that CVD patients, without significantly raised TnT serum levels, presented only a slightly increased mortality compared to patients without CVDs (Guo et al. 2020) .", [["serum", "ANATOMY", 121, 126], ["CVD", "DISEASE", 74, 77], ["CVDs", "DISEASE", 210, 214], ["patients", "ORGANISM", 78, 86], ["TnT", "GENE_OR_GENE_PRODUCT", 117, 120], ["serum", "ORGANISM_SUBSTANCE", 121, 126], ["patients", "ORGANISM", 193, 201], ["TnT", "PROTEIN", 117, 120], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 193, 201], ["this hypothesis", "PROBLEM", 11, 26], ["the study", "TEST", 28, 37], ["significantly raised TnT serum levels", "PROBLEM", 96, 133], ["a slightly increased mortality", "PROBLEM", 150, 180], ["CVDs", "PROBLEM", 210, 214], ["slightly", "OBSERVATION_MODIFIER", 152, 160], ["increased", "OBSERVATION_MODIFIER", 161, 170]]], ["Therefore, although TnT levels should always be monitored in the case of cardiac damage caused by comorbidities (hypertension, diabetes, cardiovascular but also pulmonary dysfunctions, cancer, nephrological and cerebrovascular disorders) or severe disease progression, these levels should be critically interpreted since some medications and interventions can cause an upregulation of TnT (Cardiology Magazine 2020; Harvell et al. 2016) .", [["cardiac", "ANATOMY", 73, 80], ["cardiovascular", "ANATOMY", 137, 151], ["pulmonary", "ANATOMY", 161, 170], ["cancer", "ANATOMY", 185, 191], ["nephrological", "ANATOMY", 193, 206], ["cerebrovascular", "ANATOMY", 211, 226], ["cardiac damage", "DISEASE", 73, 87], ["hypertension", "DISEASE", 113, 125], ["diabetes", "DISEASE", 127, 135], ["pulmonary dysfunctions", "DISEASE", 161, 183], ["cancer", "DISEASE", 185, 191], ["nephrological and cerebrovascular disorders", "DISEASE", 193, 236], ["TnT", "GENE_OR_GENE_PRODUCT", 20, 23], ["cardiac", "ORGAN", 73, 80], ["pulmonary", "ORGAN", 161, 170], ["cancer", "CANCER", 185, 191], ["TnT", "GENE_OR_GENE_PRODUCT", 385, 388], ["TnT", "PROTEIN", 20, 23], ["TnT", "PROTEIN", 385, 388], ["TnT levels", "TEST", 20, 30], ["cardiac damage", "PROBLEM", 73, 87], ["comorbidities", "PROBLEM", 98, 111], ["hypertension", "PROBLEM", 113, 125], ["diabetes", "PROBLEM", 127, 135], ["pulmonary dysfunctions", "PROBLEM", 161, 183], ["cancer", "PROBLEM", 185, 191], ["nephrological and cerebrovascular disorders", "PROBLEM", 193, 236], ["severe disease progression", "PROBLEM", 241, 267], ["these levels", "TEST", 269, 281], ["some medications", "TREATMENT", 321, 337], ["interventions", "TREATMENT", 342, 355], ["cardiac", "ANATOMY", 73, 80], ["damage", "OBSERVATION", 81, 87], ["hypertension", "OBSERVATION", 113, 125], ["pulmonary", "ANATOMY", 161, 170], ["dysfunctions", "OBSERVATION", 171, 183], ["cancer", "OBSERVATION", 185, 191], ["cerebrovascular", "ANATOMY", 211, 226], ["severe", "OBSERVATION_MODIFIER", 241, 247], ["disease", "OBSERVATION", 248, 255]]], ["Together with the inflammatory cytokine IL-6 and ferritin, TnT may be used to predict the outcome of the SARS-CoV-2 infection and help to reduce COVID-19 mortality (Poe et al. 2015; Rivara et al. 2012 ).Neurological implicationsA growing body of clinical findings suggest that SARS-CoV-2 gain entry into the central nervous system (CNS) ), but the exact route of access has yet to be demonstrated.", [["central nervous system", "ANATOMY", 308, 330], ["CNS", "ANATOMY", 332, 335], ["SARS", "DISEASE", 105, 109], ["infection", "DISEASE", 116, 125], ["SARS", "DISEASE", 277, 281], ["IL-6", "GENE_OR_GENE_PRODUCT", 40, 44], ["ferritin", "GENE_OR_GENE_PRODUCT", 49, 57], ["TnT", "GENE_OR_GENE_PRODUCT", 59, 62], ["SARS-CoV-2", "ORGANISM", 105, 115], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 277, 287], ["central nervous system", "ANATOMICAL_SYSTEM", 308, 330], ["CNS", "ANATOMICAL_SYSTEM", 332, 335], ["inflammatory cytokine IL-6", "PROTEIN", 18, 44], ["ferritin", "PROTEIN", 49, 57], ["TnT", "PROTEIN", 59, 62], ["SARS-CoV-2", "SPECIES", 105, 115], ["the inflammatory cytokine IL", "TEST", 14, 42], ["ferritin", "TEST", 49, 57], ["the SARS", "PROBLEM", 101, 109], ["CoV-2 infection", "PROBLEM", 110, 125], ["COVID", "TEST", 145, 150], ["SARS", "PROBLEM", 277, 281], ["inflammatory", "OBSERVATION_MODIFIER", 18, 30], ["central", "ANATOMY_MODIFIER", 308, 315], ["nervous system", "ANATOMY", 316, 330]]], ["According to similarity with other coronaviruses, including MERS-CoV and SARS-CoV and studies in animal model of infection (Netland et al. 2008) , CNS invasion was postulated to occur mainly by trans-synaptic transfer of virus particles, starting from infection in the peripheral nerve endings such as the olfactory ones (Butowt and Bilinska 2020) .", [["CNS", "ANATOMY", 147, 150], ["peripheral nerve endings", "ANATOMY", 269, 293], ["olfactory ones", "ANATOMY", 306, 320], ["infection", "DISEASE", 113, 122], ["infection", "DISEASE", 252, 261], ["MERS-CoV", "ORGANISM", 60, 68], ["SARS-CoV", "ORGANISM", 73, 81], ["CNS", "ANATOMICAL_SYSTEM", 147, 150], ["peripheral nerve endings", "MULTI-TISSUE_STRUCTURE", 269, 293], ["MERS-CoV", "SPECIES", 60, 68], ["SARS-CoV", "SPECIES", 73, 81], ["other coronaviruses", "PROBLEM", 29, 48], ["SARS", "PROBLEM", 73, 77], ["CoV", "PROBLEM", 78, 81], ["studies", "TEST", 86, 93], ["infection", "PROBLEM", 113, 122], ["CNS invasion", "PROBLEM", 147, 159], ["virus particles", "PROBLEM", 221, 236], ["infection in the peripheral nerve endings", "PROBLEM", 252, 293], ["infection", "OBSERVATION", 113, 122], ["CNS", "ANATOMY", 147, 150], ["invasion", "OBSERVATION", 151, 159], ["virus", "OBSERVATION", 221, 226], ["infection", "OBSERVATION", 252, 261], ["peripheral", "ANATOMY_MODIFIER", 269, 279], ["nerve", "ANATOMY", 280, 285]]], ["Along this line, peripheral neuronal manifestations, as the loss of smell and taste, are frequently experienced by COVID-19 individuals (Baig et al. 2020; Mao et al. 2020) .", [["peripheral neuronal", "ANATOMY", 17, 36], ["loss of smell", "DISEASE", 60, 73], ["peripheral neuronal", "CELL", 17, 36], ["peripheral neuronal manifestations", "PROBLEM", 17, 51], ["the loss of smell and taste", "PROBLEM", 56, 83], ["line", "OBSERVATION_MODIFIER", 11, 15], ["peripheral", "ANATOMY_MODIFIER", 17, 27], ["neuronal manifestations", "OBSERVATION", 28, 51]]], ["The expression of ACE2 on the surface on neurons and glial cells (Hamming et al. 2004) (Fig. 2) as well as the priming proteases TMPRSS2 and furin, all required for virus attach and entry in host cells (Hoffmann et al. 2020; Lashley et al. 2008 ) makes them suitable targets for virus infection.", [["surface", "ANATOMY", 30, 37], ["neurons", "ANATOMY", 41, 48], ["glial cells", "ANATOMY", 53, 64], ["cells", "ANATOMY", 196, 201], ["infection", "DISEASE", 285, 294], ["ACE2", "GENE_OR_GENE_PRODUCT", 18, 22], ["surface", "CELLULAR_COMPONENT", 30, 37], ["neurons", "CELL", 41, 48], ["glial cells", "CELL", 53, 64], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 129, 136], ["furin", "GENE_OR_GENE_PRODUCT", 141, 146], ["host cells", "CELL", 191, 201], ["ACE2", "PROTEIN", 18, 22], ["neurons", "CELL_TYPE", 41, 48], ["glial cells", "CELL_TYPE", 53, 64], ["priming proteases", "PROTEIN", 111, 128], ["TMPRSS2", "PROTEIN", 129, 136], ["furin", "PROTEIN", 141, 146], ["host cells", "CELL_TYPE", 191, 201], ["ACE2", "PROBLEM", 18, 22], ["the priming proteases TMPRSS2", "TREATMENT", 107, 136], ["furin", "TREATMENT", 141, 146], ["virus attach", "PROBLEM", 165, 177], ["virus infection", "PROBLEM", 279, 294], ["neurons", "ANATOMY", 41, 48], ["glial cells", "ANATOMY", 53, 64]]], ["However, recent findings from a postmortem study (Paniz-Mondolfi et al. 2020) support the hypothesis that the virus could also exploit the hematogenous route, since SARS-CoV-2 was found in neurons and capillary endothelial cells of the frontal lobe of a patient death for SARS-CoV2-associated ARDS.", [["neurons", "ANATOMY", 189, 196], ["capillary endothelial cells", "ANATOMY", 201, 228], ["frontal lobe", "ANATOMY", 236, 248], ["death", "DISEASE", 262, 267], ["SARS", "DISEASE", 272, 276], ["ARDS", "DISEASE", 293, 297], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 165, 175], ["neurons", "CELL", 189, 196], ["capillary endothelial cells", "CELL", 201, 228], ["frontal lobe", "MULTI-TISSUE_STRUCTURE", 236, 248], ["patient", "ORGANISM", 254, 261], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 272, 281], ["capillary endothelial cells", "CELL_TYPE", 201, 228], ["patient", "SPECIES", 254, 261], ["SARS-CoV", "SPECIES", 165, 173], ["a postmortem study", "TEST", 30, 48], ["the hypothesis", "PROBLEM", 86, 100], ["the virus", "PROBLEM", 106, 115], ["SARS", "PROBLEM", 165, 169], ["CoV", "TEST", 170, 173], ["a patient death", "PROBLEM", 252, 267], ["SARS", "PROBLEM", 272, 276], ["CoV2", "PROBLEM", 277, 281], ["ARDS", "PROBLEM", 293, 297], ["hematogenous", "OBSERVATION", 139, 151], ["neurons", "ANATOMY", 189, 196], ["capillary endothelial", "ANATOMY", 201, 222], ["cells", "OBSERVATION", 223, 228], ["frontal lobe", "ANATOMY", 236, 248], ["ARDS", "OBSERVATION", 293, 297]]], ["It is known that endothelial cells of blood vessels, including the cerebral ones, express ACE2.", [["endothelial cells", "ANATOMY", 17, 34], ["blood vessels", "ANATOMY", 38, 51], ["cerebral ones", "ANATOMY", 67, 80], ["endothelial cells", "CELL", 17, 34], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 38, 51], ["cerebral ones", "MULTI-TISSUE_STRUCTURE", 67, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 90, 94], ["endothelial cells", "CELL_TYPE", 17, 34], ["ACE2", "PROTEIN", 90, 94], ["endothelial cells of blood vessels", "PROBLEM", 17, 51], ["endothelial cells", "OBSERVATION", 17, 34], ["blood vessels", "ANATOMY", 38, 51], ["cerebral", "ANATOMY", 67, 75]]], ["Thus, SARS-CoV-2 could infect those cells in the cerebral blood vessels, leading to increased permeability of the blood brain barrier (BBB) and in turn promoting pathogen invasion into the brain.", [["cells", "ANATOMY", 36, 41], ["cerebral blood vessels", "ANATOMY", 49, 71], ["blood brain barrier", "ANATOMY", 114, 133], ["BBB", "ANATOMY", 135, 138], ["brain", "ANATOMY", 189, 194], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 6, 16], ["cells", "CELL", 36, 41], ["cerebral blood vessels", "MULTI-TISSUE_STRUCTURE", 49, 71], ["blood brain barrier", "MULTI-TISSUE_STRUCTURE", 114, 133], ["BBB", "MULTI-TISSUE_STRUCTURE", 135, 138], ["brain", "ORGAN", 189, 194], ["SARS-CoV", "SPECIES", 6, 14], ["SARS", "PROBLEM", 6, 10], ["increased permeability", "PROBLEM", 84, 106], ["the blood brain barrier", "PROBLEM", 110, 133], ["pathogen invasion into the brain", "PROBLEM", 162, 194], ["cerebral", "ANATOMY_MODIFIER", 49, 57], ["blood vessels", "ANATOMY", 58, 71], ["increased", "OBSERVATION_MODIFIER", 84, 93], ["permeability", "OBSERVATION_MODIFIER", 94, 106], ["blood brain", "ANATOMY", 114, 125], ["pathogen", "OBSERVATION_MODIFIER", 162, 170], ["invasion", "OBSERVATION", 171, 179], ["brain", "ANATOMY", 189, 194]]], ["A similar effect may be exerted indirectly by the virus-induced inflammatory cytokine storms, leading to brain edema and intracranial hypertension.", [["brain", "ANATOMY", 105, 110], ["intracranial", "ANATOMY", 121, 133], ["brain edema", "DISEASE", 105, 116], ["intracranial hypertension", "DISEASE", 121, 146], ["brain", "ORGAN", 105, 110], ["inflammatory cytokine", "PROTEIN", 64, 85], ["the virus", "PROBLEM", 46, 55], ["inflammatory cytokine storms", "PROBLEM", 64, 92], ["brain edema", "PROBLEM", 105, 116], ["intracranial hypertension", "PROBLEM", 121, 146], ["inflammatory cytokine storms", "OBSERVATION", 64, 92], ["brain", "ANATOMY", 105, 110], ["edema", "OBSERVATION", 111, 116], ["intracranial", "ANATOMY", 121, 133], ["hypertension", "OBSERVATION", 134, 146]]], ["Finally, the virus might also exploit a macrophage-mediated Trojan-horse mechanism (Santiago-Tirado and Doering 2017) or the lymphatic route to reach the brain, as well as other organs.Neurological implicationsSeveral COVID-19 patients showed secondary mild neurological symptoms, including headache, dizziness, and neuralgia, whereas some severe cases showed neurological complications such as encephalopathy and acute cerebrovascular diseases (Ahmad and Rathore 2020).Neurological implicationsAlong this context, besides other primary neurological manifestations such as seizures, increasing evidence indicate that SARS-CoV-2 can cause meningitis and encephalitis.", [["macrophage", "ANATOMY", 40, 50], ["lymphatic", "ANATOMY", 125, 134], ["brain", "ANATOMY", 154, 159], ["organs", "ANATOMY", 178, 184], ["neurological", "ANATOMY", 258, 270], ["neurological", "ANATOMY", 360, 372], ["cerebrovascular", "ANATOMY", 420, 435], ["neurological", "ANATOMY", 537, 549], ["neurological symptoms", "DISEASE", 258, 279], ["headache", "DISEASE", 291, 299], ["dizziness", "DISEASE", 301, 310], ["neuralgia", "DISEASE", 316, 325], ["neurological complications", "DISEASE", 360, 386], ["encephalopathy", "DISEASE", 395, 409], ["acute cerebrovascular diseases", "DISEASE", 414, 444], ["seizures", "DISEASE", 573, 581], ["SARS", "DISEASE", 617, 621], ["meningitis", "DISEASE", 638, 648], ["encephalitis", "DISEASE", 653, 665], ["macrophage", "CELL", 40, 50], ["horse", "ORGANISM", 67, 72], ["lymphatic route", "MULTI-TISSUE_STRUCTURE", 125, 140], ["brain", "ORGAN", 154, 159], ["organs", "ORGAN", 178, 184], ["patients", "ORGANISM", 227, 235], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 617, 627], ["patients", "SPECIES", 227, 235], ["the virus", "PROBLEM", 9, 18], ["Neurological implications", "PROBLEM", 185, 210], ["Several COVID", "TEST", 210, 223], ["secondary mild neurological symptoms", "PROBLEM", 243, 279], ["headache", "PROBLEM", 291, 299], ["dizziness", "PROBLEM", 301, 310], ["neuralgia", "PROBLEM", 316, 325], ["some severe cases", "PROBLEM", 335, 352], ["neurological complications", "PROBLEM", 360, 386], ["encephalopathy", "PROBLEM", 395, 409], ["acute cerebrovascular diseases", "PROBLEM", 414, 444], ["Neurological implications", "PROBLEM", 470, 495], ["other primary neurological manifestations", "PROBLEM", 523, 564], ["seizures", "PROBLEM", 573, 581], ["SARS-CoV-2", "PROBLEM", 617, 627], ["meningitis", "PROBLEM", 638, 648], ["encephalitis", "PROBLEM", 653, 665], ["lymphatic", "ANATOMY", 125, 134], ["brain", "ANATOMY", 154, 159], ["secondary", "OBSERVATION_MODIFIER", 243, 252], ["mild", "OBSERVATION_MODIFIER", 253, 257], ["neurological symptoms", "OBSERVATION", 258, 279], ["neuralgia", "OBSERVATION", 316, 325], ["encephalopathy", "OBSERVATION", 395, 409], ["acute", "OBSERVATION_MODIFIER", 414, 419], ["cerebrovascular diseases", "OBSERVATION", 420, 444], ["primary", "OBSERVATION_MODIFIER", 529, 536], ["meningitis", "OBSERVATION", 638, 648], ["encephalitis", "OBSERVATION", 653, 665]]], ["Several reports documented encephalitis without cerebrospinal fluid (CSF) virus detection in COVID-19 patients (Bernard-Valnet et al. 2020; Dogan et al. 2020; Duong et al. 2020; Ye et al. 2020 ).", [["cerebrospinal fluid", "ANATOMY", 48, 67], ["encephalitis", "DISEASE", 27, 39], ["cerebrospinal fluid (CSF) virus", "DISEASE", 48, 79], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 48, 67], ["CSF", "ORGANISM_SUBSTANCE", 69, 72], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["encephalitis", "PROBLEM", 27, 39], ["cerebrospinal fluid (CSF) virus detection", "TEST", 48, 89], ["COVID", "TEST", 93, 98], ["encephalitis", "OBSERVATION", 27, 39], ["without", "UNCERTAINTY", 40, 47], ["cerebrospinal", "ANATOMY", 48, 61], ["fluid", "OBSERVATION", 62, 67]]], ["Poyiadji and colleagues reported the first US presumptive case of COVID-19associated acute hemorrhagic necrotizing encephalopathy (Poyiadji et al. 2020 ), a rare encephalopathy previously associated with Influenza A virus (IAV) and potentially related to damaging effects of the virus-induced cytokine storm on BBB and brain parenchyma (Bailey 2020) .", [["BBB", "ANATOMY", 311, 314], ["brain parenchyma", "ANATOMY", 319, 335], ["hemorrhagic necrotizing encephalopathy", "DISEASE", 91, 129], ["encephalopathy", "DISEASE", 162, 176], ["Influenza A virus", "DISEASE", 204, 221], ["Influenza A virus", "ORGANISM", 204, 221], ["IAV", "ORGANISM", 223, 226], ["BBB", "MULTI-TISSUE_STRUCTURE", 311, 314], ["brain parenchyma", "MULTI-TISSUE_STRUCTURE", 319, 335], ["cytokine", "PROTEIN", 293, 301], ["Influenza A virus", "SPECIES", 204, 221], ["Influenza A virus", "SPECIES", 204, 221], ["IAV", "SPECIES", 223, 226], ["COVID", "TEST", 66, 71], ["acute hemorrhagic necrotizing encephalopathy", "PROBLEM", 85, 129], ["a rare encephalopathy", "PROBLEM", 155, 176], ["Influenza A virus (IAV)", "PROBLEM", 204, 227], ["the virus", "PROBLEM", 275, 284], ["induced cytokine storm on BBB and brain parenchyma", "PROBLEM", 285, 335], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["hemorrhagic", "OBSERVATION_MODIFIER", 91, 102], ["necrotizing", "OBSERVATION_MODIFIER", 103, 114], ["encephalopathy", "OBSERVATION", 115, 129], ["rare", "OBSERVATION_MODIFIER", 157, 161], ["encephalopathy", "OBSERVATION", 162, 176], ["cytokine storm", "OBSERVATION", 293, 307], ["brain", "ANATOMY", 319, 324], ["parenchyma", "ANATOMY_MODIFIER", 325, 335]]], ["The MRI brain of this SARS-CoV-2-positive 50-year-old female patient with a 3-day history of cough, fever, and altered mental status showed hemorrhagic rim resulting in lesions within the bilateral thalami, medial temporal lobes, and sub-insular brain regions.", [["brain", "ANATOMY", 8, 13], ["lesions", "ANATOMY", 169, 176], ["bilateral thalami", "ANATOMY", 188, 205], ["medial temporal lobes", "ANATOMY", 207, 228], ["sub-insular brain", "ANATOMY", 234, 251], ["cough", "DISEASE", 93, 98], ["fever", "DISEASE", 100, 105], ["hemorrhagic", "DISEASE", 140, 151], ["brain", "ORGAN", 8, 13], ["SARS-CoV-2", "ORGANISM", 22, 32], ["female", "ORGANISM", 54, 60], ["patient", "ORGANISM", 61, 68], ["lesions", "CANCER", 169, 176], ["thalami", "CANCER", 198, 205], ["medial temporal lobes", "CANCER", 207, 228], ["brain", "ORGAN", 246, 251], ["patient", "SPECIES", 61, 68], ["The MRI brain", "TEST", 0, 13], ["this SARS", "TEST", 17, 26], ["CoV", "TEST", 27, 30], ["cough", "PROBLEM", 93, 98], ["fever", "PROBLEM", 100, 105], ["altered mental status", "PROBLEM", 111, 132], ["hemorrhagic rim", "PROBLEM", 140, 155], ["lesions within the bilateral thalami, medial temporal lobes, and sub-insular brain regions", "PROBLEM", 169, 259], ["brain", "ANATOMY", 8, 13], ["cough", "OBSERVATION", 93, 98], ["fever", "OBSERVATION", 100, 105], ["hemorrhagic", "OBSERVATION_MODIFIER", 140, 151], ["rim", "OBSERVATION_MODIFIER", 152, 155], ["lesions", "OBSERVATION", 169, 176], ["bilateral", "ANATOMY_MODIFIER", 188, 197], ["thalami", "ANATOMY", 198, 205], ["medial", "ANATOMY_MODIFIER", 207, 213], ["temporal lobes", "ANATOMY", 214, 228], ["sub", "ANATOMY_MODIFIER", 234, 237], ["insular", "ANATOMY_MODIFIER", 238, 245], ["brain", "ANATOMY", 246, 251], ["regions", "ANATOMY_MODIFIER", 252, 259]]], ["CSF samples resulted negative for bacteria and herpesviruses, but no investigation was performed either for IAV or SARS-CoV-2 presence.", [["CSF samples", "ANATOMY", 0, 11], ["SARS", "DISEASE", 115, 119], ["CSF samples", "ORGANISM_SUBSTANCE", 0, 11], ["herpesviruses", "ORGANISM", 47, 60], ["SARS-CoV-2", "ORGANISM", 115, 125], ["IAV", "SPECIES", 108, 111], ["SARS-CoV", "SPECIES", 115, 123], ["CSF samples", "TEST", 0, 11], ["bacteria", "PROBLEM", 34, 42], ["herpesviruses", "PROBLEM", 47, 60], ["investigation", "TEST", 69, 82], ["IAV", "PROBLEM", 108, 111], ["SARS", "PROBLEM", 115, 119], ["negative for", "UNCERTAINTY", 21, 33]]], ["Bernard-Valnet and colleagues described two patients who developed a meningoencephalitis few days after a diagnosis of SARS-CoV-2 infection.", [["meningoencephalitis", "DISEASE", 69, 88], ["SARS-CoV-2 infection", "DISEASE", 119, 139], ["patients", "ORGANISM", 44, 52], ["SARS-CoV-2", "ORGANISM", 119, 129], ["patients", "SPECIES", 44, 52], ["SARS-CoV-2", "SPECIES", 119, 129], ["a meningoencephalitis", "PROBLEM", 67, 88], ["SARS", "PROBLEM", 119, 123], ["CoV", "PROBLEM", 124, 127], ["2 infection", "PROBLEM", 128, 139], ["meningoencephalitis", "OBSERVATION", 69, 88], ["SARS", "OBSERVATION", 119, 123], ["infection", "OBSERVATION", 130, 139]]], ["At first, their symptoms were the classic ones of COVID-19 patients, including mild respiratory symptoms.", [["respiratory", "ANATOMY", 84, 95], ["respiratory symptoms", "DISEASE", 84, 104], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["their symptoms", "PROBLEM", 10, 24], ["COVID", "TEST", 50, 55], ["mild respiratory symptoms", "PROBLEM", 79, 104], ["mild", "OBSERVATION_MODIFIER", 79, 83], ["respiratory symptoms", "OBSERVATION", 84, 104]]], ["Then, they developed severe neuropsychological symptoms, compatible with viral meningoencephalitis.", [["neuropsychological symptoms", "DISEASE", 28, 55], ["viral meningoencephalitis", "DISEASE", 73, 98], ["severe neuropsychological symptoms", "PROBLEM", 21, 55], ["viral meningoencephalitis", "PROBLEM", 73, 98], ["severe", "OBSERVATION_MODIFIER", 21, 27], ["compatible with", "UNCERTAINTY", 57, 72], ["viral meningoencephalitis", "OBSERVATION", 73, 98]]], ["However, no viruses, including SARS-CoV-2, were detected in their CSF samples (Bernard-Valnet et al. 2020) .", [["CSF samples", "ANATOMY", 66, 77], ["SARS-CoV-2", "ORGANISM", 31, 41], ["CSF samples", "ORGANISM_SUBSTANCE", 66, 77], ["SARS-CoV", "SPECIES", 31, 39], ["SARS-CoV", "SPECIES", 31, 39], ["viruses", "PROBLEM", 12, 19], ["SARS", "PROBLEM", 31, 35], ["CoV", "TEST", 36, 39], ["no", "UNCERTAINTY", 9, 11], ["viruses", "OBSERVATION", 12, 19]]], ["Another case was reported in Iran, where a hospitalized 79-year-old male, with history of fever and cough and positive for SARS-CoV-2, entered in a semi-conscious state probably due to a massive intracerebral hemorrhage in the right hemisphere with intraventricular and subarachnoid extension, as revealed with computed tomography scan.", [["intracerebral", "ANATOMY", 195, 208], ["right hemisphere", "ANATOMY", 227, 243], ["intraventricular", "ANATOMY", 249, 265], ["subarachnoid", "ANATOMY", 270, 282], ["fever", "DISEASE", 90, 95], ["cough", "DISEASE", 100, 105], ["SARS", "DISEASE", 123, 127], ["intracerebral hemorrhage", "DISEASE", 195, 219], ["male", "ORGANISM", 68, 72], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 195, 208], ["SARS-CoV", "SPECIES", 123, 131], ["fever", "PROBLEM", 90, 95], ["cough", "PROBLEM", 100, 105], ["SARS", "PROBLEM", 123, 127], ["CoV", "TEST", 128, 131], ["a massive intracerebral hemorrhage in the right hemisphere", "PROBLEM", 185, 243], ["intraventricular and subarachnoid extension", "PROBLEM", 249, 292], ["computed tomography scan", "TEST", 311, 335], ["fever", "OBSERVATION", 90, 95], ["cough", "OBSERVATION", 100, 105], ["probably due to", "UNCERTAINTY", 169, 184], ["massive", "OBSERVATION_MODIFIER", 187, 194], ["intracerebral", "OBSERVATION_MODIFIER", 195, 208], ["hemorrhage", "OBSERVATION", 209, 219], ["right", "ANATOMY_MODIFIER", 227, 232], ["hemisphere", "ANATOMY_MODIFIER", 233, 243], ["intraventricular", "ANATOMY_MODIFIER", 249, 265], ["subarachnoid extension", "OBSERVATION", 270, 292]]], ["The authors did not report results from CSF analysis, but just hypothesized that SARS-CoV-2 may directly invades the CNS via the olfactory receptors of cranial nerve I in the nasal cavity cell membrane (Sharifi-Razavi et al. 2020 ).", [["CNS", "ANATOMY", 117, 120], ["olfactory", "ANATOMY", 129, 138], ["cranial nerve", "ANATOMY", 152, 165], ["nasal cavity cell membrane", "ANATOMY", 175, 201], ["SARS", "DISEASE", 81, 85], ["CSF", "ORGANISM_SUBSTANCE", 40, 43], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 81, 91], ["CNS", "ANATOMICAL_SYSTEM", 117, 120], ["cranial nerve I", "GENE_OR_GENE_PRODUCT", 152, 167], ["cell membrane", "CELLULAR_COMPONENT", 188, 201], ["olfactory receptors", "PROTEIN", 129, 148], ["cranial nerve I", "PROTEIN", 152, 167], ["CSF analysis", "TEST", 40, 52], ["CNS", "ANATOMY", 117, 120], ["cranial nerve", "ANATOMY", 152, 165], ["nasal cavity", "ANATOMY", 175, 187], ["cell membrane", "OBSERVATION", 188, 201]]], ["Dogan and colleagues documented 6 cases of SARS-COV2-related autoimmune meningoencephalitis among the 29 most severely affected COVID-19 patients (intubated) of the 332 ones admitted to their center.", [["SARS-COV2", "DISEASE", 43, 52], ["autoimmune meningoencephalitis", "DISEASE", 61, 91], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["SARS", "PROBLEM", 43, 47], ["COV2", "PROBLEM", 48, 52], ["autoimmune meningoencephalitis", "PROBLEM", 61, 91], ["autoimmune meningoencephalitis", "OBSERVATION", 61, 91]]], ["Despite CSF samples did not show the occurrence of active CNS infection, including SARS-CoV-2, clinical tests evidenced increased levels of acuteinflammation (high ferritin, fibrinogen, CRP, and IL-6 in sera) and bilateral cerebral inflammation compatible with meningoencephalitis on MRI (Dogan et al. 2020) .Neurological implicationsVery recently, Pilotto and colleagues described the case of a SARS-CoV-2-positive 60-year-old Italian patient with a transient akinetic mutism due to encephalitis.", [["CSF samples", "ANATOMY", 8, 19], ["CNS", "ANATOMY", 58, 61], ["sera", "ANATOMY", 203, 207], ["cerebral", "ANATOMY", 223, 231], ["CNS infection", "DISEASE", 58, 71], ["cerebral inflammation", "DISEASE", 223, 244], ["meningoencephalitis", "DISEASE", 261, 280], ["akinetic mutism", "DISEASE", 461, 476], ["encephalitis", "DISEASE", 484, 496], ["CSF samples", "ORGANISM_SUBSTANCE", 8, 19], ["CNS", "ANATOMICAL_SYSTEM", 58, 61], ["ferritin", "GENE_OR_GENE_PRODUCT", 164, 172], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 174, 184], ["CRP", "GENE_OR_GENE_PRODUCT", 186, 189], ["IL-6", "GENE_OR_GENE_PRODUCT", 195, 199], ["sera", "ORGANISM_SUBSTANCE", 203, 207], ["cerebral", "ORGAN", 223, 231], ["SARS-CoV-2", "ORGANISM", 396, 406], ["patient", "ORGANISM", 436, 443], ["ferritin", "PROTEIN", 164, 172], ["fibrinogen", "PROTEIN", 174, 184], ["CRP", "PROTEIN", 186, 189], ["IL-6", "PROTEIN", 195, 199], ["patient", "SPECIES", 436, 443], ["SARS-CoV", "SPECIES", 83, 91], ["CSF samples", "TEST", 8, 19], ["active CNS infection", "PROBLEM", 51, 71], ["SARS-CoV", "TEST", 83, 91], ["clinical tests", "TEST", 95, 109], ["increased levels of acuteinflammation", "PROBLEM", 120, 157], ["high ferritin", "PROBLEM", 159, 172], ["fibrinogen", "TEST", 174, 184], ["CRP", "TEST", 186, 189], ["IL", "TEST", 195, 197], ["bilateral cerebral inflammation", "PROBLEM", 213, 244], ["meningoencephalitis", "PROBLEM", 261, 280], ["MRI", "TEST", 284, 287], ["Neurological implications", "PROBLEM", 309, 334], ["a SARS", "TEST", 394, 400], ["CoV", "TEST", 401, 404], ["a transient akinetic mutism", "PROBLEM", 449, 476], ["encephalitis", "PROBLEM", 484, 496], ["active", "OBSERVATION_MODIFIER", 51, 57], ["CNS", "ANATOMY", 58, 61], ["infection", "OBSERVATION", 62, 71], ["increased", "OBSERVATION_MODIFIER", 120, 129], ["bilateral", "ANATOMY_MODIFIER", 213, 222], ["cerebral", "ANATOMY", 223, 231], ["inflammation", "OBSERVATION", 232, 244], ["compatible with", "UNCERTAINTY", 245, 260], ["meningoencephalitis", "OBSERVATION", 261, 280], ["akinetic", "OBSERVATION_MODIFIER", 461, 469], ["mutism", "OBSERVATION", 470, 476], ["encephalitis", "OBSERVATION", 484, 496]]], ["The analysis of CSF, negative for several neurotropic viruses such as herpes (HSV-1 and 2, HHV-6, HHV-8, EBV, VZV), adenovirus, enterovirus, and Sars-CoV-2, revealed the high presence of proinflammatory cytokines, such as IL-6, TNF-\u03b1, IL-8, and pleocytosis, suggesting a possible cytokine-mediated hyperinflammation response to SARS-COV2 infection (Pilotto et al. 2020) .", [["herpes", "DISEASE", 70, 76], ["pleocytosis", "DISEASE", 245, 256], ["SARS-COV2 infection", "DISEASE", 328, 347], ["CSF", "GENE_OR_GENE_PRODUCT", 16, 19], ["herpes", "ORGANISM", 70, 76], ["HSV-1", "ORGANISM", 78, 83], ["2", "GENE_OR_GENE_PRODUCT", 88, 89], ["HHV-6", "ORGANISM", 91, 96], ["HHV-8", "ORGANISM", 98, 103], ["EBV", "ORGANISM", 105, 108], ["VZV", "ORGANISM", 110, 113], ["adenovirus", "ORGANISM", 116, 126], ["enterovirus", "ORGANISM", 128, 139], ["Sars-CoV-2", "ORGANISM", 145, 155], ["IL-6", "GENE_OR_GENE_PRODUCT", 222, 226], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 228, 233], ["IL-8", "GENE_OR_GENE_PRODUCT", 235, 239], ["SARS-COV2", "ORGANISM", 328, 337], ["CSF", "PROTEIN", 16, 19], ["proinflammatory cytokines", "PROTEIN", 187, 212], ["IL-6", "PROTEIN", 222, 226], ["TNF", "PROTEIN", 228, 231], ["IL-8", "PROTEIN", 235, 239], ["cytokine", "PROTEIN", 280, 288], ["HSV-1", "SPECIES", 78, 83], ["Sars-CoV", "SPECIES", 145, 153], ["HSV-1", "SPECIES", 78, 83], ["EBV", "SPECIES", 105, 108], ["VZV", "SPECIES", 110, 113], ["adenovirus", "SPECIES", 116, 126], ["Sars-CoV", "SPECIES", 145, 153], ["The analysis of CSF", "TEST", 0, 19], ["several neurotropic viruses", "PROBLEM", 34, 61], ["herpes", "TEST", 70, 76], ["HSV", "TEST", 78, 81], ["HHV", "TEST", 91, 94], ["HHV", "TEST", 98, 101], ["EBV", "TEST", 105, 108], ["VZV", "TEST", 110, 113], ["adenovirus", "PROBLEM", 116, 126], ["enterovirus", "PROBLEM", 128, 139], ["Sars-CoV", "TEST", 145, 153], ["proinflammatory cytokines", "PROBLEM", 187, 212], ["IL", "TEST", 222, 224], ["TNF", "TEST", 228, 231], ["IL", "TEST", 235, 237], ["pleocytosis", "PROBLEM", 245, 256], ["cytokine-mediated hyperinflammation response", "PROBLEM", 280, 324], ["SARS", "PROBLEM", 328, 332], ["COV2 infection", "PROBLEM", 333, 347], ["proinflammatory cytokines", "OBSERVATION", 187, 212], ["pleocytosis", "OBSERVATION", 245, 256]]], ["Interestingly, additional cases have been supported by positive virus detection in CSF.", [["CSF", "ORGANISM_SUBSTANCE", 83, 86], ["positive virus detection in CSF", "PROBLEM", 55, 86], ["positive virus", "OBSERVATION", 55, 69]]], ["Morigughi and colleagues described the occurrence of meningoencephalitis (diagnosis of aseptic encephalitis) in a 24-year-old male patient with SARS-CoV2 RNA positive detection in CSF samples, but not in nasopharyngeal swab.", [["CSF samples", "ANATOMY", 180, 191], ["nasopharyngeal swab", "ANATOMY", 204, 223], ["meningoencephalitis", "DISEASE", 53, 72], ["aseptic encephalitis", "DISEASE", 87, 107], ["SARS", "DISEASE", 144, 148], ["patient", "ORGANISM", 131, 138], ["CoV2", "GENE_OR_GENE_PRODUCT", 149, 153], ["CSF samples", "ORGANISM_SUBSTANCE", 180, 191], ["nasopharyngeal swab", "CANCER", 204, 223], ["patient", "SPECIES", 131, 138], ["meningoencephalitis", "PROBLEM", 53, 72], ["aseptic encephalitis", "PROBLEM", 87, 107], ["SARS", "PROBLEM", 144, 148], ["CoV2 RNA", "PROBLEM", 149, 157], ["CSF samples", "TEST", 180, 191], ["nasopharyngeal swab", "TEST", 204, 223], ["meningoencephalitis", "OBSERVATION", 53, 72], ["aseptic encephalitis", "OBSERVATION", 87, 107], ["nasopharyngeal", "ANATOMY", 204, 218], ["swab", "OBSERVATION", 219, 223]]], ["This man was found unconsciousness and with a stiff neck 9 days after symptom onset (headache, fever, and generalized fatigue at day 1, treated with antiviral and antipyretics under a first diagnosis of influenza; additional symptoms were worsening headache and sore throat at day 5) and experienced a transient generalized seizure during emergency transport to the hospital, and multiple epileptic seizures during emergency hospitalization.", [["neck", "ANATOMY", 52, 56], ["unconsciousness", "DISEASE", 19, 34], ["headache", "DISEASE", 85, 93], ["fever", "DISEASE", 95, 100], ["fatigue", "DISEASE", 118, 125], ["influenza", "DISEASE", 203, 212], ["headache", "DISEASE", 249, 257], ["sore throat", "DISEASE", 262, 273], ["seizure", "DISEASE", 324, 331], ["epileptic seizures", "DISEASE", 389, 407], ["man", "ORGANISM", 5, 8], ["man", "SPECIES", 5, 8], ["unconsciousness", "PROBLEM", 19, 34], ["a stiff neck", "PROBLEM", 44, 56], ["symptom onset", "PROBLEM", 70, 83], ["headache", "PROBLEM", 85, 93], ["fever", "PROBLEM", 95, 100], ["generalized fatigue", "PROBLEM", 106, 125], ["antiviral", "TREATMENT", 149, 158], ["antipyretics", "TREATMENT", 163, 175], ["influenza", "PROBLEM", 203, 212], ["additional symptoms", "PROBLEM", 214, 233], ["worsening headache", "PROBLEM", 239, 257], ["sore throat", "PROBLEM", 262, 273], ["a transient generalized seizure", "PROBLEM", 300, 331], ["multiple epileptic seizures", "PROBLEM", 380, 407], ["emergency hospitalization", "TREATMENT", 415, 440], ["neck", "ANATOMY", 52, 56], ["generalized", "OBSERVATION_MODIFIER", 312, 323], ["seizure", "OBSERVATION", 324, 331], ["multiple", "OBSERVATION_MODIFIER", 380, 388], ["epileptic seizures", "OBSERVATION", 389, 407]]], ["He had high CSF pressure (320mmH 2 O) and no evidence of brain edema.", [["brain", "ANATOMY", 57, 62], ["brain edema", "DISEASE", 57, 68], ["He", "ORGANISM", 0, 2], ["CSF", "ORGANISM_SUBSTANCE", 12, 15], ["brain edema", "PATHOLOGICAL_FORMATION", 57, 68], ["CSF pressure", "TEST", 12, 24], ["brain edema", "PROBLEM", 57, 68], ["high", "OBSERVATION_MODIFIER", 7, 11], ["CSF pressure", "OBSERVATION", 12, 24], ["no evidence of", "UNCERTAINTY", 42, 56], ["brain", "ANATOMY", 57, 62], ["edema", "OBSERVATION", 63, 68]]], ["Further brain MRI revealed right lateral ventriculitis and encephalitis mainly on right mesial lobe and hippocampus and panparanasal sinusitis.", [["brain", "ANATOMY", 8, 13], ["right lateral ventriculitis", "ANATOMY", 27, 54], ["right mesial lobe", "ANATOMY", 82, 99], ["hippocampus", "ANATOMY", 104, 115], ["panparanasal sinusitis", "ANATOMY", 120, 142], ["right lateral ventriculitis", "DISEASE", 27, 54], ["encephalitis", "DISEASE", 59, 71], ["panparanasal sinusitis", "DISEASE", 120, 142], ["brain", "ORGAN", 8, 13], ["mesial lobe", "MULTI-TISSUE_STRUCTURE", 88, 99], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 104, 115], ["panparanasal sinusitis", "CANCER", 120, 142], ["Further brain MRI", "TEST", 0, 17], ["right lateral ventriculitis", "PROBLEM", 27, 54], ["encephalitis", "PROBLEM", 59, 71], ["right mesial lobe", "PROBLEM", 82, 99], ["hippocampus", "PROBLEM", 104, 115], ["panparanasal sinusitis", "PROBLEM", 120, 142], ["right", "ANATOMY_MODIFIER", 27, 32], ["lateral", "ANATOMY_MODIFIER", 33, 40], ["ventriculitis", "OBSERVATION", 41, 54], ["encephalitis", "OBSERVATION", 59, 71], ["right mesial lobe", "ANATOMY", 82, 99], ["hippocampus", "ANATOMY", 104, 115], ["panparanasal", "OBSERVATION_MODIFIER", 120, 132], ["sinusitis", "OBSERVATION", 133, 142]]], ["Authors claimed that the symptoms of encephalitis and cerebropathia should be considered as first indication, as the respiratory ones, for the diagnosis of hidden COVID-19 patients, and suggest the importance to pay attention to nasal and paranasal condition in the diagnosis and treatment for SARS-CoV-2 (Moriguchi et al. 2020 ).Neurological implicationsHuang and colleagues, by updating what described by Duong and colleagues (Duong et al. 2020) , also reported a case of SARS-CoV2 encephalitis (first CSF analysis negative for herpesviruses and other microbes, subsequent CSF analysis positive for SARS-COV2) in a US 41-year-old woman with some comorbidities (type 2 diabetes mellitus and obesity) whose nasopharyngeal swab on hospital admission was positive for SARS-CoV-2 and negative for influenza A and B viruses.", [["respiratory", "ANATOMY", 117, 128], ["nasal", "ANATOMY", 229, 234], ["paranasal", "ANATOMY", 239, 248], ["nasopharyngeal swab", "ANATOMY", 707, 726], ["encephalitis", "DISEASE", 37, 49], ["cerebropathia", "DISEASE", 54, 67], ["SARS", "DISEASE", 294, 298], ["SARS-CoV2 encephalitis", "DISEASE", 474, 496], ["SARS-COV2", "DISEASE", 601, 610], ["type 2 diabetes mellitus", "DISEASE", 663, 687], ["obesity", "DISEASE", 692, 699], ["influenza A and B viruses", "DISEASE", 794, 819], ["cerebropathia", "CANCER", 54, 67], ["patients", "ORGANISM", 172, 180], ["nasal", "ORGANISM_SUBDIVISION", 229, 234], ["paranasal", "ORGAN", 239, 248], ["SARS-CoV2 encephalitis", "ORGANISM", 474, 496], ["herpesviruses", "ORGANISM", 530, 543], ["woman", "ORGANISM", 632, 637], ["nasopharyngeal swab", "ORGAN", 707, 726], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 766, 776], ["influenza A", "ORGANISM", 794, 805], ["B viruses", "ORGANISM", 810, 819], ["patients", "SPECIES", 172, 180], ["woman", "SPECIES", 632, 637], ["SARS-CoV", "SPECIES", 294, 302], ["SARS-CoV2 encephalitis", "SPECIES", 474, 496], ["SARS-CoV", "SPECIES", 766, 774], ["influenza A", "SPECIES", 794, 805], ["the symptoms", "PROBLEM", 21, 33], ["encephalitis", "PROBLEM", 37, 49], ["cerebropathia", "PROBLEM", 54, 67], ["nasal and paranasal condition", "PROBLEM", 229, 258], ["treatment", "TREATMENT", 280, 289], ["SARS", "PROBLEM", 294, 298], ["Neurological implications", "PROBLEM", 330, 355], ["SARS", "PROBLEM", 474, 478], ["CoV2 encephalitis", "PROBLEM", 479, 496], ["first CSF analysis", "TEST", 498, 516], ["herpesviruses", "PROBLEM", 530, 543], ["other microbes", "PROBLEM", 548, 562], ["CSF analysis", "TEST", 575, 587], ["SARS", "PROBLEM", 601, 605], ["some comorbidities", "PROBLEM", 643, 661], ["type 2 diabetes mellitus", "PROBLEM", 663, 687], ["obesity)", "PROBLEM", 692, 700], ["nasopharyngeal swab", "TEST", 707, 726], ["SARS", "PROBLEM", 766, 770], ["CoV", "TEST", 771, 774], ["influenza", "PROBLEM", 794, 803], ["B viruses", "PROBLEM", 810, 819], ["encephalitis", "OBSERVATION", 37, 49], ["paranasal", "ANATOMY", 239, 248], ["nasopharyngeal", "ANATOMY", 707, 721]]], ["This woman presented fever, headache, and new seizure onset and experienced no respiratory distress nor potential virus-induced abnormalities in other organs.", [["respiratory", "ANATOMY", 79, 90], ["organs", "ANATOMY", 151, 157], ["fever", "DISEASE", 21, 26], ["headache", "DISEASE", 28, 36], ["seizure", "DISEASE", 46, 53], ["respiratory distress", "DISEASE", 79, 99], ["woman", "ORGANISM", 5, 10], ["organs", "ORGAN", 151, 157], ["woman", "SPECIES", 5, 10], ["fever", "PROBLEM", 21, 26], ["headache", "PROBLEM", 28, 36], ["new seizure onset", "PROBLEM", 42, 59], ["respiratory distress", "PROBLEM", 79, 99], ["potential virus", "PROBLEM", 104, 119], ["induced abnormalities in other organs", "PROBLEM", 120, 157], ["fever", "OBSERVATION", 21, 26], ["new", "OBSERVATION_MODIFIER", 42, 45], ["seizure", "OBSERVATION", 46, 53], ["no", "UNCERTAINTY", 76, 78], ["respiratory", "ANATOMY", 79, 90], ["distress", "OBSERVATION", 91, 99], ["virus", "OBSERVATION", 114, 119], ["abnormalities", "OBSERVATION", 128, 141], ["organs", "ANATOMY", 151, 157]]], ["Neurologically, she had hallucination and disorientation, followed by lethargic status but gradually improved after hydrochlorine treatment up to showing no neurologic symptoms within by day 12 of hospitalization (Huang et al. 2020b ).Kawasaki outbreaks during COVID-19Although clinical manifestations of COVID-19 children were generally less severe than those of adult patients, young children, particularly infants, were vulnerable to SARS-CoV-2 infection.", [["neurologic", "ANATOMY", 157, 167], ["hallucination", "DISEASE", 24, 37], ["disorientation", "DISEASE", 42, 56], ["hydrochlorine", "CHEMICAL", 116, 129], ["Kawasaki outbreaks", "DISEASE", 235, 253], ["SARS-CoV-2 infection", "DISEASE", 437, 457], ["hydrochlorine", "CHEMICAL", 116, 129], ["hydrochlorine", "SIMPLE_CHEMICAL", 116, 129], ["children", "ORGANISM", 314, 322], ["patients", "ORGANISM", 370, 378], ["children", "ORGANISM", 386, 394], ["infants", "ORGANISM", 409, 416], ["SARS-CoV-2", "ORGANISM", 437, 447], ["children", "SPECIES", 314, 322], ["patients", "SPECIES", 370, 378], ["children", "SPECIES", 386, 394], ["infants", "SPECIES", 409, 416], ["SARS-CoV", "SPECIES", 437, 445], ["hallucination", "PROBLEM", 24, 37], ["disorientation", "PROBLEM", 42, 56], ["lethargic status", "PROBLEM", 70, 86], ["hydrochlorine treatment", "TREATMENT", 116, 139], ["neurologic symptoms", "PROBLEM", 157, 176], ["Kawasaki outbreaks", "PROBLEM", 235, 253], ["SARS", "PROBLEM", 437, 441], ["2 infection", "PROBLEM", 446, 457], ["infection", "OBSERVATION", 448, 457]]], ["In children, the respiratory involvement appears to have a more benign course, with almost no fatalities reported in this age group (Dong et al. 2020; Nicastro et al. 2020; Yonker et al. 2020) .Kawasaki outbreaks during COVID-19However, as observed in adults, also in children, the respiratory tract seems not to be the only system susceptible to SARS-CoV-2 infection , and the tissue damage during COVID-19 is mostly mediated by the host innate immunity and by a cytokine storm (D'Antiga 2020; Henderson et al. 2020; Mehta et al. 2020 ).", [["respiratory", "ANATOMY", 17, 28], ["respiratory tract", "ANATOMY", 282, 299], ["tissue", "ANATOMY", 378, 384], ["Kawasaki outbreaks", "DISEASE", 194, 212], ["respiratory tract", "DISEASE", 282, 299], ["SARS", "DISEASE", 347, 351], ["infection", "DISEASE", 358, 367], ["COVID-19", "CHEMICAL", 399, 407], ["COVID-19", "CHEMICAL", 399, 407], ["children", "ORGANISM", 3, 11], ["children", "ORGANISM", 268, 276], ["respiratory tract", "ORGANISM_SUBDIVISION", 282, 299], ["SARS-CoV-2", "ORGANISM", 347, 357], ["tissue", "TISSUE", 378, 384], ["cytokine", "PROTEIN", 464, 472], ["children", "SPECIES", 3, 11], ["children", "SPECIES", 268, 276], ["SARS-CoV-2", "SPECIES", 347, 357], ["the respiratory tract", "PROBLEM", 278, 299], ["SARS", "PROBLEM", 347, 351], ["CoV-2 infection", "PROBLEM", 352, 367], ["the tissue damage", "PROBLEM", 374, 391], ["COVID", "TEST", 399, 404], ["respiratory", "ANATOMY", 17, 28], ["respiratory tract", "ANATOMY", 282, 299], ["infection", "OBSERVATION", 358, 367], ["tissue", "ANATOMY", 378, 384], ["damage", "OBSERVATION", 385, 391]]], ["Kawasaki disease is an acute and typically self-limiting vasculitis, which almost exclusively interest children (Kawasaki et al. 1974) .", [["Kawasaki disease", "DISEASE", 0, 16], ["vasculitis", "DISEASE", 57, 67], ["children", "ORGANISM", 103, 111], ["children", "SPECIES", 103, 111], ["Kawasaki disease", "PROBLEM", 0, 16], ["an acute", "PROBLEM", 20, 28], ["self-limiting vasculitis", "PROBLEM", 43, 67], ["disease", "OBSERVATION", 9, 16], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["self-limiting", "OBSERVATION_MODIFIER", 43, 56], ["vasculitis", "OBSERVATION", 57, 67]]], ["Patients with Kawasaki disease, during the acute phase, might have instability at hemodynamic level, a condition known as Kawasaki disease shock syndrome (KDSS) (Kanegaye et al. 2009 ).", [["Kawasaki disease", "DISEASE", 14, 30], ["Kawasaki disease shock syndrome", "DISEASE", 122, 153], ["KDSS", "DISEASE", 155, 159], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["Kawasaki disease", "PROBLEM", 14, 30], ["instability at hemodynamic level", "PROBLEM", 67, 99], ["Kawasaki disease shock syndrome", "PROBLEM", 122, 153], ["Kawasaki disease", "OBSERVATION", 14, 30], ["instability", "OBSERVATION", 67, 78]]], ["Other patients with Kawasaki disease might present macrophage activation syndrome (MAS) .", [["macrophage", "ANATOMY", 51, 61], ["Kawasaki disease", "DISEASE", 20, 36], ["MAS", "DISEASE", 83, 86], ["patients", "ORGANISM", 6, 14], ["macrophage", "CELL", 51, 61], ["patients", "SPECIES", 6, 14], ["Kawasaki disease", "PROBLEM", 20, 36], ["macrophage activation syndrome", "PROBLEM", 51, 81], ["Kawasaki disease", "OBSERVATION", 20, 36], ["macrophage activation syndrome", "OBSERVATION", 51, 81]]], ["The cause of Kawasaki disease remains unknown although the most accredited hypothesis supports an aberrant response of the immune system to one or more unidentified pathogens in genetically predisposed patients (Rowley 2018; Shulman and Rowley 2015) .", [["immune system", "ANATOMY", 123, 136], ["Kawasaki disease", "DISEASE", 13, 29], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 202, 210], ["Kawasaki disease", "PROBLEM", 13, 29], ["an aberrant response of the immune system", "PROBLEM", 95, 136], ["Kawasaki disease", "OBSERVATION", 13, 29], ["aberrant", "OBSERVATION", 98, 106], ["pathogens", "OBSERVATION", 165, 174]]], ["In Japan, during three epidemics in 1979, 1982, and 1986 , the highest Kawasaki disease incidence was reported in January, suggesting that factors, during winter months, could trigger Kawasaki disease.", [["Kawasaki disease", "DISEASE", 71, 87], ["Kawasaki disease", "DISEASE", 184, 200], ["Kawasaki disease", "PROBLEM", 184, 200]]], ["During the SARS-CoV-2 pandemic in Italy, as reported by Verdoni and colleagues, a high number of Kawasaki-like disease cases (features of patients with Kawasaki disease diagnosed during the COVID-19 pandemic appeared to differ from canonical cohort of Kawasaki patients) occurred after the first case of COVID-19 diagnosed in Bergamo, with a monthly incidence at least 30 times greater than the monthly incidence of the previous 5 years (Verdoni et al. 2020) .Kawasaki outbreaks during COVID-19In the past 20 years, it has been proposed that viruses of the CoVs family may be implicated in the pathogenesis of Kawasaki disease.", [["SARS-CoV-2 pandemic", "DISEASE", 11, 30], ["Kawasaki-like disease", "DISEASE", 97, 118], ["Kawasaki disease", "DISEASE", 152, 168], ["Kawasaki", "DISEASE", 252, 260], ["Kawasaki outbreaks", "DISEASE", 460, 478], ["Kawasaki disease", "DISEASE", 610, 626], ["SARS-CoV-2", "ORGANISM", 11, 21], ["Kawasaki-like disease", "CANCER", 97, 118], ["patients", "ORGANISM", 138, 146], ["patients", "ORGANISM", 261, 269], ["CoVs", "GENE_OR_GENE_PRODUCT", 557, 561], ["CoVs family", "PROTEIN", 557, 568], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 261, 269], ["SARS-CoV", "SPECIES", 11, 19], ["Kawasaki-like disease cases", "PROBLEM", 97, 124], ["Kawasaki disease", "PROBLEM", 152, 168], ["the COVID", "TEST", 186, 195], ["Kawasaki disease", "PROBLEM", 610, 626], ["viruses", "OBSERVATION", 542, 549]]], ["In 2005, the New Haven coronavirus (HCoV-NH) has been found in the respiratory secretions of 8 of 11 children with Kawasaki disease versus 22 controls tested (Esper et al. 2005) .", [["respiratory secretions", "ANATOMY", 67, 89], ["HCoV-NH", "CHEMICAL", 36, 43], ["Kawasaki disease", "DISEASE", 115, 131], ["Haven coronavirus", "ORGANISM", 17, 34], ["HCoV-NH", "ORGANISM", 36, 43], ["children", "ORGANISM", 101, 109], ["children", "SPECIES", 101, 109], ["Haven coronavirus", "SPECIES", 17, 34], ["the respiratory secretions", "PROBLEM", 63, 89], ["Kawasaki disease", "PROBLEM", 115, 131], ["respiratory", "ANATOMY", 67, 78], ["secretions", "OBSERVATION", 79, 89]]], ["Skepticism on this association was expressed by a group from Japan, who did a retrospective study on nasopharyngeal swabs from 19 children with Kawasaki disease and 208 controls with respiratory tract infections.", [["nasopharyngeal swabs", "ANATOMY", 101, 121], ["respiratory tract", "ANATOMY", 183, 200], ["Kawasaki disease", "DISEASE", 144, 160], ["respiratory tract infections", "DISEASE", 183, 211], ["nasopharyngeal swabs", "CANCER", 101, 121], ["children", "ORGANISM", 130, 138], ["tract", "ORGANISM_SUBDIVISION", 195, 200], ["children", "SPECIES", 130, 138], ["a retrospective study", "TEST", 76, 97], ["nasopharyngeal swabs", "TREATMENT", 101, 121], ["Kawasaki disease", "PROBLEM", 144, 160], ["respiratory tract infections", "PROBLEM", 183, 211], ["respiratory tract", "ANATOMY", 183, 200], ["infections", "OBSERVATION", 201, 211]]], ["HCoV-NH RNA was found only in 5 of 208 controls versus 0 of 19 children with Kawasaki disease (Ebihara et al. 2005; Esper et al. 2005; Turnier et al. 2015) .", [["Kawasaki disease", "DISEASE", 77, 93], ["HCoV-NH", "GENE_OR_GENE_PRODUCT", 0, 7], ["children", "ORGANISM", 63, 71], ["HCoV-NH RNA", "RNA", 0, 11], ["children", "SPECIES", 63, 71], ["HCoV", "SPECIES", 0, 4], ["Kawasaki disease", "PROBLEM", 77, 93], ["NH RNA", "OBSERVATION", 5, 11]]], ["Another Japanese group explored, by serological tests, the association between HCoV-NL63 and HCoV-229E and Kawasaki disease.", [["Kawasaki disease", "DISEASE", 107, 123], ["HCoV", "GENE_OR_GENE_PRODUCT", 79, 83], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 93, 102], ["HCoV", "PROTEIN", 79, 83], ["HCoV-229E", "SPECIES", 93, 102], ["serological tests", "TEST", 36, 53], ["HCoV", "TEST", 79, 83], ["HCoV", "TEST", 93, 97], ["Kawasaki disease", "PROBLEM", 107, 123], ["Kawasaki disease", "OBSERVATION", 107, 123]]], ["No difference in HCoV-NL63 antibody positivity between patients and controls was detected, whereas a higher HCoV-229E antibody positivity was reported in patients with Kawasaki disease (Shirato et al. 2014) .", [["Kawasaki disease", "DISEASE", 168, 184], ["HCoV-NL63 antibody", "GENE_OR_GENE_PRODUCT", 17, 35], ["patients", "ORGANISM", 55, 63], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 108, 117], ["patients", "ORGANISM", 154, 162], ["HCoV", "PROTEIN", 17, 21], ["NL63 antibody", "PROTEIN", 22, 35], ["HCoV", "PROTEIN", 108, 112], ["229E antibody", "PROTEIN", 113, 126], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 154, 162], ["HCoV", "SPECIES", 17, 21], ["HCoV-229E", "SPECIES", 108, 117], ["HCoV", "TEST", 17, 21], ["NL63 antibody positivity", "TEST", 22, 46], ["a higher HCoV", "TEST", 99, 112], ["229E antibody positivity", "TEST", 113, 137], ["Kawasaki disease", "PROBLEM", 168, 184], ["difference", "OBSERVATION_MODIFIER", 3, 13]]], ["This data suggests that the CoVs family could represent one of the triggers of Kawasaki disease.", [["Kawasaki disease", "DISEASE", 79, 95], ["CoVs", "GENE_OR_GENE_PRODUCT", 28, 32], ["CoVs family", "PROTEIN", 28, 39], ["Kawasaki disease", "PROBLEM", 79, 95], ["Kawasaki disease", "OBSERVATION", 79, 95]]], ["In the study of Verdoni and colleagues, the presence of the virus was confirmed by the antibodies research versus SARS-CoV-2 in 8 of 10 patients affected by Kawasaki disease.", [["Kawasaki disease", "DISEASE", 157, 173], ["SARS-CoV-2", "ORGANISM", 114, 124], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["SARS-CoV", "SPECIES", 114, 122], ["the virus", "PROBLEM", 56, 65], ["the antibodies research", "TEST", 83, 106], ["SARS", "TEST", 114, 118], ["CoV", "TEST", 119, 122], ["Kawasaki disease", "PROBLEM", 157, 173], ["virus", "OBSERVATION", 60, 65], ["Kawasaki disease", "OBSERVATION", 157, 173]]], ["In the remaining two patients, the researchers speculated that confounding factors, such as the serological test performed after an infusion of high-dose immunoglobulins, played a role (Verdoni et al. 2020 ).", [["patients", "ORGANISM", 21, 29], ["high-dose immunoglobulins", "PROTEIN", 144, 169], ["patients", "SPECIES", 21, 29], ["the serological test", "TEST", 92, 112], ["high-dose immunoglobulins", "TREATMENT", 144, 169]]], ["Only 2 of 10 patients presented a naso-oropharyngeal swabs positive for SARS-CoV-2 RNA and the positivity of IgG antibodies.", [["oropharyngeal swabs", "ANATOMY", 39, 58], ["SARS", "DISEASE", 72, 76], ["patients", "ORGANISM", 13, 21], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 72, 82], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 109, 123], ["SARS-CoV-2 RNA", "RNA", 72, 86], ["IgG antibodies", "PROTEIN", 109, 123], ["patients", "SPECIES", 13, 21], ["SARS-CoV", "SPECIES", 72, 80], ["a naso-oropharyngeal swabs", "TEST", 32, 58], ["SARS", "PROBLEM", 72, 76], ["CoV", "TEST", 77, 80], ["IgG antibodies", "TEST", 109, 123], ["oropharyngeal", "ANATOMY", 39, 52]]], ["These findings suggest a late onset of the disease compared with the primary infection.", [["primary infection", "DISEASE", 69, 86], ["the disease", "PROBLEM", 39, 50], ["the primary infection", "PROBLEM", 65, 86], ["late", "OBSERVATION_MODIFIER", 25, 29], ["onset", "OBSERVATION_MODIFIER", 30, 35], ["disease", "OBSERVATION", 43, 50], ["primary", "OBSERVATION_MODIFIER", 69, 76], ["infection", "OBSERVATION", 77, 86]]], ["This could be the reason why, in the past, no active viral infection could be demonstrated in this disease (Verdoni et al. 2020) .", [["viral infection", "DISEASE", 53, 68], ["active viral infection", "PROBLEM", 46, 68], ["no", "UNCERTAINTY", 43, 45], ["active", "OBSERVATION_MODIFIER", 46, 52], ["viral", "OBSERVATION_MODIFIER", 53, 58], ["infection", "OBSERVATION", 59, 68]]], ["All these results and considerations could support the hypothesis that the immune response to SARS-CoV-2 is responsible for a Kawasaki-like disease in susceptible patients.", [["SARS", "DISEASE", 94, 98], ["Kawasaki-like disease", "DISEASE", 126, 147], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 94, 104], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171], ["SARS-CoV", "SPECIES", 94, 102], ["the hypothesis", "PROBLEM", 51, 65], ["SARS", "TEST", 94, 98], ["CoV", "TEST", 99, 102], ["a Kawasaki-like disease", "PROBLEM", 124, 147]]], ["Since patients diagnosed with Kawasaki-like disease after the viral spreading revealed a severe course, including KDSS and MAS, requiring adjunctive steroid treatment, genetic studies, in larger groups, should be done in order to investigate the susceptibility of patients developing this disease to the triggering effect of SARS-CoV-2.Kawasaki outbreaks during COVID-19Funding information Carla Prezioso was supported by Italian Ministry of Health (starting Grant: SG-2018-12366194).Kawasaki outbreaks during COVID-19Data Availibility No datasets were generated during the study.Compliance with ethical standardsCompeting interests The authors declare that they have no competing interests.Compliance with ethical standardsOpen Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.", [["Kawasaki-like disease", "DISEASE", 30, 51], ["MAS", "DISEASE", 123, 126], ["steroid", "CHEMICAL", 149, 156], ["SARS", "DISEASE", 325, 329], ["Kawasaki outbreaks", "DISEASE", 336, 354], ["Kawasaki outbreaks", "DISEASE", 484, 502], ["steroid", "CHEMICAL", 149, 156], ["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 264, 272], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 325, 335], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 264, 272], ["SARS-CoV", "SPECIES", 325, 333], ["Kawasaki-like disease", "PROBLEM", 30, 51], ["the viral spreading", "PROBLEM", 58, 77], ["KDSS", "PROBLEM", 114, 118], ["MAS", "PROBLEM", 123, 126], ["adjunctive steroid treatment", "TREATMENT", 138, 166], ["genetic studies", "TEST", 168, 183], ["this disease", "PROBLEM", 284, 296], ["Kawasaki outbreaks", "PROBLEM", 336, 354], ["the study", "TEST", 570, 579], ["ethical standards", "TREATMENT", 596, 613], ["ethical standards", "TREATMENT", 707, 724], ["Open Access", "TREATMENT", 724, 735], ["severe", "OBSERVATION_MODIFIER", 89, 95]]], ["The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.", [["The images", "TEST", 0, 10]]]], "0c6d1995eb2dd4ab53022495eca8f8ac697fb881": [["IntroductionThe highly polymorphic genes in the major histocompatibility complex (MHC) region are most notably involved in antigen presentation and recognition.", [["major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 48, 80], ["antigen", "GENE_OR_GENE_PRODUCT", 123, 130], ["major histocompatibility complex (MHC) region", "DNA", 48, 93], ["highly", "OBSERVATION_MODIFIER", 16, 22], ["polymorphic genes", "OBSERVATION", 23, 40]]], ["In humans, the classical class I region contains three genes: HLA-A, HLA-B, and HLA-C.", [["humans", "ORGANISM", 3, 9], ["HLA-A", "GENE_OR_GENE_PRODUCT", 62, 67], ["HLA-B", "GENE_OR_GENE_PRODUCT", 69, 74], ["HLA-C.", "GENE_OR_GENE_PRODUCT", 80, 86], ["classical class I region", "DNA", 15, 39], ["HLA-A", "DNA", 62, 67], ["HLA-B", "DNA", 69, 74], ["HLA", "DNA", 80, 83], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["HLA", "TEST", 62, 65], ["HLA", "TEST", 69, 72], ["HLA", "TEST", 80, 83], ["HLA", "ANATOMY", 80, 83]]], ["In macaques, there are only MHC-A and MHC-B orthologues, though there have been complex duplication events within this region, leading to MHC-A and MHC-B haplotypes with copy number variations that encode various combinations of major and minor transcripts as well as multiple pseudogenes (Daza-Vamenta et al. 2004; Fukami-Kobayashi et al. 2005; Watanabe et al. 2007 ).", [["macaques", "ORGANISM", 3, 11], ["MHC-A", "GENE_OR_GENE_PRODUCT", 28, 33], ["MHC-B", "GENE_OR_GENE_PRODUCT", 38, 43], ["MHC-A", "GENE_OR_GENE_PRODUCT", 138, 143], ["MHC-B", "GENE_OR_GENE_PRODUCT", 148, 153], ["MHC", "PROTEIN", 28, 31], ["MHC", "PROTEIN", 38, 41], ["MHC", "PROTEIN", 138, 141], ["MHC", "PROTEIN", 148, 151], ["major and minor transcripts", "RNA", 229, 256], ["macaques", "SPECIES", 3, 11], ["complex duplication events", "PROBLEM", 80, 106], ["major and minor transcripts", "TREATMENT", 229, 256], ["complex", "OBSERVATION_MODIFIER", 80, 87], ["duplication", "OBSERVATION", 88, 99]]], ["The class II region includes six distinct loci, which are the same in humans and macaques: DRA, DRB, DQA1, DQB1, DPA1, and DPB1 .", [["humans", "ORGANISM", 70, 76], ["macaques", "ORGANISM", 81, 89], ["DRA", "GENE_OR_GENE_PRODUCT", 91, 94], ["DRB", "GENE_OR_GENE_PRODUCT", 96, 99], ["DQA1", "GENE_OR_GENE_PRODUCT", 101, 105], ["DQB1", "GENE_OR_GENE_PRODUCT", 107, 111], ["DPA1", "GENE_OR_GENE_PRODUCT", 113, 117], ["DPB1", "GENE_OR_GENE_PRODUCT", 123, 127], ["class II region", "DNA", 4, 19], ["DRA", "DNA", 91, 94], ["DRB", "DNA", 96, 99], ["DQA1", "DNA", 101, 105], ["DQB1", "DNA", 107, 111], ["DPA1", "DNA", 113, 117], ["DPB1", "DNA", 123, 127], ["humans", "SPECIES", 70, 76], ["macaques", "SPECIES", 81, 89], ["humans", "SPECIES", 70, 76], ["DRB", "TREATMENT", 96, 99], ["DQA1", "TEST", 101, 105], ["DQB1", "TEST", 107, 111], ["DPA1", "TREATMENT", 113, 117], ["DPB1", "TREATMENT", 123, 127], ["six", "OBSERVATION_MODIFIER", 29, 32], ["distinct", "OBSERVATION_MODIFIER", 33, 41], ["loci", "OBSERVATION_MODIFIER", 42, 46]]], ["Because macaques are commonly used as models for infectious disease, vaccine, and transplant studies, an emphasis has been placed on characterizing their MHC polymorphisms Shiina and Blancher 2019) .IntroductionResearchers using nonhuman primate (NHP) transplantation models need to control for differences in the MHC genotypes of donor and recipient tissues and often will vary degrees of disparity when testing tolerance therapies (Burwitz et al. 2017; Kean et al. 2012; Shiina and Blancher 2019) .", [["tissues", "ANATOMY", 351, 358], ["infectious disease", "DISEASE", 49, 67], ["macaques", "ORGANISM", 8, 16], ["nonhuman primate", "ORGANISM", 229, 245], ["NHP", "ORGANISM", 247, 250], ["donor", "TISSUE", 331, 336], ["recipient tissues", "TISSUE", 341, 358], ["MHC", "PROTEIN", 154, 157], ["macaques", "SPECIES", 8, 16], ["infectious disease", "PROBLEM", 49, 67], ["vaccine", "TREATMENT", 69, 76], ["transplant studies", "TEST", 82, 100], ["nonhuman primate (NHP)", "TREATMENT", 229, 251], ["transplantation models", "TREATMENT", 252, 274], ["donor and recipient tissues", "TREATMENT", 331, 358], ["testing tolerance therapies", "TREATMENT", 405, 432]]], ["The National Institutes of Health (NIH) has recognized the need for and importance of transplant research conducted in NHP models since many immunomodulatory strategies that Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00251-020-01159-5) contains supplementary material, which is available to authorized users. promote tolerance in rodent models have failed to translate successfully to humans (Knechtle et al. 2019) .", [["humans", "ORGANISM", 437, 443], ["humans", "SPECIES", 437, 443], ["humans", "SPECIES", 437, 443], ["transplant research", "TREATMENT", 86, 105], ["many immunomodulatory strategies", "TREATMENT", 136, 168], ["Electronic supplementary material", "TREATMENT", 174, 207]]], ["This led to the creation of the Nonhuman Primate Transplantation Tolerance Cooperative Study Group, whose goals include the development of novel regimens for immune tolerance induction, as well as understanding the mechanisms responsible for induction, maintenance, and/or loss of tolerance in NHP models of kidney, pancreatic islet, heart, and lung transplantation.", [["kidney", "ANATOMY", 308, 314], ["pancreatic islet", "ANATOMY", 316, 332], ["heart", "ANATOMY", 334, 339], ["lung", "ANATOMY", 345, 349], ["kidney", "ORGAN", 308, 314], ["pancreatic islet", "MULTI-TISSUE_STRUCTURE", 316, 332], ["heart", "ORGAN", 334, 339], ["lung", "ORGAN", 345, 349], ["novel regimens", "TREATMENT", 139, 153], ["immune tolerance induction", "TREATMENT", 158, 184], ["loss of tolerance", "PROBLEM", 273, 290], ["lung transplantation", "TREATMENT", 345, 365], ["kidney", "ANATOMY", 308, 314], ["pancreatic", "ANATOMY", 316, 326], ["islet", "OBSERVATION", 327, 332], ["heart", "ANATOMY", 334, 339], ["lung", "ANATOMY", 345, 349], ["transplantation", "OBSERVATION", 350, 365]]], ["In support of these studies, the NIH has established several breeding colonies in order to provide Indian-origin rhesus macaques, Mauritian-origin cynomolgus macaques (MCM), and Indonesian-origin cynomolgus macaques (ICM) to NHP transplant researchers.", [["colonies", "ANATOMY", 70, 78], ["ICM", "ANATOMY", 217, 220], ["rhesus", "ORGANISM", 113, 119], ["macaques", "ORGANISM", 120, 128], ["cynomolgus", "ORGANISM", 147, 157], ["macaques", "ORGANISM", 158, 166], ["cynomolgus", "ORGANISM", 196, 206], ["macaques", "ORGANISM", 207, 215], ["rhesus macaques", "SPECIES", 113, 128], ["cynomolgus macaques", "SPECIES", 147, 166], ["cynomolgus macaques", "SPECIES", 196, 215], ["rhesus macaques", "SPECIES", 113, 128], ["Mauritian-origin cynomolgus macaques", "SPECIES", 130, 166], ["Indonesian-origin cynomolgus macaques", "SPECIES", 178, 215], ["these studies", "TEST", 14, 27], ["several breeding colonies", "PROBLEM", 53, 78], ["origin", "ANATOMY_MODIFIER", 140, 146], ["cynomolgus macaques", "OBSERVATION", 147, 166], ["cynomolgus macaques", "OBSERVATION", 196, 215]]], ["The MCM population displays extremely restricted MHC diversity with only seven ancestral MHC haplotypes ).", [["MHC", "PROTEIN", 49, 52], ["MHC haplotypes", "PROTEIN", 89, 103], ["extremely", "OBSERVATION_MODIFIER", 28, 37], ["restricted", "OBSERVATION_MODIFIER", 38, 48], ["MHC diversity", "OBSERVATION", 49, 62], ["MHC haplotypes", "OBSERVATION", 89, 103]]], ["This population appears to have originated from a very small number of founding individuals who were introduced to Mauritius in the early 1500s (Lawler et al. 1995; Tosi and Coke 2007) .", [["very", "OBSERVATION_MODIFIER", 50, 54], ["small", "OBSERVATION_MODIFIER", 55, 60], ["number", "OBSERVATION_MODIFIER", 61, 67]]], ["While this restricted genetic diversity of the MCM population makes them extremely valuable for many types of biomedical research, it can be a disadvantage for transplant researchers whose objective is to maximize the amount of MHC disparity between donor and recipient tissues.", [["tissues", "ANATOMY", 270, 277], ["MHC", "GENE_OR_GENE_PRODUCT", 228, 231], ["donor", "TISSUE", 250, 255], ["recipient tissues", "TISSUE", 260, 277], ["MHC", "PROTEIN", 228, 231], ["transplant researchers", "TREATMENT", 160, 182], ["donor and recipient tissues", "TREATMENT", 250, 277], ["recipient tissues", "OBSERVATION", 260, 277]]], ["In contrast, the ICM population displays extensive MHC diversity (Otting et al. 2012) which makes them an ideal NHP model for studies designed to evaluate the preclinical safety and efficacy of immune tolerance induction regimens that may be translated to clinical transplantation.IntroductionA number of investigators have used ICM (Ezzelarab et al. 2016; Zhang et al. 2015) as well as cynomolgus macaques from various other geographic origins (Kato et al. 2017; Matsunami et al. 2019; Shiina and Blancher 2019) for transplantation studies.", [["ICM", "ANATOMY", 17, 20], ["macaques", "ORGANISM", 398, 406], ["MHC", "PROTEIN", 51, 54], ["cynomolgus macaques", "SPECIES", 387, 406], ["cynomolgus macaques", "SPECIES", 387, 406], ["immune tolerance induction regimens", "TREATMENT", 194, 229], ["clinical transplantation", "TREATMENT", 256, 280], ["transplantation studies", "TEST", 517, 540], ["extensive", "OBSERVATION_MODIFIER", 41, 50], ["MHC diversity", "OBSERVATION", 51, 64]]], ["For instance, ICM were used in a study to investigate T cell and alloantibody responses with purposely mismatched donor and recipient pairs (Ezzelarab et al. 2016) .", [["ICM", "ANATOMY", 14, 17], ["T cell", "ANATOMY", 54, 60], ["T cell", "CELL", 54, 60], ["a study", "TEST", 31, 38]]], ["Another study (Morizane et al. 2017 ) utilizing a Filipino cynomolgus macaque model showed that when donor and recipient are matched for MHC genotypes, there are improved outcomes with neural cell grafts.", [["neural cell grafts", "ANATOMY", 185, 203], ["cynomolgus", "ORGANISM", 59, 69], ["macaque", "ORGANISM", 70, 77], ["neural cell grafts", "TISSUE", 185, 203], ["MHC", "PROTEIN", 137, 140], ["cynomolgus macaque", "SPECIES", 59, 77], ["Filipino cynomolgus macaque", "SPECIES", 50, 77], ["Another study", "TEST", 0, 13], ["a Filipino cynomolgus macaque model", "TREATMENT", 48, 83], ["donor and recipient", "TREATMENT", 101, 120], ["MHC genotypes", "PROBLEM", 137, 150], ["neural cell grafts", "TREATMENT", 185, 203], ["improved", "OBSERVATION_MODIFIER", 162, 170], ["neural cell grafts", "OBSERVATION", 185, 203]]], ["Additionally, they observed inflammation in mismatched donor-recipient pairs.", [["inflammation", "DISEASE", 28, 40], ["inflammation in mismatched donor-recipient pairs", "PROBLEM", 28, 76], ["inflammation", "OBSERVATION", 28, 40], ["mismatched donor-recipient pairs", "OBSERVATION", 44, 76]]], ["This indicates that the ability to accurately and efficiently characterize MHC genetics of model species like ICM is and will remain a necessity .IntroductionPrior to this study, several reports have characterized ICM MHC sequence variants.", [["ICM", "ANATOMY", 110, 113], ["ICM", "CANCER", 110, 113], ["MHC", "PROTEIN", 75, 78], ["ICM MHC sequence variants", "DNA", 214, 239], ["model species", "PROBLEM", 91, 104], ["this study", "TEST", 167, 177]]], ["In 2008, 48 novel MHC class I sequences were documented in 42 animals by Sanger sequencing of cDNA clones (Pendley et al. 2008) .", [["MHC class I sequences", "DNA", 18, 39], ["cDNA clones", "DNA", 94, 105]]], ["Likewise, Kita et al. (2009) surveyed 27 cynomolgus macaques of Indonesian descent and identified 34 novel Mafa-A sequences.", [["macaques", "ORGANISM", 52, 60], ["Mafa-A", "CANCER", 107, 113], ["Mafa-A sequences", "DNA", 107, 123], ["cynomolgus macaques", "SPECIES", 41, 60], ["cynomolgus macaques", "SPECIES", 41, 60]]], ["Another study in 2011 (Creager et al. 2011) performed Sanger sequencing of MHC class II cDNA clones from a dozen unrelated ICM and identified 58 new transcript sequences.", [["ICM", "ANATOMY", 123, 126], ["ICM", "CANCER", 123, 126], ["MHC class II cDNA clones", "DNA", 75, 99], ["58 new transcript sequences", "DNA", 142, 169], ["Another study", "TEST", 0, 13], ["new transcript sequences", "TEST", 145, 169]]], ["In the most comprehensive MHC genotyping analysis of ICM to date (Otting et al. 2012 ), Otting and colleagues characterized the class I and class II alleles that are associated with 32 extended MHC haplotypes in 120 ICM from a pedigreed breeding colony at the Biomedical Primate Research Centre (BPRC) in the Netherlands.", [["ICM", "ANATOMY", 216, 219], ["MHC", "PROTEIN", 26, 29], ["class I and class II alleles", "DNA", 128, 156], ["MHC", "PROTEIN", 194, 197]]], ["More recently, these investigators evaluated MHC class II sequences in 79 ICM housed at the same colony that we examined in the present study (Otting et al. 2017) .", [["ICM", "ANATOMY", 74, 77], ["colony", "ANATOMY", 97, 103], ["MHC class II sequences", "DNA", 45, 67]]], ["They identified 22 novel and extended 10 partial Mafa-DQ and Mafa-DP sequences.", [["Mafa-DQ", "GENE_OR_GENE_PRODUCT", 49, 56], ["Mafa-DP", "GENE_OR_GENE_PRODUCT", 61, 68], ["Mafa-DQ and Mafa-DP sequences", "DNA", 49, 78]]], ["Despite these previous studies characterizing ICM MHC sequence variants, we hypothesized that many additional MHC sequences remained to be characterized in this NIH-sponsored ICM breeding colony.IntroductionSeveral years ago, our group introduced the use of Pacific Biosciences (PacBio) single-molecule real-time sequencing to determine full-length MHC class I transcript sequences (Westbrook et al. 2015) .", [["colony", "ANATOMY", 188, 194], ["MHC class I", "GENE_OR_GENE_PRODUCT", 349, 360], ["ICM MHC sequence variants", "DNA", 46, 71], ["MHC sequences", "DNA", 110, 123], ["NIH-sponsored ICM breeding colony", "CELL_LINE", 161, 194], ["Pacific Biosciences", "DNA", 258, 277], ["MHC class I transcript sequences", "DNA", 349, 381], ["these previous studies", "TEST", 8, 30], ["many additional MHC sequences", "PROBLEM", 94, 123], ["Pacific Biosciences", "TREATMENT", 258, 277], ["breeding colony", "OBSERVATION", 179, 194]]], ["Rapid improvements in PacBio circular consensus sequencing technology have made it possible to generate highly accurate sequences of cDNA amplicons from MHC class I and class II transcripts that span complete open reading frames of approximately 1100 bp and 800 bp, respectively (Karl et al. 2014 .", [["MHC class I", "GENE_OR_GENE_PRODUCT", 153, 164], ["class II", "GENE_OR_GENE_PRODUCT", 169, 177], ["cDNA amplicons", "DNA", 133, 147], ["MHC class I and class II transcripts", "RNA", 153, 189], ["open reading frames", "DNA", 209, 228], ["bp", "TEST", 251, 253], ["bp", "TEST", 262, 264]]], ["This sequencing approach has proven useful in investigations of several understudied NHP populations such as Vietnamese, Cambodian, and Cambodian/Indonesian mixed-origin cynomolgus macaques at Chinese breeding centers .", [["cynomolgus", "ORGANISM", 170, 180], ["macaques", "ORGANISM", 181, 189], ["cynomolgus macaques", "SPECIES", 170, 189], ["cynomolgus macaques", "SPECIES", 170, 189], ["This sequencing approach", "TREATMENT", 0, 24]]], ["In a similar study of pig-tailed macaques from multiple breeding centers, PacBio sequencing of MHC class I cDNA amplicons was used to define over 300 novel Mane sequences as well as 192 Mane-A and Mane-B regional haplotypes (Semler et al. 2018) .", [["pig", "ORGANISM", 22, 25], ["macaques", "ORGANISM", 33, 41], ["MHC class I", "GENE_OR_GENE_PRODUCT", 95, 106], ["MHC class I cDNA amplicons", "DNA", 95, 121], ["Mane sequences", "DNA", 156, 170], ["pig", "SPECIES", 22, 25], ["macaques", "SPECIES", 33, 41], ["pig-tailed macaques", "SPECIES", 22, 41], ["a similar study", "TEST", 3, 18], ["pig-tailed macaques", "TREATMENT", 22, 41], ["multiple breeding centers", "TREATMENT", 47, 72], ["cDNA amplicons", "TREATMENT", 107, 121]]], ["Here, we have extended this PacBio circular consensus sequencing approach to full-length cDNA amplicons from MHC class II as well as class I transcripts.IntroductionIn addition to PacBio sequencing, we made use of an extensive database of short tandem repeat (STR) data spanning the 5 Mb MHC region that has been generated over multiple generations of this NIH-sponsored ICM breeding colony (Penedo et al. 2005; Larsen et al. 2010) .", [["MHC class II", "GENE_OR_GENE_PRODUCT", 109, 121], ["class I", "GENE_OR_GENE_PRODUCT", 133, 140], ["cDNA amplicons", "DNA", 89, 103], ["MHC class II", "PROTEIN", 109, 121], ["class I transcripts", "RNA", 133, 152], ["short tandem repeat", "DNA", 239, 258], ["5 Mb MHC region", "DNA", 283, 298], ["this PacBio circular consensus sequencing approach", "TREATMENT", 23, 73], ["full-length cDNA amplicons", "TREATMENT", 77, 103], ["short tandem repeat (STR)", "TREATMENT", 239, 264]]], ["This is analogous to the approach that Otting et al. (Otting et al. 2012 ) employed to characterize extended MHC haplotypes in the BPRC cynomolgus macaque breeding groups.", [["macaque", "ORGANISM", 147, 154], ["MHC", "PROTEIN", 109, 112], ["cynomolgus macaque", "SPECIES", 136, 154], ["BPRC cynomolgus macaque", "SPECIES", 131, 154], ["extended MHC haplotypes", "PROBLEM", 100, 123]]], ["Doxiadis and colleagues (Doxiadis et al. 2013 ) employed a similar experimental strategy combining STR data with Sanger sequencing results in order to characterize the class I and class II transcript content of 176 founder haplotypes in a large breeding colony of rhesus macaques at the BPRC.", [["colony", "ANATOMY", 254, 260], ["rhesus", "ORGANISM", 264, 270], ["macaques", "ORGANISM", 271, 279], ["rhesus macaques", "SPECIES", 264, 279], ["rhesus macaques", "SPECIES", 264, 279], ["Doxiadis", "TREATMENT", 0, 8], ["Sanger sequencing", "TEST", 113, 130], ["large", "OBSERVATION_MODIFIER", 239, 244]]], ["Likewise, a related approach with pyrosequencing was utilized to characterize a closed colony of sooty mangabeys (Cercocebus atys) at the Yerkes National Primate Research Center for which STR data was available (Heimbruch et al. 2015) .", [["sooty", "ORGANISM", 97, 102], ["mangabeys", "ORGANISM", 103, 112], ["Cercocebus atys", "ORGANISM", 114, 129], ["sooty mangabeys", "SPECIES", 97, 112], ["Cercocebus atys", "SPECIES", 114, 129], ["sooty mangabeys", "SPECIES", 97, 112], ["Cercocebus atys", "SPECIES", 114, 129], ["pyrosequencing", "TREATMENT", 34, 48], ["STR data", "TEST", 188, 196], ["closed", "OBSERVATION_MODIFIER", 80, 86], ["colony", "OBSERVATION_MODIFIER", 87, 93], ["sooty mangabeys", "OBSERVATION", 97, 112]]], ["This study yielded 121 novel MHC class I transcript sequences that were assigned to 22 MHC haplotypes that included combinations of both Ceat-A and Ceat-B transcripts.", [["Ceat-A", "GENE_OR_GENE_PRODUCT", 137, 143], ["Ceat-B", "GENE_OR_GENE_PRODUCT", 148, 154], ["MHC class I transcript sequences", "DNA", 29, 61], ["MHC haplotypes", "DNA", 87, 101], ["Ceat-A and Ceat-B transcripts", "RNA", 137, 166], ["This study", "TEST", 0, 10], ["both Ceat", "TREATMENT", 132, 141], ["Ceat", "TREATMENT", 148, 152]]], ["Here, we combine PacBio sequencing with MHC STR patterns to unambiguously assign specific Mafa class I and class II transcripts to the extended MHC haplotypes that are segregating in this pedigreed ICM population.AnimalsAll animals evaluated in this study were members of the NIHsponsored breeding colony at Alpha Genesis Inc. in Yemassee, SC, USA. that houses a cohort of approximately 350 ICM.", [["Mafa class I", "GENE_OR_GENE_PRODUCT", 90, 102], ["class II", "GENE_OR_GENE_PRODUCT", 107, 115], ["MHC STR", "DNA", 40, 47], ["Mafa class I and class II transcripts", "RNA", 90, 127], ["MHC haplotypes", "DNA", 144, 158], ["pedigreed ICM population", "CELL_LINE", 188, 212], ["the extended MHC haplotypes", "TREATMENT", 131, 158], ["this study", "TEST", 245, 255]]], ["This colony was established in 2002 and supplemented with additional groups of breeders in 2005 and 2010.", [["colony", "ANATOMY", 5, 11]]], ["The effective number of founding individuals was 79 for this breeding population.", [["this breeding population", "PROBLEM", 56, 80], ["effective", "OBSERVATION_MODIFIER", 4, 13]]], ["Demographic information about the 293 individuals that were evaluated by sequencing in this study is provided in Supplemental Figure 1 .", [["individuals", "ORGANISM", 38, 49], ["this study", "TEST", 87, 97]]], ["Whole blood samples were obtained during routine health checks from this cohort for sequence analyses.", [["Whole blood samples", "ANATOMY", 0, 19], ["blood samples", "ORGANISM_SUBSTANCE", 6, 19], ["Whole blood samples", "TEST", 0, 19], ["routine health checks", "TEST", 41, 62], ["sequence analyses", "TEST", 84, 101]]], ["These individuals spanned multiple generations which allowed us to use pedigree data to compare multiple offspring from common sires and dams.", [["dams", "ORGANISM_SUBDIVISION", 137, 141], ["pedigree data", "TEST", 71, 84]]], ["All animals were cared for according to the regulations and guidelines of the Institutional Care and Use Committee at Alpha Genesis Inc.STR haplotype patternsSTR analyses were completed as described previously (Penedo et al. 2005; Larsen et al. 2010) to determine parentage and place individuals within the pedigree.", [["STR", "CHEMICAL", 136, 139], ["the Institutional Care", "TREATMENT", 74, 96], ["STR haplotype patternsSTR analyses", "TEST", 136, 170]]], ["Next, STR allele sizes for a panel of 11 STR loci spanning the extended MHC region ( Fig. 1) were compared between full-and half-siblings versus their parents in order to identify shared STR patterns that define the ancestral MHC haplotypes in this colony.", [["colony", "ANATOMY", 249, 255], ["STR allele", "DNA", 6, 16], ["STR loci", "DNA", 41, 49], ["MHC region", "DNA", 72, 82], ["MHC haplotypes", "DNA", 226, 240], ["a panel", "TEST", 27, 34], ["the ancestral MHC haplotypes in this colony", "PROBLEM", 212, 255], ["sizes", "OBSERVATION_MODIFIER", 17, 22], ["ancestral MHC haplotypes", "OBSERVATION", 216, 240]]], ["Based on this analysis, each animal was assigned a pair of MHC haplotype codes, e.g., MHC-MAFA-NIAID1-00001 and MHC-MAFA-NIAID1-00002.", [["MHC-MAFA-NIAID1-00002", "CHEMICAL", 112, 133], ["MHC haplotype codes", "DNA", 59, 78], ["this analysis", "TEST", 9, 22]]], ["Supplemental Figure 2 provides a list of the STR allele patterns that are associated with each of the 100 extended haplotypes that were defined by PacBio sequencing in this study.STR haplotype patternsRNA isolation, cDNA synthesis, and PCR amplification RNA was isolated from whole blood in PAXgene Blood RNA tubes (Qiagen, Venlo, Netherlands) with a Maxwell 16 instrument using Maxwell 16 LEV SimplyRNA Blood kits Figure 3 ).", [["whole blood", "ANATOMY", 276, 287], ["STR", "CHEMICAL", 179, 182], ["LEV", "CHEMICAL", 390, 393], ["blood", "ORGANISM_SUBSTANCE", 282, 287], ["Blood", "ORGANISM_SUBSTANCE", 299, 304], ["STR allele", "DNA", 45, 55], ["the STR allele patterns", "TREATMENT", 41, 64], ["this study", "TEST", 168, 178], ["STR haplotype patternsRNA isolation", "PROBLEM", 179, 214], ["cDNA synthesis", "TREATMENT", 216, 230], ["PCR amplification RNA", "PROBLEM", 236, 257], ["whole blood in PAXgene Blood RNA tubes", "TREATMENT", 276, 314], ["a Maxwell 16 instrument", "TREATMENT", 349, 372], ["RNA tubes", "OBSERVATION", 305, 314]]], ["These 50 \u03bcl reactions included 1 \u03bcl cDNA, 0.1 \u03bcM primers, and Phusion High-Fidelity master mix.", [["1 \u03bcl cDNA", "DNA", 31, 40], ["1 \u03bcl cDNA", "TREATMENT", 31, 40], ["M primers", "TREATMENT", 47, 56], ["Phusion", "TEST", 62, 69]]], ["PCR reactions were run on an Applied Biosystems Thermal Cycler (ThermoFisher Scientific, Waltham, MA, USA) with reaction conditions of 98\u00b0C for 3 min; 23 cycles of 98\u00b0C for 5 s, 60\u00b0C for 10 s, and 72\u00b0C for 20 s; followed by 72\u00b0C for 5 min.", [["PCR reactions", "PROBLEM", 0, 13], ["Thermal Cycler", "TREATMENT", 48, 62]]], ["A similar process was used for MHC class II with a few distinctions (Karl et al. 2014) .", [["MHC class II", "PROTEIN", 31, 43]]], ["First, each of the class II loci required a separate PCR reaction and primers (Supplemental Figure 3 ).", [["class II loci", "DNA", 19, 32], ["a separate PCR reaction", "TREATMENT", 42, 65], ["primers (Supplemental Figure", "TREATMENT", 70, 98]]], ["Additionally, we used 30 PCR cycles instead of 23, but with the same reaction conditions.", [["30 PCR cycles", "TREATMENT", 22, 35]]], ["All PCR products were monitored with FlashGels (Lonza, Basel, Switzerland) to confirm the anticipated length depending on the locus.", [["locus", "CELLULAR_COMPONENT", 126, 131], ["All PCR products", "TREATMENT", 0, 16]]], ["PCR amplicons were then subjected to two rounds of cleanup with the AMPure XP PCR purification kit (Agencourt Bioscience Corporation, Beverly, MA, USA) in a 0.7:1 ratio of beads to PCR sample.", [["PCR amplicons", "DNA", 0, 13], ["PCR amplicons", "TEST", 0, 13], ["cleanup", "TREATMENT", 51, 58], ["the AMPure XP PCR", "TEST", 64, 81], ["PCR sample", "TEST", 181, 191]]], ["Purified amplicons were quantified using Qubit High Sensitivity kits (ThermoFisher Scientific, Waltham, MA, USA).PacBio library preparation and sequencingFor class I, amplicons were normalized to equal concentrations of 10 ng/\u03bcl in pools of 32-48 samples per PacBio library.", [["samples", "ANATOMY", 247, 254], ["PacBio library", "DNA", 259, 273], ["Purified amplicons", "TREATMENT", 0, 18], ["PacBio library preparation", "TREATMENT", 113, 139], ["amplicons", "TEST", 167, 176]]], ["For class II, we pooled 32-48 samples by loci, and each pool was quantified with Qubit High Sensitivity kits.", [["loci", "TEST", 41, 45]]], ["These individual subpools were then combined into a final pool with 500 ng DNA total in the ratio 3 DRB: 1 DQA:PacBio circular consensus sequence analysisRaw sequence data was processed using the SMRT Link v6.0.0 command-line toolset (https://www.pacb.com/ support/software-downloads/).", [["DNA", "CELLULAR_COMPONENT", 75, 78], ["SMRT", "PROTEIN", 196, 200], ["PacBio circular consensus sequence analysis", "TEST", 111, 154], ["Raw sequence data", "TEST", 154, 171]]], ["Briefly, SMRT Link Dataset was run on raw sequencing data to produce a processed XML file.", [["SMRT", "GENE_OR_GENE_PRODUCT", 9, 13], ["SMRT", "PROTEIN", 9, 13], ["sequencing data", "TEST", 42, 57]]], ["The resulting XML file was converted into BAM format containing circular consensus sequences (CCS) using the SMRT Link CCS tool with the minimum and maximum length parameters set to 1000 and 1500 for MHC class I and 700 and 1000 for MHC class II.", [["MHC class II", "GENE_OR_GENE_PRODUCT", 233, 245], ["circular consensus sequences", "DNA", 64, 92], ["SMRT", "PROTEIN", 109, 113], ["MHC class I", "PROTEIN", 200, 211], ["MHC class II", "PROTEIN", 233, 245], ["circular consensus sequences", "TEST", 64, 92], ["maximum length parameters", "TEST", 149, 174]]], ["BAM files were then converted to fastq format using the SMRT Link BAM2FASTQ tool.", [["SMRT", "PROTEIN", 56, 60]]], ["These demultiplexed fastq files are available for download (https://go.wisc.edu/5sq9i9).", [["demultiplexed fastq files", "DNA", 6, 31]]], ["Long Amplicon Analysis (LAA) was run on each demultiplexed fastq file.", [["demultiplexed fastq file", "DNA", 45, 69], ["Long Amplicon Analysis", "TEST", 0, 22]]], ["For both MHC class I and II, the Max_Clustering_ Reads parameter was set to 5000 and Max_reads parameter was set to 20,000.", [["MHC class I", "GENE_OR_GENE_PRODUCT", 9, 20], ["MHC class I and II", "DNA", 9, 27], ["Max_reads parameter", "TEST", 85, 104]]], ["Resulting amplicon sequences were mapped against the most recent library as of each sequencing run of known fulllength Mafa MHC sequences in the NHP Immuno Polymorphism Database (IPD-MHC) using bbmap (http:// sourceforge.net/projects/bbmap/) in semiperfect mode.", [["fulllength Mafa MHC sequences", "DNA", 108, 137], ["bbmap", "PROTEIN", 234, 239], ["Resulting amplicon sequences", "PROBLEM", 0, 28], ["known fulllength Mafa MHC sequences", "PROBLEM", 102, 137]]], ["Fulllength LAA sequences that matched with perfect identity were removed from further analysis, as these represented known alleles.", [["LAA sequences", "DNA", 11, 24], ["alleles", "DNA", 123, 130], ["Fulllength LAA sequences", "TEST", 0, 24], ["further analysis", "TEST", 78, 94]]], ["The remaining LAA sequences were mapped to a library of known partial Mafa MHC sequences using bbmap in semiperfect mode.", [["Mafa MHC", "GENE_OR_GENE_PRODUCT", 70, 78], ["LAA sequences", "DNA", 14, 27], ["Mafa MHC sequences", "DNA", 70, 88]]], ["Sequences that perfectly matched a partial sequence in the database were marked as putative extensions.", [["a partial sequence in the database", "TEST", 33, 67]]], ["Sequences that differed by one or more single nucleotide variants were marked as putative novel alleles.", [["putative novel alleles", "DNA", 81, 103]]], ["Next, reads for each animal were mapped against the database containing putative novels, putative extensions, and known sequences.DNA isolation, multiplex PCR, and Illumina MiSeq analysisGenomic DNAs were isolated from whole blood EDTA samples with a Maxwell 16 instrument using Maxwell 16 LEV Blood DNA kits according to the manufacturer's protocol (Promega, Madison, WI, USA).", [["DNAs", "ANATOMY", 195, 199], ["blood", "ANATOMY", 225, 230], ["samples", "ANATOMY", 236, 243], ["EDTA", "CHEMICAL", 231, 235], ["DNA", "CELLULAR_COMPONENT", 130, 133], ["blood EDTA samples", "ORGANISM_SUBSTANCE", 225, 243], ["Genomic DNAs", "DNA", 187, 199], ["DNA isolation", "TEST", 130, 143], ["multiplex PCR", "TEST", 145, 158], ["Illumina MiSeq analysis", "TEST", 164, 187], ["Genomic DNAs", "PROBLEM", 187, 199], ["whole blood EDTA samples", "TEST", 219, 243], ["Maxwell 16 LEV Blood DNA kits", "TREATMENT", 279, 308], ["the manufacturer's protocol", "TREATMENT", 322, 349]]], ["These genomic DNAs were used as templates for PCR with a panel of primers that flank the highly polymorphic peptide binding domains encoded by exon 2 of class I (Mafa-A, Mafa-B, Mafa-I, Mafa-E) and class II (Mafa-DRB, Mafa-DQA, Mafa-DQB, Mafa-DPA, and Mafa-DPB) loci.", [["DNAs", "CELLULAR_COMPONENT", 14, 18], ["Mafa-A", "GENE_OR_GENE_PRODUCT", 162, 168], ["Mafa-B", "GENE_OR_GENE_PRODUCT", 170, 176], ["Mafa-I", "GENE_OR_GENE_PRODUCT", 178, 184], ["Mafa-E", "GENE_OR_GENE_PRODUCT", 186, 192], ["class II", "GENE_OR_GENE_PRODUCT", 198, 206], ["Mafa-DRB", "GENE_OR_GENE_PRODUCT", 208, 216], ["Mafa-DQA", "GENE_OR_GENE_PRODUCT", 218, 226], ["Mafa-DQB", "GENE_OR_GENE_PRODUCT", 228, 236], ["Mafa-DPA", "GENE_OR_GENE_PRODUCT", 238, 246], ["Mafa-DPB", "GENE_OR_GENE_PRODUCT", 252, 260], ["genomic DNAs", "DNA", 6, 18], ["exon 2", "DNA", 143, 149], ["class I", "DNA", 153, 160], ["Mafa", "DNA", 162, 166], ["A", "DNA", 167, 168], ["Mafa", "DNA", 170, 174], ["B", "DNA", 175, 176], ["Mafa", "DNA", 178, 182], ["I", "DNA", 183, 184], ["Mafa", "DNA", 186, 190], ["E", "DNA", 191, 192], ["class II", "DNA", 198, 206], ["Mafa", "DNA", 208, 212], ["DRB", "DNA", 213, 216], ["Mafa", "DNA", 218, 222], ["DQA", "DNA", 223, 226], ["Mafa", "DNA", 228, 232], ["DQB", "DNA", 233, 236], ["Mafa", "DNA", 238, 242], ["DPA", "DNA", 243, 246], ["Mafa", "DNA", 252, 256], ["DPB", "DNA", 257, 260], ["These genomic DNAs", "PROBLEM", 0, 18], ["PCR", "TEST", 46, 49], ["a panel", "TEST", 55, 62], ["Mafa", "TEST", 162, 166], ["Mafa", "TEST", 170, 174], ["Mafa", "TEST", 178, 182], ["Mafa", "TEST", 186, 190], ["Mafa", "TEST", 208, 212], ["DRB", "TEST", 213, 216], ["Mafa", "TEST", 218, 222], ["DQA", "TEST", 223, 226], ["Mafa", "TEST", 228, 232], ["DQB", "TEST", 233, 236], ["Mafa", "TEST", 238, 242], ["DPA", "TEST", 243, 246], ["Mafa", "TEST", 252, 256], ["Mafa", "ANATOMY", 238, 242], ["Mafa", "ANATOMY", 252, 256], ["DPB", "ANATOMY", 257, 260]]], ["These PCR products were generated with a Fluidigm Access Array 48.48 (Fluidigm, San Francisco, CA, USA) which allows us to multiplex all reactions in a single experiment as described previously (Karl et al. 2014 .", [["These PCR products", "TEST", 0, 18], ["a Fluidigm Access Array", "TEST", 39, 62]]], ["After cleanup and pooling, these amplicons were sequenced on an Illumina MiSeq instrument (Illumina, San Diego, CA, USA).", [["cleanup", "TREATMENT", 6, 13], ["pooling", "PROBLEM", 18, 25], ["these amplicons", "TREATMENT", 27, 42], ["an Illumina MiSeq instrument", "TREATMENT", 61, 89]]], ["The resulting Illumina sequence reads were mapped against a custom reference database of Mafa class I and class II sequences as previously described (Caskey et al. 2019 ).Allele validation and haplotype analysisValidation of novel and extended sequences was a multi-step process.", [["Mafa class I", "GENE_OR_GENE_PRODUCT", 89, 101], ["Illumina sequence reads", "DNA", 14, 37], ["Mafa class I and class II sequences", "DNA", 89, 124], ["Mafa class I", "SPECIES", 89, 101], ["The resulting Illumina sequence reads", "PROBLEM", 0, 37], ["Allele validation", "TEST", 171, 188], ["haplotype analysisValidation", "TEST", 193, 221]]], ["First, we used Geneious (Biomatters, Auckland, New Zealand) software to visualize and confirm that the sequences had the expected start and stop amino acid sequences and that there were not any significant gaps or insertions such that the length was within the expected range for each locus.", [["amino acid", "CHEMICAL", 145, 155], ["amino acid", "CHEMICAL", 145, 155], ["amino acid", "AMINO_ACID", 145, 155], ["the sequences", "TEST", 99, 112], ["amino acid sequences", "TEST", 145, 165], ["any significant gaps", "PROBLEM", 190, 210], ["significant", "OBSERVATION_MODIFIER", 194, 205], ["gaps", "OBSERVATION", 206, 210], ["length", "OBSERVATION_MODIFIER", 239, 245]]], ["Next, we considered the number of PacBio CCS reads that supported a particular sequence relative to other reads in the same animal and compared across related animals.", [["PacBio CCS reads", "RNA", 34, 50], ["a particular sequence", "TEST", 66, 87]]], ["A potential novel allele that was supported by a minimum of three identical CCS reads in one or more animals was considered valid if there were not alleles of the same lineage with better read support within the same animal(s).", [["allele", "DNA", 18, 24], ["CCS reads", "DNA", 76, 85], ["A potential novel allele", "PROBLEM", 0, 24]]], ["These criteria prevent mischaracterization of PCR artifacts and sequencing errors, such as chimeras (Caskey et al. 2019; Fichot and Norman 2013) , as valid new MHC sequences.Allele validation and haplotype analysisMafa class I and class II transcripts that are associated with extended MHC haplotypes in this breeding colony were assigned based on their identification in multiple individuals that share a specific MHC-MAFA-NIAID1 STR pattern.", [["colony", "ANATOMY", 318, 324], ["Mafa class I", "GENE_OR_GENE_PRODUCT", 214, 226], ["class II", "GENE_OR_GENE_PRODUCT", 231, 239], ["MHC sequences", "DNA", 160, 173], ["Mafa class I and class II transcripts", "RNA", 214, 251], ["MHC", "PROTEIN", 286, 289], ["MHC", "PROTEIN", 415, 418], ["NIAID1", "PROTEIN", 424, 430], ["PCR artifacts", "PROBLEM", 46, 59], ["sequencing errors", "PROBLEM", 64, 81], ["Allele validation", "TEST", 174, 191], ["haplotype analysis", "TEST", 196, 214], ["extended MHC haplotypes", "PROBLEM", 277, 300], ["a specific MHC", "TEST", 404, 418]]], ["In a few cases where PacBio class I and/or class II sequencing results were only available for a single individual representing one of the less frequent MHC haplotypes, transcripts that remained after those associated with a more common, shared haplotype had been identified were inferred to segregate with these rare MHC haplotypes.", [["PacBio class I", "GENE_OR_GENE_PRODUCT", 21, 35], ["PacBio class I", "DNA", 21, 35], ["MHC haplotypes", "DNA", 153, 167], ["MHC haplotypes", "DNA", 318, 332], ["the less frequent MHC haplotypes", "PROBLEM", 135, 167]]], ["The Mafa-A, Mafa-B, and Mafa-DRB gene clusters are physically linked with a strong tendency to travel together as regional haplotypes ).", [["Mafa-A", "GENE_OR_GENE_PRODUCT", 4, 10], ["Mafa-B", "GENE_OR_GENE_PRODUCT", 12, 18], ["Mafa-DRB", "GENE_OR_GENE_PRODUCT", 24, 32], ["Mafa-A, Mafa-B, and Mafa-DRB gene clusters", "DNA", 4, 46], ["The Mafa", "TEST", 0, 8], ["Mafa", "TEST", 12, 16], ["Mafa", "ANATOMY", 24, 28]]], ["Since each of these gene clusters is separated by approximately 1 Mb on chromosome 4, however, an occasional recombination event may occur that breaks the linkage between these haplotype blocks.", [["chromosome 4", "ANATOMY", 72, 84], ["chromosome 4", "CELLULAR_COMPONENT", 72, 84], ["chromosome 4", "DNA", 72, 84], ["an occasional recombination event", "PROBLEM", 95, 128], ["clusters", "OBSERVATION_MODIFIER", 25, 33]]], ["To provide a concise description of each of these allele combinations, we developed a series of abbreviated Mafa-A, Mafa-B, and Mafa-DRB haplotype designations .", [["Mafa-A", "GENE_OR_GENE_PRODUCT", 108, 114], ["Mafa-B", "CELL", 116, 122], ["Mafa", "GENE_OR_GENE_PRODUCT", 128, 132], ["Mafa-A, Mafa-B, and Mafa-DRB haplotype designations", "DNA", 108, 159], ["abbreviated Mafa", "TEST", 96, 112], ["Mafa", "TEST", 116, 120], ["Mafa", "ANATOMY", 128, 132], ["DRB haplotype", "OBSERVATION", 133, 146]]], ["The specific Mafa transcript sequences that we have defined for each of these regional haplotypes in the Alpha Genesis breeding colony are summarized in Supplemental Figures 4-6.Results and discussionNovel Mafa transcripts and extensions of partial Mafa sequencesResults and discussionIn the initial phase of this study, we performed MHC class I allele discovery by PacBio circular consensus sequencing of full-length cDNA amplicons from a total of 293 ICM in this breeding colony.", [["ICM", "ANATOMY", 453, 456], ["colony", "ANATOMY", 474, 480], ["Mafa", "GENE_OR_GENE_PRODUCT", 13, 17], ["Mafa transcript sequences", "DNA", 13, 38], ["Mafa transcripts", "RNA", 206, 222], ["Mafa sequences", "DNA", 249, 263], ["MHC class I allele", "DNA", 334, 352], ["cDNA amplicons", "DNA", 418, 432], ["these regional haplotypes", "PROBLEM", 72, 97], ["partial Mafa sequences", "TEST", 241, 263], ["this study", "TEST", 309, 319], ["full-length cDNA amplicons", "TREATMENT", 406, 432], ["Alpha Genesis", "OBSERVATION", 105, 118], ["breeding colony", "OBSERVATION", 119, 134], ["breeding colony", "OBSERVATION", 465, 480]]], ["PacBio sequencing yielded an average of 1668 MHC class I reads per animal that were either identical to known Mafa alleles, extensions of previously described partial Mafa sequences, or validated as novel Mafa allelic variants.", [["Mafa", "GENE_OR_GENE_PRODUCT", 110, 114], ["Mafa", "GENE_OR_GENE_PRODUCT", 167, 171], ["Mafa", "GENE_OR_GENE_PRODUCT", 205, 209], ["MHC class I reads", "DNA", 45, 62], ["Mafa alleles", "DNA", 110, 122], ["Mafa sequences", "DNA", 167, 181], ["Mafa allelic variants", "DNA", 205, 226], ["PacBio sequencing", "TEST", 0, 17]]], ["These novel Mafa transcript sequences differed by one or more synonymous or nonsynonymous nucleotide changes compared with previously reported Mafa sequences available in IPD-MHC (Maccari et al. 2017) .", [["nucleotide", "CHEMICAL", 90, 100], ["Mafa", "GENE_OR_GENE_PRODUCT", 12, 16], ["Mafa transcript sequences", "DNA", 12, 37], ["Mafa sequences", "DNA", 143, 157], ["MHC", "PROTEIN", 175, 178], ["nonsynonymous nucleotide changes", "PROBLEM", 76, 108]]], ["In total, we identified 141 class I sequences in this study (Table 1 For characterization of MHC class II sequences, we adopted a targeted allele discovery strategy that made use of STR profiles for the MHC region that had been used to define extended MHC haplotypes in this ICM breeding colony.", [["colony", "ANATOMY", 288, 294], ["141 class I sequences", "DNA", 24, 45], ["MHC class II sequences", "DNA", 93, 115], ["MHC region", "DNA", 203, 213], ["MHC", "PROTEIN", 252, 255], ["this study", "TEST", 49, 59], ["STR profiles", "TREATMENT", 182, 194], ["the MHC region", "TREATMENT", 199, 213]]], ["Based on knowledge of these STR patterns, we selected 76 representative animals that carried a total of 100 distinct ancestral MHC haplotypes.", [["MHC haplotypes", "DNA", 127, 141], ["MHC haplotypes", "OBSERVATION", 127, 141]]], ["PacBio sequencing was performed with full-length cDNA amplicons for MHC class II loci and yielded a total of 3857 MHC class II reads per animal.", [["cDNA amplicons", "DNA", 49, 63], ["MHC class II loci", "DNA", 68, 85], ["MHC class II reads", "DNA", 114, 132], ["PacBio sequencing", "TEST", 0, 17], ["full-length cDNA amplicons", "TREATMENT", 37, 63]]], ["We identified a total of 61 additional full-length class II sequences.", [["full-length class II sequences", "DNA", 39, 69]]], ["As summarized in Table 1 , 39 of these class II sequences were novel and they included 17 Mafa-DRB, 12 Mafa-DQA1, 4 Mafa-DQB1, 3 Mafa-DPA1, and 3 Mafa-DPB1 allelic variants that have also been deposited in IPD-MHC (Table 1) .Results and discussionDefining transcripts associated with regional and extended MHC haplotypes After characterizing new class I and class II sequences with PacBio sequencing, we turned our efforts to defining the transcripts that are associated with the extended MHC haplotypes that are currently segregating in the Alpha Genesis breeding colony.", [["Mafa-DRB", "GENE_OR_GENE_PRODUCT", 90, 98], ["Mafa-DQA1", "GENE_OR_GENE_PRODUCT", 103, 112], ["Mafa-DQB1", "GENE_OR_GENE_PRODUCT", 116, 125], ["DPA1", "GENE_OR_GENE_PRODUCT", 134, 138], ["DPB1", "GENE_OR_GENE_PRODUCT", 151, 155], ["class II sequences", "DNA", 39, 57], ["DRB", "DNA", 95, 98], ["Mafa", "DNA", 103, 107], ["DQA1", "DNA", 108, 112], ["DQB1", "DNA", 121, 125], ["Mafa-DPA1", "DNA", 129, 138], ["Mafa-DPB1 allelic variants", "DNA", 146, 172], ["MHC", "PROTEIN", 210, 213], ["MHC haplotypes", "PROTEIN", 306, 320], ["class I and class II sequences", "DNA", 346, 376], ["MHC haplotypes", "DNA", 489, 503], ["Alpha Genesis breeding colony", "CELL_LINE", 542, 571], ["Mafa", "TEST", 90, 94], ["Mafa", "TEST", 103, 107], ["DQA1", "TEST", 108, 112], ["Mafa", "TEST", 116, 120], ["DQB1", "TEST", 121, 125], ["Mafa-DPA1", "TEST", 129, 138], ["3 Mafa-DPB1 allelic variants", "TREATMENT", 144, 172], ["regional and extended MHC haplotypes", "PROBLEM", 284, 320], ["PacBio sequencing", "TEST", 382, 399], ["the extended MHC haplotypes", "PROBLEM", 476, 503], ["MHC haplotypes", "OBSERVATION", 306, 320], ["Alpha Genesis", "OBSERVATION", 542, 555], ["breeding colony", "OBSERVATION", 556, 571]]], ["Each of these extended MHC haplotypes has been defined by distinct patterns of allele sizes for a panel of eleven STR markers that span the 5 Mb MHC genomic region Figure 2 ) (Penedo et al. 2005; Larsen et al. 2010) .", [["MHC", "PROTEIN", 23, 26], ["MHC", "PROTEIN", 145, 148], ["allele sizes", "PROBLEM", 79, 91], ["a panel", "TEST", 96, 103], ["eleven STR markers", "PROBLEM", 107, 125], ["sizes", "OBSERVATION_MODIFIER", 86, 91]]], ["As illustrated in Fig. 2 , each extended MHC haplotype in cynomolgus macaques encodes multiple Mafa-A, Mafa-B, and Mafa-DRB transcripts.", [["cynomolgus macaques", "ORGANISM", 58, 77], ["Mafa-A", "GENE_OR_GENE_PRODUCT", 95, 101], ["Mafa-B", "GENE_OR_GENE_PRODUCT", 103, 109], ["Mafa-DRB", "GENE_OR_GENE_PRODUCT", 115, 123], ["MHC haplotype", "DNA", 41, 54], ["Mafa-A, Mafa-B, and Mafa-DRB transcripts", "RNA", 95, 135], ["cynomolgus macaques", "SPECIES", 58, 77], ["cynomolgus macaques", "SPECIES", 58, 77], ["each extended MHC haplotype", "TREATMENT", 27, 54], ["Mafa", "TEST", 95, 99], ["Mafa", "TEST", 103, 107], ["Mafa", "ANATOMY", 115, 119], ["DRB transcripts", "OBSERVATION", 120, 135]]], ["In addition, there is considerable copy number variation between haplotypes as well as a wide range of steady-state RNA levels in whole blood for Mafa-A and Mafa-B transcripts from different loci.", [["whole blood", "ANATOMY", 130, 141], ["blood", "ORGANISM_SUBSTANCE", 136, 141], ["Mafa-A", "GENE_OR_GENE_PRODUCT", 146, 152], ["Mafa-B", "GENE_OR_GENE_PRODUCT", 157, 163], ["Mafa-A and Mafa-B transcripts", "RNA", 146, 175], ["considerable copy number variation between haplotypes", "PROBLEM", 22, 75], ["Mafa", "TEST", 146, 150], ["number", "OBSERVATION_MODIFIER", 40, 46], ["variation", "OBSERVATION_MODIFIER", 47, 56], ["different loci", "OBSERVATION", 181, 195]]], ["In order to describe the complex, high-resolution Mafa genotypes associated with each of the extended MHC haplotypes, we developed an abbreviated, regional haplotype nomenclature system for the Mafa-A, Mafa-B, and Mafa-DRB gene clusters that is similar to MHC allele nomenclature (Fig. 2) .", [["Mafa-A", "GENE_OR_GENE_PRODUCT", 194, 200], ["Mafa-B", "CELL", 202, 208], ["Mafa-DRB", "GENE_OR_GENE_PRODUCT", 214, 222], ["MHC", "PROTEIN", 102, 105], ["Mafa-A, Mafa-B, and Mafa-DRB gene clusters", "DNA", 194, 236], ["MHC allele", "DNA", 256, 266], ["the Mafa", "TEST", 190, 198], ["Mafa", "TEST", 202, 206], ["DRB gene clusters", "PROBLEM", 219, 236], ["Mafa", "ANATOMY", 214, 218]]], ["Each of these regional haplotype designations begins with the species name (Mafa) and a \"diagnostic\" allele lineage for a major transcript that is expressed at high steady-state levels, e.g. A018.", [["regional haplotype", "OBSERVATION", 14, 32]]], ["Regional haplotypes that differ in their combinations of major transcripts are distinguished by a \".\" delimiter followed by two digits in ascending order of their identification in various cynomolgus macaque populations.", [["macaque", "ORGANISM", 200, 207], ["major transcripts", "RNA", 57, 74], ["cynomolgus macaque populations", "CELL_TYPE", 189, 219], ["cynomolgus macaque", "SPECIES", 189, 207], ["cynomolgus macaque", "SPECIES", 189, 207], ["Regional haplotypes", "PROBLEM", 0, 19], ["various cynomolgus macaque populations", "TREATMENT", 181, 219], ["ascending", "ANATOMY_MODIFIER", 138, 147], ["cynomolgus macaque", "OBSERVATION", 189, 207]]], ["A final \".\" delimiter separates closely related haplotypes that share the same major transcript lineages but differ due to nonsynonymous and/or synonymous allelic variants.", [["nonsynonymous and/or synonymous allelic variants", "PROBLEM", 123, 171], ["synonymous allelic variants", "OBSERVATION", 144, 171]]], ["For example, the regional Mafa-A018.01.05 haplotype illustrated in Fig. 2 includes major Mafa-A105:66 transcripts and it represents the fifth combination of allelic variants noted to date.", [["Mafa-A105:66", "GENE_OR_GENE_PRODUCT", 89, 101], ["Mafa", "DNA", 26, 30], ["major Mafa-A105:66 transcripts", "RNA", 83, 113], ["the regional Mafa", "TEST", 13, 30], ["allelic variants", "PROBLEM", 157, 173], ["regional", "ANATOMY_MODIFIER", 17, 25], ["Mafa", "ANATOMY", 26, 30], ["allelic variants", "OBSERVATION", 157, 173]]], ["Using this abbreviated haplotype system, the extended MHC haplotypes defined by the MHC-MAFA-NIAID1-000061 STR pattern can be described by the following string: A018.01.05|B147.04.02|DRBW020.04.02|DQA26_01_01| DQB15_01_02|DPA02_13_02|DPB15_02.Results and discussionGenotyping results for a representative group of four progeny from sire CX7K is presented in Fig. 3 to illustrate how PacBio sequencing data is used to define the Mafa transcripts that are associated with extended MHC haplotypes.", [["Mafa", "GENE_OR_GENE_PRODUCT", 428, 432], ["MHC", "PROTEIN", 54, 57], ["MHC-MAFA-NIAID1", "DNA", 84, 99], ["sire CX7K", "CELL_LINE", 332, 341], ["Mafa transcripts", "RNA", 428, 444], ["MHC", "PROTEIN", 479, 482], ["this abbreviated haplotype system", "TREATMENT", 6, 39], ["the extended MHC haplotypes", "TREATMENT", 41, 68], ["DPB15_02", "TEST", 234, 242], ["PacBio sequencing data", "TEST", 383, 405]]], ["In this example, each of the offspring inherited the same paternal MHC haplotype that is defined by the MHC-MAFA-NIAID1-000048 STR pattern.", [["paternal MHC haplotype", "DNA", 58, 80], ["MHC", "PROTEIN", 104, 107]]], ["The values in the body of Fig. 3 indicate the PacBio sequence read support for each of the class I and class II transcripts that were identified in each animal and color coding denotes the haplotype for each sequence.", [["body", "ANATOMY", 18, 22], ["body", "ORGANISM_SUBDIVISION", 18, 22], ["class II", "GENE_OR_GENE_PRODUCT", 103, 111], ["PacBio sequence", "DNA", 46, 61], ["class I and class II transcripts", "RNA", 91, 123], ["The values", "TEST", 0, 10], ["the PacBio sequence", "TEST", 42, 61]]], ["Transcripts highlighted in yellow are shared by all four of these offspring and thus are assigned to the paternal haplotype that was inherited from the CX7K sire.", [["CX7K sire", "DNA", 152, 161], ["yellow", "OBSERVATION", 27, 33]]], ["The Mafa-B gene cluster of this extended haplotype includes a diagnostic major Mafa-B147:04, Mafa-B027:03:01 transcripts expressed by H592 are designated as the Mafa-B147.04.02 regional haplotype.", [["Mafa-B", "GENE_OR_GENE_PRODUCT", 4, 10], ["Mafa-B027:03:01", "GENE_OR_GENE_PRODUCT", 93, 108], ["H592", "CANCER", 134, 138], ["Mafa-B gene cluster", "DNA", 4, 23], ["Mafa", "DNA", 79, 83], ["B147:04", "DNA", 84, 91], [", Mafa-B027:03:01 transcripts", "RNA", 91, 120], ["H592", "DNA", 134, 138], ["Mafa", "DNA", 161, 165]]], ["This Mafa-B haplotype is one building block of the MHC-MAFA-NIAID1-000061 extended haplotype that was inherited from dam CX95.Results and discussionBy iterating this process with PacBio genotyping results from groups of related animals that share STR patterns from common ancestors, we defined the class I and class II transcripts that are associated with 100 extended MHC haplotypes in this breeding colony as summarized in Table 2 .", [["colony", "ANATOMY", 401, 407], ["Mafa-B", "GENE_OR_GENE_PRODUCT", 5, 11], ["MHC-MAFA-NIAID1", "GENE_OR_GENE_PRODUCT", 51, 66], ["Mafa-B haplotype", "DNA", 5, 21], ["MHC-MAFA-NIAID1-000061 extended haplotype", "DNA", 51, 92], ["dam CX95", "DNA", 117, 125], ["class I and class II transcripts", "RNA", 298, 330], ["MHC", "PROTEIN", 369, 372], ["PacBio genotyping", "TEST", 179, 196]]], ["Supplemental Figures 4-6 provide lists of the Mafa-A, Mafa-B, and Mafa-DRB transcripts that are associated with each of the abbreviated, regional Mafa haplotype designations displayed in Table 2 .", [["Mafa-A", "GENE_OR_GENE_PRODUCT", 46, 52], ["Mafa-B", "GENE_OR_GENE_PRODUCT", 54, 60], ["Mafa-DRB", "GENE_OR_GENE_PRODUCT", 66, 74], ["Mafa-A, Mafa-B, and Mafa-DRB transcripts", "RNA", 46, 86], ["Supplemental Figures", "TREATMENT", 0, 20], ["the Mafa", "TREATMENT", 42, 50], ["DRB transcripts", "PROBLEM", 71, 86], ["Mafa", "ANATOMY", 66, 70], ["DRB transcripts", "OBSERVATION", 71, 86]]], ["Complete PacBio read support per transcript is available for all animals sequenced in this study in Supplemental Figure 8 .", [["this study", "TEST", 86, 96]]], ["In a few cases where PacBio read support was low, these results were augmented with lineagelevel MiSeq genotyping results with exon 2 genomic DNA amplicons as shown in Supplemental Figure 9 .Results and discussionAs a result of these efforts, we identified 70 distinct combinations of Mafa-A transcripts (Supplemental Figure 4) and 78 distinct combinations of Mafa-B transcripts (Supplemental Figure 5 ).", [["DNA", "CELLULAR_COMPONENT", 142, 145], ["Mafa-A", "GENE_OR_GENE_PRODUCT", 285, 291], ["Mafa-B", "GENE_OR_GENE_PRODUCT", 360, 366], ["exon 2 genomic DNA amplicons", "DNA", 127, 155], ["Mafa", "PROTEIN", 285, 289], ["Mafa", "PROTEIN", 360, 364], ["B transcripts", "PROTEIN", 365, 378], ["exon 2 genomic DNA amplicons", "TREATMENT", 127, 155], ["A transcripts (Supplemental Figure", "TREATMENT", 290, 324], ["Mafa-B transcripts (Supplemental Figure", "TREATMENT", 360, 399]]], ["At least 45 combinations of Mafa-DRB transcripts were also observed in this cohort (Supplemental Figure 6 ).", [["Mafa-DRB", "GENE_OR_GENE_PRODUCT", 28, 36], ["Mafa-DRB transcripts", "RNA", 28, 48], ["Mafa-DRB transcripts", "TREATMENT", 28, 48], ["DRB transcripts", "OBSERVATION", 33, 48]]], ["Since Mafa-DQ and Mafa-DP haplotypes each only include single genes for the alpha and beta chains, the individual alleles for these four loci are listed for each extended MHC The majority of the regional Mafa-A, Mafa-B, and Mafa-DRB haplotypes detected in this breeding colony are restricted to one or two extended MHC haplotypes (Supplemental Figures 4-6) .", [["colony", "ANATOMY", 270, 276], ["Mafa-DQ", "GENE_OR_GENE_PRODUCT", 6, 13], ["Mafa-DP", "GENE_OR_GENE_PRODUCT", 18, 25], ["alpha", "GENE_OR_GENE_PRODUCT", 76, 81], ["beta chains", "GENE_OR_GENE_PRODUCT", 86, 97], ["Mafa-A", "GENE_OR_GENE_PRODUCT", 204, 210], ["Mafa-B", "GENE_OR_GENE_PRODUCT", 212, 218], ["Mafa-DRB", "GENE_OR_GENE_PRODUCT", 224, 232], ["Mafa-DQ and Mafa-DP haplotypes", "DNA", 6, 36], ["alpha and beta chains", "PROTEIN", 76, 97], ["MHC", "PROTEIN", 171, 174], ["regional Mafa-A, Mafa-B, and Mafa-DRB haplotypes", "DNA", 195, 243], ["MHC", "PROTEIN", 315, 318], ["Mafa", "TEST", 6, 10], ["the alpha and beta chains", "TREATMENT", 72, 97], ["the regional Mafa", "TEST", 191, 208], ["Mafa", "TEST", 212, 216], ["DRB haplotypes", "PROBLEM", 229, 243], ["this breeding colony", "PROBLEM", 256, 276], ["regional Mafa", "ANATOMY", 195, 208], ["Mafa", "ANATOMY", 224, 228], ["DRB haplotypes", "OBSERVATION", 229, 243]]], ["This observation is consistent with a previous study by Otting and colleagues that characterized 32 multilocus MHC haplotypes for pedigreed cynomolgus macaque breeding groups at the Biomedical Primate Research Center (BPRC) in the Netherlands (Otting et al. 2012) .", [["macaque", "ORGANISM", 151, 158], ["cynomolgus macaque", "SPECIES", 140, 158], ["cynomolgus macaque", "SPECIES", 140, 158], ["a previous study", "TEST", 36, 52], ["pedigreed cynomolgus macaque breeding groups", "TREATMENT", 130, 174], ["consistent with", "UNCERTAINTY", 20, 35]]], ["Several Mafa-A and Mafa-B regional haplotypes are shared by multiple extended haplotypes however and do appear to be somewhat enriched in the Alpha Genesis breeding colony.", [["Mafa-A", "GENE_OR_GENE_PRODUCT", 8, 14], ["Mafa-B", "GENE_OR_GENE_PRODUCT", 19, 25], ["Alpha", "GENE_OR_GENE_PRODUCT", 142, 147], ["Alpha Genesis breeding colony", "CELL_LINE", 142, 171], ["Mafa", "TEST", 8, 12], ["B regional haplotypes", "PROBLEM", 24, 45], ["multiple extended haplotypes", "PROBLEM", 60, 88], ["regional haplotypes", "OBSERVATION", 26, 45], ["somewhat", "OBSERVATION_MODIFIER", 117, 125], ["enriched", "OBSERVATION", 126, 134], ["Alpha Genesis", "OBSERVATION", 142, 155], ["breeding colony", "OBSERVATION", 156, 171]]], ["For example, the Mafa-A004.01.02, Mafa-A010.01.05, and Mafa- Fig. 3 PacBio sequencing results for four of the 293 macaques in this study.", [["Mafa-A010.01.05", "CELL", 34, 49], ["macaques", "ORGANISM", 114, 122], ["macaques", "SPECIES", 114, 122], ["the Mafa", "TEST", 13, 21], ["Mafa", "TEST", 34, 38], ["Mafa", "TEST", 55, 59], ["PacBio sequencing", "TEST", 68, 85], ["this study", "TEST", 126, 136], ["Mafa", "ANATOMY", 17, 21], ["Fig", "OBSERVATION_MODIFIER", 61, 64]]], ["MHC class I results are shown on the left and class II data is on the right side.", [["left", "ANATOMY", 37, 41], ["MHC class I", "PROTEIN", 0, 11], ["left", "ANATOMY_MODIFIER", 37, 41], ["right", "ANATOMY_MODIFIER", 70, 75]]], ["For each macaque, we list the animal ID, sire ID, dam ID, and number reads mapped with PacBio sequencing.", [["macaque", "ORGANISM", 9, 16]]], ["Only major Mafa-B reads are listed for illustrative purposes, but complete data including minor transcripts can be found in Supplemental Figure 8 .", [["major Mafa-B reads", "DNA", 5, 23]]], ["Each of these animals shares a common sire and inherited the paternal haplotype containing the MHC-MAFA-NIAID1-000048 STR pattern (yellow).", [["MHC", "PROTEIN", 95, 98]]], ["Each of the progeny expresses a series of class I and class II transcripts in common (yellow) that are represented by the number of identical PacBio sequences reads that were detected in each animal.", [["PacBio", "GENE_OR_GENE_PRODUCT", 142, 148], ["class I and class II transcripts", "RNA", 42, 74], ["PacBio sequences", "DNA", 142, 158]]], ["These co-segregating transcripts are used to define the abbreviated regional haplotypes listed below the STR profiles.", [["co-segregating transcripts", "RNA", 6, 32], ["the abbreviated regional haplotypes", "PROBLEM", 52, 87]]], ["The remaining transcripts expressed by each animal are highlighted in a different color and inferred to segregate as the maternal haplotype inherited from their respective dams.", [["a different color", "PROBLEM", 70, 87], ["transcripts", "OBSERVATION", 14, 25]]], ["Diagonally shaded boxes indicate that a transcript such as Mafa-B17:01:02 for the extended haplotype defined by the shared MHC-MAFA-NIAID1-000048 STR pattern B013.08.01 haplotypes are each associated with six extended MHC haplotypes (Supplemental Figures 4 and 5) .", [["Mafa-B17:01:02", "GENE_OR_GENE_PRODUCT", 59, 73], ["MHC-MAFA-NIAID1", "GENE_OR_GENE_PRODUCT", 123, 138], ["Mafa", "DNA", 59, 63], ["B17:01:02", "DNA", 64, 73], ["MHC-MAFA-NIAID1", "DNA", 123, 138], ["MHC", "PROTEIN", 218, 221], ["Diagonally shaded boxes", "PROBLEM", 0, 23], ["the extended haplotype", "PROBLEM", 78, 100], ["haplotypes", "PROBLEM", 169, 179], ["six extended MHC haplotypes", "TREATMENT", 205, 232], ["Supplemental Figures", "TEST", 234, 254]]], ["These extended MHC haplotypes do not appear to result from simple recombination events in the class I region that arose in recent ancestors of this breeding colony.", [["colony", "ANATOMY", 157, 163], ["MHC", "PROTEIN", 15, 18], ["class I region", "DNA", 94, 108], ["simple recombination events", "PROBLEM", 59, 86], ["this breeding colony", "PROBLEM", 143, 163]]], ["As illustrated in Fig. 4 , the STR patterns flanking the Mafa-A004.01.02 haplotypes provide evidence of a conserved genomic region that is marked by three to six common telomeric and centromeric STR alleles in four extended MHC haplotypes, but each of these Mafa-A004.01.02 haplotype blocks is linked to distinct Mafa-B and class II haplotypes.", [["Mafa", "GENE_OR_GENE_PRODUCT", 57, 61], ["telomeric", "CELLULAR_COMPONENT", 169, 178], ["centromeric", "CELLULAR_COMPONENT", 183, 194], ["Mafa", "GENE_OR_GENE_PRODUCT", 258, 262], ["Mafa-B", "GENE_OR_GENE_PRODUCT", 313, 319], ["class II", "GENE_OR_GENE_PRODUCT", 324, 332], ["STR patterns", "DNA", 31, 43], ["Mafa", "DNA", 57, 61], ["conserved genomic region", "DNA", 106, 130], ["common telomeric and centromeric STR alleles", "DNA", 162, 206], ["MHC haplotypes", "DNA", 224, 238], ["Mafa", "DNA", 258, 262], ["Mafa", "DNA", 313, 317], ["a conserved genomic region", "PROBLEM", 104, 130], ["centromeric STR alleles", "PROBLEM", 183, 206], ["these Mafa", "TEST", 252, 262], ["haplotype blocks", "PROBLEM", 274, 290], ["Mafa", "ANATOMY", 57, 61], ["marked", "OBSERVATION_MODIFIER", 139, 145]]], ["As illustrated in Fig. 1 , the first three STRs (222I18, MOG-CA and 151L13) reside approximately 0.3-0.6-Mb telomeric to the Mafa-A gene cluster and the next three STRs (162B17A, 162B17B, and 246K06) are localized a comparable distance from the centromere (Daza-Vamenta et al. 2004; Kean et al. 2012) where they flank the Mafa-E genes.", [["centromere", "ANATOMY", 245, 255], ["MOG-CA", "GENE_OR_GENE_PRODUCT", 57, 63], ["Mafa-A", "GENE_OR_GENE_PRODUCT", 125, 131], ["centromere", "CELLULAR_COMPONENT", 245, 255], ["Mafa-E", "GENE_OR_GENE_PRODUCT", 322, 328], ["STRs", "DNA", 43, 47], ["Mafa-A gene cluster", "DNA", 125, 144], ["STRs", "DNA", 164, 168], ["Mafa", "DNA", 322, 326], ["E genes", "DNA", 327, 334], ["three STRs", "TEST", 37, 47], ["MOG", "TEST", 57, 60], ["CA", "TEST", 61, 63], ["three STRs", "TEST", 158, 168], ["Fig", "OBSERVATION_MODIFIER", 18, 21], ["Mafa", "ANATOMY", 125, 129], ["flank", "ANATOMY", 312, 317], ["Mafa", "ANATOMY", 322, 326]]], ["Interestingly, the major Mafa-A1008 transcripts that are closely related allelic variants.", [["Mafa", "GENE_OR_GENE_PRODUCT", 25, 29], ["A1008", "GENE_OR_GENE_PRODUCT", 30, 35], ["major Mafa-A1008 transcripts", "RNA", 19, 47], ["allelic variants", "PROBLEM", 73, 89], ["allelic variants", "OBSERVATION", 73, 89]]], ["The associated Mafa-B008.02.02 and Mafa-B008.02.01 regional haplotypes are distinguished by Mafa-B195:01 versus Mafa-B195:02 major transcripts, respectively (Supplemental Figure 5) .", [["Mafa", "GENE_OR_GENE_PRODUCT", 15, 19], ["Mafa-B008.02.01", "GENE_OR_GENE_PRODUCT", 35, 50], ["Mafa-B008.02.02 and Mafa-B008.02.01 regional haplotypes", "DNA", 15, 70], ["B195:01", "DNA", 97, 104], ["Mafa", "TEST", 15, 19], ["Mafa", "TEST", 35, 39], ["regional haplotypes", "TEST", 51, 70], ["Mafa", "TEST", 92, 96], ["Mafa", "TEST", 112, 116], ["Mafa", "ANATOMY", 15, 19]]], ["Fortunately, the rhesus macaque orthologue (Mamu-B008 sequences encodes one of the most thoroughly characterized MHC class I proteins in NHPs due to its strong association with exceptional control of simian immunodeficiency virus replication (Loffredo et al. 2007 ).", [["simian immunodeficiency virus replication", "DISEASE", 200, 241], ["rhesus macaque", "ORGANISM", 17, 31], ["Mamu-B008", "ORGANISM", 44, 53], ["MHC class I", "GENE_OR_GENE_PRODUCT", 113, 124], ["NHPs", "ORGANISM", 137, 141], ["simian immunodeficiency virus", "ORGANISM", 200, 229], ["rhesus macaque orthologue", "DNA", 17, 42], ["Mamu-B008 sequences", "DNA", 44, 63], ["MHC class I proteins", "PROTEIN", 113, 133], ["rhesus macaque", "SPECIES", 17, 31], ["simian immunodeficiency virus", "SPECIES", 200, 229], ["rhesus macaque", "SPECIES", 17, 31], ["simian immunodeficiency virus", "SPECIES", 200, 229], ["the rhesus macaque orthologue", "TEST", 13, 42], ["simian immunodeficiency virus replication", "TREATMENT", 200, 241], ["simian immunodeficiency", "OBSERVATION", 200, 223]]], ["Loffredo and coworkers have performed extensive epitope mapping studies and defined a detailed peptide-binding motif for the Mamu-B008:02 only differs from its rhesus counterpart by a single V189M substitution in the alpha 2 domain that is not expected to be involved in peptide binding, it is expected to bind the same spectrum of peptides as those described for Mamu-B008:03 protein (associated with the MHC-MAFA-NIAID1-000002 haplotype) is also closely related to Mamu-B008:03 protein is identical to the HLA008:01 (Loffredo et al. 2009 ).", [["Mamu-B008:02", "SIMPLE_CHEMICAL", 125, 137], ["rhesus", "ORGANISM", 160, 166], ["alpha 2", "GENE_OR_GENE_PRODUCT", 217, 224], ["Mamu-B008:03", "GENE_OR_GENE_PRODUCT", 364, 376], ["MHC-MAFA-NIAID1-000002", "GENE_OR_GENE_PRODUCT", 406, 428], ["Mamu-B008:03", "GENE_OR_GENE_PRODUCT", 467, 479], ["Mamu", "PROTEIN", 125, 129], ["B008:02", "PROTEIN", 130, 137], ["alpha 2 domain", "PROTEIN", 217, 231], ["Mamu", "PROTEIN", 364, 368], ["B008:03 protein", "PROTEIN", 369, 384], ["MHC-MAFA-NIAID1", "PROTEIN", 406, 421], ["Mamu", "PROTEIN", 467, 471], ["B008:03 protein", "PROTEIN", 472, 487], ["extensive epitope mapping studies", "TEST", 38, 71], ["a single V189M substitution", "TREATMENT", 182, 209], ["Mamu", "TEST", 364, 368], ["Mamu", "TEST", 467, 471], ["not expected", "UNCERTAINTY", 240, 252]]], ["The Mafa-B008:01; this residue is an aspartic acid in HLA-B007:05) of the most common MHC-MAFA-NIAID1-000005 haplotype also has a rhesus homolog (Mamu-A1008:01 expression is strongly associated with spontaneous control of simian immunodeficiency virus (Loffredo et al. 2009 ), the high frequency of Mafa-B063:03:02 transcript that differs from the Mafa-A1104:01:02 and Mafa-B104:03, Mafa-B057:04, Mafa-B050:08, Mafa-B114:02, and Mafa-I028 and Mafa-B028:03, Mafa-B068:02, and Mafa-I124 lineage, the BPRC haplotype was reported to include a Mafa-B028 and/or Mafa-B028 and B*021 genes was likely to have arisen in a common ancestor who predated the divergence of cynomolgus, rhesus and pigtailed macaques (Smith et al. 2007 ).Concluding remarksHere, we describe a comprehensive, high-resolution characterization of the Mafa class I and class II transcripts that are associated with 100 extended MHC haplotypes in a large, pedigreed colony of ICM.", [["Mafa-I124 lineage", "ANATOMY", 475, 492], ["colony", "ANATOMY", 929, 935], ["ICM", "ANATOMY", 939, 942], ["aspartic acid", "CHEMICAL", 37, 50], ["simian immunodeficiency virus", "DISEASE", 222, 251], ["ICM", "DISEASE", 939, 942], ["aspartic acid", "CHEMICAL", 37, 50], ["Mafa-B008:01", "GENE_OR_GENE_PRODUCT", 4, 16], ["aspartic acid", "AMINO_ACID", 37, 50], ["MHC-MAFA-NIAID1-000005", "GENE_OR_GENE_PRODUCT", 86, 108], ["rhesus", "ORGANISM", 130, 136], ["Mamu-A1008:01", "GENE_OR_GENE_PRODUCT", 146, 159], ["simian immunodeficiency virus", "ORGANISM", 222, 251], ["Mafa-B063:03:02", "GENE_OR_GENE_PRODUCT", 299, 314], ["Mafa-A1104:01:02", "CELL", 348, 364], ["Mafa-B104:03", "CELL", 369, 381], ["Mafa-B057:04", "CELL", 383, 395], ["Mafa-B050:08", "CELL", 397, 409], ["Mafa-B114:02", "CELL", 411, 423], ["Mafa-I028", "CELL", 429, 438], ["Mafa-B028:03", "CELL", 443, 455], ["Mafa-B068:02", "CELL", 457, 469], ["Mafa-I124 lineage", "CELL", 475, 492], ["BPRC", "GENE_OR_GENE_PRODUCT", 498, 502], ["Mafa", "GENE_OR_GENE_PRODUCT", 539, 543], ["Mafa-B028", "GENE_OR_GENE_PRODUCT", 556, 565], ["B*021", "GENE_OR_GENE_PRODUCT", 570, 575], ["cynomolgus", "ORGANISM", 660, 670], ["rhesus", "ORGANISM", 672, 678], ["macaques", "ORGANISM", 693, 701], ["Mafa class I", "GENE_OR_GENE_PRODUCT", 816, 828], ["class II", "GENE_OR_GENE_PRODUCT", 833, 841], ["ICM", "CANCER", 939, 942], ["Mafa", "PROTEIN", 4, 8], ["MHC-MAFA-NIAID1", "PROTEIN", 86, 101], ["Mafa-B063:03:02 transcript", "RNA", 299, 325], ["BPRC haplotype", "DNA", 498, 512], ["Mafa-B028 and/or Mafa-B028 and B*021 genes", "DNA", 539, 581], ["Mafa class I and class II transcripts", "RNA", 816, 853], ["MHC", "PROTEIN", 892, 895], ["simian immunodeficiency virus", "SPECIES", 222, 251], ["pigtailed macaques", "SPECIES", 683, 701], ["simian immunodeficiency virus", "SPECIES", 222, 251], ["Mafa-I028", "SPECIES", 429, 438], ["Mafa-B028:03, Mafa-B068:02", "SPECIES", 443, 469], ["Mafa-I124", "SPECIES", 475, 484], ["Mafa-B028", "SPECIES", 556, 565], ["this residue", "PROBLEM", 18, 30], ["an aspartic acid in HLA", "PROBLEM", 34, 57], ["simian immunodeficiency virus", "PROBLEM", 222, 251], ["the Mafa", "TEST", 344, 352], ["Mafa", "TEST", 369, 373], ["Mafa", "TEST", 383, 387], ["Mafa", "TEST", 397, 401], ["Mafa", "TEST", 411, 415], ["Mafa", "TEST", 429, 433], ["Mafa", "TEST", 443, 447], ["Mafa", "TEST", 457, 461], ["Mafa", "TEST", 475, 479], ["the BPRC haplotype", "TEST", 494, 512], ["a Mafa", "TEST", 537, 543], ["Mafa", "TEST", 556, 560], ["large", "OBSERVATION_MODIFIER", 912, 917], ["colony", "OBSERVATION_MODIFIER", 929, 935]]], ["PacBio sequencing of this cohort yielded 202 new Mafa transcript sequences with full-length coding regions, bringing the number in IPD-MHC Release 3.3.0.0 (2019-06-13) build 126 to a total of 2489 Mafa sequences.", [["Mafa", "GENE_OR_GENE_PRODUCT", 49, 53], ["Mafa", "GENE_OR_GENE_PRODUCT", 197, 201], ["Mafa transcript sequences", "DNA", 49, 74], ["full-length coding regions", "DNA", 80, 106], ["MHC", "PROTEIN", 135, 138], ["2489 Mafa sequences", "DNA", 192, 211], ["full-length coding regions", "TREATMENT", 80, 106]]], ["This study was informed by an extensive database of STR patterns for a panel of markers that span the 5-Mb MHC genomic region that has been collected since this breeding colony was established in 2002.", [["colony", "ANATOMY", 170, 176], ["5-Mb MHC genomic region", "DNA", 102, 125], ["This study", "TEST", 0, 10], ["a panel", "TEST", 69, 76], ["markers", "TEST", 80, 87]]], ["The STR data allowed us to define the allele content of extended MHC haplotypes for individuals that were known to share chromosomes that were identical by descent rather than simply inferring haplotypes based on combinations of class I and class II transcripts that appear to travel together in multiple animals who lack known pedigree relationships.", [["chromosomes", "ANATOMY", 121, 132], ["chromosomes", "CELLULAR_COMPONENT", 121, 132], ["class II", "GENE_OR_GENE_PRODUCT", 241, 249], ["MHC", "PROTEIN", 65, 68], ["chromosomes", "DNA", 121, 132], ["class I and class II transcripts", "RNA", 229, 261]]], ["A large majority of the 70 Mafa-A, 78 Mafa-B, and 45 Mafa-DRB haplotypes identified here were only associated with one or two of the 100 extended MHC haplotypes that we characterized.", [["Mafa-A", "CANCER", 27, 33], ["Mafa-B", "CELL", 38, 44], ["Mafa-DRB", "GENE_OR_GENE_PRODUCT", 53, 61], ["MHC haplotypes", "DNA", 146, 160], ["Mafa", "TEST", 38, 42], ["Mafa", "TEST", 53, 57], ["DRB haplotypes", "TEST", 58, 72], ["large", "OBSERVATION_MODIFIER", 2, 7], ["majority", "OBSERVATION_MODIFIER", 8, 16], ["Mafa", "ANATOMY", 53, 57], ["DRB haplotypes", "OBSERVATION", 58, 72]]], ["This extensive MHC diversity was derived from only approximately 79 founding animals for this breeding colony.", [["colony", "ANATOMY", 103, 109], ["MHC", "PROTEIN", 15, 18], ["this breeding colony", "PROBLEM", 89, 109], ["extensive", "OBSERVATION_MODIFIER", 5, 14], ["MHC diversity", "OBSERVATION", 15, 28]]], ["In contrast, a comparable study of Indian-origin rhesus only identified 17 Mamu-A, 18 Mamu-B, and 22 Mamu-DRB haplotypes in the BPRC breeding colony that was established with 137 founding animals (Doxiadis et al. 2013) .Concluding remarksAlthough this dataset is restricted to a single ICM breeding colony, it provides a glimpse of extraordinary MHC diversity that must be present in the wild population of ICM as a whole.", [["colony", "ANATOMY", 142, 148], ["colony", "ANATOMY", 299, 305], ["ICM", "ANATOMY", 407, 410], ["rhesus", "ORGANISM", 49, 55], ["Mamu-A", "CANCER", 75, 81], ["Mamu-B", "CELL", 86, 92], ["MHC", "GENE_OR_GENE_PRODUCT", 346, 349], ["MHC", "PROTEIN", 346, 349], ["a comparable study", "TEST", 13, 31], ["Mamu", "TEST", 75, 79], ["Mamu", "TEST", 86, 90], ["22 Mamu-DRB haplotypes", "PROBLEM", 98, 120], ["the BPRC breeding colony", "PROBLEM", 124, 148], ["a single ICM breeding colony", "PROBLEM", 277, 305], ["DRB haplotypes", "OBSERVATION", 106, 120], ["breeding colony", "OBSERVATION", 133, 148]]], ["It is reasonable to predict that the high level of genetic diversity described here for the MHC region will extend across the rest of the ICM genome.", [["ICM genome", "ANATOMY", 138, 148], ["MHC region", "DNA", 92, 102], ["ICM genome", "DNA", 138, 148], ["ICM genome", "OBSERVATION", 138, 148]]], ["As previously noted, MCM are thought to be derived from a founder population of ICM (Lawler et al. 1995; Tosi and Coke 2007) which significantly limited the genomic diversity in MCM, especially in the MHC region where only seven ancestral haplotypes are observed.", [["MCM", "GENE_OR_GENE_PRODUCT", 21, 24], ["MHC region", "DNA", 201, 211], ["MCM", "PROBLEM", 21, 24], ["the genomic diversity in MCM", "PROBLEM", 153, 181], ["seven ancestral haplotypes", "PROBLEM", 223, 249], ["thought to be", "UNCERTAINTY", 29, 42], ["genomic diversity", "OBSERVATION", 157, 174], ["MCM", "OBSERVATION_MODIFIER", 178, 181], ["MHC", "ANATOMY", 201, 204], ["region", "ANATOMY_MODIFIER", 205, 211], ["seven", "OBSERVATION_MODIFIER", 223, 228], ["ancestral haplotypes", "OBSERVATION", 229, 249]]], ["While this restricted genetic diversity is valuable in many areas of research, it can present a challenge for transplant investigators whose goal is to maximize MHC disparity between donor and recipient tissues.", [["tissues", "ANATOMY", 203, 210], ["donor", "TISSUE", 183, 188], ["recipient tissues", "TISSUE", 193, 210], ["MHC", "PROTEIN", 161, 164], ["transplant investigators", "TREATMENT", 110, 134], ["donor and recipient tissues", "TREATMENT", 183, 210], ["many", "OBSERVATION_MODIFIER", 55, 59], ["areas", "OBSERVATION_MODIFIER", 60, 65], ["recipient tissues", "OBSERVATION", 193, 210]]], ["The ICM population, in contrast, exhibits considerably more diversity, increasing its value as a model species for biomedical research, such as transplantation studies.", [["ICM", "ANATOMY", 4, 7], ["ICM population", "CELL_LINE", 4, 18], ["The ICM population", "TEST", 0, 18], ["biomedical research", "TEST", 115, 134], ["transplantation studies", "TEST", 144, 167], ["ICM", "OBSERVATION_MODIFIER", 4, 7], ["population", "OBSERVATION", 8, 18], ["considerably", "OBSERVATION_MODIFIER", 42, 54], ["more diversity", "OBSERVATION_MODIFIER", 55, 69]]], ["This pedigreed cynomolgus macaque cohort also provides a valuable resource for future studies designed to characterize additional immune-important genomic regions such as the killer immunoglobulin-like receptors (Bimber and Evans 2015; Prall et al. 2017; Bruijnesteijn et al. 2018) and Fc gamma receptors (Haj et al. 2019) .", [["macaque", "ORGANISM", 26, 33], ["killer immunoglobulin-like receptors", "GENE_OR_GENE_PRODUCT", 175, 211], ["Fc gamma receptors", "GENE_OR_GENE_PRODUCT", 286, 304], ["killer immunoglobulin-like receptors", "PROTEIN", 175, 211], ["Bimber", "PROTEIN", 213, 219], ["2018", "PROTEIN", 276, 280], ["Fc gamma receptors", "PROTEIN", 286, 304], ["cynomolgus macaque", "SPECIES", 15, 33], ["cynomolgus macaque", "SPECIES", 15, 33], ["future studies", "TEST", 79, 93], ["the killer immunoglobulin", "TREATMENT", 171, 196]]]], "01241d4bb5a495117a55e7a4b3669092b52debc2": [["intervention.", [["intervention", "TREATMENT", 0, 12]]], ["The predictors indicated by the current study may help to identify those at high-risk.", [["the current study", "TEST", 28, 45]]], ["The current study also contributes to geriatric psychiatry by indicating that the older survivors suffered less emotional reactivity and fewer stress response symptoms from infectious diseases than the younger ones.", [["infectious diseases", "DISEASE", 173, 192], ["The current study", "TEST", 0, 17], ["fewer stress response symptoms", "PROBLEM", 137, 167], ["infectious diseases", "PROBLEM", 173, 192], ["infectious", "OBSERVATION_MODIFIER", 173, 183]]]], "19ffc482a90e9d09a7a91237d833b06b27fdd565": [["Low-income and middle-income countries (LMICs) experience many barriers in carrying out their non-communicable diseases (NCDs) strategies.", [["non-communicable diseases", "DISEASE", 94, 119], ["NCDs", "DISEASE", 121, 125], ["middle", "ANATOMY_MODIFIER", 15, 21]]], ["This is evident in the deceleration that has occurred in reducing premature mortality from major NCDs since 2010 1 and is painfully manifest in the conclusions of the latest WHO national country capacity survey.", [["NCDs", "DISEASE", 97, 101], ["the deceleration", "PROBLEM", 19, 35], ["reducing premature mortality", "PROBLEM", 57, 85], ["deceleration", "OBSERVATION", 23, 35], ["reducing", "OBSERVATION_MODIFIER", 57, 65], ["premature", "OBSERVATION_MODIFIER", 66, 75], ["mortality", "OBSERVATION_MODIFIER", 76, 85]]], ["2 This survey found that generally integrated NCD policies were of inadequate breadth, 'Best Buy' interventions vastly underused, NCD surveillance systems insufficiently robust, lack of clinical guidelines for leading NCDs, cancer-screening programme reach was often inadequate, essential NCD technologies and medicines remained widely unavailable, and palliative care was sparse.", [["cancer", "ANATOMY", 224, 230], ["NCDs", "DISEASE", 218, 222], ["cancer", "DISEASE", 224, 230], ["cancer", "CANCER", 224, 230], ["cancer", "PROBLEM", 224, 230], ["medicines", "TREATMENT", 310, 319], ["cancer", "OBSERVATION", 224, 230]]], ["These weaknesses predated the COVID-19 pandemic, however, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) brutally exposed the limitations of many countries' health systems as well as the significant vulnerability of the large numbers of people living with NCDs that insufficient action has created.", [["Acute Respiratory Syndrome", "DISEASE", 65, 91], ["NCDs", "DISEASE", 270, 274], ["people", "ORGANISM", 251, 257], ["people", "SPECIES", 251, 257], ["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV", "SPECIES", 58, 115], ["These weaknesses", "PROBLEM", 0, 16], ["the COVID", "TEST", 26, 35], ["pandemic", "PROBLEM", 39, 47], ["Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 58, 103], ["CoV", "TEST", 112, 115], ["Severe", "OBSERVATION_MODIFIER", 58, 64], ["Acute", "OBSERVATION_MODIFIER", 65, 70], ["Respiratory Syndrome", "OBSERVATION", 71, 91], ["large", "OBSERVATION_MODIFIER", 234, 239], ["numbers", "OBSERVATION_MODIFIER", 240, 247]]], ["Key barriers to NCD strategy implementation have been well articulated in the last decade.", [["NCD strategy implementation", "TREATMENT", 16, 43]]], ["The 2020 WHO Independent High-Level Commission on NCDs highlights the need for political support to advance the NCD agenda, and need to develop sustainable financing for programmes, service delivery and human resources.", [["NCDs", "DISEASE", 50, 54], ["human", "ORGANISM", 203, 208], ["human", "SPECIES", 203, 208], ["human", "SPECIES", 203, 208], ["political support", "TREATMENT", 79, 96], ["the NCD agenda", "TREATMENT", 108, 122]]], ["3 In a brief sentence in this report, some commissioners highlighted the need for more tailored support to LMIC to implement NCD strategies.", [["more tailored support", "TREATMENT", 82, 103], ["NCD strategies", "TREATMENT", 125, 139]]], ["We contend that tailored technical support is actually pivotal to enable Summary box \u25ba Barriers to implementing effective noncommunicable disease (NCD) strategies are well known, yet the value of tailored technical support to countries has been overlooked and downplayed. \u25ba We present a model of steps focused at key NCD implementation junctures that often require tailored technical support to ensure progress. \u25ba National investment cases provide countries with evidence based, locally tailored and costed packages of NCD interventions and policies appropriate to national needs and circumstances. \u25ba Tailored technical support can empower national stakeholders to put investment cases into operation by partnering local expertise with specialist guidance for specific policies and programmes, using implementation science to surmount implementation obstacles and building national NCD capacity.BMJ Global Healththe Report's more prominent recommendations to be put into practice, and provision of such support requires serious consideration-and urgently-if we are collectively to move closer to achieving Sustainable Development Goal (SDG) 3.4 in 10 years time.", [["noncommunicable disease", "DISEASE", 122, 145], ["NCD", "DISEASE", 147, 150], ["tailored technical support", "TREATMENT", 16, 42], ["effective noncommunicable disease (NCD) strategies", "TREATMENT", 112, 162], ["tailored technical support", "TREATMENT", 365, 391], ["NCD interventions", "TREATMENT", 519, 536], ["such support", "TREATMENT", 998, 1010]]], ["Common features are external provision of specialist knowledge, partnership with local stakeholders and capacity-building.", [["external", "OBSERVATION_MODIFIER", 20, 28]]], ["Tailored technical support is meant here as provision of specialist guidance to support country-specific application of technical tools, and capacity enhancement when needed, to enable an LMIC to advance its NCD priorities.IDENTIFYING THE PIVOTAL POINTS TO STRENGTHEN NATIONAL IMPLEMENTATIONDrawing on our experience preparing NCD investment cases and designing NCD strategies and implementation by partnering with health ministries in multiple countries, we present a model to suggest how national NCD implementation may be strengthened.", [["technical tools", "TEST", 120, 135], ["an LMIC", "TREATMENT", 185, 192], ["NCD strategies", "TREATMENT", 362, 376]]], ["We propose that providing tailored technical support at these critical junctures when needed, working in partnership with national stakeholders, can galvanise NCD implementation.IDENTIFYING THE PIVOTAL POINTS TO STRENGTHEN NATIONAL IMPLEMENTATIONThe components may be viewed as steps that can be applied sequentially or the model can identify the missing components in a specific context where some are already in place.", [["tailored technical support", "TREATMENT", 26, 52]]], ["Thus, a country may use an investment case to review and reprioritise an existing strategy; some countries may have stronger NCD stakeholder capacity and may not need to address this; some may have sustainable funding mechanisms under development yet can beneficially align these to the newly identified priority interventions and revised strategy.", [["an existing strategy", "TREATMENT", 70, 90], ["priority interventions", "TREATMENT", 304, 326]]], ["In this way the model may be flexibly used, recognising that LMICs are at different starting points and relating to their particular circumstances and contexts.", [["may be", "UNCERTAINTY", 22, 28]]], ["For many countries, an investment case is the starting point.THE IMPACT OF NCD INVESTMENT CASESAn investment case uses economic and political analysis to provide countries with an evidence-based agenda for implementing NCD policies that provide best valuefor-money and is feasible in that country.", [["political analysis", "TEST", 132, 150], ["implementing NCD policies", "TREATMENT", 206, 231]]], ["The process of conducting an investment case has been described elsewhere 4 and involves careful review of existing NCD programmes and policies, discussions with national stakeholders to determine how to augment existing programmes in scale and scope, costing these and calculating return on investment-for population health and the national economy.", [["scope", "TEST", 245, 250]]], ["This inclusive process is a key for establishing credibility and laying the groundwork for policy and delivery to evolve.THE IMPACT OF NCD INVESTMENT CASESThe impact of individual investment cases varies from country to country and can be hard to measure and harder to attribute.", [["delivery", "TREATMENT", 102, 110]]], ["Testimonials from policy-makers who have commissioned and used investment cases, as well as the large backlog of country requests for investment Figure 1 Pivotal points for tailored technical support to support NCD implementation.", [["tailored technical support", "TREATMENT", 173, 199], ["NCD implementation", "TREATMENT", 211, 229]]], ["NCD, non-communicable disease.THE IMPACT OF NCD INVESTMENT CASESBMJ Global Health cases, lends authenticity to their value.", [["NCD", "DISEASE", 0, 3], ["non-communicable disease", "DISEASE", 5, 29], ["non-communicable disease", "PROBLEM", 5, 29], ["non-communicable disease", "OBSERVATION", 5, 29]]], ["5 6 Notably, many country requests for investment case support have been made but are yet unfunded.", [["investment case support", "TREATMENT", 39, 62]]], ["7 While not every investment case results in immediate or attributable impact, a growing set of examples shows that investment cases can be game-changing to obtain political 'buy-in' and can catalyse multisectoral dialogue on funding solutions.", [["funding solutions", "TREATMENT", 226, 243]]], ["5 6 8 The evidence from these experiences is that investment cases can catalyse a cascade of national actions such as expanding existing service coverage or implementing new prevention policies.", [["national actions", "TREATMENT", 93, 109], ["expanding existing service coverage", "TREATMENT", 118, 153], ["new prevention policies", "TREATMENT", 170, 193]]], ["9 In 2017, the Health Ministry was able to introduce the results of a pilot tobacco control investment case into debate over stalled tobacco control legislation.", [["tobacco", "ORGANISM", 76, 83], ["tobacco", "ORGANISM", 133, 140], ["tobacco", "SPECIES", 133, 140], ["a pilot tobacco control investment", "TREATMENT", 68, 102]]], ["After the investment case was presented the Georgian Parliament agreed on multiple policy changes to reduce tobacco use in the country.", [["tobacco", "ORGANISM", 108, 115], ["tobacco", "SPECIES", 108, 115]]], ["Similarly, investment case results were cited in the tobacco control legislation presented to the Armenian Parliament.", [["tobacco", "ORGANISM", 53, 60], ["tobacco", "SPECIES", 53, 60]]], ["11 During the Cabinet briefing on the investment case findings, the prime minister directed the minister of finance to immediately raise tobacco taxes.", [["tobacco", "ORGANISM", 137, 144], ["tobacco", "SPECIES", 137, 144]]], ["In Kenya, a recently completed NCD investment case drew attention to the high price tag of increasing NCD treatment coverage.", [["the high price tag", "TREATMENT", 69, 87], ["increasing NCD treatment coverage", "TREATMENT", 91, 124]]], ["12 As for many countries, action on their investment case recommendations now awaits an accompanying funding strategy.FROM INVESTMENT CASE TO NCD IMPLEMENTATIONAn investment case coalesces stakeholders, creates a sense of urgency and fosters 'buy in', and identifies clear investment priorities.", [["urgency", "PROBLEM", 222, 229]]], ["These are prerequisites to achieving sustainable funding for NCD strategy implementationwhether from the ministry of finance or external sources.", [["NCD strategy", "TREATMENT", 61, 73]]], ["An investment case quantifies the health and economic benefits of implementing NCD prevention and control, yet those results are theoretical without a financing plan to show policymakers and development partners how the strategies can be realised.", [["NCD prevention", "TREATMENT", 79, 93]]], ["The choice of financing mechanisms may be constrained for many low-resource countries and must be determined by responsible national financial officials in line with their development strategies.FROM INVESTMENT CASE TO NCD IMPLEMENTATIONBut once the NCD investment case is in hand, priority interventions are agreed, and financing is assured, how is effective implementation achieved?FROM INVESTMENT CASE TO NCD IMPLEMENTATIONThe WHO Global Coordinating Mechanism Working Group on Financing for NCDs developed a tool to assist countries to assess options, yet national capacity to employ this may be stymied without specialist guidance.", [["NCDs", "DISEASE", 495, 499], ["hand", "ORGANISM_SUBDIVISION", 276, 280]]], ["Such gaps commonly emerge around data analysis, programme costing, budgeting, fiscal and legal policy formulation, demand forecasting, procurement of medical supplies and resource mobilisation.", [["data analysis", "TEST", 33, 46], ["legal policy formulation", "TREATMENT", 89, 113], ["medical supplies", "TREATMENT", 150, 166], ["resource mobilisation", "TREATMENT", 171, 192]]], ["These policy and programme development components require specialised technical skills and can be provided through tailored technical support alongside capacity development so functions can be sustained as programmes mature.", [["tailored technical support", "TREATMENT", 115, 141]]], ["Each step may require targeted technical support.FROM INVESTMENT CASE TO NCD IMPLEMENTATIONFor example, a 2017 investment case developed by the Jamaican government with support from the United Nations Development Program (UNDP) examined the return on investment from scaling up NCD clinical interventions and implementing or intensifying prevention policies.", [["targeted technical support", "TREATMENT", 22, 48], ["clinical interventions", "TREATMENT", 282, 304], ["intensifying prevention policies", "TREATMENT", 325, 357]]], ["4 The results showed a potential saving of US$640 million and 6600 lives in Jamaica between 2017 and 2032 from implementing the intervention package.", [["the intervention package", "TREATMENT", 124, 148]]], ["This analysis spurred an immediate response from the government's top echelons to implement the NCD programme to accelerate their ambitious economic growth targets.", [["This analysis", "TEST", 0, 13], ["the NCD programme", "TREATMENT", 92, 109]]], ["The experience highlighted specific knowledge and skill gaps that had hitherto hindered the Health Ministry from achieving high level policy attention, despite having an NCD strategy and strong inter-governmental apparatus.", [["an NCD strategy", "TREATMENT", 167, 182]]], ["Gaps had included lack of costing for NCD programme components, need for greater interministry coordination (promptly acted on following the investment case), and greater awareness of the contribution that improved health would make to economic goals.FROM INVESTMENT CASE TO NCD IMPLEMENTATIONUntil the current pandemic, the links between communicable and NCDs had been overlooked by many global and national health officials, and there is now urgency to determine how to protect people with NCDs and to create stronger population resilience.", [["NCDs", "DISEASE", 356, 360], ["NCDs", "DISEASE", 492, 496], ["people", "ORGANISM", 480, 486], ["people", "SPECIES", 480, 486], ["NCD programme components", "TREATMENT", 38, 62], ["urgency", "PROBLEM", 444, 451]]], ["Investment cases can assist governments by identifying synergies between addressing chronic disease and pandemic resilience, such as health system strengthening measures to ensure services to treat and manage NCDs functioning during pandemics, averting excess NCD mortality and acute admissions.", [["chronic disease", "DISEASE", 84, 99], ["NCDs", "DISEASE", 209, 213], ["chronic disease", "PROBLEM", 84, 99], ["pandemic resilience", "TREATMENT", 104, 123], ["health system strengthening measures", "TREATMENT", 133, 169]]], ["This evidence can then be used to identify sustainable financing mechanisms.STRENGTHENING NATIONAL NCD CAPACITIESGlobal guidelines, protocols and tool-kits offer highquality support to national NCD planning.", [["highquality support", "TREATMENT", 162, 181], ["national NCD planning", "TREATMENT", 185, 206]]], ["14 15 Yet it is a leap of faith to envisage that managers can take these 'off BMJ Global Health the shelf' and apply them, even when there is high-level 'buy-in' to address NCDs, or that civil society organisations can identify how they can contribute.", [["NCDs", "DISEASE", 173, 177]]], ["This is evident from the increased number of NCD plans that sit in place alongside a low level of health system readiness to deliver policies, programmes and services.", [["increased", "OBSERVATION_MODIFIER", 25, 34], ["number", "OBSERVATION_MODIFIER", 35, 41]]], ["14 16 Ironically, given the scarcity of NCD funding, bottlenecks are created whereby available NCD funds remain unspent.STRENGTHENING NATIONAL NCD CAPACITIESGrowth in the number of NCD-trained national health and policy professionals is encouraging.", [["NCD funding", "TREATMENT", 40, 51]]], ["Yet an NCD skill deficit is common and NCD departments are often still small and pulled in many directions.", [["an NCD skill deficit", "PROBLEM", 4, 24], ["deficit", "OBSERVATION", 17, 24]]], ["The current paradigm must shift from: 'I'm a [HIV/maternal health person] and new to NCDs', to each LMIC having a cadre of national officers confident in their NCD expertise.", [["NCDs", "DISEASE", 85, 89], ["person", "SPECIES", 66, 72]]], ["Adding this to their experience in the existing (dominant) priorities, such as communicable disease, maternal and reproductive health, will be a major step towards health system integration solutions.", [["communicable disease", "DISEASE", 79, 99], ["communicable disease", "PROBLEM", 79, 99]]], ["Empowering civil society as partners in the NCD agenda is a vital complement to this.STRENGTHENING NATIONAL NCD CAPACITIESStrengthening national NCD capacity is a mediumterm goal.", [["a mediumterm goal", "TREATMENT", 161, 178]]], ["Just as with the HIV/AIDS pandemic and COVID-19, there is a critical need to support countries while health crises are underway.", [["HIV/AIDS pandemic", "DISEASE", 17, 34], ["HIV", "SPECIES", 17, 20], ["COVID", "TEST", 39, 44]]], ["Even where national NCD capacity is stronger, provision of technical support on the policy, system and programmatic mechanisms that can address specific conditions and risk factors can enhance and accelerate progress and reduce health and economic losses.COPRODUCTION OF NATIONALLY OWNED AND LED OUTCOMESMuch has been and can further be learnt from earlier experience in collectively advancing global and national health.", [["economic losses", "PROBLEM", 239, 254]]], ["Best results come when national stakeholders are 'in the driver's seat' with tailored technical support on board as mechanic/navigator, providing specific assistance to facilitate an effective journey.", [["mechanic/navigator", "TREATMENT", 116, 134]]], ["For example, it has been useful to partner government economists and lawyers with global counterparts who specialise in specific risk factors or conditions to develop fiscal and regulatory measures that are resistant to challenges from global commercial and industrial interests.", [["fiscal and regulatory measures", "TREATMENT", 167, 197]]], ["Such collaborations have been notable in tobacco control, 17 partly owing to the complex, globalised legal, fiscal and commercial influences on the issue at national level, but also because funders recognised unmet need among national governments and prioritised technical assistance and national capacity building.", [["tobacco", "ORGANISM", 41, 48], ["tobacco", "SPECIES", 41, 48]]], ["18 Global specialists can also introduce new techniques or technologies to build national capacity to apply these to NCDs.", [["NCDs", "DISEASE", 117, 121], ["new techniques", "TREATMENT", 41, 55]]], ["Escalating NCD prevalence and cost of treating NCDs on the island and evacuating emergency and complex patients for care overseas generated the political will to reorient bilateral funding towards NCDs.", [["NCDs", "DISEASE", 47, 51], ["NCDs", "DISEASE", 197, 201], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["bilateral", "ANATOMY_MODIFIER", 171, 180]]], ["Significant value was added by partnerships that married local contextual expertise with solid evidence from other sources and highly specific support to co-produce solutions to what would otherwise be implementation challenges.", [["Significant value", "PROBLEM", 0, 17]]], ["Implementation science addresses the need to develop, test, evaluate and retest the interventions and processes that constitute an NCD programme.", [["test", "TEST", 54, 58]]], ["19 The Consolidated Framework on Implementation Research (CFIR) identified five key aspects of implementation that influence intervention outcomes.", [["Consolidated", "OBSERVATION_MODIFIER", 7, 19], ["Framework", "OBSERVATION_MODIFIER", 20, 29]]], ["21 Thus, an investment case may identify a specific intervention as a cost-effective priority based on national data; implementation research can then indicate how this may impact population groups differently and suggest ways BMJ Global Health that the implementation process and supporting actions should be tailored.", [["a specific intervention", "TREATMENT", 41, 64], ["national data", "TEST", 103, 116]]], ["22 BHP is applying implementation science to identify which of the obesity prevention strategies identified elsewhere as successful will be effective and acceptable in Kuala Lumpur's poorest communities.", [["BHP", "CHEMICAL", 3, 6], ["obesity", "DISEASE", 67, 74], ["the obesity prevention strategies", "TREATMENT", 63, 96], ["obesity", "OBSERVATION", 67, 74]]], ["'Discrete choice experiments', 'knowledge, attitude and practices' surveys, interviews and focus groups are being used to elicit stakeholder needs, preferences and constraints to inform design, delivery and modification of interventions on how to enable healthier food and drink consumption and increase physical activity.", [["delivery", "TREATMENT", 194, 202], ["interventions", "TREATMENT", 223, 236]]], ["Support to apply an implementation science lens to NCD plans can in the short-term bridge the divide between plans and implementation, employ available evidence in a contextrelevant manner, and in the medium-term build national capacity to apply the techniques.IMPLEMENTATION SCIENCE: A TOOL TO IDENTIFY CONTEXT-SPECIFIC SOLUTIONSThe analysis presented in this paper: the need to put in place-specific components to strengthen national implementation of NCD strategies and programmes, and to provide tailored technical support to enable this, relates to two particular aspects that the CFIR identified as influential on implementation outcomes.", [["NCD strategies", "TREATMENT", 454, 468], ["tailored technical support", "TREATMENT", 500, 526]]], ["Within the 'inner setting' (the national context for NCD implementation), the 'Structural Characteristics' of the lead organisation (government/ministry) includes its 'social architecture', age, maturity and size, and these characteristics can influence its ability to successfully implement policies and plans.", [["NCD implementation", "TREATMENT", 53, 71], ["social architecture", "OBSERVATION", 168, 187], ["size", "OBSERVATION_MODIFIER", 208, 212]]], ["Within the 'outer setting' (external influences that can encourage a government to act to address NCDs), 'Cosmopolitanism' describes the degree that an organisation is networked with other external organisations.", [["NCDs", "DISEASE", 98, 102]]], ["Our contention is that the current status of underdevelopment of NCD capacity at national level (priority, funding, capacity) may combine with an absence of external technical support and thus create a cycle of poor implementation.IMPLEMENTATION SCIENCE: A TOOL TO IDENTIFY CONTEXT-SPECIFIC SOLUTIONSWhile perhaps politically unfashionable to highlight direct support needs, we contend that at the present time technical support is essential to empower national health providers and policy-makers to operationalise effective NCD strategies.", [["NCD", "DISEASE", 65, 68], ["NCD capacity", "PROBLEM", 65, 77], ["external technical support", "TREATMENT", 157, 183], ["NCD strategies", "TREATMENT", 525, 539]]], ["In the complex world of global health organisations, there are various institutions, foundations and agencies that can provide components of the required support, depending on their technical capabilities in relation to specific issues, delivery capacity and infrastructure and relationships in different countries.", [["delivery capacity", "PROBLEM", 237, 254]]], ["Serious progress on SDG 3.4 in LMICs requires bilateral and multilateral donor organisations and philanthropic foundations to enable these implementation support partnerships.IMPLEMENTATION SCIENCE: A TOOL TO IDENTIFY CONTEXT-SPECIFIC SOLUTIONSTwitter Angela Jackson-Morris and Rachel Nugent IMPLEMENTATION SCIENCE: A TOOL TO IDENTIFY CONTEXT-SPECIFIC SOLUTIONSContributors AJ-M initiated the conceptual model.", [["SDG 3.4", "CHEMICAL", 20, 27], ["SDG", "TEST", 20, 23], ["bilateral and multilateral donor organisations", "TREATMENT", 46, 92], ["philanthropic foundations", "TREATMENT", 97, 122], ["bilateral", "ANATOMY_MODIFIER", 46, 55]]], ["AJ-M and RN coproduced and revised the manuscript.IMPLEMENTATION SCIENCE: A TOOL TO IDENTIFY CONTEXT-SPECIFIC SOLUTIONSFunding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.IMPLEMENTATION SCIENCE: A TOOL TO IDENTIFY CONTEXT-SPECIFIC SOLUTIONSCompeting interests None declared.IMPLEMENTATION SCIENCE: A TOOL TO IDENTIFY CONTEXT-SPECIFIC SOLUTIONSPatient consent for publication Not required.IMPLEMENTATION SCIENCE: A TOOL TO IDENTIFY CONTEXT-SPECIFIC SOLUTIONSProvenance and peer review Not commissioned; externally peer reviewed.IMPLEMENTATION SCIENCE: A TOOL TO IDENTIFY CONTEXT-SPECIFIC SOLUTIONSData availability statement All data relevant to the study are included in the article or uploaded as supplementary information.IMPLEMENTATION SCIENCE: A TOOL TO IDENTIFY CONTEXT-SPECIFIC SOLUTIONSOpen access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial.", [["the study", "TEST", 742, 751]]], ["See: http:// creativecommons. org/ licenses/ by-nc/ 4.", [["http", "GENE_OR_GENE_PRODUCT", 5, 9], ["org", "GENE_OR_GENE_PRODUCT", 30, 33]]], ["0/.ORCID iDsAngela Jackson-Morris http:// orcid. org/ 0000-0001-8348-7077 Rachel Nugent http:// orcid. org/ 0000-0001-6421-9077", [["org/ 0000-0001-6421-9077", "CHEMICAL", 103, 127], ["org/ 0000-0001-8348-7077", "SPECIES", 49, 73], ["org/ 0000-0001-6421-9077", "SPECIES", 103, 127]]]], "PMC7223326": [["IntroductionIn the recent decades, dengue has emerged as one of the world\u2019s most dominant tropical diseases (Guzman et al. 2016) with around 390 million (95% credible interval 284 to 528 million) cases recorded per year, of which only 96 million (95% credible interval 67 to 136 million) cases were manifested clinically (Giraldo-Garc\u00eda and Casta\u00f1o-Osorio, 2019; Bhatt et al. 2013).", [["dengue", "DISEASE", 35, 41], ["dengue", "SPECIES", 35, 41], ["dominant tropical diseases", "PROBLEM", 81, 107], ["Giraldo", "TEST", 322, 329]]], ["According to World Health Organization (WHO), an estimate of 3.9 billion people in 128 countries are living in areas with a high risk of dengue infection (Brady et al. 2012).", [["dengue infection", "DISEASE", 137, 153], ["people", "ORGANISM", 73, 79], ["people", "SPECIES", 73, 79], ["dengue", "SPECIES", 137, 143], ["dengue infection", "PROBLEM", 137, 153], ["dengue", "OBSERVATION_MODIFIER", 137, 143], ["infection", "OBSERVATION", 144, 153]]], ["The recently estimated annual 390 million dengue cases reveals that the dengue disease burden has tripled as compared to previous predictions of 50 to 100 million reported cases without dengue warning signs.", [["dengue", "DISEASE", 42, 48], ["dengue", "DISEASE", 72, 78], ["dengue", "DISEASE", 186, 192], ["dengue", "SPECIES", 72, 78], ["dengue", "SPECIES", 186, 192], ["the dengue disease burden", "PROBLEM", 68, 93], ["dengue warning signs", "PROBLEM", 186, 206], ["dengue disease", "OBSERVATION", 72, 86]]], ["Nonetheless, 250,000 to 500,000 patients were hospitalised due to dengue with warning signs (DWS+) and severe dengue (SD), and the total annual cost of dengue burden was estimated globally around US$ 8.9 billion (Giraldo-Garc\u00eda and Casta\u00f1o-Osorio, 2019; Guzman et al. 2016).", [["dengue", "DISEASE", 66, 72], ["dengue", "DISEASE", 110, 116], ["SD", "DISEASE", 118, 120], ["dengue", "DISEASE", 152, 158], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["dengue", "SPECIES", 152, 158], ["dengue", "PROBLEM", 66, 72], ["warning signs", "TEST", 78, 91], ["severe dengue (SD)", "PROBLEM", 103, 121], ["dengue burden", "PROBLEM", 152, 165], ["Giraldo", "TEST", 213, 220], ["severe", "OBSERVATION_MODIFIER", 103, 109], ["dengue", "OBSERVATION", 110, 116]]], ["In spite of having paucity of effective vaccines and drugs to expel dengue comprehensively, still it\u2019s enduring a big challenge to human (Martina et al. 2009).", [["dengue", "DISEASE", 68, 74], ["human", "ORGANISM", 131, 136], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 131, 136], ["effective vaccines", "TREATMENT", 30, 48], ["drugs", "TREATMENT", 53, 58]]], ["Therefore, next-generation vaccine strategies such as inactivated purified virus, DNA or protein-based subunit vaccines, and their fusion chimeras are now going under investigation and some of them even under clinical trials (Coller et al. 2011; Danko et al. 2011; Liu et al. 2015).IntroductionRecently, Dengvaxia (CYD-TDV), a tetravalent live attenuated vaccine has been approved for use in some of the highly dengue endemic areas where the sero-prevalence is higher than 70% (Guy et al. 2015; Pang et al. 2018).", [["Dengvaxia", "CHEMICAL", 304, 313], ["CYD-TDV", "CHEMICAL", 315, 322], ["dengue", "DISEASE", 411, 417], ["DNA", "CELLULAR_COMPONENT", 82, 85], ["next-generation vaccine strategies", "TREATMENT", 11, 45], ["inactivated purified virus", "TREATMENT", 54, 80], ["protein-based subunit vaccines", "TREATMENT", 89, 119], ["their fusion chimeras", "TREATMENT", 125, 146], ["Dengvaxia (CYD-TDV", "TREATMENT", 304, 322], ["a tetravalent live attenuated vaccine", "TREATMENT", 325, 362], ["highly", "OBSERVATION_MODIFIER", 404, 410], ["dengue", "OBSERVATION", 411, 417]]], ["According to WHO, it has shown significant efficacy and acceptable safety profile during clinical trials in seropositive individuals; however, it carries a risk of severe dengue infection in seronegative individuals, and also failed to confer subsequent protection in DENV-2 positive people in areas with less exposure of dengue (Arredondo-Garc\u00eda et al. 2018; Durbin et al. 2011; Guy et al. 2011).", [["dengue infection", "DISEASE", 171, 187], ["dengue", "DISEASE", 322, 328], ["DENV-2", "ORGANISM", 268, 274], ["people", "ORGANISM", 284, 290], ["people", "SPECIES", 284, 290], ["dengue", "SPECIES", 171, 177], ["DENV-2", "SPECIES", 268, 274], ["dengue", "SPECIES", 322, 328], ["severe dengue infection in seronegative individuals", "PROBLEM", 164, 215], ["DENV", "PROBLEM", 268, 272], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["severe", "OBSERVATION_MODIFIER", 164, 170], ["dengue", "OBSERVATION_MODIFIER", 171, 177], ["infection", "OBSERVATION", 178, 187]]], ["Several other vaccine candidates were also formulated based on live-attenuated dengue viruses (e.g. TV003, TV005) and inactivated purified virus (e.g. DPIV), of which some have already completed clinical trials and some are currently going under phase II to III clinical trials (Whitehead et al. 2017; Diaz et al. 2018).", [["dengue", "DISEASE", 79, 85], ["dengue viruses", "SPECIES", 79, 93], ["TV003", "SPECIES", 100, 105], ["DPIV", "SPECIES", 151, 155], ["Several other vaccine candidates", "TREATMENT", 0, 32], ["attenuated dengue viruses", "PROBLEM", 68, 93], ["TV003", "TEST", 100, 105], ["inactivated purified virus", "PROBLEM", 118, 144]]], ["On the other hand, DNA or protein-based alternative subunit vaccines (e.g. TVDV, DEN-80) and dengue-flavivirus chimeras (e.g. EDIII-p64k, 80E-STF2, EDIII-HbsAg) are going either under preclinical study or phase I clinical test (Govindarajan et al. 2015; Danko et al. 2018; Casta\u00f1o-Osorio et al., 2019).", [["DEN-80", "CHEMICAL", 81, 87], ["dengue", "DISEASE", 93, 99], ["DNA", "CELLULAR_COMPONENT", 19, 22], ["DEN-80", "ORGANISM", 81, 87], ["dengue-flavivirus chimeras", "ORGANISM", 93, 119], ["80E-STF2", "GENE_OR_GENE_PRODUCT", 138, 146], ["EDIII-HbsAg", "GENE_OR_GENE_PRODUCT", 148, 159], ["EDIII", "PROTEIN", 126, 131], ["p64k", "PROTEIN", 132, 136], ["80E", "PROTEIN", 138, 141], ["STF2", "PROTEIN", 142, 146], ["EDIII", "PROTEIN", 148, 153], ["HbsAg", "PROTEIN", 154, 159], ["dengue-flavivirus", "SPECIES", 93, 110], ["TVDV", "SPECIES", 75, 79], ["dengue-flavivirus", "SPECIES", 93, 110], ["protein", "TEST", 26, 33], ["alternative subunit vaccines", "TREATMENT", 40, 68], ["TVDV", "TEST", 75, 79], ["dengue", "PROBLEM", 93, 99], ["flavivirus chimeras", "TEST", 100, 119], ["EDIII", "TEST", 126, 131], ["STF2", "TEST", 142, 146], ["EDIII", "TEST", 148, 153], ["preclinical study", "TEST", 184, 201], ["flavivirus chimeras", "OBSERVATION", 100, 119]]], ["Although, still most of them are seemed to be slow immunity booster and require a strong adjuvant and longer immunisation to achieve full protection against each of the dengue serotype, which all make them ill-suited for universal vaccine licence (Casta\u00f1o-Osorio et al., 2019).IntroductionThe dengue envelope (E) protein is composed of three ecto-domains, a membrane-proximal stem and a transmembrane anchor (Klein et al. 2013).", [["membrane", "ANATOMY", 358, 366], ["stem", "ANATOMY", 376, 380], ["transmembrane", "ANATOMY", 387, 400], ["dengue", "DISEASE", 169, 175], ["dengue", "DISEASE", 293, 299], ["membrane", "CELLULAR_COMPONENT", 358, 366], ["stem", "TISSUE", 376, 380], ["transmembrane", "CELLULAR_COMPONENT", 387, 400], ["dengue envelope (E) protein", "PROTEIN", 293, 320], ["ecto-domains", "PROTEIN", 342, 354], ["membrane-proximal stem", "PROTEIN", 358, 380], ["transmembrane anchor", "PROTEIN", 387, 407], ["dengue", "SPECIES", 169, 175], ["slow immunity booster", "PROBLEM", 46, 67], ["a strong adjuvant", "TREATMENT", 80, 97], ["longer immunisation", "TREATMENT", 102, 121], ["full protection", "TREATMENT", 133, 148], ["the dengue serotype", "PROBLEM", 165, 184], ["universal vaccine licence", "TREATMENT", 221, 246], ["The dengue envelope (E) protein", "TREATMENT", 289, 320], ["a membrane-proximal stem", "TREATMENT", 356, 380], ["a transmembrane anchor", "TREATMENT", 385, 407], ["proximal stem", "ANATOMY", 367, 380]]], ["Various crystal structures have shown that the ecto-domains are arranged into three antiparallel dimer on virus surface in a icosahedral symmetry, where ecto-domain I (EI) is located at the centre holding domain II (EDII) and III (EDIII) in two opposite sites in each of the monomer of a dimeric unit (Fibriansah et al. 2015; Kuhn et al. 2002; Modis et al. 2004).", [["ecto-domain I", "GENE_OR_GENE_PRODUCT", 153, 166], ["ecto-domains", "PROTEIN", 47, 59], ["antiparallel dimer", "PROTEIN", 84, 102], ["ecto-domain I", "PROTEIN", 153, 166], ["EI", "PROTEIN", 168, 170], ["centre holding domain II", "PROTEIN", 190, 214], ["EDII", "PROTEIN", 216, 220], ["III", "PROTEIN", 226, 229], ["EDIII", "PROTEIN", 231, 236], ["icosahedral symmetry", "OBSERVATION", 125, 145]]], ["Most of the protective antibodies against dengue virus are identified to domain III, and initially were thought to be a potential subunit vaccine target (Murphy and Whitehead 2011; Sukupolvi-Petty et al. 2010).", [["dengue", "DISEASE", 42, 48], ["dengue virus", "ORGANISM", 42, 54], ["protective antibodies", "PROTEIN", 12, 33], ["domain III", "PROTEIN", 73, 83], ["dengue virus", "SPECIES", 42, 54], ["dengue virus", "SPECIES", 42, 54], ["the protective antibodies", "TREATMENT", 8, 33], ["dengue virus", "PROBLEM", 42, 54], ["Sukupolvi", "TEST", 181, 190]]], ["Although, recombinant EDIII domain injected by plasmid DNA or purified from bacterial expression systems was found to be poorly immunogenic, and has shown low protective efficacy in animal model (Guzman et al. 2010).", [["plasmid", "ANATOMY", 47, 54], ["EDIII", "GENE_OR_GENE_PRODUCT", 22, 27], ["plasmid DNA", "CELLULAR_COMPONENT", 47, 58], ["recombinant EDIII domain", "PROTEIN", 10, 34], ["plasmid DNA", "DNA", 47, 58], ["recombinant EDIII domain", "TREATMENT", 10, 34], ["plasmid DNA", "PROBLEM", 47, 58], ["bacterial expression systems", "PROBLEM", 76, 104], ["low protective", "OBSERVATION_MODIFIER", 155, 169]]], ["On the other hand, EDII has been reported as the dimerisation domain and consists of the most conserved fusion (Fu) and bc loop (Li et al. 2019; Zhang et al. 2004).", [["EDII", "CHEMICAL", 19, 23], ["EDII", "GENE_OR_GENE_PRODUCT", 19, 23], ["EDII", "PROTEIN", 19, 23], ["dimerisation domain", "PROTEIN", 49, 68], ["Fu", "PROTEIN", 112, 114], ["bc loop", "PROTEIN", 120, 127], ["the most conserved fusion", "TREATMENT", 85, 110], ["fusion", "OBSERVATION", 104, 110]]], ["Several studies have also shown that the conserved Fu loop is highly immunogenic (Lai et al. 2008; Cherrier et al. 2009; Smith et al. 2013), and induces cross-reactive antibodies, of which some are cross-talk with adjacent bc loop (Gallichotte et al., 2015; Cherrier et al. 2009).", [["Fu loop", "DNA", 51, 58], ["cross-reactive antibodies", "PROTEIN", 153, 178], ["Several studies", "TEST", 0, 15], ["cross-reactive antibodies", "PROBLEM", 153, 178], ["adjacent bc loop", "TREATMENT", 214, 230], ["Fu loop", "OBSERVATION", 51, 58]]], ["Moreover, during endocytosis, both of the loops are found to involve in tertiary conformation of membrane fusion (Nayak et al. 2009; Sukupolvi-Petty et al. 2010).", [["membrane", "ANATOMY", 97, 105], ["membrane", "CELLULAR_COMPONENT", 97, 105], ["membrane fusion", "TREATMENT", 97, 112], ["loops", "ANATOMY", 42, 47], ["membrane fusion", "OBSERVATION", 97, 112]]], ["Therefore, it has been anticipated that both of the loops might have integrated role for boosting cross-neutralizing immunity.IntroductionIn this study, we aim to develop an alternative vaccine by combining Fu and bc loop together in a single ORF for production of a fusion antigen.", [["ORF", "DNA", 243, 246], ["fusion antigen", "PROTEIN", 267, 281], ["boosting cross-neutralizing immunity", "TREATMENT", 89, 125], ["this study", "TEST", 141, 151], ["an alternative vaccine", "TREATMENT", 171, 193], ["combining Fu and bc loop", "TREATMENT", 197, 221], ["a single ORF", "TREATMENT", 234, 246], ["a fusion antigen", "PROBLEM", 265, 281]]], ["Although, the recombinant antigen in isolation tends to be poorly immunogenic in vivo; the use of potent immunomodulating compounds, fusion partner or suitable delivery systems improve specific immune response (Higgins et al. 2007; Gar\u00e7on et al. 2011).", [["recombinant antigen", "PROTEIN", 14, 33], ["the recombinant antigen in isolation", "PROBLEM", 10, 46], ["potent immunomodulating compounds", "TREATMENT", 98, 131], ["fusion partner", "TREATMENT", 133, 147], ["suitable delivery systems", "TREATMENT", 151, 176]]], ["Herein, we have expressed the recombinant Fubc antigenic protein, optimised its large-scale purification protocol and finally evaluated its protein-specific immune response in BALB/c mice.", [["Fubc", "GENE_OR_GENE_PRODUCT", 42, 46], ["BALB/c mice", "ORGANISM", 176, 187], ["recombinant Fubc antigenic protein", "PROTEIN", 30, 64], ["mice", "SPECIES", 183, 187], ["mice", "SPECIES", 183, 187], ["its large-scale purification protocol", "TREATMENT", 76, 113], ["its protein", "TEST", 136, 147]]], ["Prior to the animal challenge, its secondary structure was checked by CD spectroscopy, and binding specificity was cross-checked with a characterised anti-fusion loop scFv antibody (Rathore et al. 2019).Animals ::: Materials and methodsAll of the male and female BALB/c mice were obtained from National Institute of Nutrition, Telangana, Hyderabad, India and were maintained in standard light: dark (12:12) cycle with the supplement of adequate standard food, and water was provided from ad libitum.", [["female", "ORGANISM", 256, 262], ["BALB/c mice", "ORGANISM", 263, 274], ["anti-fusion loop scFv antibody", "PROTEIN", 150, 180], ["mice", "SPECIES", 270, 274], ["mice", "SPECIES", 270, 274], ["the animal challenge", "TREATMENT", 9, 29], ["CD spectroscopy", "TEST", 70, 85], ["binding specificity", "TEST", 91, 110], ["a characterised anti-fusion loop scFv antibody", "TREATMENT", 134, 180]]], ["All of the animals were acclimated and randomly distributed into different experimental groups.", [["animals", "ORGANISM", 11, 18]]], ["Furthermore, all the in vivo experiments were performed in accordance with the committee for the purpose of control and supervision on experiments on animals (CPCSEA) guidelines and were approved by the South Asian University Institutional Animal Ethics Committee (IAEC) that was responsible for the care and use of laboratory animals.Construction and cloning of Fubc gene ::: Materials and methodsThe DNA sequence of Fubc gene was retrieved from fusion (Fu) and bc loop of DENV serotype 2 envelope protein deposited in the protein data bank (PDB: 1OAN).", [["Fubc", "GENE_OR_GENE_PRODUCT", 363, 367], ["DNA", "CELLULAR_COMPONENT", 402, 405], ["Fubc", "GENE_OR_GENE_PRODUCT", 418, 422], ["DENV serotype 2", "GENE_OR_GENE_PRODUCT", 474, 489], ["Fubc gene", "DNA", 363, 372], ["Fubc gene", "DNA", 418, 427], ["Fu", "PROTEIN", 455, 457], ["DENV serotype 2 envelope protein", "PROTEIN", 474, 506], ["1OAN", "PROTEIN", 548, 552], ["The DNA sequence", "TEST", 398, 414], ["Fubc gene", "TREATMENT", 418, 427], ["fusion (Fu)", "TREATMENT", 447, 458], ["bc loop", "TREATMENT", 463, 470], ["DENV serotype", "PROBLEM", 474, 487]]], ["In order to construct stable and immunogenic protein, highly conserved fusion (Fu) and bc loops and their neighbouring residues (amino acid residues 62 to 122) were selected by using antigen variability analyser (AVANA), pBLAST and multiple sequence alignment tool of NCBI.", [["amino acid", "CHEMICAL", 129, 139], ["amino acid", "CHEMICAL", 129, 139], ["amino acid", "AMINO_ACID", 129, 139], ["immunogenic protein", "PROTEIN", 33, 52], ["Fu", "PROTEIN", 79, 81], ["bc loops", "PROTEIN", 87, 95], ["amino acid residues 62 to 122", "PROTEIN", 129, 158], ["immunogenic protein", "PROBLEM", 33, 52], ["bc loops", "PROBLEM", 87, 95], ["amino acid residues", "TEST", 129, 148], ["pBLAST", "TREATMENT", 221, 227], ["stable", "OBSERVATION_MODIFIER", 22, 28], ["bc loops", "ANATOMY", 87, 95]]], ["For convenient expression in bacteria, all of the oligos were codon optimised for E. coli, using codon optimisation tool of Integrated DNA Technology.", [["E. coli", "ORGANISM", 82, 89], ["DNA", "CELLULAR_COMPONENT", 135, 138], ["E. coli", "SPECIES", 82, 89], ["E. coli", "SPECIES", 82, 89], ["convenient expression in bacteria", "PROBLEM", 4, 37], ["the oligos", "TREATMENT", 46, 56], ["codon optimised", "TREATMENT", 62, 77], ["E. coli", "PROBLEM", 82, 89], ["bacteria", "OBSERVATION", 29, 37]]], ["Complete Fubc gene was constructed by assembly PCR reactions using four 60 nucleotide long overlapping oligonucleotides.", [["nucleotide", "CHEMICAL", 75, 85], ["nucleotide", "CHEMICAL", 75, 85], ["Fubc", "GENE_OR_GENE_PRODUCT", 9, 13], ["Fubc gene", "DNA", 9, 18], ["60 nucleotide long overlapping oligonucleotides", "DNA", 72, 119], ["assembly PCR reactions", "PROBLEM", 38, 60], ["nucleotide long overlapping oligonucleotides", "TREATMENT", 75, 119]]], ["For cloning into pET28a expression vector, two unique restriction sites, EcoRI and XhoI, were also incorporated at the 5\u2032 and 3\u2032 ends respectively during the final amplification of Fubc full-length gene using forward and reverse primers.", [["pET28a", "GENE_OR_GENE_PRODUCT", 17, 23], ["EcoRI", "GENE_OR_GENE_PRODUCT", 73, 78], ["XhoI", "GENE_OR_GENE_PRODUCT", 83, 87], ["pET28a expression vector", "DNA", 17, 41], ["restriction sites", "DNA", 54, 71], ["EcoRI", "DNA", 73, 78], ["XhoI", "DNA", 83, 87], ["5\u2032 and 3\u2032 ends", "DNA", 119, 133], ["Fubc full-length gene", "DNA", 181, 202], ["forward and reverse primers", "DNA", 209, 236], ["cloning into pET28a expression vector", "TREATMENT", 4, 41], ["two unique restriction sites", "TREATMENT", 43, 71], ["EcoRI and XhoI", "TREATMENT", 73, 87], ["Fubc full-length gene", "TREATMENT", 181, 202], ["forward and reverse primers", "TREATMENT", 209, 236]]], ["Initially, the full-length Fubc gene was cloned into a TA cloning vector using InsTAclone kit (Thermo Scientific).", [["Fubc", "GENE_OR_GENE_PRODUCT", 27, 31], ["full-length Fubc gene", "DNA", 15, 36], ["TA cloning vector", "DNA", 55, 72], ["the full-length Fubc gene", "TREATMENT", 11, 36], ["a TA cloning vector", "TREATMENT", 53, 72], ["InsTAclone kit", "TREATMENT", 79, 93]]], ["Positive clones were screened using X-gal blue-white screening method and digested with EcoRI and XhoI restriction enzymes.", [["clones", "ANATOMY", 9, 15], ["clones", "CELL", 9, 15], ["X-gal", "GENE_OR_GENE_PRODUCT", 36, 41], ["EcoRI", "GENE_OR_GENE_PRODUCT", 88, 93], ["XhoI restriction enzymes", "GENE_OR_GENE_PRODUCT", 98, 122], ["EcoRI", "DNA", 88, 93], ["XhoI restriction enzymes", "PROTEIN", 98, 122], ["Positive clones", "PROBLEM", 0, 15], ["white screening method", "TEST", 47, 69], ["EcoRI and XhoI restriction enzymes", "TEST", 88, 122], ["clones", "OBSERVATION", 9, 15]]], ["The digested Fubc gene was further sub-cloned into a pET28a expression vector.", [["Fubc", "GENE_OR_GENE_PRODUCT", 13, 17], ["pET28a", "GENE_OR_GENE_PRODUCT", 53, 59], ["digested Fubc gene", "DNA", 4, 22], ["pET28a expression vector", "DNA", 53, 77], ["The digested Fubc gene", "TREATMENT", 0, 22], ["a pET28a expression vector", "TREATMENT", 51, 77]]], ["The recombinant plasmid (Fubc + pET28a) was transformed into E. coli XL-10 GOLD for cloning, and subsequently into E. coli BL-21 Rosetta (DE3) for protein expression.Expression of recombinant Fubc protein ::: Materials and methodsThe E. coli BL-21 (Rosetta) cells carrying Fubc gene in pET28a vector were grown overnight at 37 \u00b0C in 10 ml LB broth (Luria-Bertani medium) containing 50 \u03bcg/ml kanamycin (Sigma, USA).", [["plasmid", "ANATOMY", 16, 23], ["cells", "ANATOMY", 258, 263], ["kanamycin", "CHEMICAL", 391, 400], ["kanamycin", "CHEMICAL", 391, 400], ["Fubc + pET28a", "GENE_OR_GENE_PRODUCT", 25, 38], ["E. coli", "ORGANISM", 61, 68], ["E. coli", "ORGANISM", 115, 122], ["BL-21 Rosetta", "ORGANISM", 123, 136], ["DE3", "GENE_OR_GENE_PRODUCT", 138, 141], ["Fubc", "GENE_OR_GENE_PRODUCT", 192, 196], ["E. coli", "ORGANISM", 234, 241], ["BL-21", "ORGANISM", 242, 247], ["Rosetta) cells", "CELL", 249, 263], ["Fubc", "GENE_OR_GENE_PRODUCT", 273, 277], ["pET28a", "GENE_OR_GENE_PRODUCT", 286, 292], ["kanamycin", "SIMPLE_CHEMICAL", 391, 400], ["recombinant plasmid", "DNA", 4, 23], ["Fubc", "DNA", 25, 29], ["pET28a", "DNA", 32, 38], ["recombinant Fubc protein", "PROTEIN", 180, 204], ["E. coli BL-21 (Rosetta) cells", "CELL_LINE", 234, 263], ["Fubc gene", "DNA", 273, 282], ["pET28a vector", "DNA", 286, 299], ["E. coli", "SPECIES", 61, 68], ["E. coli", "SPECIES", 115, 122], ["E. coli", "SPECIES", 234, 241], ["E. coli", "SPECIES", 61, 68], ["E. coli BL-21 Rosetta (DE3", "SPECIES", 115, 141], ["E. coli", "SPECIES", 234, 241], ["The recombinant plasmid", "TREATMENT", 0, 23], ["E. coli XL", "TEST", 61, 71], ["E. coli BL", "TEST", 115, 125], ["protein expression", "PROBLEM", 147, 165], ["The E. coli BL", "TEST", 230, 244], ["Fubc gene in pET28a vector", "TREATMENT", 273, 299], ["Luria-Bertani medium)", "TREATMENT", 349, 370], ["coli XL", "OBSERVATION", 64, 71]]], ["Overnight grown 1 ml primary culture was used to inoculate kanamycin containing 100 ml secondary culture and was further incubated at 37 \u00b0C. The incubated secondary culture was induced by 0.5 mM isopropyl \u03b2-D-1-thiogalactopyranoside (IPTG) when its OD600 reached at around 0.5, and the culture was grown for another 4 h at 37 \u00b0C. The cells were harvested by centrifugation at 4000 rpm for 10 min.", [["cells", "ANATOMY", 334, 339], ["kanamycin", "CHEMICAL", 59, 68], ["isopropyl \u03b2-D-1-thiogalactopyranoside", "CHEMICAL", 195, 232], ["IPTG", "CHEMICAL", 234, 238], ["kanamycin", "CHEMICAL", 59, 68], ["isopropyl \u03b2-D-1-thiogalactopyranoside", "CHEMICAL", 195, 232], ["IPTG", "CHEMICAL", 234, 238], ["kanamycin", "SIMPLE_CHEMICAL", 59, 68], ["isopropyl \u03b2-D-1-thiogalactopyranoside", "SIMPLE_CHEMICAL", 195, 232], ["IPTG", "SIMPLE_CHEMICAL", 234, 238], ["cells", "CELL", 334, 339], ["primary culture", "TEST", 21, 36], ["kanamycin", "TREATMENT", 59, 68], ["secondary culture", "TEST", 87, 104], ["The incubated secondary culture", "TEST", 141, 172], ["thiogalactopyranoside (IPTG", "TREATMENT", 211, 238], ["the culture", "TEST", 282, 293]]], ["The resulting cell pellet was re-suspended in lysis buffer containing 50 mM Tris-HCl pH 8.0, 1 mM CaCl2, with 0.5% Triton X-100, Lysozyme 0.1 mg/ml, 1 mM EDTA and 1 mM PMSF.", [["cell pellet", "ANATOMY", 14, 25], ["Tris-HCl", "CHEMICAL", 76, 84], ["CaCl2", "CHEMICAL", 98, 103], ["Triton X-100", "CHEMICAL", 115, 127], ["Tris-HCl", "CHEMICAL", 76, 84], ["CaCl2", "CHEMICAL", 98, 103], ["EDTA", "CHEMICAL", 154, 158], ["PMSF", "CHEMICAL", 168, 172], ["cell", "CELL", 14, 18], ["Tris-HCl", "SIMPLE_CHEMICAL", 76, 84], ["CaCl2", "SIMPLE_CHEMICAL", 98, 103], ["Triton X-100", "SIMPLE_CHEMICAL", 115, 127], ["Lysozyme", "SIMPLE_CHEMICAL", 129, 137], ["EDTA", "SIMPLE_CHEMICAL", 154, 158], ["PMSF", "SIMPLE_CHEMICAL", 168, 172], ["The resulting cell pellet", "TEST", 0, 25], ["lysis buffer", "TREATMENT", 46, 58], ["Tris", "TEST", 76, 80], ["HCl pH", "TEST", 81, 87], ["1 mM CaCl2", "TREATMENT", 93, 103], ["Lysozyme", "TREATMENT", 129, 137], ["cell pellet", "OBSERVATION", 14, 25]]], ["Then, the resuspended cells were kept on a rocker for an hour at room temperature, and sonication was done using 30% amplitude for five times 30 s on/off pulse.", [["cells", "ANATOMY", 22, 27], ["cells", "CELL", 22, 27], ["resuspended cells", "CELL_TYPE", 10, 27], ["the resuspended cells", "TREATMENT", 6, 27]]], ["The lysed sample was separated into supernatant and pellet by centrifugation at 10,000 rpm for 10 min at 4 \u00b0C. Finally, Fubc expression level in supernatant and pellet were checked on 15% SDS-PAGE.Solubilisation and purification of Fubc protein ::: Materials and methodsA major fraction of the Fubc protein was observed in pellet after a number of efforts made to recover it in a soluble form.", [["sample", "ANATOMY", 10, 16], ["supernatant", "ANATOMY", 36, 47], ["supernatant", "ANATOMY", 145, 156], ["pellet", "ANATOMY", 161, 167], ["SDS", "CHEMICAL", 188, 191], ["Fubc", "GENE_OR_GENE_PRODUCT", 120, 124], ["Fubc", "GENE_OR_GENE_PRODUCT", 232, 236], ["Fubc", "GENE_OR_GENE_PRODUCT", 294, 298], ["Fubc", "PROTEIN", 120, 124], ["Fubc protein", "PROTEIN", 232, 244], ["Fubc protein", "PROTEIN", 294, 306], ["The lysed sample", "TREATMENT", 0, 16], ["Fubc expression level", "TEST", 120, 141], ["Solubilisation", "TREATMENT", 197, 211], ["the Fubc protein", "TEST", 290, 306]]], ["Then, it was decided to recover soluble protein from pellet fraction.", [["soluble protein", "PROTEIN", 32, 47]]], ["The resulting pellet protein was washed 4 to 5 times with TE 50/20 (50 mM Tris pH 8.0 and 20 mM EDTA 20) buffer to remove impurities and extra salts.", [["EDTA", "CHEMICAL", 96, 100], ["extra salts", "SIMPLE_CHEMICAL", 137, 148], ["The resulting pellet protein", "TREATMENT", 0, 28], ["TE", "TEST", 58, 60], ["Tris pH", "TEST", 74, 81], ["20 mM EDTA", "TREATMENT", 90, 100], ["extra salts", "TREATMENT", 137, 148], ["pellet protein", "OBSERVATION", 14, 28]]], ["The remaining pellet was re-solubilised using mild denaturing agent such as 4.0 M urea and 5% n-propanol along with PBS buffer (pH 8.1) (Sarker et al. 2019) and was centrifuged at 20,000 rpm for 10 min.", [["urea", "CHEMICAL", 82, 86], ["n-propanol", "CHEMICAL", 94, 104], ["urea", "CHEMICAL", 82, 86], ["n-propanol", "CHEMICAL", 94, 104], ["urea", "SIMPLE_CHEMICAL", 82, 86], ["n-propanol", "SIMPLE_CHEMICAL", 94, 104], ["mild denaturing agent", "TREATMENT", 46, 67], ["4.0 M urea", "TREATMENT", 76, 86], ["5% n-propanol", "TREATMENT", 91, 104], ["PBS buffer", "TREATMENT", 116, 126], ["pH", "TEST", 128, 130]]], ["The soluble protein fraction was initially purified by using Ni-NTA agarose beads and was confirmed by western blot using anti-His antibody.", [["Ni-NTA", "CHEMICAL", 61, 67], ["Ni-NTA", "CHEMICAL", 61, 67], ["His", "CHEMICAL", 127, 130], ["anti-His antibody", "PROTEIN", 122, 139], ["The soluble protein fraction", "TEST", 0, 28], ["Ni-NTA agarose beads", "TREATMENT", 61, 81], ["protein fraction", "OBSERVATION", 12, 28]]], ["Therefore, soluble protein fraction was subjected to gel filtration in Superose 6 10/300 column by using fast protein liquid chromatography (FPLC) for large-scale good quality protein production.", [["soluble protein fraction", "TEST", 11, 35], ["gel filtration", "TREATMENT", 53, 67], ["fast protein liquid chromatography", "TEST", 105, 139], ["FPLC", "TEST", 141, 145], ["protein production", "OBSERVATION", 176, 194]]], ["The column was pre-equilibrated with PBS (50 mM phosphate buffer pH 7.4 and 150 mM NaCl), and the protein sample was eluted with the same PBS buffer.", [["sample", "ANATOMY", 106, 112], ["phosphate", "CHEMICAL", 48, 57], ["NaCl", "CHEMICAL", 83, 87], ["phosphate", "CHEMICAL", 48, 57], ["NaCl", "CHEMICAL", 83, 87], ["PBS", "TREATMENT", 37, 40], ["mM phosphate buffer pH", "TEST", 45, 67], ["NaCl", "TEST", 83, 87], ["the protein sample", "TEST", 94, 112], ["the same PBS buffer", "TREATMENT", 129, 148]]], ["0.5 ml protein sample was injected in each run by using 0.5 ml loop at 0.4 ml/min flow rate.", [["sample", "ANATOMY", 15, 21], ["0.5 ml protein sample", "TREATMENT", 0, 21], ["flow rate", "TEST", 82, 91]]], ["The elution profile of injected protein was followed by monitoring UV absorbance at 280 nm on the AKTA FPLC system with U9-L UV monitor.", [["injected protein", "TREATMENT", 23, 39], ["monitoring UV absorbance", "TEST", 56, 80], ["the AKTA FPLC system", "TEST", 94, 114], ["U9", "TEST", 120, 122]]], ["Different peaks greater than 20 mAU were collected in fraction collector and checked using a 15% SDS PAGE.", [["Different peaks", "TEST", 0, 15], ["fraction collector", "TEST", 54, 72], ["a 15% SDS PAGE", "TREATMENT", 91, 105], ["peaks", "OBSERVATION_MODIFIER", 10, 15], ["greater", "OBSERVATION_MODIFIER", 16, 23]]], ["Multiple runs of FPLC were carried out, and the fraction containing Fubc protein was pooled together.", [["Fubc", "GENE_OR_GENE_PRODUCT", 68, 72], ["Fubc protein", "PROTEIN", 68, 80], ["Multiple runs of FPLC", "PROBLEM", 0, 21], ["Fubc protein", "TEST", 68, 80]]], ["Finally, Fubc was concentrated and desalted by using 0.5 ml Millipore-Amicone filter with a cut-off of 3 kDa.", [["Fubc", "SIMPLE_CHEMICAL", 9, 13], ["Fubc", "PROTEIN", 9, 13], ["0.5 ml Millipore-Amicone filter", "TREATMENT", 53, 84]]], ["Concentration of the purified Fubc was also measured by using BCA protein assay kit.CD spectroscopy of recombinant Fubc protein ::: Materials and methodsIn order to assure the proper folding of purified (> 95%) Fubc protein, secondary structure was analysed by CD spectroscopy at far UV wavelength ranging from 180 to 260 nm.", [["Fubc", "GENE_OR_GENE_PRODUCT", 30, 34], ["Fubc", "GENE_OR_GENE_PRODUCT", 115, 119], ["Fubc", "GENE_OR_GENE_PRODUCT", 211, 215], ["Fubc", "PROTEIN", 30, 34], ["recombinant Fubc protein", "PROTEIN", 103, 127], ["Fubc protein", "PROTEIN", 211, 223], ["the purified Fubc", "TEST", 17, 34], ["BCA protein assay kit", "TEST", 62, 83], ["CD spectroscopy", "TEST", 84, 99], ["Fubc protein", "TEST", 211, 223], ["secondary structure", "PROBLEM", 225, 244], ["CD spectroscopy", "TEST", 261, 276]]], ["To achieve the best conformational reading, CD spectrum was obtained at the different protein and buffer concentrations, because the CD spectrum of a protein needs to be adequately intense for interpreting the data as the intensity of a CD spectrum directly relies on the protein and buffer concentration (Kelly et al. 2005; Miles and Wallace 2006).", [["CD spectrum", "TEST", 44, 55], ["buffer concentrations", "TREATMENT", 98, 119], ["the protein and buffer concentration", "TREATMENT", 268, 304]]], ["The CD spectra of PBS buffer and Fubc protein samples at 0.1 mg/ml and 0.2 mg/ml concentrations (diluted in 50 mM and 10 mM PBS buffer, pH 7.4) were recorded at far UV spectra ranging from 200 to 280 nm with a step size of 1 nm to bandwidth 1 nm.", [["The CD spectra of PBS buffer", "TREATMENT", 0, 28], ["Fubc protein samples", "TREATMENT", 33, 53], ["pH", "TEST", 136, 138], ["UV spectra", "TEST", 165, 175], ["a step size", "TEST", 208, 219], ["size", "OBSERVATION_MODIFIER", 215, 219]]], ["The measurement was performed at room temperature (22 \u00b0C), and the UV spectra were recorded for each sample with five scans.", [["The measurement", "TEST", 0, 15], ["the UV spectra", "TEST", 63, 77], ["five scans", "TEST", 113, 123]]], ["The baseline CD spectrum of the buffer was deducted from the spectrum containing the protein to yield the actual Fubc protein CD spectrum.", [["Fubc protein", "PROTEIN", 113, 125], ["the buffer", "TREATMENT", 28, 38]]], ["The mean residue ellipticity [\u03b8] mrw at wavelength \u03bb was quoted in units of degree cm2/dmol, and was calculated as [\u03b8] mrw, \u03bb = MRW \u00d7 \u03b8\u03bb/10 \u00d7 d \u00d7 c, where \u03b8 is the observed ellipticity (degrees) at wavelength \u03bb, d is the path length (cm) and c is the concentration (g/ml).", [["MRW", "PROTEIN", 128, 131], ["\u03b8\u03bb", "PROTEIN", 134, 136], ["\u03b8", "PROTEIN", 155, 156], ["The mean residue ellipticity", "PROBLEM", 0, 28], ["dmol", "PROBLEM", 87, 91], ["mrw", "TEST", 119, 122], ["ellipticity", "OBSERVATION_MODIFIER", 17, 28]]], ["MRW is the mean residual weight for the peptide bond which is given as MRW = M/(N \u2212 1); where M is the molecular mass of the polypeptide chain (in Da), and N is the number of amino acids in the chain; the number of peptide bonds is N \u2212 1.Adjuvants and preparation of Fubc immunogens ::: Materials and methodsComplete and incomplete Freund\u2019s adjuvant (Sigma, USA) was used for primary (day 0) and booster immunisation (days 7, 14 and 21) respectively.", [["amino acids", "CHEMICAL", 175, 186], ["N", "CHEMICAL", 156, 157], ["amino acids", "CHEMICAL", 175, 186], ["amino acids", "AMINO_ACID", 175, 186], ["polypeptide chain", "PROTEIN", 125, 142], ["the peptide bond", "TEST", 36, 52], ["MRW", "TEST", 71, 74], ["methods", "TREATMENT", 301, 308], ["mass", "OBSERVATION", 113, 117]]], ["To prepare a primary dose of the immunogen, complete Freund\u2019s adjuvant (FA) was mixed with equal volume of purified Fubc (25 \u03bcg) in PBS and emulsified by vigorous vortex.", [["FA", "CHEMICAL", 72, 74], ["Fubc", "CHEMICAL", 116, 120], ["Freund\u2019s adjuvant", "SIMPLE_CHEMICAL", 53, 70], ["FA", "SIMPLE_CHEMICAL", 72, 74], ["Fubc", "SIMPLE_CHEMICAL", 116, 120], ["the immunogen", "TREATMENT", 29, 42], ["complete Freund\u2019s adjuvant", "TREATMENT", 44, 70], ["purified Fubc", "TREATMENT", 107, 120], ["vigorous vortex", "OBSERVATION", 154, 169]]], ["Similarly, three booster doses of immunogen were prepared with an equal volume of Fubc protein (25 \u03bcg) and incomplete Freund\u2019s adjuvant.", [["Fubc", "SIMPLE_CHEMICAL", 82, 86], ["Fubc protein", "PROTEIN", 82, 94], ["immunogen", "TREATMENT", 34, 43], ["Fubc protein", "TREATMENT", 82, 94], ["incomplete Freund\u2019s adjuvant", "TREATMENT", 107, 135]]], ["All of the immunogens were prepared according to the protocol \u201cImmunization of Mice\u201d by Maira-Litr\u00e1n, 2017.", [["Mice", "ORGANISM", 79, 83], ["Mice", "SPECIES", 79, 83], ["the immunogens", "TREATMENT", 7, 21]]], ["Finally, emulsified Fubc immunogens were checked by observing stable droplet on the water surface.Experimental design for mice immunisation ::: Materials and methodsHealthy BALB/c mice (10 weeks old, male and female) were randomly distributed into four different groups.", [["mice", "ORGANISM", 122, 126], ["BALB/c mice", "ORGANISM", 173, 184], ["mice", "SPECIES", 122, 126], ["mice", "SPECIES", 180, 184], ["mice", "SPECIES", 122, 126], ["mice", "SPECIES", 180, 184], ["emulsified Fubc immunogens", "TREATMENT", 9, 35], ["stable", "OBSERVATION_MODIFIER", 62, 68]]], ["Each group was immunised with different antigen preparations.", [["different antigen preparations", "TREATMENT", 30, 60]]], ["Out of the four, two groups were immunised with Fubc antigen: one group was injected with Fubc protein with adjuvant and other was with Fubc protein without adjuvant.", [["Fubc antigen", "CHEMICAL", 48, 60], ["Fubc antigen", "GENE_OR_GENE_PRODUCT", 48, 60], ["Fubc", "GENE_OR_GENE_PRODUCT", 90, 94], ["Fubc", "GENE_OR_GENE_PRODUCT", 136, 140], ["Fubc antigen", "PROTEIN", 48, 60], ["Fubc protein", "PROTEIN", 90, 102], ["Fubc protein", "PROTEIN", 136, 148], ["Fubc protein", "TREATMENT", 90, 102], ["adjuvant", "TREATMENT", 108, 116], ["Fubc protein", "TREATMENT", 136, 148], ["adjuvant", "TREATMENT", 157, 165]]], ["Rest of the two groups were immunised with Fu and bc peptide: one group was injected with Fu and Bc peptides with adjuvant, and other was Fu and bc peptide without adjuvant.", [["bc peptide", "SIMPLE_CHEMICAL", 50, 60], ["Bc peptides", "SIMPLE_CHEMICAL", 97, 108], ["bc peptide", "SIMPLE_CHEMICAL", 145, 155], ["Fu and bc peptide", "TEST", 43, 60], ["Fu and Bc peptides", "TREATMENT", 90, 108], ["adjuvant", "TREATMENT", 114, 122], ["Fu and bc peptide", "TEST", 138, 155], ["adjuvant", "TREATMENT", 164, 172]]], ["Each of the groups was also subdivided into male and female sets, and with each set, one adjuvant control was used replacing adjuvant with PBS buffer.", [["one adjuvant control", "TREATMENT", 85, 105], ["adjuvant with PBS buffer", "TREATMENT", 125, 149]]], ["The mice of each group were subcutaneously immunised with emulsified antigen preparations, first dose (day 0) with CFA and three subsequent booster doses (at days 7, 14 and 21) with IFA (according to protocol Maira-Litr\u00e1n 2017).", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["emulsified antigen preparations", "TREATMENT", 58, 89], ["CFA", "TREATMENT", 115, 118], ["three subsequent booster doses", "TREATMENT", 123, 153], ["IFA", "TEST", 182, 185]]], ["After 5 days of the final booster dose, blood samples were collected by retro-orbital cavity, and all the antisera isolated from blood were stored at \u2212 80 \u00b0C for further analysis.ELISA to check murine IgG response against Fubc protein ::: Materials and methodsRecombinant Fubc protein-specific IgG was measured by indirect ELISA.", [["blood samples", "ANATOMY", 40, 53], ["retro-orbital cavity", "ANATOMY", 72, 92], ["blood", "ANATOMY", 129, 134], ["blood samples", "ORGANISM_SUBSTANCE", 40, 53], ["retro-orbital cavity", "MULTI-TISSUE_STRUCTURE", 72, 92], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["murine", "ORGANISM", 194, 200], ["IgG", "GENE_OR_GENE_PRODUCT", 201, 204], ["Fubc", "GENE_OR_GENE_PRODUCT", 222, 226], ["Fubc", "GENE_OR_GENE_PRODUCT", 272, 276], ["IgG", "GENE_OR_GENE_PRODUCT", 294, 297], ["murine IgG", "PROTEIN", 194, 204], ["Fubc protein", "PROTEIN", 222, 234], ["Recombinant Fubc protein", "PROTEIN", 260, 284], ["IgG", "PROTEIN", 294, 297], ["murine", "SPECIES", 194, 200], ["the final booster dose", "TREATMENT", 16, 38], ["blood samples", "TEST", 40, 53], ["further analysis", "TEST", 162, 178], ["ELISA", "TEST", 179, 184], ["methodsRecombinant Fubc protein", "TEST", 253, 284], ["specific IgG", "TEST", 285, 297], ["retro-orbital cavity", "ANATOMY", 72, 92]]], ["For this, 96 well ELISA plates were coated by incubating overnight at 4 \u00b0C with Fubc protein (1 \u03bcg/well) in 50 mM sodium carbonate-bicarbonate buffer pH 9.5.", [["sodium carbonate-bicarbonate", "CHEMICAL", 114, 142], ["sodium carbonate", "CHEMICAL", 114, 130], ["bicarbonate", "CHEMICAL", 131, 142], ["sodium carbonate-bicarbonate", "SIMPLE_CHEMICAL", 114, 142], ["Fubc protein", "PROTEIN", 80, 92], ["Fubc protein", "TEST", 80, 92], ["50 mM sodium carbonate", "TREATMENT", 108, 130], ["bicarbonate buffer pH", "TREATMENT", 131, 152]]], ["Blocking was done for 2 h with 2% BSA in PBST (PBS plus 0.05% Tween 20).", [["BSA", "CHEMICAL", 34, 37], ["Tween 20", "CHEMICAL", 62, 70], ["BSA", "SIMPLE_CHEMICAL", 34, 37], ["2% BSA in PBST", "TREATMENT", 31, 45], ["PBS", "TEST", 47, 50]]], ["Serum collected from immunised and control mice were incubated for 1 h at 37 \u00b0C after making 7 double dilutions in PBST starting from 1/500 \u03bcl.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["mice", "ORGANISM", 43, 47], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 43, 47], ["Serum", "TEST", 0, 5], ["7 double dilutions", "TREATMENT", 93, 111]]], ["Subsequently, the ELISA plate was washed once with PBST, and 100 \u03bcl of anti-mouse HRP-conjugated secondary antibody (1:1000 dilution in PBST) was added and incubated for 30 min at room temperature.", [["HRP", "GENE_OR_GENE_PRODUCT", 82, 85], ["anti-mouse HRP", "PROTEIN", 71, 85], ["conjugated secondary antibody", "PROTEIN", 86, 115], ["anti-mouse", "SPECIES", 71, 81], ["anti-mouse", "SPECIES", 71, 81], ["the ELISA plate", "TREATMENT", 14, 29], ["PBST", "TREATMENT", 51, 55], ["anti-mouse HRP", "TREATMENT", 71, 85], ["conjugated secondary antibody", "TREATMENT", 86, 115]]], ["Then, the plate was washed three more times with PBST, and the binding reaction was developed by adding 200 \u03bcl/well OPD substrate (prepared in a phosphate-citrate buffer, 0.05 M, pH \u2212 5.0 plus 0.03% H2O2).", [["phosphate-citrate", "CHEMICAL", 145, 162], ["H2O2", "CHEMICAL", 199, 203], ["phosphate-citrate", "CHEMICAL", 145, 162], ["H2O2", "CHEMICAL", 199, 203], ["phosphate-citrate", "SIMPLE_CHEMICAL", 145, 162], ["H2O2", "SIMPLE_CHEMICAL", 199, 203], ["the plate", "TREATMENT", 6, 15], ["PBST", "TREATMENT", 49, 53], ["the binding reaction", "PROBLEM", 59, 79], ["a phosphate-citrate buffer", "TREATMENT", 143, 169], ["pH", "TEST", 179, 181]]], ["The reaction was stopped by adding 50 \u03bcl of 2.5 M H2SO4 just after observing an optimum colour, and the absorbance was measured at 492-nm wavelength using BioTek Synergy HT microplate reader (Winooski, VT).", [["H2SO4", "CHEMICAL", 50, 55], ["H2SO4", "CHEMICAL", 50, 55], ["The reaction", "PROBLEM", 0, 12], ["2.5 M H2SO4", "TREATMENT", 44, 55], ["the absorbance", "TEST", 100, 114], ["BioTek Synergy HT microplate", "TREATMENT", 155, 183]]], ["Mean absorbance was plotted against anti-sera dilutions, and two-way ANOVA was performed to find a statistically significant difference between two groups.", [["Mean absorbance", "TEST", 0, 15], ["anti-sera dilutions", "TREATMENT", 36, 55], ["a statistically significant difference between two groups", "PROBLEM", 97, 154], ["significant", "OBSERVATION_MODIFIER", 113, 124], ["difference", "OBSERVATION", 125, 135]]], ["Comparison of the immune response in different groups of antisera was made by converting each ELISA curve to linear equations (y = mx + c), and computing serum dilutions for a fixed ELISA absorbance.", [["serum", "ANATOMY", 154, 159], ["serum", "ORGANISM_SUBSTANCE", 154, 159], ["antisera", "TREATMENT", 57, 65], ["linear equations", "TEST", 109, 125], ["computing serum dilutions", "TEST", 144, 169], ["a fixed ELISA absorbance", "PROBLEM", 174, 198], ["ELISA absorbance", "OBSERVATION", 182, 198]]], ["The data are expressed as mean \u00b1 standard deviation (SD). p values of < 0.05 were considered statistically significant.Validation of Fubc immune response by SPR ::: Materials and methodsTo validate the immune response generated by recombinant Fubc, collected mice anti-sera were allowed for SPR interaction experiment with a Autolab ESPRIT instrument.", [["Fubc", "SIMPLE_CHEMICAL", 133, 137], ["Fubc", "GENE_OR_GENE_PRODUCT", 243, 247], ["mice", "ORGANISM", 259, 263], ["anti-sera", "CELL", 264, 273], ["recombinant Fubc", "PROTEIN", 231, 247], ["mice", "SPECIES", 259, 263], ["mice", "SPECIES", 259, 263], ["p values", "TEST", 58, 66], ["a Autolab ESPRIT instrument", "TREATMENT", 323, 350]]], ["Similar to ELISA, here also recombinant Fubc protein of DENV envelope was immobilised on a gold plate of SPR device.", [["Fubc", "GENE_OR_GENE_PRODUCT", 40, 44], ["DENV", "ORGANISM", 56, 60], ["recombinant Fubc protein", "PROTEIN", 28, 52], ["DENV", "SPECIES", 56, 60], ["ELISA", "TEST", 11, 16], ["DENV envelope", "PROBLEM", 56, 69], ["a gold plate of SPR device", "TREATMENT", 89, 115], ["DENV", "OBSERVATION", 56, 60]]], ["For coupling of Fubc protein on gold disc, 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC) and N-hydroxysuccinimide (NHS) were applied for activation.", [["1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide", "CHEMICAL", 43, 89], ["EDAC", "CHEMICAL", 91, 95], ["N-hydroxysuccinimide", "CHEMICAL", 101, 121], ["NHS", "CHEMICAL", 123, 126], ["1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide", "CHEMICAL", 43, 89], ["EDAC", "CHEMICAL", 91, 95], ["N-hydroxysuccinimide", "CHEMICAL", 101, 121], ["NHS", "CHEMICAL", 123, 126], ["Fubc", "GENE_OR_GENE_PRODUCT", 16, 20], ["gold disc", "SIMPLE_CHEMICAL", 32, 41], ["1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide", "SIMPLE_CHEMICAL", 43, 89], ["EDAC", "SIMPLE_CHEMICAL", 91, 95], ["N-hydroxysuccinimide", "SIMPLE_CHEMICAL", 101, 121], ["NHS", "SIMPLE_CHEMICAL", 123, 126], ["Fubc protein", "PROTEIN", 16, 28], ["Fubc protein", "PROBLEM", 16, 28], ["gold disc", "TREATMENT", 32, 41], ["Ethyl", "TREATMENT", 45, 50], ["3-dimethylaminopropyl) carbodiimide (EDAC)", "TREATMENT", 54, 96], ["N-hydroxysuccinimide (NHS)", "TREATMENT", 101, 127]]], ["NHS activates the carboxymethyl groups by creating a highly reactive succinimide ester on the disc surface, which reacts with amine and other nucleophilic groups on proteins that subsequently help to bind the target protein on activated disc surface.", [["disc surface", "ANATOMY", 94, 106], ["disc surface", "ANATOMY", 237, 249], ["succinimide ester", "CHEMICAL", 69, 86], ["amine", "CHEMICAL", 126, 131], ["carboxymethyl", "CHEMICAL", 18, 31], ["succinimide ester", "CHEMICAL", 69, 86], ["amine", "CHEMICAL", 126, 131], ["NHS", "SIMPLE_CHEMICAL", 0, 3], ["succinimide ester", "SIMPLE_CHEMICAL", 69, 86], ["disc surface", "CELLULAR_COMPONENT", 94, 106], ["amine", "SIMPLE_CHEMICAL", 126, 131], ["disc surface", "CELLULAR_COMPONENT", 237, 249], ["target protein", "PROTEIN", 209, 223], ["the carboxymethyl groups", "TREATMENT", 14, 38], ["a highly reactive succinimide ester on the disc surface", "TREATMENT", 51, 106], ["reactive", "OBSERVATION_MODIFIER", 60, 68], ["succinimide ester", "OBSERVATION", 69, 86], ["disc", "ANATOMY", 94, 98], ["surface", "ANATOMY_MODIFIER", 99, 106], ["disc", "ANATOMY", 237, 241]]], ["Ethanolamine was added to block the remaining activated carboxymethyl group.", [["Ethanolamine", "CHEMICAL", 0, 12], ["Ethanolamine", "CHEMICAL", 0, 12], ["carboxymethyl", "CHEMICAL", 56, 69], ["Ethanolamine", "SIMPLE_CHEMICAL", 0, 12], ["carboxymethyl", "SIMPLE_CHEMICAL", 56, 69], ["Ethanolamine", "TREATMENT", 0, 12], ["block the remaining activated carboxymethyl group", "TREATMENT", 26, 75]]], ["For the qualitative assay, all of the serum samples (diluted in running buffer) were applied at a flow rate of 20 \u03bcl/min over 2 min.", [["serum samples", "ANATOMY", 38, 51], ["serum samples", "ORGANISM_SUBSTANCE", 38, 51], ["the qualitative assay", "TEST", 4, 25], ["the serum samples", "TEST", 34, 51], ["running buffer)", "TREATMENT", 64, 79], ["a flow rate", "TREATMENT", 96, 107]]], ["In between injections, the surface of the sensor chip was regenerated by injecting 2 M NaCl at the same flow rate for 15 s.", [["surface", "ANATOMY", 27, 34], ["NaCl", "CHEMICAL", 87, 91], ["NaCl", "CHEMICAL", 87, 91], ["surface", "CELLULAR_COMPONENT", 27, 34], ["injections", "TREATMENT", 11, 21], ["the sensor chip", "TREATMENT", 38, 53], ["2 M NaCl", "TREATMENT", 83, 91]]], ["In addition, surface coupling was done by using buffer (150 mM NaCl, 3 mM EDTA, 0.005% surfactant P20 and 10 mM HEPES-NaOH) at pH 7.4, and the buffer containing 50 mM phosphate and 150 mM NaCl at pH 7.1 was used for sample running.", [["surface", "ANATOMY", 13, 20], ["sample", "ANATOMY", 216, 222], ["NaCl", "CHEMICAL", 63, 67], ["HEPES-NaOH", "CHEMICAL", 112, 122], ["phosphate", "CHEMICAL", 167, 176], ["NaCl", "CHEMICAL", 188, 192], ["NaCl", "CHEMICAL", 63, 67], ["EDTA", "CHEMICAL", 74, 78], ["HEPES", "CHEMICAL", 112, 117], ["NaOH", "CHEMICAL", 118, 122], ["phosphate", "CHEMICAL", 167, 176], ["NaCl", "CHEMICAL", 188, 192], ["EDTA", "SIMPLE_CHEMICAL", 74, 78], ["phosphate", "SIMPLE_CHEMICAL", 167, 176], ["3 mM EDTA", "TREATMENT", 69, 78], ["0.005% surfactant P20", "TREATMENT", 80, 101], ["10 mM HEPES-NaOH", "TREATMENT", 106, 122], ["pH", "TEST", 127, 129], ["the buffer", "TREATMENT", 139, 149], ["50 mM phosphate", "TREATMENT", 161, 176], ["150 mM NaCl at pH", "TREATMENT", 181, 198]]], ["Initially, a series of serum dilutions were applied as analytes to find an optimum refractive index.", [["serum", "ANATOMY", 23, 28], ["serum", "ORGANISM_SUBSTANCE", 23, 28], ["serum dilutions", "TREATMENT", 23, 38], ["an optimum refractive index", "TEST", 72, 99], ["refractive index", "OBSERVATION", 83, 99]]], ["It was observed that the refractive index at 1:500 dilution was within the detection limit among the series of serial dilutions (Fig. 6a).", [["the refractive index", "TEST", 21, 41], ["serial dilutions", "TEST", 111, 127], ["refractive", "OBSERVATION_MODIFIER", 25, 35], ["index", "OBSERVATION_MODIFIER", 36, 41]]], ["Therefore, 1:500 dilution of different experimental samples was applied as standard for further comparative analysis between Fubc immune response with and without Freund\u2019s adjuvant.", [["samples", "ANATOMY", 52, 59], ["Fubc", "SIMPLE_CHEMICAL", 125, 129], ["Freund", "ORGANISM", 163, 169], ["different experimental samples", "TREATMENT", 29, 59], ["further comparative analysis", "TEST", 88, 116], ["Freund\u2019s adjuvant", "TREATMENT", 163, 180]]], ["Serum control (the serum collected before immunisation) sample with the identical dilution was also applied to find the basal (non-specific) immune response of serum.", [["Serum", "ANATOMY", 0, 5], ["serum", "ANATOMY", 19, 24], ["sample", "ANATOMY", 56, 62], ["serum", "ANATOMY", 160, 165], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["serum", "ORGANISM_SUBSTANCE", 160, 165], ["Serum control", "TEST", 0, 13], ["the serum", "TEST", 15, 24], ["the identical dilution", "TREATMENT", 68, 90], ["the basal (non-specific) immune response of serum", "PROBLEM", 116, 165]]], ["Finally, refractive index was then analysed from association and dissociation curve of the SPR sensorgram.Accession number ::: Materials and methodsThe Fubc synthetic gene sequence was deposited in GenBank database with accession number MN781186.Designing of recombinant Fubc antigen ::: ResultsGenerally, dengue envelope (E) folded into three distinct domains (designated by domain I, II and III), membrane proximal stem and a transmembrane anchor (Klein et al. 2013).", [["membrane proximal stem", "ANATOMY", 399, 421], ["transmembrane", "ANATOMY", 428, 441], ["dengue", "DISEASE", 306, 312], ["Fubc", "GENE_OR_GENE_PRODUCT", 152, 156], ["Fubc antigen", "GENE_OR_GENE_PRODUCT", 271, 283], ["membrane", "CELLULAR_COMPONENT", 399, 407], ["Fubc synthetic gene sequence", "DNA", 152, 180], ["recombinant Fubc antigen", "PROTEIN", 259, 283], ["domain I, II and III", "PROTEIN", 376, 396], ["membrane proximal stem", "PROTEIN", 399, 421], ["transmembrane anchor", "PROTEIN", 428, 448], ["refractive index", "TEST", 9, 25], ["the SPR sensorgram", "TEST", 87, 105], ["a transmembrane anchor", "TREATMENT", 426, 448], ["refractive index", "OBSERVATION", 9, 25], ["membrane", "ANATOMY_MODIFIER", 399, 407], ["proximal stem", "ANATOMY", 408, 421]]], ["Throughout these structural element, four highly conserved regions have been identified by in silico sequence analysis, and two of them were found in the domain II with a very less informational entropy (Rathore et al. 2019).", [["domain II", "PROTEIN", 154, 163], ["silico sequence analysis", "TEST", 94, 118], ["structural element", "OBSERVATION", 17, 35]]], ["Further studies have revealed that these conserved regions are the part of previously characterised flavivirus fusion (Fu) and bc loop (Kuhn et al. 2002).", [["Further studies", "TEST", 0, 15], ["previously characterised flavivirus fusion", "PROBLEM", 75, 117], ["flavivirus fusion", "OBSERVATION", 100, 117]]], ["During the process of endocytosis, this hydrophobic fusion loop remains buried at the dimer interface in the prefusion state and forms cluster into larger hydrophobic surface at one end to form trimer at later state that finally initiates membrane fusion (Klein et al. 2013).", [["surface", "ANATOMY", 167, 174], ["membrane", "ANATOMY", 239, 247], ["membrane", "CELLULAR_COMPONENT", 239, 247], ["hydrophobic fusion loop", "PROTEIN", 40, 63], ["endocytosis", "PROBLEM", 22, 33], ["this hydrophobic fusion loop", "TREATMENT", 35, 63], ["membrane fusion", "TREATMENT", 239, 254], ["endocytosis", "OBSERVATION", 22, 33], ["fusion loop", "OBSERVATION", 52, 63], ["prefusion state", "OBSERVATION", 109, 124], ["larger", "OBSERVATION_MODIFIER", 148, 154], ["hydrophobic", "OBSERVATION_MODIFIER", 155, 166], ["surface", "OBSERVATION_MODIFIER", 167, 174], ["membrane fusion", "OBSERVATION", 239, 254]]], ["In addition to this structural property, Fu and bc regions consist some of the most potent antigenic epitopes that were identified by DENV neutralising conformation sensitive anti-DENV hMAbs (Goncalvez et al. 2007; Costin et al. 2013; Yamanaka et al. 2013).", [["Fu", "GENE_OR_GENE_PRODUCT", 41, 43], ["anti-DENV", "ORGANISM", 175, 184], ["hMAbs", "SIMPLE_CHEMICAL", 185, 190], ["Fu and bc regions", "PROTEIN", 41, 58], ["antigenic epitopes", "PROTEIN", 91, 109], ["anti-DENV hMAbs", "PROTEIN", 175, 190], ["DENV", "SPECIES", 134, 138], ["Fu and bc regions", "PROBLEM", 41, 58], ["the most potent antigenic epitopes", "PROBLEM", 75, 109], ["DENV neutralising conformation", "TEST", 134, 164], ["most potent", "OBSERVATION_MODIFIER", 79, 90]]], ["Therefore, these two conserved Fu and bc loops have been selected to design a recombinant Fubc antigenic protein for the development of dengue subunit vaccine.Designing of recombinant Fubc antigen ::: ResultsIn this study, an alignment of the domain II amino acid sequences of DENV1\u20134 envelope proteins spanning residues from 61 to 120 was used to find optimum conserved sequence for the development of Fubc fusion protein (Fig. 1a).", [["dengue", "DISEASE", 136, 142], ["amino acid", "CHEMICAL", 253, 263], ["amino acid", "CHEMICAL", 253, 263], ["Fu", "GENE_OR_GENE_PRODUCT", 31, 33], ["Fubc", "GENE_OR_GENE_PRODUCT", 90, 94], ["Fubc antigen", "GENE_OR_GENE_PRODUCT", 184, 196], ["amino acid", "AMINO_ACID", 253, 263], ["Fubc", "GENE_OR_GENE_PRODUCT", 403, 407], ["recombinant Fubc antigenic protein", "PROTEIN", 78, 112], ["recombinant Fubc antigen", "PROTEIN", 172, 196], ["domain II amino acid sequences", "PROTEIN", 243, 273], ["DENV1\u20134 envelope proteins", "PROTEIN", 277, 302], ["Fubc fusion protein", "PROTEIN", 403, 422], ["Fig. 1a", "PROTEIN", 424, 431], ["dengue", "SPECIES", 136, 142], ["Fu and bc loops", "TEST", 31, 46], ["a recombinant Fubc antigenic protein", "TREATMENT", 76, 112], ["dengue subunit vaccine", "TREATMENT", 136, 158], ["this study", "TEST", 211, 221], ["the domain II amino acid sequences", "TEST", 239, 273], ["Fubc fusion protein", "TREATMENT", 403, 422]]], ["The structural details of truncated Fubc protein compare to whole envelope in dengue and Fu, and bc peptides were also analysed by modelling each of their three dimensional structure.", [["dengue", "DISEASE", 78, 84], ["Fubc", "GENE_OR_GENE_PRODUCT", 36, 40], ["Fu", "GENE_OR_GENE_PRODUCT", 89, 91], ["bc peptides", "GENE_OR_GENE_PRODUCT", 97, 108], ["truncated Fubc protein", "PROTEIN", 26, 48], ["dengue", "SPECIES", 78, 84], ["truncated Fubc protein", "PROBLEM", 26, 48], ["dengue and Fu, and bc peptides", "TEST", 78, 108]]], ["It reveals that the presence of three anti-parallel \u03b2-strands and one disulphide linkage play a crucial role in preserving the three dimensional conformations of truncated Fubc protein same as in original DENV envelope protein (Fig. 1b, c).", [["disulphide", "CHEMICAL", 70, 80], ["Fubc", "GENE_OR_GENE_PRODUCT", 172, 176], ["anti-parallel \u03b2-strands", "PROTEIN", 38, 61], ["Fubc protein", "PROTEIN", 172, 184], ["DENV envelope protein", "PROTEIN", 205, 226], ["Fig. 1b, c)", "PROTEIN", 228, 239], ["three anti-parallel \u03b2-strands", "TREATMENT", 32, 61], ["truncated Fubc protein same", "PROBLEM", 162, 189], ["original DENV envelope protein", "TEST", 196, 226]]], ["Ironically, due to the absence of anti-parallel \u03b2-strands and a single protein frame of Fu and bc loops, these two separately expressed peptides fail to form similar three-dimensional conformation as in original DENV envelop (Fig. 1c).", [["Fu", "GENE_OR_GENE_PRODUCT", 88, 90], ["anti-parallel \u03b2-strands", "PROTEIN", 34, 57], ["Fu and bc loops", "PROTEIN", 88, 103], ["anti-parallel \u03b2-strands", "PROBLEM", 34, 57], ["Fu and bc loops", "TEST", 88, 103], ["bc loops", "ANATOMY", 95, 103], ["DENV", "OBSERVATION", 212, 216]]], ["The electrostatic and solvent accessible areas of Fubc truncated protein are also comparable with original dengue envelope.", [["dengue", "DISEASE", 107, 113], ["Fubc truncated protein", "PROTEIN", 50, 72], ["Fubc truncated protein", "PROBLEM", 50, 72], ["original dengue envelope", "PROBLEM", 98, 122], ["electrostatic", "OBSERVATION_MODIFIER", 4, 17], ["solvent", "OBSERVATION_MODIFIER", 22, 29], ["accessible", "OBSERVATION_MODIFIER", 30, 40], ["areas", "OBSERVATION_MODIFIER", 41, 46], ["Fubc", "OBSERVATION_MODIFIER", 50, 54], ["truncated protein", "OBSERVATION", 55, 72], ["dengue envelope", "OBSERVATION", 107, 122]]], ["Hence, it is speculated that the recombinant Fubc protein would be an alternative vaccine target of whole dengue envelope.Development of recombinant Fubc gene ::: ResultsFor in vitro synthesis of short antigenic protein, a recombinant Fubc gene was constructed by assembly PCR using overlapping oligonucleotides, designed from Fu and bc loop encoding DNA sequences of dengue envelope.", [["dengue", "DISEASE", 106, 112], ["dengue", "DISEASE", 368, 374], ["Fubc", "GENE_OR_GENE_PRODUCT", 45, 49], ["Fubc", "GENE_OR_GENE_PRODUCT", 149, 153], ["Fubc", "GENE_OR_GENE_PRODUCT", 235, 239], ["Fu", "GENE_OR_GENE_PRODUCT", 327, 329], ["DNA", "CELLULAR_COMPONENT", 351, 354], ["recombinant Fubc protein", "PROTEIN", 33, 57], ["recombinant Fubc gene", "DNA", 137, 158], ["short antigenic protein", "PROTEIN", 196, 219], ["recombinant Fubc gene", "DNA", 223, 244], ["Fu and bc loop", "DNA", 327, 341], ["the recombinant Fubc protein", "PROBLEM", 29, 57], ["an alternative vaccine", "TREATMENT", 67, 89], ["whole dengue envelope", "PROBLEM", 100, 121], ["short antigenic protein", "PROBLEM", 196, 219], ["a recombinant Fubc gene", "TREATMENT", 221, 244], ["overlapping oligonucleotides", "TREATMENT", 283, 311], ["Fu and bc loop", "TREATMENT", 327, 341], ["dengue envelope", "PROBLEM", 368, 383], ["recombinant Fubc", "OBSERVATION", 137, 153]]], ["Therefore, full length of Fubc gene was amplified by using 5\u02ca and 3\u02ca end primers flanked by EcoRI and XhoI restriction sites.", [["Fubc", "GENE_OR_GENE_PRODUCT", 26, 30], ["EcoRI", "GENE_OR_GENE_PRODUCT", 92, 97], ["XhoI", "GENE_OR_GENE_PRODUCT", 102, 106], ["Fubc gene", "DNA", 26, 35], ["5\u02ca and 3\u02ca end primers", "DNA", 59, 80], ["EcoRI and XhoI restriction sites", "DNA", 92, 124], ["full length of Fubc gene", "TREATMENT", 11, 35], ["3\u02ca end primers", "TREATMENT", 66, 80], ["EcoRI and XhoI restriction sites", "TREATMENT", 92, 124]]], ["The Fubc gene was then cloned into a TA cloning vector, and the clones were screened by colony PCR using Fubc gene specific end primers.", [["clones", "ANATOMY", 64, 70], ["Fubc", "GENE_OR_GENE_PRODUCT", 4, 8], ["clones", "CELL", 64, 70], ["Fubc gene", "DNA", 4, 13], ["TA cloning vector", "DNA", 37, 54], ["Fubc gene specific end primers", "DNA", 105, 135], ["The Fubc gene", "TREATMENT", 0, 13], ["a TA cloning vector", "TREATMENT", 35, 54], ["the clones", "TREATMENT", 60, 70], ["colony PCR", "TEST", 88, 98], ["Fubc gene specific end primers", "PROBLEM", 105, 135]]], ["Two positive clones were then confirmed by restriction digestion using EcoRI and XhoI enzymes (Fig. S1a\u2013d).", [["EcoRI", "GENE_OR_GENE_PRODUCT", 71, 76], ["XhoI", "GENE_OR_GENE_PRODUCT", 81, 85], ["EcoRI", "DNA", 71, 76], ["XhoI enzymes", "PROTEIN", 81, 93], ["Fig. S1a\u2013d", "PROTEIN", 95, 105], ["Two positive clones", "PROBLEM", 0, 19], ["EcoRI and XhoI enzymes", "TEST", 71, 93], ["positive clones", "OBSERVATION", 4, 19]]], ["The digested and purified Fubc insert gene was further sub-cloned into pET28a expression vector, and the positive clones were confirmed by restriction digestion (Fig. S2b) and Sanger sequencing.Expression and purification of recombinant Fubc protein ::: ResultsPrimarily, the recombinant Fubc protein expression was observed only in pellet fraction; there was no such Fubc equivalent protein band in supernatant fraction, while they were separated on SDS PAGE (Fig. S2c).", [["clones", "ANATOMY", 114, 120], ["supernatant", "ANATOMY", 400, 411], ["Fubc", "GENE_OR_GENE_PRODUCT", 26, 30], ["pET28a", "GENE_OR_GENE_PRODUCT", 71, 77], ["Fubc", "GENE_OR_GENE_PRODUCT", 237, 241], ["Fubc", "GENE_OR_GENE_PRODUCT", 288, 292], ["digested and purified Fubc insert gene", "DNA", 4, 42], ["pET28a expression vector", "DNA", 71, 95], ["recombinant Fubc protein", "PROTEIN", 225, 249], ["recombinant Fubc protein", "PROTEIN", 276, 300], ["Fubc equivalent protein band", "PROTEIN", 368, 396], ["purified Fubc insert gene", "TREATMENT", 17, 42], ["the positive clones", "PROBLEM", 101, 120], ["Sanger sequencing", "TEST", 176, 193], ["the recombinant Fubc protein expression", "PROBLEM", 272, 311], ["pellet fraction", "TEST", 333, 348], ["such Fubc equivalent protein band in supernatant fraction", "PROBLEM", 363, 420], ["positive clones", "OBSERVATION", 105, 120], ["protein expression", "OBSERVATION", 293, 311], ["pellet fraction", "OBSERVATION_MODIFIER", 333, 348], ["no", "UNCERTAINTY", 360, 362], ["supernatant fraction", "OBSERVATION", 400, 420]]], ["Therefore, Fubc expression level was checked further by lowering growth temperature and IPTG concentration, but no significant change was noticed in supernatant fraction.", [["supernatant", "ANATOMY", 149, 160], ["IPTG", "CHEMICAL", 88, 92], ["IPTG", "CHEMICAL", 88, 92], ["Fubc", "GENE_OR_GENE_PRODUCT", 11, 15], ["IPTG", "SIMPLE_CHEMICAL", 88, 92], ["Fubc", "PROTEIN", 11, 15], ["Fubc expression level", "TEST", 11, 32], ["IPTG concentration", "TREATMENT", 88, 106], ["significant change", "PROBLEM", 115, 133], ["no", "UNCERTAINTY", 112, 114], ["significant", "OBSERVATION_MODIFIER", 115, 126], ["change", "OBSERVATION", 127, 133], ["supernatant fraction", "OBSERVATION", 149, 169]]], ["Chaperone-assisted folding system did not help remarkably to express the Fubc recombinant protein in the soluble form.", [["Fubc", "GENE_OR_GENE_PRODUCT", 73, 77], ["Fubc recombinant protein", "PROTEIN", 73, 97], ["Chaperone-assisted folding system", "TREATMENT", 0, 33]]], ["Therefore, the insoluble pellet fraction of Fubc protein was further utilised in mild solubilisation process (Sarker et al. 2019) to recover soluble Fubc protein.", [["Fubc", "GENE_OR_GENE_PRODUCT", 44, 48], ["Fubc", "GENE_OR_GENE_PRODUCT", 149, 153], ["Fubc protein", "PROTEIN", 44, 56], ["Fubc protein", "PROTEIN", 149, 161], ["the insoluble pellet fraction", "TEST", 11, 40], ["Fubc protein", "PROBLEM", 44, 56], ["mild solubilisation process", "PROBLEM", 81, 108], ["mild", "OBSERVATION_MODIFIER", 81, 85], ["solubilisation process", "OBSERVATION", 86, 108]]], ["Initially, the recovered soluble Fubc protein fraction was purified by using Ni-NTA agarose beads, and the purified protein band was confirmed by Western blot analysis using anti-His tag monoclonal antibody (Fig. S3).", [["Ni-NTA", "CHEMICAL", 77, 83], ["Ni-NTA", "CHEMICAL", 77, 83], ["His", "CHEMICAL", 179, 182], ["Fubc", "GENE_OR_GENE_PRODUCT", 33, 37], ["Fubc protein fraction", "PROTEIN", 33, 54], ["anti-His tag monoclonal antibody", "PROTEIN", 174, 206], ["the recovered soluble Fubc protein fraction", "PROBLEM", 11, 54], ["Ni-NTA agarose beads", "TREATMENT", 77, 97], ["the purified protein band", "TEST", 103, 128], ["blot analysis", "TEST", 154, 167], ["anti", "TEST", 174, 178], ["His tag monoclonal antibody", "TEST", 179, 206]]], ["Although, Ni-NTA affinity chromatography has not revealed good purification quality and the yield was also not sufficient.", [["Ni-NTA", "SIMPLE_CHEMICAL", 10, 16], ["Ni-NTA affinity chromatography", "TEST", 10, 40]]], ["Furthermore, gel filtration chromatography was used to recover good quality large-scale recombinant protein, and single distinct peak greater than 20 mAU was observed at approximately 20.57 ml position for all of injected Fubc protein samples (Fig. 2a).", [["recombinant protein", "PROTEIN", 88, 107], ["Fubc protein samples", "PROTEIN", 222, 242], ["gel filtration chromatography", "TEST", 13, 42], ["injected Fubc protein samples", "TREATMENT", 213, 242]]], ["After pooling together, the peak fractions were separated on 15% SDS-PAGE, and single bright band was observed at molecular weight 11.5 kDa (Fig. 2b).Structural studies of recombinant Fubc protein ::: ResultsOriginally, the Fu and bc loop of dengue envelope is composed of three anti-parallel \u03b2-sheets.", [["dengue", "DISEASE", 242, 248], ["Fubc", "GENE_OR_GENE_PRODUCT", 184, 188], ["recombinant Fubc protein", "PROTEIN", 172, 196], ["anti-parallel \u03b2-sheets", "PROTEIN", 279, 301], ["the peak fractions", "TEST", 24, 42], ["single bright band", "PROBLEM", 79, 97], ["the Fu", "TEST", 220, 226], ["dengue envelope", "PROBLEM", 242, 257]]], ["And the formation of recombinant Fubc secondary structure was characterised here by negative bending at 208 nm and 222 nm wavelength (Kumagai et al. 2017).", [["recombinant Fubc secondary structure", "PROTEIN", 21, 57], ["recombinant Fubc secondary structure", "PROBLEM", 21, 57]]], ["The CD spectrum of recombinant Fubc protein has showed significantly decreased spectral peaks around 222 and 208 nm that signify the formation of \u03b2-sheet (Fig. 3).", [["Fubc", "GENE_OR_GENE_PRODUCT", 31, 35], ["recombinant Fubc protein", "PROTEIN", 19, 43], ["The CD spectrum", "TEST", 0, 15], ["recombinant Fubc protein", "TEST", 19, 43], ["significantly decreased spectral peaks", "PROBLEM", 55, 93], ["significantly", "OBSERVATION_MODIFIER", 55, 68], ["decreased", "OBSERVATION_MODIFIER", 69, 78], ["spectral peaks", "OBSERVATION", 79, 93], ["208 nm", "OBSERVATION_MODIFIER", 109, 115]]], ["In addition, it was noticed that the acquired CD spectrum of Fubc at a protein concentration of 0.1 mg/ml in 10 mM PBS buffer was adequately intense (Fig. 2).", [["Fubc", "CHEMICAL", 61, 65], ["Fubc", "SIMPLE_CHEMICAL", 61, 65], ["Fubc at a protein concentration", "TREATMENT", 61, 92], ["10 mM PBS buffer", "TREATMENT", 109, 125]]], ["Therefore, it can be inferred from Fig. 3 (lower panel) that Fubc at concentrations of 0.2 mg/mL and 0.1 mg/mL in 10 mM PBS retained the best globular folded state as compared to other conditions.Immune response to the purified Fubc protein in BALB/c mice ::: ResultsFrom indirect ELISA, it was observed that the serum IgG levels in both male and female groups treated with Fubc proteins were significantly higher than those treated with only adjuvant and PBS control (Fig. 4a, b).", [["serum", "ANATOMY", 313, 318], ["Fubc", "CHEMICAL", 61, 65], ["Fubc", "SIMPLE_CHEMICAL", 61, 65], ["Fubc", "GENE_OR_GENE_PRODUCT", 228, 232], ["BALB/c mice", "ORGANISM", 244, 255], ["serum", "ORGANISM_SUBSTANCE", 313, 318], ["IgG", "GENE_OR_GENE_PRODUCT", 319, 322], ["Fubc", "GENE_OR_GENE_PRODUCT", 374, 378], ["globular folded state", "PROTEIN", 142, 163], ["Fubc protein", "PROTEIN", 228, 240], ["serum IgG", "PROTEIN", 313, 322], ["Fubc proteins", "PROTEIN", 374, 387], ["mice", "SPECIES", 251, 255], ["mice", "SPECIES", 251, 255], ["Fubc at concentrations", "TREATMENT", 61, 83], ["indirect ELISA", "TEST", 272, 286], ["the serum IgG levels", "TEST", 309, 329], ["Fubc proteins", "PROBLEM", 374, 387], ["adjuvant and PBS control", "TREATMENT", 443, 467], ["globular folded", "OBSERVATION", 142, 157]]], ["In addition, the response with only Fubc recombinant protein (without adjuvant) in the female group was also observed higher than their male counterpart group (Fig. 4b).", [["Fubc recombinant", "GENE_OR_GENE_PRODUCT", 36, 52], ["Fubc recombinant protein", "PROTEIN", 36, 60], ["Fubc recombinant protein", "PROBLEM", 36, 60], ["adjuvant", "TREATMENT", 70, 78]]], ["All of the ELISA data were also found statistically significant by two-way ANOVA (Table S1).", [["the ELISA data", "TEST", 7, 21]]], ["Similarly, by SPR assay, high level immune response was also observed for serum injected with recombinant Fubc protein along with adjuvant, and without any adjuvant, the response was also higher than the control (serum with PBS only) (Fig. 6b).DiscussionIn post-dengue infection, most of the circulating antibodies are non-neutralizing and found to be raised against dengue envelope E protein and the prM protein (Wahala and de Silva 2011).", [["serum", "ANATOMY", 74, 79], ["serum", "ANATOMY", 213, 218], ["post-dengue infection", "DISEASE", 257, 278], ["serum", "ORGANISM_SUBSTANCE", 74, 79], ["Fubc", "GENE_OR_GENE_PRODUCT", 106, 110], ["serum", "ORGANISM_SUBSTANCE", 213, 218], ["dengue envelope E protein", "GENE_OR_GENE_PRODUCT", 367, 392], ["prM", "GENE_OR_GENE_PRODUCT", 401, 404], ["recombinant Fubc protein", "PROTEIN", 94, 118], ["circulating antibodies", "PROTEIN", 292, 314], ["dengue envelope E protein", "PROTEIN", 367, 392], ["prM protein", "PROTEIN", 401, 412], ["dengue", "SPECIES", 367, 373], ["SPR assay", "TEST", 14, 23], ["high level immune response", "PROBLEM", 25, 51], ["recombinant Fubc protein", "TREATMENT", 94, 118], ["adjuvant", "TREATMENT", 130, 138], ["any adjuvant", "TREATMENT", 152, 164], ["PBS", "TEST", 224, 227], ["post-dengue infection", "PROBLEM", 257, 278], ["the circulating antibodies", "TEST", 288, 314], ["dengue envelope E protein", "PROBLEM", 367, 392], ["the prM protein", "TEST", 397, 412], ["infection", "OBSERVATION", 269, 278]]], ["Due to the absence of highly specific neutralising antibodies in secondary infections, cross-reactive non-neutralising antibodies usually enhance the dengue severity (De Alwis et al. 2014).", [["infections", "DISEASE", 75, 85], ["dengue", "DISEASE", 150, 156], ["neutralising antibodies", "PROTEIN", 38, 61], ["cross-reactive non-neutralising antibodies", "PROTEIN", 87, 129], ["dengue", "SPECIES", 150, 156], ["highly specific neutralising antibodies", "PROBLEM", 22, 61], ["secondary infections", "PROBLEM", 65, 85], ["cross-reactive non-neutralising antibodies", "PROBLEM", 87, 129], ["the dengue severity", "PROBLEM", 146, 165], ["secondary infections", "OBSERVATION", 65, 85]]], ["According to the revised dengue case classification (DENCO), 2 to 3% of secondary infections with another serotype causes life threating dengue with warning signs (DWS+) and severe dengue (SD).", [["dengue", "DISEASE", 25, 31], ["infections", "DISEASE", 82, 92], ["dengue", "DISEASE", 137, 143], ["dengue", "DISEASE", 181, 187], ["SD", "DISEASE", 189, 191], ["secondary infections", "PROBLEM", 72, 92], ["dengue", "PROBLEM", 137, 143], ["warning signs", "TEST", 149, 162], ["severe dengue (SD)", "PROBLEM", 174, 192], ["infections", "OBSERVATION", 82, 92], ["severe", "OBSERVATION_MODIFIER", 174, 180], ["dengue", "OBSERVATION", 181, 187]]], ["It was reported that serotype-cross-reactive non-neutralising antibodies enhance the entry of dengue genome into Fc receptor-bearing monocyte cells and promote disease severity by a process known as antibody-depended enhancement (ADE) (Casta\u00f1o-Osorio et al. 2019; Flipse et al. 2013).", [["monocyte cells", "ANATOMY", 133, 147], ["dengue", "DISEASE", 94, 100], ["Fc receptor", "GENE_OR_GENE_PRODUCT", 113, 124], ["monocyte cells", "CELL", 133, 147], ["non-neutralising antibodies", "PROTEIN", 45, 72], ["dengue genome", "DNA", 94, 107], ["Fc receptor", "PROTEIN", 113, 124], ["monocyte cells", "CELL_TYPE", 133, 147], ["dengue", "SPECIES", 94, 100], ["serotype", "TEST", 21, 29], ["reactive non-neutralising antibodies", "PROBLEM", 36, 72], ["promote disease severity", "PROBLEM", 152, 176], ["antibody", "TEST", 199, 207], ["depended enhancement", "PROBLEM", 208, 228], ["bearing monocyte cells", "OBSERVATION", 125, 147]]], ["That means nature of the antibody response to DENV is most likely to play a major role in defining disease outcome.", [["DENV", "ORGANISM", 46, 50], ["DENV", "SPECIES", 46, 50], ["the antibody response", "PROBLEM", 21, 42], ["DENV", "PROBLEM", 46, 50], ["most likely", "UNCERTAINTY", 54, 65]]], ["Therefore, it is predictable that antibodies that recognise specific neutralizing epitopes help in virus clearance and reduce symptoms; however, antibodies that recognise non-neutralising epitopes lead to more severe forms of disease like DWS+/SD.", [["DWS", "DISEASE", 239, 242], ["SD", "DISEASE", 244, 246], ["antibodies", "PROTEIN", 34, 44], ["neutralizing epitopes", "PROTEIN", 69, 90], ["antibodies", "PROTEIN", 145, 155], ["non-neutralising epitopes", "PROTEIN", 171, 196], ["antibodies", "PROBLEM", 34, 44], ["specific neutralizing epitopes", "PROBLEM", 60, 90], ["virus clearance", "PROBLEM", 99, 114], ["symptoms", "PROBLEM", 126, 134], ["antibodies", "PROBLEM", 145, 155], ["non-neutralising epitopes", "PROBLEM", 171, 196], ["disease", "PROBLEM", 226, 233], ["SD", "PROBLEM", 244, 246], ["more severe", "OBSERVATION_MODIFIER", 205, 216], ["disease", "OBSERVATION", 226, 233]]], ["Hence, there is an urgent need for an advanced vaccine which could generate highly specific and cross-neutralising antibody (Costin et al. 2013).DiscussionRecently, several attempts have been made towards the development of a potent dengue vaccine.", [["dengue", "DISEASE", 233, 239], ["cross-neutralising antibody", "PROTEIN", 96, 123], ["dengue", "SPECIES", 233, 239], ["an advanced vaccine", "TREATMENT", 35, 54], ["a potent dengue vaccine", "TREATMENT", 224, 247]]], ["The most advanced candidate, Dengvaxia (CYD-TDV), was licenced in some of the dengue endemic countries (Imai and Ferguson 2018).", [["dengue", "DISEASE", 78, 84], ["Dengvaxia", "SIMPLE_CHEMICAL", 29, 38], ["Dengvaxia (CYD-TDV", "TREATMENT", 29, 47]]], ["However, it was revealed risky in children or na\u00efve dengue patient with severe infection as they were vaccinated (Arredondo-Garc\u00eda et al. 2018).", [["dengue", "DISEASE", 52, 58], ["infection", "DISEASE", 79, 88], ["children", "ORGANISM", 34, 42], ["patient", "ORGANISM", 59, 66], ["children", "SPECIES", 34, 42], ["patient", "SPECIES", 59, 66], ["severe infection", "PROBLEM", 72, 88], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["infection", "OBSERVATION", 79, 88]]], ["Therefore, considering safety issues, production of recombinant subunit vaccine with efficient immune protective properties is looking attractive (Govindarajan et al. 2015).", [["recombinant subunit vaccine", "TREATMENT", 52, 79], ["efficient immune protective properties", "TREATMENT", 85, 123]]], ["Meanwhile, an admixture of four live attenuated recombinant dengue vaccine TV003/TV005 have completed Phase III clinical trial and licenced to several manufacturers including Butantan, VaBiotech and Merk (Whitehead et al. 2017).", [["dengue", "DISEASE", 60, 66], ["TV003", "CHEMICAL", 75, 80], ["TV005", "CHEMICAL", 81, 86], ["TV003", "ORGANISM", 75, 80], ["dengue vaccine TV003/TV005", "SPECIES", 60, 86], ["attenuated recombinant dengue vaccine TV003", "TREATMENT", 37, 80], ["TV005", "TREATMENT", 81, 86], ["Butantan", "TREATMENT", 175, 183]]], ["Moreover, some recombinant tetravalent vaccines (e.g. DEN-80E, TVDV) expressing the prM and E genes of each of the four DENV serotypes from plasmid DNA, have already completed phase I clinical trial (Govindarajan et al. 2015; Danko et al. 2018).", [["DEN-80E", "CHEMICAL", 54, 61], ["DEN-80E", "ORGANISM", 54, 61], ["TVDV", "ORGANISM", 63, 67], ["prM", "GENE_OR_GENE_PRODUCT", 84, 87], ["E", "GENE_OR_GENE_PRODUCT", 92, 93], ["DNA", "CELLULAR_COMPONENT", 148, 151], ["prM and E genes", "DNA", 84, 99], ["plasmid DNA", "DNA", 140, 151], ["TVDV", "SPECIES", 63, 67], ["DENV", "SPECIES", 120, 124], ["some recombinant tetravalent vaccines", "TREATMENT", 10, 47], ["the four DENV serotypes", "PROBLEM", 111, 134], ["plasmid DNA", "PROBLEM", 140, 151]]], ["It has also been shown that the recombinant dengue envelope domain III can inhibit dengue infectivity, and induce dengue-neutralising immunoglobulin in mice (Hermida et al. 2006).", [["dengue", "DISEASE", 44, 50], ["dengue", "DISEASE", 83, 89], ["dengue", "DISEASE", 114, 120], ["dengue envelope domain III", "GENE_OR_GENE_PRODUCT", 44, 70], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 134, 148], ["mice", "ORGANISM", 152, 156], ["recombinant dengue envelope domain III", "PROTEIN", 32, 70], ["neutralising immunoglobulin", "PROTEIN", 121, 148], ["mice", "SPECIES", 152, 156], ["dengue", "SPECIES", 83, 89], ["dengue", "SPECIES", 114, 120], ["mice", "SPECIES", 152, 156], ["the recombinant dengue envelope domain III", "PROBLEM", 28, 70], ["dengue infectivity", "PROBLEM", 83, 101], ["dengue", "PROBLEM", 114, 120]]], ["In addition, a number of antibodies which were raised in mice and chimpanzees against dengue domain II fusion loop were found cross-reactive to other flaviviruses (Goncalvez et al. 2004; Stiasny et al. 2006).", [["dengue", "DISEASE", 86, 92], ["mice", "ORGANISM", 57, 61], ["chimpanzees", "ORGANISM", 66, 77], ["antibodies", "PROTEIN", 25, 35], ["dengue domain II fusion loop", "PROTEIN", 86, 114], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 57, 61], ["antibodies", "TEST", 25, 35], ["dengue domain II fusion loop", "TREATMENT", 86, 114]]], ["Although, the hMABs specific to dengue domain II fusion loop were not found equally effective on other flaviviruses including WNV, YFV and other DENV strain (Costin et al. 2013).", [["dengue", "DISEASE", 32, 38], ["hMABs", "GENE_OR_GENE_PRODUCT", 14, 19], ["dengue domain II", "GENE_OR_GENE_PRODUCT", 32, 48], ["WNV", "ORGANISM", 126, 129], ["YFV", "ORGANISM", 131, 134], ["DENV strain", "ORGANISM", 145, 156], ["hMABs", "PROTEIN", 14, 19], ["dengue domain II", "PROTEIN", 32, 48], ["WNV", "SPECIES", 126, 129], ["YFV", "SPECIES", 131, 134], ["DENV", "SPECIES", 145, 149], ["dengue domain II fusion loop", "TREATMENT", 32, 60], ["other flaviviruses", "PROBLEM", 97, 115], ["WNV", "PROBLEM", 126, 129], ["YFV", "PROBLEM", 131, 134], ["other DENV strain", "PROBLEM", 139, 156], ["DENV strain", "OBSERVATION", 145, 156]]], ["Therefore, it was conjectured that adjacent to the fusion loop, additional contact residues of original domain II surface structure might be involved to raise cross-neutralizing antibodies.DiscussionSeveral studies have identified that adjacent to the fusion loop, another similar loop exists in most of the flaviviral (e.g. WNV, TBE, JEV, YFV) envelope (Fibriansah and Lok, 2016; Li et al. 2019).", [["JEV", "ORGANISM", 335, 338], ["YFV", "ORGANISM", 340, 343], ["domain II surface structure", "PROTEIN", 104, 131], ["neutralizing antibodies", "PROTEIN", 165, 188], ["WNV", "SPECIES", 325, 328], ["TBE", "SPECIES", 330, 333], ["JEV", "SPECIES", 335, 338], ["YFV", "SPECIES", 340, 343], ["the fusion loop", "TREATMENT", 47, 62], ["original domain II surface structure", "PROBLEM", 95, 131], ["cross-neutralizing antibodies", "PROBLEM", 159, 188], ["DiscussionSeveral studies", "TEST", 189, 214], ["the fusion loop", "TREATMENT", 248, 263], ["WNV", "PROBLEM", 325, 328], ["TBE", "PROBLEM", 330, 333], ["fusion loop", "OBSERVATION", 51, 62], ["fusion loop", "OBSERVATION", 252, 263], ["similar", "OBSERVATION_MODIFIER", 273, 280], ["loop", "OBSERVATION", 281, 285]]], ["Our previous bioinformatics studies have also shown that the envelope of all DENV serotype consists of four conserved regions (> 90%), and two of them were found in domain II, in which one is fusion loop (Fu) with more than 99% conservation and another is its nearby bc loop (Fig. 1a) (Rathore et al. 2019).", [["DENV serotype", "ORGANISM", 77, 90], ["domain II", "PROTEIN", 165, 174], ["fusion loop", "PROTEIN", 192, 203], ["Fu", "PROTEIN", 205, 207], ["bc loop", "PROTEIN", 267, 274], ["Our previous bioinformatics studies", "TEST", 0, 35], ["all DENV serotype", "PROBLEM", 73, 90], ["fusion loop", "TREATMENT", 192, 203], ["DENV", "OBSERVATION", 77, 81], ["fusion loop", "OBSERVATION", 192, 203]]], ["Therefore, these two highly conserved loops were targeted in this study for the development of a fusion protein.", [["fusion protein", "PROTEIN", 97, 111], ["this study", "TEST", 61, 71], ["a fusion protein", "TREATMENT", 95, 111], ["loops", "OBSERVATION", 38, 43], ["fusion", "OBSERVATION", 97, 103]]], ["By using reverse DNA technology, we have previously shown the structural integrity (Fig. 1b\u2013d) and binding specificity of Fubc protein with an anti-fusion loop scFv antibody, derived from dengue and WNV-specific MAb E53 (Rodenhuis-Zybert et al. 2011; Rathore et al. 2019).DiscussionThe very early challenge of subunit vaccine design is to produce large quantities of functional protein.", [["dengue", "DISEASE", 188, 194], ["DNA", "CELLULAR_COMPONENT", 17, 20], ["Fubc", "GENE_OR_GENE_PRODUCT", 122, 126], ["WNV", "ORGANISM", 199, 202], ["Fubc protein", "PROTEIN", 122, 134], ["anti-fusion loop scFv antibody", "PROTEIN", 143, 173], ["MAb E53", "PROTEIN", 212, 219], ["functional protein", "PROTEIN", 367, 385], ["dengue", "SPECIES", 188, 194], ["WNV", "SPECIES", 199, 202], ["Fubc protein", "PROBLEM", 122, 134], ["an anti-fusion loop scFv antibody", "TREATMENT", 140, 173], ["dengue", "PROBLEM", 188, 194], ["WNV", "TEST", 199, 202], ["specific MAb", "TEST", 203, 215], ["subunit vaccine", "TREATMENT", 310, 325]]], ["Hereby, we have successfully optimised the expression and purification methods for the production of large-scale high-quality recombinant Fubc protein.", [["Fubc", "GENE_OR_GENE_PRODUCT", 138, 142], ["Fubc protein", "PROTEIN", 138, 150], ["purification methods", "TREATMENT", 58, 78]]], ["The E. coli expression system was used here, and the recombinant protein was found to be expressed in higher quantity, though most of the protein was extracted initially in pellet fraction.", [["E. coli", "ORGANISM", 4, 11], ["recombinant protein", "PROTEIN", 53, 72], ["E. coli", "SPECIES", 4, 11], ["E. coli", "SPECIES", 4, 11], ["The E. coli expression system", "TREATMENT", 0, 29], ["the recombinant protein", "TEST", 49, 72], ["the protein", "TEST", 134, 145], ["coli expression", "OBSERVATION", 7, 22], ["higher quantity", "OBSERVATION_MODIFIER", 102, 117], ["pellet fraction", "OBSERVATION", 173, 188]]], ["No significant change was noticed by altering regular growth temperature and inducer concentration.", [["significant change", "PROBLEM", 3, 21], ["inducer concentration", "TREATMENT", 77, 98], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["change", "OBSERVATION", 15, 21], ["growth temperature", "OBSERVATION_MODIFIER", 54, 72]]], ["Therefore, we have utilised the mild-solubilisation methodology to recover soluble Fubc protein from insoluble pellet protein.", [["Fubc", "GENE_OR_GENE_PRODUCT", 83, 87], ["Fubc protein", "PROTEIN", 83, 95], ["insoluble pellet protein", "PROTEIN", 101, 125], ["the mild-solubilisation methodology", "TREATMENT", 28, 63]]], ["For purification, firstly, we have used convenient Ni-NTA affinity purification method, and by adjusting the lysis and elution buffer, we were able to purify recombinant Fubc protein to some extent but the quality and quantity was not sufficient.", [["NTA", "CHEMICAL", 54, 57], ["Ni-NTA", "CHEMICAL", 51, 57], ["Ni-NTA", "SIMPLE_CHEMICAL", 51, 57], ["Fubc", "GENE_OR_GENE_PRODUCT", 170, 174], ["Fubc protein", "PROTEIN", 170, 182], ["convenient Ni-NTA affinity purification method", "TREATMENT", 40, 86], ["the lysis and elution buffer", "TREATMENT", 105, 133], ["some extent", "OBSERVATION_MODIFIER", 186, 197]]], ["Finally, to scale up the quality protein production, size exclusion chromatography was used in AKTA FPLC system.", [["size exclusion chromatography", "TEST", 53, 82]]], ["To confirm the recombinant protein expression, simple western blot was performed by using anti-His monoclonal antibody as primary.", [["His", "CHEMICAL", 95, 98], ["anti-His monoclonal antibody", "PROTEIN", 90, 118], ["the recombinant protein expression", "PROBLEM", 11, 45], ["simple western blot", "TEST", 47, 66], ["His monoclonal antibody", "TREATMENT", 95, 118]]], ["Furthermore, in vitro structural integrity and functional authenticity of the experimental Fubc protein were also verified by CD spectroscopy (Fig. 3) and indirect ELISA (Fig. 4).DiscussionHowever, most of the hMABs identified earlier from dengue patient serum were predominantly cross-reactive and recognise epitopes containing highly conserved residues at the Fu loop of domain II (Lai et al. 2008).", [["serum", "ANATOMY", 255, 260], ["dengue", "DISEASE", 240, 246], ["Fubc", "GENE_OR_GENE_PRODUCT", 91, 95], ["hMABs", "GENE_OR_GENE_PRODUCT", 210, 215], ["patient", "ORGANISM", 247, 254], ["serum", "ORGANISM_SUBSTANCE", 255, 260], ["Fubc protein", "PROTEIN", 91, 103], ["hMABs", "PROTEIN", 210, 215], ["epitopes", "PROTEIN", 309, 317], ["Fu loop", "PROTEIN", 362, 369], ["domain II", "PROTEIN", 373, 382], ["patient", "SPECIES", 247, 254], ["dengue", "SPECIES", 240, 246], ["the experimental Fubc protein", "TEST", 74, 103], ["CD spectroscopy", "TEST", 126, 141], ["indirect ELISA", "TEST", 155, 169], ["dengue patient serum", "TEST", 240, 260], ["integrity", "OBSERVATION_MODIFIER", 33, 42]]], ["However, having such sequence homology in Fu loop of all flaviviruses, these hMABs are non-neutralizing against heterologous serotypes (Lai et al. 2008; Smith et al. 2013) and thus was found to be responsible for ADE in animals (Goncalvez et al. 2007).", [["ADE", "DISEASE", 213, 216], ["hMABs", "GENE_OR_GENE_PRODUCT", 77, 82], ["such sequence homology", "PROBLEM", 16, 38], ["all flaviviruses", "PROBLEM", 53, 69], ["these hMABs", "TEST", 71, 82], ["heterologous serotypes", "PROBLEM", 112, 134]]], ["Previously, it has also been stated that this scenario might happen due to the cryptic nature and poor accessibility of the fusion loop epitope on the surface of the mature virion (Lai et al. 2008; Cherrier et al. 2009).", [["surface", "ANATOMY", 151, 158], ["surface", "CELLULAR_COMPONENT", 151, 158], ["fusion loop epitope", "PROTEIN", 124, 143], ["the fusion loop epitope", "TREATMENT", 120, 143], ["fusion loop", "OBSERVATION", 124, 135], ["mature", "OBSERVATION_MODIFIER", 166, 172], ["virion", "OBSERVATION_MODIFIER", 173, 179]]], ["However, in addition to the partially exposed fusion loop on immature flaviviruses, some neutralizing hMAbs were also found to bind with bc loop (Costin et al. 2013).", [["hMAbs", "GENE_OR_GENE_PRODUCT", 102, 107], ["hMAbs", "PROTEIN", 102, 107], ["bc loop", "PROTEIN", 137, 144], ["the partially exposed fusion loop", "PROBLEM", 24, 57], ["immature flaviviruses", "PROBLEM", 61, 82], ["some neutralizing hMAbs", "PROBLEM", 84, 107], ["bc loop", "TREATMENT", 137, 144], ["fusion loop", "OBSERVATION", 46, 57], ["immature", "OBSERVATION_MODIFIER", 61, 69], ["flaviviruses", "OBSERVATION", 70, 82]]], ["Therefore, it is suggestive that along with conserved fusion loop, adjacent less conserved linker sequence and bc loop might be required to be exposed as a whole to generate effective cross-neutralizing immunity.", [["linker sequence", "PROTEIN", 91, 106], ["bc loop", "PROTEIN", 111, 118], ["conserved fusion loop", "TREATMENT", 44, 65], ["adjacent less conserved linker sequence and bc loop", "PROBLEM", 67, 118], ["fusion loop", "OBSERVATION", 54, 65]]], ["Our current mouse immunisation experiment also supports this idea as it was observed that the antibody response to full length Fubc protein was stronger than the response elicited by the Fu and Bc peptides in separate (Figs.", [["mouse", "ORGANISM", 12, 17], ["Fubc", "GENE_OR_GENE_PRODUCT", 127, 131], ["Bc peptides", "GENE_OR_GENE_PRODUCT", 194, 205], ["Fubc protein", "PROTEIN", 127, 139], ["mouse", "SPECIES", 12, 17], ["mouse", "SPECIES", 12, 17], ["Our current mouse immunisation experiment", "TREATMENT", 0, 41], ["the antibody response", "TEST", 90, 111], ["full length Fubc protein", "TEST", 115, 139], ["the Fu and Bc peptides", "TEST", 183, 205]]], ["4 and 5).DiscussionMoreover, without Freund\u2019s adjuvant, recombinant Fubc protein was found immunogenic, and the response in female mice was stronger than in male (Figs.", [["Fubc", "GENE_OR_GENE_PRODUCT", 68, 72], ["mice", "ORGANISM", 131, 135], ["recombinant Fubc protein", "PROTEIN", 56, 80], ["mice", "SPECIES", 131, 135], ["mice", "SPECIES", 131, 135], ["Freund\u2019s adjuvant", "TREATMENT", 37, 54], ["recombinant Fubc protein", "TEST", 56, 80], ["immunogenic", "PROBLEM", 91, 102], ["without", "UNCERTAINTY", 29, 36]]], ["These observations were also symmetrical with other studies where it was stated that female mice have a better immune response due to the higher number of leukocytes occupying the naive peritoneal and pleural cavities, and also have a number of T- and B-lymphocytes as well as macrophages (Terres et al. 1968; Weinstein et al. 1984; Klein et al. 2015).", [["leukocytes", "ANATOMY", 155, 165], ["peritoneal", "ANATOMY", 186, 196], ["pleural cavities", "ANATOMY", 201, 217], ["T-", "ANATOMY", 245, 247], ["B-lymphocytes", "ANATOMY", 252, 265], ["macrophages", "ANATOMY", 277, 288], ["mice", "ORGANISM", 92, 96], ["leukocytes", "CELL", 155, 165], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 186, 196], ["pleural cavities", "MULTI-TISSUE_STRUCTURE", 201, 217], ["T", "CELL", 245, 246], ["B-lymphocytes", "CELL", 252, 265], ["macrophages", "CELL", 277, 288], ["leukocytes", "CELL_TYPE", 155, 165], ["T- and B-lymphocytes", "CELL_TYPE", 245, 265], ["macrophages", "CELL_TYPE", 277, 288], ["mice", "SPECIES", 92, 96], ["mice", "SPECIES", 92, 96], ["other studies", "TEST", 46, 59], ["leukocytes occupying the naive peritoneal and pleural cavities", "PROBLEM", 155, 217], ["T", "TEST", 245, 246], ["macrophages", "PROBLEM", 277, 288], ["leukocytes", "OBSERVATION", 155, 165], ["naive", "ANATOMY_MODIFIER", 180, 185], ["peritoneal", "ANATOMY", 186, 196], ["pleural", "ANATOMY", 201, 208], ["cavities", "ANATOMY_MODIFIER", 209, 217], ["lymphocytes", "ANATOMY", 254, 265], ["macrophages", "ANATOMY", 277, 288]]], ["Therefore, we have used female mice serum samples for further qualitative ELISA and SPR test to quantify immune response of recombinant Fubc protein.", [["serum samples", "ANATOMY", 36, 49], ["mice", "ORGANISM", 31, 35], ["serum samples", "ORGANISM_SUBSTANCE", 36, 49], ["Fubc", "GENE_OR_GENE_PRODUCT", 136, 140], ["recombinant Fubc protein", "PROTEIN", 124, 148], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35], ["female mice serum samples", "TEST", 24, 49], ["further qualitative ELISA", "TEST", 54, 79], ["SPR test", "TEST", 84, 92], ["recombinant Fubc protein", "PROBLEM", 124, 148]]], ["It was noticed that IgG antibody response to Fu, and bc peptides were significantly lower than the response observed to Fubc recombinant protein, and the immune response achieved to Fu and Bc peptide with Freund\u2019s adjuvant was significantly higher as compared to the peptides without adjuvant and serum control (Fig. 5).", [["serum", "ANATOMY", 297, 302], ["IgG antibody", "GENE_OR_GENE_PRODUCT", 20, 32], ["Fu", "GENE_OR_GENE_PRODUCT", 45, 47], ["bc peptides", "GENE_OR_GENE_PRODUCT", 53, 64], ["Fubc recombinant", "GENE_OR_GENE_PRODUCT", 120, 136], ["Bc peptide", "SIMPLE_CHEMICAL", 189, 199], ["Freund", "ORGANISM", 205, 211], ["serum", "ORGANISM_SUBSTANCE", 297, 302], ["IgG antibody", "PROTEIN", 20, 32], ["Fubc recombinant protein", "PROTEIN", 120, 144], ["IgG antibody response", "TEST", 20, 41], ["Fu", "TEST", 45, 47], ["bc peptides", "TEST", 53, 64], ["Fubc recombinant protein", "PROBLEM", 120, 144], ["Fu", "TEST", 182, 184], ["Bc peptide", "TEST", 189, 199], ["Freund\u2019s adjuvant", "TREATMENT", 205, 222], ["adjuvant and serum control", "TREATMENT", 284, 310]]], ["Two-way ANOVA was also performed to analyse the significance of IgG immune responses between Fubc + FA and Fubc without FA; Fu, bc Peptide + FA and Fu, bc Peptide without FA.", [["FA", "CHEMICAL", 171, 173], ["IgG", "GENE_OR_GENE_PRODUCT", 64, 67], ["Fubc + FA", "SIMPLE_CHEMICAL", 93, 102], ["Fubc", "SIMPLE_CHEMICAL", 107, 111], ["FA", "SIMPLE_CHEMICAL", 120, 122], ["bc Peptide + FA", "SIMPLE_CHEMICAL", 128, 143], ["Fu, bc Peptide", "SIMPLE_CHEMICAL", 148, 162], ["FA", "SIMPLE_CHEMICAL", 171, 173], ["IgG", "PROTEIN", 64, 67], ["IgG immune responses", "TEST", 64, 84], ["Fubc", "TEST", 93, 97], ["FA", "TEST", 100, 102], ["Fubc", "TEST", 107, 111], ["FA", "TEST", 120, 122], ["Fu", "TEST", 124, 126], ["bc Peptide", "TEST", 128, 138], ["FA", "TEST", 141, 143], ["Fu", "TEST", 148, 150], ["FA", "PROBLEM", 171, 173]]], ["From F values and P values obtained by ANOVA test, it can be interpreted that the difference between Fubc protein with Freund\u2019s adjuvant and Fu, bc Peptide with Freund\u2019s adjuvant were significantly higher than protein and peptides injected without Freund\u2019s adjuvant (Table S2).", [["Fubc", "GENE_OR_GENE_PRODUCT", 101, 105], ["Freund", "ORGANISM", 119, 125], ["Fu", "SIMPLE_CHEMICAL", 141, 143], ["bc Peptide", "SIMPLE_CHEMICAL", 145, 155], ["Freund", "ORGANISM", 161, 167], ["Fubc protein", "PROTEIN", 101, 113], ["P values", "TEST", 18, 26], ["ANOVA test", "TEST", 39, 49], ["Fubc protein", "TEST", 101, 113], ["Freund\u2019s adjuvant", "TREATMENT", 119, 136], ["Fu, bc Peptide", "TEST", 141, 155], ["Freund\u2019s adjuvant", "TREATMENT", 161, 178], ["protein and peptides", "TREATMENT", 210, 230], ["Freund\u2019s adjuvant", "TREATMENT", 248, 265]]], ["Also, the IgG response to recombinant Fubc protein was recorded better than Fu and bc peptides in both cases either with or without adjuvant.", [["IgG", "GENE_OR_GENE_PRODUCT", 10, 13], ["Fubc", "GENE_OR_GENE_PRODUCT", 38, 42], ["bc peptides", "GENE_OR_GENE_PRODUCT", 83, 94], ["IgG", "PROTEIN", 10, 13], ["recombinant Fubc protein", "PROTEIN", 26, 50], ["the IgG response", "TEST", 6, 22], ["recombinant Fubc protein", "TEST", 26, 50], ["Fu and bc peptides", "TEST", 76, 94], ["adjuvant", "TREATMENT", 132, 140]]], ["In addition, the p value of IgG immune response between Fubc protein with FA and without FA was found insignificant (p = 0.1740 > 0.05) that suggests that Fubc without any adjuvant is sufficient to elicit significant immune response (Table S2).", [["Fubc", "CHEMICAL", 155, 159], ["IgG", "GENE_OR_GENE_PRODUCT", 28, 31], ["Fubc", "GENE_OR_GENE_PRODUCT", 56, 60], ["FA", "SIMPLE_CHEMICAL", 74, 76], ["FA", "SIMPLE_CHEMICAL", 89, 91], ["Fubc", "SIMPLE_CHEMICAL", 155, 159], ["IgG", "PROTEIN", 28, 31], ["Fubc protein", "PROTEIN", 56, 68], ["the p value", "TEST", 13, 24], ["IgG", "TEST", 28, 31], ["Fubc protein", "TEST", 56, 68], ["FA", "TEST", 74, 76], ["FA", "TEST", 89, 91], ["any adjuvant", "TREATMENT", 168, 180]]], ["Consistently, it was observed by SPR experiment that the refractive index of Fubc + FA was significantly higher than Fubc + without FA and serum control (Fig. 6b).DiscussionSince, the newly developed Fubc recombinant protein expresses vastly in E. coli and induces significant immune response in mice, it might be a good agent of dengue subunit vaccine development.", [["serum", "ANATOMY", 139, 144], ["dengue", "DISEASE", 330, 336], ["Fubc + FA", "CHEMICAL", 77, 86], ["Fubc + FA", "SIMPLE_CHEMICAL", 77, 86], ["Fubc +", "SIMPLE_CHEMICAL", 117, 123], ["FA", "SIMPLE_CHEMICAL", 132, 134], ["serum", "ORGANISM_SUBSTANCE", 139, 144], ["Fubc", "GENE_OR_GENE_PRODUCT", 200, 204], ["E. coli", "ORGANISM", 245, 252], ["mice", "ORGANISM", 296, 300], ["Fubc", "PROTEIN", 77, 81], ["Fubc", "PROTEIN", 117, 121], ["Fubc recombinant protein", "PROTEIN", 200, 224], ["E. coli", "SPECIES", 245, 252], ["mice", "SPECIES", 296, 300], ["E. coli", "SPECIES", 245, 252], ["mice", "SPECIES", 296, 300], ["dengue", "SPECIES", 330, 336], ["the refractive index", "TEST", 53, 73], ["Fubc + FA", "TEST", 77, 86], ["Fubc", "TEST", 117, 121], ["FA", "TEST", 132, 134], ["Fubc recombinant protein expresses", "PROBLEM", 200, 234], ["E. coli", "PROBLEM", 245, 252], ["dengue subunit vaccine", "TREATMENT", 330, 352], ["E. coli", "OBSERVATION", 245, 252], ["significant", "OBSERVATION_MODIFIER", 265, 276], ["immune response", "OBSERVATION", 277, 292]]], ["Due to the presence of highly conserved fusion loop epitope, overlapping less conserved linker sequences and also bc epitope, this fusion protein might induce cross-neutralisation immunity against heterologous dengue serotypes.", [["dengue", "DISEASE", 210, 216], ["bc epitope", "GENE_OR_GENE_PRODUCT", 114, 124], ["fusion loop epitope", "PROTEIN", 40, 59], ["conserved linker sequences", "PROTEIN", 78, 104], ["bc epitope", "PROTEIN", 114, 124], ["fusion protein", "PROTEIN", 131, 145], ["dengue", "SPECIES", 210, 216], ["highly conserved fusion loop epitope", "PROBLEM", 23, 59], ["overlapping less conserved linker sequences", "PROBLEM", 61, 104], ["bc epitope", "PROBLEM", 114, 124], ["this fusion protein", "TREATMENT", 126, 145], ["heterologous dengue serotypes", "PROBLEM", 197, 226], ["fusion loop", "OBSERVATION", 40, 51]]], ["Though, still a lot of investigations, like the evaluation of a proper adjuvant to induce robust immune response, the memory immune response generated against the Fubc protein both by humoral and cell-mediated immunity, and whether this memory response will provide protection against a secondary encounter with DENV, are required before going clinical trial.", [["cell", "ANATOMY", 196, 200], ["Fubc", "GENE_OR_GENE_PRODUCT", 163, 167], ["cell", "CELL", 196, 200], ["DENV", "ORGANISM", 312, 316], ["Fubc protein", "PROTEIN", 163, 175], ["DENV", "SPECIES", 312, 316], ["the evaluation", "TEST", 44, 58], ["a proper adjuvant", "TREATMENT", 62, 79], ["robust immune response", "PROBLEM", 90, 112], ["the Fubc protein", "TEST", 159, 175], ["DENV", "PROBLEM", 312, 316]]], ["Nevertheless, the production process and immune response of this fusion protein would provide new insight for the development of dengue subunit vaccine.", [["dengue", "DISEASE", 129, 135], ["fusion protein", "PROTEIN", 65, 79], ["dengue", "SPECIES", 129, 135], ["the production process", "PROBLEM", 14, 36], ["this fusion protein", "TREATMENT", 60, 79], ["dengue subunit vaccine", "TREATMENT", 129, 151]]]], "ee4c3569203a966855b41389909dc96e74da50fe": [["IntroductionCoronavirus disease (COVID-19) is an epidemic illness that was discovered in Wuhan of China at the end of 2019.", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["illness", "DISEASE", 58, 65], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["COVID", "TEST", 33, 38], ["an epidemic illness", "PROBLEM", 46, 65], ["epidemic", "OBSERVATION_MODIFIER", 49, 57], ["illness", "OBSERVATION", 58, 65]]], ["Subsequently, WHO declares COVID-19 as a global pandemic.", [["COVID", "TEST", 27, 32], ["a global pandemic", "PROBLEM", 39, 56], ["pandemic", "OBSERVATION", 48, 56]]], ["As of May 22, 2020, COVID-19 has affected about 4.99 million people and claimed over 3,27,738 deaths globally 1 and these figures are increasing every day.", [["deaths", "DISEASE", 94, 100], ["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67], ["COVID", "TEST", 20, 25], ["increasing", "OBSERVATION_MODIFIER", 134, 144]]], ["In India, the first COVID-19 case was reported on January 30, 2020, in Kerala, and then gradually spreads across in all states and union territories except Daman and Diu, Nagaland, and Lakshadweep 2 .", [["Nagaland", "TREATMENT", 171, 179]]], ["The COVID-19 has mostly affected the urban areas particularly the megacities of India which became the epicenters of COVID-19 spreads.", [["COVID-19", "CHEMICAL", 4, 12], ["COVID-19", "DNA", 4, 12], ["The COVID", "TEST", 0, 9], ["COVID", "TEST", 117, 122], ["urban", "OBSERVATION_MODIFIER", 37, 42]]], ["The geographic distribution of COVID-19 incidences showed that the disease was not uniformly affecting all parts of the Indian megacities but lead to spatial clustering of cases 3 .IntroductionThe existence of an inverse relationship between the socioeconomic status (SES) of populations and higher incidences of lower respiratory tract infection among populations in society was well recognized 4 .", [["lower respiratory tract", "ANATOMY", 313, 336], ["lower respiratory tract infection", "DISEASE", 313, 346], ["lower respiratory tract", "ORGANISM_SUBDIVISION", 313, 336], ["COVID", "PROTEIN", 31, 36], ["COVID", "TEST", 31, 36], ["the disease", "PROBLEM", 63, 74], ["lower respiratory tract infection", "PROBLEM", 313, 346], ["geographic", "OBSERVATION_MODIFIER", 4, 14], ["distribution", "OBSERVATION_MODIFIER", 15, 27], ["disease", "OBSERVATION", 67, 74], ["higher", "OBSERVATION_MODIFIER", 292, 298], ["lower", "ANATOMY_MODIFIER", 313, 318], ["respiratory tract", "ANATOMY", 319, 336], ["infection", "OBSERVATION", 337, 346]]], ["Despite the preliminary evidence of social inequality in COVID-19 incidences and the possibility of SES deprivation as a major contributor to COVID-19 infection, research on the relationship between SES deprivation and COVID-19 incidences is inadequate.", [["infection", "DISEASE", 151, 160], ["COVID-19", "GENE_OR_GENE_PRODUCT", 142, 150], ["SES deprivation", "PROBLEM", 100, 115], ["COVID-19 infection", "PROBLEM", 142, 160], ["SES deprivation", "TREATMENT", 199, 214], ["COVID", "TEST", 219, 224], ["infection", "OBSERVATION", 151, 160]]], ["It has, therefore, become imperative that the role of SES deprivation on COVID-19 incidences be evaluated.", [["SES deprivation", "PROBLEM", 54, 69], ["COVID", "TEST", 73, 78]]], ["To fill up the existing research gap this study attempted to provide scientific evidence about the influence of SES deprivation on spatial clustering of COVID-19 hotspots in Chennai megacity.IntroductionIn the absence of individual data, we have employed ecological (or contextual) measures of SES deprivation to describe the inequalities in COVID-19 incidences.", [["COVID-19 hotspots", "DNA", 153, 170], ["this study", "TEST", 37, 47], ["SES deprivation", "PROBLEM", 112, 127], ["SES deprivation", "TREATMENT", 294, 309]]], ["In this article, we have modified and improved the IMD developed by Isa Baud 5 for Chennai megacity by incorporating specific indicators of SES deprivation that affect COVID-19, such as nonavailability to a drinking water source within premises or not having a toilet inside houses.", [["Chennai megacity", "TREATMENT", 83, 99], ["SES deprivation", "PROBLEM", 140, 155], ["COVID", "TEST", 168, 173]]], ["The households (HH) without having the availability of a drinking water source within premises were compelled to collect drinking water from community stand posts and tube well.", [["tube", "ANATOMY", 167, 171], ["tube", "TISSUE", 167, 171], ["tube", "OBSERVATION", 167, 171]]], ["Limited availability of community latrines, stand posts, and tube well certainly increases the chance of community transmission of the virus.", [["tube", "ANATOMY", 61, 65], ["tube", "TISSUE", 61, 65], ["community latrines", "TREATMENT", 24, 42], ["tube", "TREATMENT", 61, 65], ["the virus", "PROBLEM", 131, 140]]], ["Examining the spatial inequalities in COVID-19 incidences in Chennai megacity will provide important insights into the spatial pattern of the disease.", [["COVID", "TEST", 38, 43], ["the disease", "PROBLEM", 138, 149], ["disease", "OBSERVATION", 142, 149]]], ["The development of an IMD representing SES disadvantage would explore the linkages between living environment deprivation and COVID-19 incidences.IntroductionUltimately, the outcome of this study will provide useful insights to policymakers for targeted interventions to combat the COVID-19 pandemic.MethodsThe study area is Chennai megacity (13.04\u00b0N-80.17\u00b0E) is the fourth-largest metropolis in India (after Mumbai, New Delhi, and Kolkata) with a population of 10.2 million.", [["an IMD", "PROBLEM", 19, 25], ["SES disadvantage", "PROBLEM", 39, 55], ["this study", "TEST", 185, 195], ["targeted interventions", "TREATMENT", 245, 267], ["the COVID", "TEST", 278, 287], ["pandemic", "PROBLEM", 291, 299], ["Chennai megacity", "TEST", 325, 341], ["largest", "OBSERVATION_MODIFIER", 374, 381]]], ["With mild and moderate winters and very hot summers, the average air temperature ranges from 21-35\u00b0C (70-95\u00b0F) and relative humidity varies from 45-95%.MethodsThe first COVID-19 in Chennai was detected on March 9, 2020, and later community transmission has taken place rapidly.", [["Chennai", "CANCER", 181, 188], ["COVID-19", "DNA", 169, 177], ["mild and moderate winters and very hot summers", "PROBLEM", 5, 51], ["the average air temperature", "TEST", 53, 80], ["relative humidity", "TEST", 115, 132], ["mild", "OBSERVATION_MODIFIER", 5, 9], ["moderate", "OBSERVATION_MODIFIER", 14, 22], ["winters", "OBSERVATION", 23, 30]]], ["The number of confirmed COVID-19 cases in 155 wards of Chennai megacity reported in this study was collected from the official website of Greater Chennai online database releases from May 15, 2020, to May 21, 2020.", [["COVID", "DISEASE", 24, 29], ["COVID", "TEST", 24, 29], ["Chennai megacity", "PROBLEM", 55, 71], ["this study", "TEST", 84, 94]]], ["The two datasets were compared to ensure consistency of COVID-19 incidences before executing the statistical analysis.MethodsSince SES is a complex and multidimensional phenomenon, in the absence of individual data, which were not available at this pandemic situation, we developed well recognized ecological (or contextual) measures of SES in the form of an index that represents area-based deprivation for 155 electoral wards (sub-cities) of Chennai megacity.", [["COVID", "TEST", 56, 61], ["the statistical analysis", "TEST", 93, 117], ["an index", "PROBLEM", 356, 364], ["Chennai megacity", "PROBLEM", 444, 460], ["index", "OBSERVATION", 359, 364]]], ["Table.S1 summarizes the domains of selected widely used IMDs developed earlier and most IMDs includeincome, employment, socioeconomic status, education, housing quality, and ownership of goods or items 7, 8 .", [["S1", "PROTEIN", 6, 8]]], ["The dimensions and indicators selected to devise an IMD for 155 electoral wards of Chennai megacity are slightly different from IMDs developed earlier because information on income is not available in the Census of India (see Table.", [["Chennai megacity", "PROBLEM", 83, 99], ["slightly", "OBSERVATION_MODIFIER", 104, 112], ["different", "OBSERVATION_MODIFIER", 113, 122]]], ["S1).", [["S1", "GENE_OR_GENE_PRODUCT", 0, 2], ["S1", "PROTEIN", 0, 2]]], ["The IMD is devised by employing GWPCA.", [["GWPCA", "PROTEIN", 32, 37]]], ["The local principal components and local variance derived from GWPCA are suitable in devising IMD 8 .MethodsMathematically, the local eigen decomposition of GWPCA transformation can be written in its algebraic expression as: ) is a diagonal matrix obtained from optimal bandwidths (here adaptive) based on the 'Bi-square' kernel weighting scheme.", [["the local eigen decomposition of GWPCA transformation", "TREATMENT", 124, 177], ["a diagonal matrix", "TREATMENT", 230, 247], ["local", "OBSERVATION_MODIFIER", 4, 9], ["principal", "OBSERVATION_MODIFIER", 10, 19], ["components", "OBSERVATION_MODIFIER", 20, 30]]], ["The detailed description of GWPCA is given in the appendix section.", [["appendix section", "ANATOMY", 50, 66], ["GWPCA", "CHEMICAL", 28, 33], ["GWPCA", "SIMPLE_CHEMICAL", 28, 33], ["appendix section", "MULTI-TISSUE_STRUCTURE", 50, 66], ["GWPCA", "PROTEIN", 28, 33], ["appendix", "ANATOMY", 50, 58]]], ["To reduce noise and locate important factors of IMD, the first 3 PCs with eigenvalues greater than 1 (i.e., \u03bbi \u2265 1) were retained.", [["eigenvalues", "TEST", 74, 85]]], ["The hotspot analysis tool of ArcGIS 10.2 software (Getis-Ord Gi*) was used to explore the spatial clustering of COVID-19 incidences and high IMD values (mathematical expression given in the supplementary material).", [["The hotspot analysis", "TEST", 0, 20], ["ArcGIS", "TEST", 29, 35], ["COVID", "TEST", 112, 117], ["high IMD values", "PROBLEM", 136, 151]]], ["The distribution of COVID-19 cases in Chennai megacity was negative binomial because its variance was higher than the means (see Table.", [["COVID", "TEST", 20, 25], ["Chennai megacity", "TEST", 38, 54], ["distribution", "OBSERVATION_MODIFIER", 4, 16]]], ["S2).", [["S2", "PROTEIN", 0, 2]]], ["Therefore, we employed Poisson regression (PR) and negative binomial regression (NBR) to analyze the impact of individual domains of IMD on COVID-19 incidences in Chennai megacity (see supplementary material for details).ResultsThe descriptive analysis of COVID-19 incidences is reported in Table.", [["IMD", "DISEASE", 133, 136], ["negative binomial regression", "PROBLEM", 51, 79], ["COVID", "TEST", 140, 145], ["The descriptive analysis", "TEST", 228, 252], ["COVID", "TEST", 256, 261]]], ["S2 shows that variability (\u03c3 =54.52) of COVID-19 incidences is higher than mean (\u00b5=49.49) and it is following negative binomial distribution.", [["S2", "PROTEIN", 0, 2], ["COVID", "TEST", 40, 45], ["variability", "OBSERVATION_MODIFIER", 14, 25], ["higher", "OBSERVATION_MODIFIER", 63, 69], ["binomial distribution", "OBSERVATION", 119, 140]]], ["The first three components with eigenvalues greater than 1 (i.e., \u03bbi \u2265 1) accounted for 80.7% of the total variance in the data and the first component alone explained more than 47 percent variance in the data.", [["eigenvalues", "TEST", 32, 43], ["the total variance", "TEST", 97, 115]]], ["The product of the proportion of local variance explained by three components and the component score was summed to devise the initial IMD.", [["IMD", "DISEASE", 135, 138], ["local variance", "PROBLEM", 33, 47], ["local variance", "OBSERVATION", 33, 47]]], ["The IMD score of 0 stands for the least deprived ward (Ward No. 125) and 100 for most deprived wards (Ward No. 40).", [["The IMD score", "TEST", 0, 13]]], ["1(e) showed the spatial distribution of COVID-19 and IMD hotspots.", [["COVID-19 and IMD hotspots", "DNA", 40, 65], ["COVID", "TEST", 40, 45]]], ["Hotspot areas for both COVID-19 and IMD were mainly located in the northern and central parts.", [["both COVID", "TEST", 18, 28], ["northern", "ANATOMY_MODIFIER", 67, 75], ["central", "ANATOMY_MODIFIER", 80, 87]]], ["This area is crowded with a higher concentration of slums, the majority of the HH with poor housing conditions and lack of HH services are located in this zone of the megacity.", [["poor housing conditions", "PROBLEM", 87, 110], ["HH services", "TREATMENT", 123, 134], ["crowded", "OBSERVATION", 13, 20], ["higher concentration", "OBSERVATION_MODIFIER", 28, 48], ["megacity", "OBSERVATION", 167, 175]]], ["Spatial risks of COVID-19 infections were predominantly concentrated in the wards with high IMD which were mostly located in the north-eastern parts of Chennai megacity.Discussion and ConclusionWe formulated IMD using multiple socioeconomic indicators at the electoral ward level in Chennai megacity and examined the relationship between the IMD and COVID-19 incidences.", [["infections", "DISEASE", 26, 36], ["COVID-19", "ORGANISM", 17, 25], ["COVID", "TEST", 17, 22], ["19 infections", "PROBLEM", 23, 36], ["high IMD", "PROBLEM", 87, 95], ["predominantly", "OBSERVATION_MODIFIER", 42, 55], ["concentrated", "OBSERVATION_MODIFIER", 56, 68], ["high IMD", "OBSERVATION_MODIFIER", 87, 95], ["north", "ANATOMY_MODIFIER", 129, 134], ["Chennai megacity", "OBSERVATION", 152, 168]]], ["The hot-spot analysis indicates that formulated IMD was significantly related to higher incidences of COVID-19 in areas with higher IMD.Discussion and ConclusionThe critical matters of the study were the selection of domains and the method of index formulation.", [["IMD", "DISEASE", 132, 135], ["The hot-spot analysis", "TEST", 0, 21], ["COVID", "TEST", 102, 107], ["the study", "TEST", 185, 194], ["the method of index formulation", "TREATMENT", 229, 260], ["higher IMD", "OBSERVATION", 125, 135]]], ["The selection of domains was based on the previous IMDs, data availability in the Indian context, and factors that directly or indirectly affect the transmission of COVID-19.", [["COVID-19", "CHEMICAL", 165, 173], ["COVID-19", "CHEMICAL", 165, 173], ["the previous IMDs", "TEST", 38, 55], ["COVID", "TEST", 165, 170]]], ["The indicators of IMD were drawn from the Census of India, the most reliable data sources on SES in India.", [["IMD", "PROBLEM", 18, 21]]], ["To formulate a composite index of SES deprivation, we used GWPCA which is preferred over widely used normal PCA at recent.", [["a composite index of SES deprivation", "TREATMENT", 13, 49], ["GWPCA", "TREATMENT", 59, 64]]], ["GWPCA as an emerging and promising tool 7 has a certain advantage over PCA such as it provides covariance structure, component scores, loadings, and explained variance for each electoral wards 8 .", [["GWPCA", "CHEMICAL", 0, 5], ["PCA", "TREATMENT", 71, 74]]], ["Therefore, we were able to devise IMD by utilizing the local component weights of IMD indicators which were not possible in normal PCA 8 .Discussion and ConclusionThe regression results of this study support the findings of the earlier study that addressed the possible impact of SES on COVID 19 incidences 9 .", [["this study", "TEST", 189, 199], ["the earlier study", "TEST", 224, 241]]], ["To the best of our knowledge, this study was the first attempt on COVID-19 which quantitatively establish the influence of areadeprivation on COVID-19 incidences.", [["this study", "TEST", 30, 40], ["COVID", "TEST", 66, 71], ["COVID", "TEST", 142, 147]]], ["The results of Poisson Regression and Negative Binomial Regression suggested that area-deprivation has both positive and inverse associations with the incidences of COVID-19 infections in Chennai megacity.", [["infections", "DISEASE", 174, 184], ["Poisson Regression", "TEST", 15, 33], ["Binomial Regression", "TEST", 47, 66], ["COVID", "TEST", 165, 170], ["19 infections in Chennai megacity", "PROBLEM", 171, 204]]], ["This further strengthens the findings of Ahmed et al. (2020) 10 that the socioeconomic disadvantages and inequalities have a profound role in the spread of COVID-19.", [["COVID", "TEST", 156, 161]]], ["The findings of this study suggest approaches to combat the COVID-19 pandemic must incorporate SES dynamics to develop a mitigation strategy.Discussion and ConclusionIn conclusion, this study formulated an IMD for area-deprivation measures of SES disadvantage, and the index showed a substantial relation to COVID-19 incidences, especially for poor availability of WaSH services and poor housing conditions.", [["this study", "TEST", 16, 26], ["the COVID", "TEST", 56, 65], ["a mitigation strategy", "TREATMENT", 119, 140], ["this study", "TEST", 181, 191], ["SES disadvantage", "PROBLEM", 243, 259], ["the index", "TEST", 265, 274], ["COVID", "TEST", 308, 313], ["WaSH services", "TREATMENT", 365, 378]]], ["This study highlights that the risks of COVID-19 infections tend to be higher in SES deprived areas and the north-eastern part of Chennai megacity was predominantly high-risk areas.", [["infections", "DISEASE", 49, 59], ["COVID-19", "ORGANISM", 40, 48], ["This study", "TEST", 0, 10], ["COVID", "TEST", 40, 45], ["19 infections", "PROBLEM", 46, 59], ["Chennai megacity", "PROBLEM", 130, 146], ["predominantly", "OBSERVATION_MODIFIER", 151, 164], ["high", "OBSERVATION_MODIFIER", 165, 169]]], ["Although a more contextual discussion on IMD formulation is needed, the proposed index based on a common set of SES indicators may be readily applicable for research on the relationship between COVID-19 and SES deprivation.", [["IMD formulation", "TREATMENT", 41, 56], ["the proposed index", "TEST", 68, 86], ["COVID", "TEST", 194, 199], ["SES deprivation", "TREATMENT", 207, 222]]], ["Our results can guide measures of COVID-19 control and prevention by considering spatial risks and area-deprivation.", [["area-deprivation", "DISEASE", 99, 115], ["COVID-19 control", "TREATMENT", 34, 50], ["prevention", "TREATMENT", 55, 65], ["area-deprivation", "TREATMENT", 99, 115]]]], "PMC7437405": [["MATERIALS AND METHODSThis prospective cohort study included all patients with confirmed SARS-CoV-2 managed in the ICUs of Landspitali University Hospital and Akureyri Hospital, the only two hospitals offering ICU care in Iceland.", [["SARS", "DISEASE", 88, 92], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["METHODSThis prospective cohort study", "TEST", 14, 50], ["SARS", "PROBLEM", 88, 92], ["ICU care", "TREATMENT", 209, 217]]], ["In general, all patients with a progressive hypoxic respiratory failure secondary to COVID-19 were evaluated for a potential ICU admission by the on-call critical care physician following consultation with internal or emergency medicine physicians.", [["respiratory", "ANATOMY", 52, 63], ["respiratory failure", "DISEASE", 52, 71], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["a progressive hypoxic respiratory failure", "PROBLEM", 30, 71], ["progressive", "OBSERVATION_MODIFIER", 32, 43], ["hypoxic", "OBSERVATION_MODIFIER", 44, 51], ["respiratory failure", "OBSERVATION", 52, 71]]], ["Patients considered at high risk of requiring mechanical ventilation were admitted to the ICU, after weighing the benefits of ICU admission with underlying comorbidities and frailty.MATERIALS AND METHODSClinical data were prospectively collected using Research electronic data capture (REDCap), a secure, web-based data capture platform.", [["frailty", "DISEASE", 174, 181], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["mechanical ventilation", "TREATMENT", 46, 68], ["underlying comorbidities", "PROBLEM", 145, 169], ["frailty", "PROBLEM", 174, 181], ["METHODSClinical data", "TEST", 196, 216], ["mechanical ventilation", "OBSERVATION", 46, 68]]], ["The primary outcomes were the incidence of ICU admission for COVID-19 following SARS-CoV-2 diagnosis and the incidence of all-cause hospital mortality among those patients admitted to the ICU for COVID-19.", [["SARS", "DISEASE", 80, 84], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171], ["COVID", "TEST", 61, 66], ["SARS", "PROBLEM", 80, 84], ["COVID", "TEST", 196, 201]]], ["In addition to descriptive statistics, incidence and survival ratios are reported with 95% CI using the Clopper-Pearson exact method with the \u201cbinom\u201d package.", [["survival ratios", "TEST", 53, 68], ["the \u201cbinom\u201d package", "TREATMENT", 138, 157]]], ["All statistics and image processing were performed in R, Version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria), using RStudio, Version 1.1.423 (RStudio, Boston, MA).", [["image processing", "TEST", 19, 35], ["Version", "TEST", 145, 152]]], ["The study was approved by the National Bioethics Committee (VSN-20-071), waiving individual consent.RESULTSOut of 51,622 individuals tested on May 5, 2020, 18,357 (35.6%) were tested for symptoms suggestive of SARS-CoV-2 and the remainder were tested as a part of population screening.", [["SARS", "DISEASE", 210, 214], ["SARS-CoV", "SPECIES", 210, 218], ["The study", "TEST", 0, 9], ["symptoms", "PROBLEM", 187, 195], ["SARS", "PROBLEM", 210, 214], ["CoV", "TEST", 215, 218], ["population screening", "TEST", 264, 284]]], ["Of all tested, 1,799 (3.5%; 95% CI, 3.3\u20133.6%) were positive for SARS-CoV-2, and of those, 118 (6.7%, 95% CI 5.5\u20137.8%) were admitted to the hospital.", [["SARS", "DISEASE", 64, 68], ["SARS-CoV", "SPECIES", 64, 72], ["CI", "TEST", 32, 34], ["SARS", "TEST", 64, 68], ["CoV", "TEST", 69, 72], ["CI", "TEST", 105, 107]]], ["The first patient was admitted to the ICU on March 14, 2020, and the last patient was admitted on April 13, 2020.", [["patient", "ORGANISM", 10, 17], ["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 10, 17], ["patient", "SPECIES", 74, 81]]], ["In total, 27 out of 1,799 (1.5%; 95% CI, 1.0\u20132.2%) SARS-CoV-2 positive individuals were admitted to the ICU due to COVID-19.", [["SARS", "DISEASE", 51, 55], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 51, 61], ["individuals", "ORGANISM", 71, 82], ["COVID-19", "DNA", 115, 123], ["CI", "TEST", 37, 39], ["\u2013", "TEST", 44, 45], ["SARS", "TEST", 51, 55], ["CoV", "TEST", 56, 59], ["COVID", "TEST", 115, 120]]], ["Two patients admitted to the ICU for other indications (hemorrhagic shock and urosepsis) were positive for SARS-CoV-2 but were excluded from further analysis as they were minimally symptomatic or had recovered from COVID-19.", [["hemorrhagic shock", "DISEASE", 56, 73], ["urosepsis", "DISEASE", 78, 87], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["SARS-CoV", "SPECIES", 107, 115], ["hemorrhagic shock", "PROBLEM", 56, 73], ["urosepsis", "PROBLEM", 78, 87], ["SARS", "PROBLEM", 107, 111], ["CoV", "TEST", 112, 115], ["further analysis", "TEST", 141, 157], ["minimally symptomatic", "PROBLEM", 171, 192], ["COVID", "TEST", 215, 220], ["urosepsis", "OBSERVATION", 78, 87]]], ["The population incidence of an ICU admission for COVID-19 was, therefore, 7.4 (95% CI, 4.9\u201310.8) admissions per 100,000 individuals.RESULTSThe clinical course for all 27 patients is shown in Figure 1, and patient characteristics, laboratory profile, and ward management prior to admission are described in Table 1.", [["patients", "ORGANISM", 170, 178], ["patient", "ORGANISM", 205, 212], ["patients", "SPECIES", 170, 178], ["patient", "SPECIES", 205, 212], ["COVID", "TEST", 49, 54], ["CI", "TEST", 83, 85], ["laboratory profile", "TEST", 230, 248], ["ward management", "TREATMENT", 254, 269]]], ["Most patients were admitted to the ICU due to hypoxic respiratory failure after clinical deterioration on the general ward.", [["respiratory", "ANATOMY", 54, 65], ["respiratory failure", "DISEASE", 54, 73], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["hypoxic respiratory failure", "PROBLEM", 46, 73], ["clinical deterioration", "PROBLEM", 80, 102], ["hypoxic", "OBSERVATION_MODIFIER", 46, 53], ["respiratory failure", "OBSERVATION", 54, 73]]], ["Of the 27 patients admitted to the ICU, 16 required mechanical ventilation, and prone positioning and diuretics were frequently used (Table 2).RESULTSThe last patient was discharged from the ICU on April 28, 2020, and on final follow-up, May 6, 2020, four patients had died, but the other 23 patients were all discharged from both the ICU and the hospital.", [["patients", "ORGANISM", 10, 18], ["patient", "ORGANISM", 159, 166], ["patients", "ORGANISM", 256, 264], ["patients", "ORGANISM", 292, 300], ["patients", "SPECIES", 10, 18], ["patient", "SPECIES", 159, 166], ["patients", "SPECIES", 256, 264], ["patients", "SPECIES", 292, 300], ["mechanical ventilation", "TREATMENT", 52, 74], ["prone positioning", "TREATMENT", 80, 97], ["diuretics", "TREATMENT", 102, 111], ["mechanical ventilation", "OBSERVATION", 52, 74]]], ["Out of 16 patients receiving invasive mechanical ventilation, three died, but the other 13 had been successfully liberated from mechanical ventilation.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["invasive mechanical ventilation", "TREATMENT", 29, 60], ["mechanical ventilation", "TREATMENT", 128, 150], ["mechanical ventilation", "OBSERVATION", 38, 60], ["mechanical ventilation", "OBSERVATION", 128, 150]]], ["The hospital mortality of all patients who required ICU admission due to COVID-19 was, therefore, four of 27 (15%, 95% CI, 4\u201334%), and the mortality of all patients who required mechanical ventilation was three of 16 (19%; 95% CI, 4\u201346%).DISCUSSIONWhen determining the ratio of ICU admissions among COVID-19 patients, it is of paramount importance to eliminate bias due to tertiary care referrals or restricted ability to screen for SARS-CoV-2.", [["SARS", "DISEASE", 433, 437], ["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 156, 164], ["patients", "ORGANISM", 308, 316], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 156, 164], ["patients", "SPECIES", 308, 316], ["SARS-CoV", "SPECIES", 433, 441], ["COVID", "TEST", 73, 78], ["CI", "TEST", 119, 121], ["mechanical ventilation", "TREATMENT", 178, 200], ["CI", "TEST", 227, 229], ["SARS", "PROBLEM", 433, 437]]], ["We found that in our cohort, 1.5% of all patients with a confirmed SARS-CoV-2 required ICU for COVID-19.", [["SARS", "DISEASE", 67, 71], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["CoV", "TEST", 72, 75], ["COVID", "TEST", 95, 100]]], ["This estimate is substantially lower than initial published estimates from Italy and China, predicting that around 5\u20137% of positive patients would require ICU (1, 2).", [["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["substantially lower", "PROBLEM", 17, 36], ["substantially", "OBSERVATION_MODIFIER", 17, 30], ["lower", "OBSERVATION_MODIFIER", 31, 36]]], ["The population screening performed in Iceland indicated a low prevalence among asymptomatic individuals at the peak of the pandemic, with only 0.6% of randomly screened individuals positive for SARS-CoV-2 compared with 13.3% of patients with symptoms suggestive of COVID-19 (6).", [["SARS", "DISEASE", 194, 198], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 228, 236], ["SARS-CoV", "SPECIES", 194, 202], ["The population screening", "TEST", 0, 24], ["asymptomatic individuals", "PROBLEM", 79, 103], ["SARS", "TEST", 194, 198], ["CoV", "TEST", 199, 202], ["symptoms", "PROBLEM", 242, 250], ["COVID", "TEST", 265, 270], ["low prevalence", "OBSERVATION_MODIFIER", 58, 72]]], ["It is, therefore, likely that our reported rate differs from prior reports due to extensive testing of individuals that likely captures more cases, including patients with milder symptoms.DISCUSSIONOur mortality ratio of 15% compares favorably to initial population reports describing up to 50\u201378% mortality among patients treated for COVID-19 in the ICU (3\u20135).", [["patients", "ORGANISM", 158, 166], ["patients", "ORGANISM", 314, 322], ["patients", "SPECIES", 158, 166], ["patients", "SPECIES", 314, 322], ["extensive testing", "TEST", 82, 99], ["milder symptoms", "PROBLEM", 172, 187], ["mortality ratio", "TEST", 202, 217], ["COVID", "TEST", 335, 340]]], ["There could be several explanations for this, including better overall health of the admitted patients as well as nationwide approval and participation in population health measures resulting reduced incidence of COVID-19.", [["COVID-19", "CHEMICAL", 213, 221], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["COVID", "TEST", 213, 218]]], ["This contributed to a pandemic that was managed within the capacity of the entire healthcare system, including the ICU.", [["a pandemic", "PROBLEM", 20, 30], ["pandemic", "OBSERVATION", 22, 30]]], ["The centralized follow-up of all SARS-CoV-2 positive patients provided frequent contact with patients at home and an early evaluation of patients deteriorating at home, including an evaluation for ICU admission.", [["SARS", "DISEASE", 33, 37], ["SARS-CoV-2", "ORGANISM", 33, 43], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 93, 101], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 137, 145], ["SARS-CoV", "SPECIES", 33, 41], ["all SARS", "TEST", 29, 37], ["CoV", "TEST", 38, 41], ["an early evaluation", "TEST", 114, 133], ["an evaluation", "TEST", 179, 192]]], ["Additionally, a careful multidisciplinary assessment weighing the benefit of ICU care of each individual against disease status and the overall burden of comorbidity and frailty was performed, and this can result in fewer ICU admissions and better outcomes.", [["a careful multidisciplinary assessment", "TEST", 14, 52], ["ICU care", "TREATMENT", 77, 85], ["disease status", "PROBLEM", 113, 127], ["comorbidity", "PROBLEM", 154, 165]]], ["Among limitations is the small size of the Icelandic population that is genetically homogenous and geographically isolated.", [["the Icelandic population", "PROBLEM", 39, 63], ["small", "OBSERVATION_MODIFIER", 25, 30], ["size", "OBSERVATION_MODIFIER", 31, 35], ["Icelandic", "OBSERVATION_MODIFIER", 43, 52], ["population", "OBSERVATION", 53, 63], ["genetically", "OBSERVATION_MODIFIER", 72, 83], ["homogenous", "OBSERVATION_MODIFIER", 84, 94], ["geographically", "OBSERVATION_MODIFIER", 99, 113], ["isolated", "OBSERVATION_MODIFIER", 114, 122]]], ["This might render our findings less applicable to other populations.DISCUSSIONWe hope that in addition to assisting with surge planning for COVID-19, our findings will encourage other nationwide reports of ICU outcomes.", [["COVID", "TREATMENT", 140, 145]]], ["This would allow a dialogue on how different response strategies to COVID-19 are associated with ICU outcomes, with the hope that the response to future pandemics could be improved.", [["COVID-19", "DNA", 68, 76]]]], "PMC7172790": [["Endemism is high at each taxonomic level (Teeling et al., 2005), and the patterns of distribution suggest that the geographic separation of the Old and New Worlds has been an effective barrier to the movement of bats.", [["Endemism", "PROBLEM", 0, 8], ["high", "OBSERVATION_MODIFIER", 12, 16], ["geographic", "OBSERVATION_MODIFIER", 115, 125], ["separation", "OBSERVATION_MODIFIER", 126, 136], ["New", "OBSERVATION_MODIFIER", 152, 155], ["effective", "OBSERVATION_MODIFIER", 175, 184]]], ["For example, one of the two proposed suborders, Yinpterochiroptera (which includes three microbat families: Rhinopomatidae, Rhinolophidae and Megadermatidae, as well as the megabat family Pteropodidae), has an exclusively Old World distribution.", [["Yinpterochiroptera", "CHEMICAL", 48, 66], ["Rhinopomatidae", "TREATMENT", 108, 122], ["Rhinolophidae", "TREATMENT", 124, 137], ["Megadermatidae", "TREATMENT", 142, 156]]], ["Within the other proposed suborder, Yangochiroptera, no species and only five genera are common to both (Eick et al., 2005, Teeling et al., 2005).", [["species", "PROBLEM", 56, 63], ["no", "UNCERTAINTY", 53, 55]]], ["Evidence for movement of bats between these regions is limited.", [["movement of bats between these regions", "PROBLEM", 13, 51], ["movement", "OBSERVATION_MODIFIER", 13, 21]]], ["New World species of the genus Myotis are estimated to have initially diverged 12.2 \u00b1 2.0 MYA, indicating that Myotis arrived from the Old World before this (Stadelmann et al., 2007).", [["the genus Myotis", "PROBLEM", 21, 37], ["genus Myotis", "ANATOMY", 25, 37]]], ["It is not known when the other genera found in both the Old and New Worlds made the crossing.IntroductionOccasionally, New World bats are reported in Europe.", [["not known", "UNCERTAINTY", 6, 15]]], ["Some, such as Myotis lucifugus, have been accidentally transported onboard ships (Constantine, 2003).", [["Myotis lucifugus", "ORGANISM", 14, 30], ["Myotis lucifugus", "SPECIES", 14, 30], ["Myotis lucifugus", "SPECIES", 14, 30]]], ["Examples include Hoary Bats (Lasiurus cinereus) that are occasionally found in Iceland, the Galapagos Islands, and Orkney Islands (see Constantine (2003) and references therein), and bats found in Bermuda, over 1000 km from the United States (Constantine, 2003).", [["Hoary Bats", "ORGANISM", 17, 27], ["Lasiurus cinereus", "ORGANISM", 29, 46], ["Lasiurus cinereus", "SPECIES", 29, 46], ["Lasiurus cinereus", "SPECIES", 29, 46], ["Galapagos Islands", "OBSERVATION", 92, 109]]], ["In addition, some have colonised isolated islands; the Hawaiian Hoary Bat (Lasiurus cinereus semotus) is thought to be most closely related to a subspecies of Hoary Bat from North America, implying natural movement over a distance of over 4000 km (Morales and Bickham, 1995).", [["Hawaiian", "ORGANISM", 55, 63], ["Hoary Bat", "ORGANISM", 64, 73], ["Lasiurus cinereus semotus", "ORGANISM", 75, 100], ["Hoary Bat", "ORGANISM", 159, 168], ["Lasiurus", "SPECIES", 75, 83], ["cinereus semotus", "SPECIES", 84, 100], ["Lasiurus cinereus semotus", "SPECIES", 75, 100], ["colonised isolated islands", "PROBLEM", 23, 49], ["colonised", "OBSERVATION_MODIFIER", 23, 32], ["isolated", "OBSERVATION_MODIFIER", 33, 41], ["islands", "OBSERVATION", 42, 49], ["thought to be", "UNCERTAINTY", 105, 118], ["natural movement", "OBSERVATION", 198, 214]]], ["However, such movements are difficult to study as the distances travelled, the infrequency of movements, and the unlikelihood of capturing one of the relevant individuals render traditional approaches such as banding, radiotracking, and stable isotope analysis unlikely to yield useful results.IntroductionSome species of trypanosomes, single-celled parasites that are found in the blood of vertebrates, cause important diseases in humans and livestock (Hoare, 1972).", [["blood", "ANATOMY", 382, 387], ["blood", "ORGANISM_SUBSTANCE", 382, 387], ["humans", "ORGANISM", 432, 438], ["humans", "SPECIES", 432, 438], ["humans", "SPECIES", 432, 438], ["banding", "TREATMENT", 209, 216], ["IntroductionSome species of trypanosomes", "PROBLEM", 294, 334], ["single-celled parasites", "TREATMENT", 336, 359], ["trypanosomes", "OBSERVATION_MODIFIER", 322, 334]]], ["For example, in Africa, some variants of Trypanosoma brucei are responsible for Sleeping Sickness in humans, while a range of other species cause similar wasting diseases of livestock (known as nagana).", [["Trypanosoma brucei", "DISEASE", 41, 59], ["Sleeping Sickness", "DISEASE", 80, 97], ["wasting diseases of livestock", "DISEASE", 154, 183], ["Trypanosoma brucei", "ORGANISM", 41, 59], ["humans", "ORGANISM", 101, 107], ["Trypanosoma brucei", "SPECIES", 41, 59], ["humans", "SPECIES", 101, 107], ["Trypanosoma brucei", "SPECIES", 41, 59], ["humans", "SPECIES", 101, 107], ["Trypanosoma brucei", "PROBLEM", 41, 59], ["Sleeping Sickness in humans", "PROBLEM", 80, 107], ["similar wasting diseases of livestock", "PROBLEM", 146, 183], ["Trypanosoma brucei", "OBSERVATION", 41, 59], ["wasting", "OBSERVATION_MODIFIER", 154, 161], ["diseases", "OBSERVATION", 162, 170]]], ["In South and Central America, Trypanosoma cruzi causes Chagas Disease in humans and is also known to infect a wide range of reservoir animals (Hoare, 1972, Miles et al., 2009).", [["Trypanosoma cruzi", "DISEASE", 30, 47], ["Chagas Disease", "DISEASE", 55, 69], ["Trypanosoma cruzi", "ORGANISM", 30, 47], ["humans", "ORGANISM", 73, 79], ["Trypanosoma cruzi", "SPECIES", 30, 47], ["humans", "SPECIES", 73, 79], ["Trypanosoma cruzi", "SPECIES", 30, 47], ["humans", "SPECIES", 73, 79], ["Trypanosoma cruzi", "PROBLEM", 30, 47], ["Chagas Disease in humans", "PROBLEM", 55, 79], ["Central", "ANATOMY_MODIFIER", 13, 20], ["Trypanosoma cruzi", "OBSERVATION", 30, 47], ["Chagas Disease", "OBSERVATION", 55, 69], ["wide", "OBSERVATION_MODIFIER", 110, 114]]], ["Trypanosomes have been described from bats from all continents in which they occur (Hoare, 1972, Molyneux, 1991).", [["Trypanosomes", "GENE_OR_GENE_PRODUCT", 0, 12]]], ["Many bat trypanosomes (including T. dionisii and T. vespertilionis) are morphologically indistinguishable from T. cruzi.", [["bat trypanosomes", "ORGANISM", 5, 21], ["T. dionisii", "ORGANISM", 33, 44], ["T. vespertilionis", "ORGANISM", 49, 66], ["T. cruzi", "ORGANISM", 111, 119], ["T. dionisii", "SPECIES", 33, 44], ["T. vespertilionis", "SPECIES", 49, 66], ["T. cruzi", "SPECIES", 111, 119], ["T. dionisii", "SPECIES", 33, 44], ["T. vespertilionis", "SPECIES", 49, 66], ["T. cruzi", "SPECIES", 111, 119], ["Many bat trypanosomes", "PROBLEM", 0, 21], ["bat trypanosomes", "OBSERVATION", 5, 21]]], ["Therefore these bat trypanosomes can only be assigned to the T. cruzi subgenus T. (Schizotrypanum) sp. based on morphology alone.", [["bat trypanosomes", "ORGANISM", 16, 32], ["T. cruzi subgenus", "ORGANISM", 61, 78], ["T. (Schizotrypanum) sp", "ORGANISM", 79, 101], ["T. cruzi", "SPECIES", 61, 69], ["T. cruzi", "SPECIES", 61, 69], ["these bat trypanosomes", "PROBLEM", 10, 32]]], ["As little is known of the host specificity of most bat trypanosomes, their diversity may have been considerably over- or underestimated (Hoare, 1972).", [["bat trypanosomes", "ORGANISM", 51, 67], ["considerably", "OBSERVATION_MODIFIER", 99, 111]]], ["The objective of this study was to examine occurrence and diversity of trypanosome species in British bats.", [["British bats", "SPECIES", 94, 106], ["this study", "TEST", 17, 27], ["trypanosome species", "PROBLEM", 71, 90], ["trypanosome species", "OBSERVATION", 71, 90]]], ["Because many parasites, including species of bat trypanosome, can persist in related groups of hosts, understanding their phylogeography can provide valuable clues to the historical movements of host organisms.PCR detection and identification of trypanosomes ::: Materials and methodsOne-hundred and eighty-eight blood samples from 13 species of bat were collected in southern Britain in 2006 (collected under Natural England licence 20082696 and preceding licences, and Home Office licence PPL30/2243).", [["blood samples", "ANATOMY", 313, 326], ["bat trypanosome", "ORGANISM", 45, 60], ["blood samples", "ORGANISM_SUBSTANCE", 313, 326], ["bat", "ORGANISM", 346, 349], ["bat trypanosome", "SPECIES", 45, 60], ["many parasites", "PROBLEM", 8, 22], ["species of bat trypanosome", "PROBLEM", 34, 60], ["host organisms", "PROBLEM", 195, 209], ["PCR detection", "TEST", 210, 223], ["blood samples", "TEST", 313, 326], ["parasites", "OBSERVATION", 13, 22]]], ["Bats were identified by F. Mathews (Exeter) using standard field guides (Greenaway and Hutson, 1990, Dietz and von Helversen, 2004).", [["Bats", "CELL", 0, 4]]], ["Genomic DNA was extracted from blood samples using the DNeasy Kit (Qiagen Inc.), using negative controls to test for contamination during DNA extraction.", [["blood samples", "ANATOMY", 31, 44], ["DNA", "CELLULAR_COMPONENT", 8, 11], ["blood samples", "ORGANISM_SUBSTANCE", 31, 44], ["DNA", "CELLULAR_COMPONENT", 138, 141], ["Genomic DNA", "PROBLEM", 0, 11], ["blood samples", "TEST", 31, 44], ["the DNeasy Kit", "TREATMENT", 51, 65], ["contamination", "PROBLEM", 117, 130], ["DNA extraction", "TREATMENT", 138, 152]]], ["As blood samples were collected at different times, DNA quality was tested using primers 5\u2032-GGCCGCGGTAYYHYRACC-3\u2032 and 5\u2032-GATKGCGCTGTTATCCCTRG-3\u2032, designed to be specific for a \u223c400 bp region of the vertebrate mitochondrial 16S ribosomal RNA gene, using a touchdown PCR program (Hamilton and Tyler, 2008), which indicated the presence of amplifiable DNA in 154 DNA samples.", [["blood samples", "ANATOMY", 3, 16], ["mitochondrial", "ANATOMY", 209, 222], ["samples", "ANATOMY", 364, 371], ["blood samples", "ORGANISM_SUBSTANCE", 3, 16], ["DNA", "CELLULAR_COMPONENT", 52, 55], ["mitochondrial", "CELLULAR_COMPONENT", 209, 222], ["ribosomal", "CELLULAR_COMPONENT", 227, 236], ["DNA", "CELLULAR_COMPONENT", 349, 352], ["DNA", "CELLULAR_COMPONENT", 360, 363], ["\u223c400 bp region", "DNA", 176, 190], ["vertebrate mitochondrial 16S ribosomal RNA gene", "DNA", 198, 245], ["amplifiable DNA", "DNA", 337, 352], ["blood samples", "TEST", 3, 16], ["DNA quality", "TEST", 52, 63], ["primers", "TEST", 81, 88], ["GGCCGCGGTAYYHYRACC", "TEST", 92, 110], ["a touchdown PCR program", "TREATMENT", 253, 276], ["amplifiable DNA", "PROBLEM", 337, 352], ["DNA samples", "TEST", 360, 371]]], ["To test for the presence of trypanosomal DNA, PCR reactions were carried out using trypanosome-specific rDNA primers 18S-1f and 18S-4r (Hamilton et al., 2008) and trypanosome-positive samples were further analysed by fluorescent fragment length barcoding (FFLB), a method that discriminates between species using length differences of four ribosomal regions (Hamilton et al., 2008).", [["samples", "ANATOMY", 184, 191], ["ribosomal", "ANATOMY", 340, 349], ["DNA", "CELLULAR_COMPONENT", 41, 44], ["18S-1f", "GENE_OR_GENE_PRODUCT", 117, 123], ["18S-4r", "SIMPLE_CHEMICAL", 128, 134], ["trypanosomal DNA", "DNA", 28, 44], ["trypanosome-specific rDNA primers", "DNA", 83, 116], ["18S", "DNA", 117, 120], ["18S", "DNA", 128, 131], ["ribosomal regions", "DNA", 340, 357], ["trypanosomal DNA", "PROBLEM", 28, 44], ["PCR reactions", "PROBLEM", 46, 59], ["trypanosome", "TEST", 83, 94], ["specific rDNA primers", "TEST", 95, 116], ["18S", "TEST", 128, 131], ["Hamilton et al.", "TEST", 136, 151], ["trypanosome", "TEST", 163, 174], ["fluorescent fragment length barcoding (FFLB)", "PROBLEM", 217, 261], ["a method", "TEST", 263, 271], ["trypanosomal DNA", "OBSERVATION", 28, 44]]], ["FFLB profiles were also obtained from isolates of Trypanosoma dionisii and T. vespertilionis, two trypanosome species known from European bats, for comparison.", [["Trypanosoma dionisii", "DISEASE", 50, 70], ["FFLB", "GENE_OR_GENE_PRODUCT", 0, 4], ["Trypanosoma dionisii", "ORGANISM", 50, 70], ["T. vespertilionis", "ORGANISM", 75, 92], ["FFLB", "PROTEIN", 0, 4], ["Trypanosoma dionisii", "SPECIES", 50, 70], ["T. vespertilionis", "SPECIES", 75, 92], ["Trypanosoma dionisii", "SPECIES", 50, 70], ["T. vespertilionis", "SPECIES", 75, 92], ["FFLB profiles", "TEST", 0, 13], ["Trypanosoma dionisii", "PROBLEM", 50, 70], ["T. vespertilionis", "PROBLEM", 75, 92], ["two trypanosome species", "PROBLEM", 94, 117], ["Trypanosoma dionisii", "OBSERVATION", 50, 70]]], ["Trypanosomal gGAPDH and partial 18S rDNA genes were amplified and sequenced as described previously (Hamilton et al., 2008) from two individual bats giving each novel FFLB profile.", [["Trypanosomal gGAPDH", "GENE_OR_GENE_PRODUCT", 0, 19], ["18S", "GENE_OR_GENE_PRODUCT", 32, 35], ["rDNA", "CELLULAR_COMPONENT", 36, 40], ["FFLB", "CANCER", 167, 171], ["Trypanosomal gGAPDH and partial 18S rDNA genes", "DNA", 0, 46], ["FFLB", "PROTEIN", 167, 171], ["Trypanosomal gGAPDH", "TREATMENT", 0, 19], ["partial 18S rDNA genes", "PROBLEM", 24, 46], ["partial", "OBSERVATION_MODIFIER", 24, 31], ["18S rDNA", "OBSERVATION", 32, 40]]], ["Attempts to amplify longer 18S rDNA regions from one genotype (New1) failed, likely due to limited DNA quantity/quality.", [["rDNA", "CELLULAR_COMPONENT", 31, 35], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["18S rDNA regions", "DNA", 27, 43], ["longer 18S rDNA regions", "PROBLEM", 20, 43], ["limited DNA quantity/quality", "PROBLEM", 91, 119], ["likely due to", "UNCERTAINTY", 77, 90]]], ["GenBank accession numbers are: New 1 gGAPDH FN599056 (853 bp); 18S rDNA FN599057 (526 bp); New 2 gGAPDH FN599055 (858 bp); 18S rDNA FN599058 (1445 bp).18S rDNA alignment ::: Phylogenetic analyses ::: Materials and methodsThe two partial 18S rDNA sequences obtained in this study, which cover the most variable (V7\u2013V8) region of this gene, were manually aligned with sequences from other T. dionisii isolates.", [["T. dionisii isolates", "ORGANISM", 387, 407], ["18S rDNA FN599057", "DNA", 63, 80], ["gGAPDH FN599055", "DNA", 97, 112], ["858 bp", "DNA", 114, 120], ["18S rDNA FN599058", "DNA", 123, 140], ["18S rDNA sequences", "DNA", 237, 255], ["V7", "DNA", 311, 313], ["T. dionisii", "SPECIES", 387, 398], ["T. dionisii", "SPECIES", 387, 398], ["bp", "TEST", 58, 60], ["18S rDNA", "TEST", 63, 71], ["bp", "TEST", 86, 88], ["bp", "TEST", 118, 120], ["bp", "TEST", 147, 149], ["Phylogenetic analyses", "TEST", 174, 195], ["The two partial 18S rDNA sequences", "TEST", 221, 255], ["this study", "TEST", 268, 278]]], ["The alignment contained 22 taxa, and all 541 characters in the V7\u2013V8 region were included in subsequent analyses.GAPDH alignment 1 ::: Phylogenetic analyses ::: Materials and methodsThe new gGAPDH gene sequences obtained in this study were manually aligned with those from other trypanosomes in the T. cruzi clade.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 113, 118], ["gGAPDH", "GENE_OR_GENE_PRODUCT", 190, 196], ["T. cruzi clade", "ORGANISM", 299, 313], ["V7\u2013V8 region", "DNA", 63, 75], ["gGAPDH gene sequences", "DNA", 190, 211], ["T. cruzi", "SPECIES", 299, 307], ["T. cruzi", "SPECIES", 299, 307], ["22 taxa", "TEST", 24, 31], ["Phylogenetic analyses", "TEST", 135, 156], ["The new gGAPDH gene sequences", "TEST", 182, 211], ["this study", "TEST", 224, 234], ["22 taxa", "OBSERVATION_MODIFIER", 24, 31], ["cruzi clade", "OBSERVATION", 302, 313]]], ["This alignment contained 23 sequences and analyses were based on 836 characters.", [["analyses", "TEST", 42, 50]]], ["A trypanosome from a kangaroo, the most divergent taxon within this clade (Stevens et al., 1999, Hamilton et al., 2007), was used as an outgroup.GAPDH alignment 2 ::: Phylogenetic analyses ::: Materials and methodsFor molecular dating analysis, the new gGAPDH sequences, and others from recent studies, were added to the alignment of Hamilton et al. (2007).", [["kangaroo", "ORGANISM", 21, 29], ["GAPDH", "GENE_OR_GENE_PRODUCT", 145, 150], ["gGAPDH sequences", "DNA", 253, 269], ["a kangaroo", "TREATMENT", 19, 29], ["Phylogenetic analyses", "TEST", 167, 188], ["molecular dating analysis", "TEST", 218, 243], ["the new gGAPDH sequences", "TEST", 245, 269], ["recent studies", "TEST", 287, 301]]], ["Forty-nine trypanosomal and 23 other trypanosomatid sequences were selected from this alignment to represent known trypanosomatid diversity, and four bodonid sequences were used as outgroups.", [["trypanosomal", "ANATOMY", 11, 23], ["trypanosomal", "CANCER", 11, 23], ["trypanosomal and 23 other trypanosomatid sequences", "DNA", 11, 61], ["bodonid sequences", "DNA", 150, 167], ["23 other trypanosomatid sequences", "TEST", 28, 61], ["known trypanosomatid diversity", "PROBLEM", 109, 139], ["four bodonid sequences", "TREATMENT", 145, 167], ["trypanosomatid diversity", "OBSERVATION", 115, 139]]], ["This analysis included 839 characters.", [["This analysis", "TEST", 0, 13]]], ["All alignments were analysed by maximum likelihood (ML), maximum parsimony, and ML distance analysis as implemented in the program PAUP version 4.0b10 (Swofford, 2003), essentially as described previously (Hamilton et al., 2007).Molecular dating ::: Materials and methodsDivergence dates were estimated from gGAPDH gene alignment 2.", [["gGAPDH gene alignment 2", "DNA", 308, 331], ["maximum parsimony", "TEST", 57, 74], ["ML distance analysis", "TEST", 80, 100], ["methodsDivergence dates", "TEST", 264, 287], ["gene alignment", "OBSERVATION", 315, 329]]], ["Although concatenated 18S rDNA and gGAPDH gene alignments generally provide increased resolution (Hamilton et al., 2007, McInnes et al., 2009), analyses were based on gGAPDH, as only short 18S rDNA sequences could be obtained from genotype New 1.", [["18S", "GENE_OR_GENE_PRODUCT", 22, 25], ["rDNA", "CELLULAR_COMPONENT", 26, 30], ["gGAPDH", "GENE_OR_GENE_PRODUCT", 35, 41], ["gGAPDH", "GENE_OR_GENE_PRODUCT", 167, 173], ["rDNA", "CELLULAR_COMPONENT", 193, 197], ["18S rDNA", "DNA", 22, 30], ["gGAPDH gene alignments", "DNA", 35, 57], ["gGAPDH", "DNA", 167, 173], ["short 18S rDNA sequences", "DNA", 183, 207], ["concatenated 18S rDNA and gGAPDH gene alignments", "PROBLEM", 9, 57], ["short 18S rDNA sequences", "TEST", 183, 207], ["18S rDNA", "OBSERVATION", 22, 30], ["increased", "OBSERVATION_MODIFIER", 76, 85], ["resolution", "OBSERVATION_MODIFIER", 86, 96]]], ["Dates were calculated from the optimal ML tree using PATHd8 (Fig. 1) (Britton et al., 2007) and BEAST v. 1.6.1 using a Bayesian Markov chain Monte Carlo (MCMC) approach (Drummond and Rambaut, 2007).", [["a Bayesian Markov chain Monte Carlo (MCMC) approach", "TREATMENT", 117, 168]]], ["Posterior probability distributions of node ages were obtained using GTR with rate variation (six gamma categories) and an uncorrelated log-normal model of rate variation.", [["node", "ANATOMY", 39, 43], ["node", "MULTI-TISSUE_STRUCTURE", 39, 43], ["GTR", "TREATMENT", 69, 72], ["rate variation", "TEST", 78, 92], ["node", "OBSERVATION", 39, 43], ["normal model", "OBSERVATION_MODIFIER", 140, 152], ["rate variation", "OBSERVATION", 156, 170]]], ["As, under certain circumstances, BEAST may become stuck on local optima, monophyletic clades (indicated in Fig. 1) were predefined in order to obtain a topology that corresponded to the phylogeny obtained from more robust phylogenetic methods based on more comprehensive concatenated datasets (Hamilton et al., 2007, McInnes et al., 2009).", [["local optima", "TREATMENT", 59, 71], ["monophyletic clades", "PROBLEM", 73, 92]]], ["A Yule tree prior (Yule, 1925) was employed, which assumes a constant speciation rate for each branch on the tree, although the population structures of T. dionisii and most other trypanosome species are not known.", [["tree", "ORGANISM_SUBDIVISION", 109, 113], ["T. dionisii", "ORGANISM", 153, 164], ["T. dionisii", "SPECIES", 153, 164], ["T. dionisii", "SPECIES", 153, 164], ["T. dionisii", "PROBLEM", 153, 164], ["most other trypanosome species", "PROBLEM", 169, 199], ["tree", "ANATOMY_MODIFIER", 109, 113], ["T. dionisii", "OBSERVATION", 153, 164], ["trypanosome species", "OBSERVATION", 180, 199]]], ["In order to assess that the MCMC chains were had stabilized, lnL plots were examined using Tracer v. 1.4 (Rambaut and Drummond, 2007).", [["the MCMC chains", "TEST", 24, 39], ["lnL plots", "TEST", 61, 70], ["Tracer v.", "TEST", 91, 100]]], ["Four host-restricted trypanosomatid clades, which received robust bootstrap support in trees based on concatenated 18S rDNA and gGAPDH genes (Hamilton et al., 2007, McInnes et al., 2009), were used for calibration.", [["18S", "GENE_OR_GENE_PRODUCT", 115, 118], ["rDNA", "CELLULAR_COMPONENT", 119, 123], ["concatenated 18S rDNA", "DNA", 102, 123], ["gGAPDH genes", "DNA", 128, 140], ["restricted trypanosomatid clades", "PROBLEM", 10, 42], ["robust bootstrap support", "TREATMENT", 59, 83], ["trypanosomatid clades", "OBSERVATION", 21, 42]]], ["The oldest estimated divergence dates for their host groups were used as the maximum times of divergence of the parasite clades, as host-restricted parasites are likely to have diversified after diversification of their hosts (Stevens and Rambaut, 2001).", [["the parasite clades", "TREATMENT", 108, 127]]], ["We used 390 \u00b1 \u00bd million years ago (MYA) for the origin of trypanosomatids, based on the origin of insects (Gaunt and Miles, 2002); evidence suggests that the ancestral trypanosomatid was an insect parasite (Hamilton et al., 2004).", [["trypanosomatids", "PROBLEM", 58, 73], ["the ancestral trypanosomatid", "PROBLEM", 154, 182], ["trypanosomatids", "OBSERVATION", 58, 73]]], ["To evaluate the effect of priors on the analysis, we conducted an analysis after removing all sequence data.", [["the analysis", "TEST", 36, 48], ["an analysis", "TEST", 63, 74], ["all sequence data", "TEST", 90, 107]]], ["This resulted in markedly different inferred divergence times, suggesting that the data are driving the results of these analyses rather than the priors.ResultsWe identified four distinct trypanosome genotypes in a survey of 154 British bats from which amplifiable DNA was obtained using fluorescent fragment length barcoding (Table 1).", [["DNA", "CELLULAR_COMPONENT", 265, 268], ["amplifiable DNA", "DNA", 253, 268], ["these analyses", "TEST", 115, 129], ["the priors", "TEST", 142, 152], ["four distinct trypanosome genotypes", "PROBLEM", 174, 209], ["fluorescent fragment length barcoding", "TREATMENT", 288, 325], ["markedly", "OBSERVATION_MODIFIER", 17, 25], ["distinct", "OBSERVATION_MODIFIER", 179, 187], ["trypanosome genotypes", "OBSERVATION", 188, 209]]], ["Two of the FFLB profiles from European isolates matched those of previously described bat trypanosomes, T. dionisii (hereafter T. dionisii A) and T. vespertilionis.", [["FFLB", "GENE_OR_GENE_PRODUCT", 11, 15], ["bat trypanosomes", "ORGANISM", 86, 102], ["T. dionisii", "ORGANISM", 104, 115], ["T. dionisii A", "ORGANISM", 127, 140], ["T. vespertilionis", "ORGANISM", 146, 163], ["FFLB", "PROTEIN", 11, 15], ["T. dionisii", "SPECIES", 104, 115], ["T. dionisii", "SPECIES", 127, 138], ["T. vespertilionis", "SPECIES", 146, 163], ["T. dionisii", "SPECIES", 104, 115], ["T. dionisii", "SPECIES", 127, 138], ["T. vespertilionis", "SPECIES", 146, 163], ["the FFLB profiles", "TEST", 7, 24], ["European isolates", "TREATMENT", 30, 47], ["T. vespertilionis", "PROBLEM", 146, 163]]], ["The other two profiles were new: \u2018New 1\u2019 from Serotine Bats (Eptesicus serotinus) and Whiskered Bats (Myotis mystacinus), and \u2018New 2\u2019 from Noctule Bats (Nyctalus noctula) (Table 2).", [["Serotine Bats", "ORGANISM", 46, 59], ["Eptesicus serotinus", "ORGANISM", 61, 80], ["Whiskered Bats", "ORGANISM", 86, 100], ["Myotis mystacinus", "ORGANISM", 102, 119], ["Nyctalus noctula", "ORGANISM", 153, 169], ["Eptesicus serotinus", "SPECIES", 61, 80], ["Myotis mystacinus", "SPECIES", 102, 119], ["Nyctalus noctula", "SPECIES", 153, 169], ["Eptesicus serotinus", "SPECIES", 61, 80], ["Myotis mystacinus", "SPECIES", 102, 119], ["Nyctalus noctula", "SPECIES", 153, 169], ["Serotine Bats", "TREATMENT", 46, 59], ["new", "OBSERVATION_MODIFIER", 28, 31]]], ["Phylogenetic analysis using 18S rRNA and gGAPDH gene sequences revealed that both are new strains of T. dionisii and are closely related to each other (Fig. 1, Fig. 2).", [["18S", "GENE_OR_GENE_PRODUCT", 28, 31], ["rRNA", "CELLULAR_COMPONENT", 32, 36], ["gGAPDH", "GENE_OR_GENE_PRODUCT", 41, 47], ["T. dionisii", "ORGANISM", 101, 112], ["18S rRNA and gGAPDH gene sequences", "DNA", 28, 62], ["T. dionisii", "SPECIES", 101, 112], ["T. dionisii", "SPECIES", 101, 112], ["Phylogenetic analysis", "TEST", 0, 21], ["18S rRNA", "TEST", 28, 36], ["gGAPDH gene sequences", "TEST", 41, 62], ["T. dionisii", "PROBLEM", 101, 112], ["new", "OBSERVATION_MODIFIER", 86, 89]]], ["Their gGAPDH and 18S rDNA (V7\u2013V8 region) genes differed by 0.48% (4 out of 836 bp) and 1% (6 out of 541 bp), respectively, from each other compared to a minimum gGAPDH divergence of 4.4% from T. dionisii A. Phylogenetic analysis placed both new strains in T. dionisii group B, previously only known from South America (Maia da Silva et al., 2009, Cavazzana et al., 2010), rather than with European T. dionisii group A (Fig. 1, Fig. 2).", [["gGAPDH", "GENE_OR_GENE_PRODUCT", 6, 12], ["18S", "GENE_OR_GENE_PRODUCT", 17, 20], ["rDNA", "CELLULAR_COMPONENT", 21, 25], ["V7\u2013V8", "GENE_OR_GENE_PRODUCT", 27, 32], ["T. dionisii A.", "ORGANISM", 192, 206], ["T. dionisii group B", "ORGANISM", 256, 275], ["gGAPDH and 18S rDNA", "DNA", 6, 25], ["V7", "DNA", 27, 29], ["T. dionisii", "SPECIES", 192, 203], ["T. dionisii group", "SPECIES", 256, 273], ["T. dionisii group", "SPECIES", 398, 415], ["T. dionisii", "SPECIES", 192, 203], ["T. dionisii", "SPECIES", 256, 267], ["T. dionisii", "SPECIES", 398, 409], ["Their gGAPDH", "TEST", 0, 12], ["18S rDNA", "TEST", 17, 25], ["bp", "TEST", 79, 81], ["bp", "TEST", 104, 106], ["Phylogenetic analysis", "TEST", 207, 228], ["rDNA", "ANATOMY_MODIFIER", 21, 25]]], ["In South America, T. dionisii group B has been found in 12 bat species from four families (Molossidae, Noctilionidae, Phyllostomidae, and Vespertilionidae) including insectivorous, frugivorous, and haematophagous species (Cavazzana et al., 2010).", [["T. dionisii", "ORGANISM", 18, 29], ["B", "GENE_OR_GENE_PRODUCT", 36, 37], ["Phyllostomidae", "GENE_OR_GENE_PRODUCT", 118, 132], ["Vespertilionidae", "GENE_OR_GENE_PRODUCT", 138, 154], ["T. dionisii group", "SPECIES", 18, 35], ["T. dionisii", "SPECIES", 18, 29], ["Noctilionidae", "TREATMENT", 103, 116], ["Phyllostomidae", "TREATMENT", 118, 132], ["Vespertilionidae", "TREATMENT", 138, 154], ["haematophagous species", "PROBLEM", 198, 220]]], ["Within T. dionisii group B, sequences from European and South American isolates differed by a minimum of 0.2% (1 out of 541 bp) for V7\u2013V8 18S rDNA and 0.72% (6 out of 836 bp) for the gGAPDH gene.ResultsMaximum times of divergence between the sequences from South American and the new European T. dionisii B strains were estimated from the gGAPDH dataset, using maximum calibration points, under the assumption that divergences of host-restricted parasite clades post-date divergence of their hosts.", [["T. dionisii", "ORGANISM", 7, 18], ["rDNA", "CELLULAR_COMPONENT", 142, 146], ["gGAPDH", "GENE_OR_GENE_PRODUCT", 183, 189], ["T. dionisii B strains", "ORGANISM", 293, 314], ["V7\u2013V8 18S rDNA", "DNA", 132, 146], ["gGAPDH gene", "DNA", 183, 194], ["gGAPDH dataset", "DNA", 339, 353], ["T. dionisii", "SPECIES", 7, 18], ["T. dionisii", "SPECIES", 293, 304], ["T. dionisii", "SPECIES", 7, 18], ["T. dionisii", "SPECIES", 293, 304], ["bp", "TEST", 124, 126], ["V7\u2013V8 18S rDNA", "TEST", 132, 146], ["bp", "TEST", 171, 173], ["B strains", "PROBLEM", 305, 314], ["maximum calibration points", "TREATMENT", 361, 387]]], ["Analysis using PATHd8 suggests that the most similar sequences from Old and New World strains diverged 3.2 MYA, whereas Bayesian analysis in BEAST suggested they diverged 5.0 MYA (95% CI for maximum time 11.4 MYA).", [["PATHd8", "GENE_OR_GENE_PRODUCT", 15, 21], ["PATHd8", "DNA", 15, 21], ["Analysis", "TEST", 0, 8], ["PATHd8", "TEST", 15, 21], ["New World strains", "PROBLEM", 76, 93], ["Bayesian analysis", "TEST", 120, 137], ["CI", "TEST", 184, 186]]], ["Dates for divergence of the UK strains were 1.6 and 8.7 MYA (95% CI for maximum time 17.5 MYA) using these two methods, respectively.", [["UK", "GENE_OR_GENE_PRODUCT", 28, 30], ["the UK strains", "TEST", 24, 38], ["CI", "TEST", 65, 67]]], ["Given the conservative divergence dates used for the host taxa, and that host-restricted trypanosome clades may have evolved some time after diversification of their host groups, true divergence dates for parasites are likely to have been considerably more recent.", [["the host taxa", "TREATMENT", 49, 62], ["host-restricted trypanosome clades", "TREATMENT", 73, 107], ["parasites", "PROBLEM", 205, 214]]], ["Despite these limitations, the data clearly show that divergence must have occurred well after the separation of the Old and New Worlds, and possibly considerably more recently.DiscussionThis study has identified strains of bat parasite in the United Kingdom that are closely related to those from Brazil.", [["bat parasite", "ORGANISM", 224, 236], ["the data", "TEST", 27, 35], ["This study", "TEST", 187, 197], ["strains of bat parasite", "PROBLEM", 213, 236]]], ["We suggest that movement of bats between the Old and New Worlds within the last \u223c5 million years (MY), certainly since geographical isolation of the Old and New Worlds, is the most likely explanation for the observed distribution of these trypanosomes.", [["trypanosomes", "CELL", 239, 251], ["these trypanosomes", "PROBLEM", 233, 251], ["movement", "OBSERVATION_MODIFIER", 16, 24], ["New", "OBSERVATION_MODIFIER", 157, 160], ["most likely explanation for", "UNCERTAINTY", 176, 203], ["trypanosomes", "OBSERVATION", 239, 251]]], ["Of course, movement may also have been considerably more recent, but this is difficult to determine, as other calibration points are not available.", [["considerably", "OBSERVATION_MODIFIER", 39, 51], ["more recent", "OBSERVATION_MODIFIER", 52, 63]]], ["Neither can the route of movement be inferred, as the wider distribution of these strains in either the Old or the New Worlds is currently unknown.", [["these strains", "PROBLEM", 76, 89]]], ["Furthermore, although T. dionisii is a parasite specific to bats, a lack of specificity to particular species of bat host could be a critical factor in facilitating the spread of T. dionisii strains within continents.", [["T. dionisii", "ORGANISM", 22, 33], ["bat", "ORGANISM", 113, 116], ["T. dionisii strains", "ORGANISM", 179, 198], ["T. dionisii", "SPECIES", 22, 33], ["T. dionisii", "SPECIES", 179, 190], ["T. dionisii", "SPECIES", 22, 33], ["T. dionisii", "SPECIES", 179, 190], ["T. dionisii strains", "PROBLEM", 179, 198]]], ["Trypanosoma (Schizotrypanum) sp. has been reported from \u223c70 species and in all continents in which bats are found (Hoare, 1972), but molecular studies would be required to determine the true distribution of species and strains.DiscussionThe most likely explanation for the presence of T. dionisii B in the New and Old Worlds is movement of an infected bat.", [["Trypanosoma (Schizotrypanum) sp", "ORGANISM", 0, 31], ["bats", "ORGANISM", 99, 103], ["T. dionisii B", "ORGANISM", 285, 298], ["bat", "ORGANISM", 352, 355], ["T. dionisii", "SPECIES", 285, 296], ["T. dionisii", "SPECIES", 285, 296], ["molecular studies", "TEST", 133, 150], ["strains", "PROBLEM", 219, 226], ["an infected bat", "PROBLEM", 340, 355], ["most likely", "UNCERTAINTY", 241, 252], ["infected", "OBSERVATION", 343, 351]]], ["Although T. dionisii can enter cells (Baker, 1985, Oliveira et al., 2009) and forms cysts in the muscular tissue of the heart (Gardner and Molyneux, 1988a), suggesting pathogenicity, British bats have been shown to live for over a year with T. (Schizotrypanum) sp.", [["cells", "ANATOMY", 31, 36], ["cysts", "ANATOMY", 84, 89], ["muscular tissue", "ANATOMY", 97, 112], ["heart", "ANATOMY", 120, 125], ["T. dionisii", "ORGANISM", 9, 20], ["cells", "CELL", 31, 36], ["muscular tissue", "TISSUE", 97, 112], ["heart", "ORGAN", 120, 125], ["bats", "ORGANISM", 191, 195], ["T. (Schizotrypanum) sp", "ORGANISM", 241, 263], ["T. dionisii", "SPECIES", 9, 20], ["T. dionisii", "SPECIES", 9, 20], ["cysts in the muscular tissue", "PROBLEM", 84, 112], ["pathogenicity", "PROBLEM", 168, 181], ["cysts", "OBSERVATION", 84, 89], ["muscular tissue", "ANATOMY", 97, 112], ["heart", "ANATOMY", 120, 125]]], ["(Gardner and Molyneux, 1988a) with no obvious detrimental effects.", [["obvious detrimental effects", "PROBLEM", 38, 65], ["no obvious", "UNCERTAINTY", 35, 45]]], ["Thus, bats are probably capable of normal flying and movement (including some long-distance flights) while infected.", [["bats", "ORGANISM", 6, 10], ["infected", "PROBLEM", 107, 115], ["infected", "OBSERVATION", 107, 115]]], ["Movement of T. dionisii by birds is an unlikely explanation, since it falls in the T. cruzi clade that is only known in mammals (Stevens et al., 1999, Hamilton et al., 2007).", [["T. dionisii", "ORGANISM", 12, 23], ["birds", "ORGANISM", 27, 32], ["T. cruzi", "ORGANISM", 83, 91], ["T. dionisii", "SPECIES", 12, 23], ["T. cruzi", "SPECIES", 83, 91], ["T. dionisii", "SPECIES", 12, 23], ["T. cruzi", "SPECIES", 83, 91], ["the T. cruzi clade", "PROBLEM", 79, 97], ["unlikely explanation", "UNCERTAINTY", 39, 59]]], ["Movement by the invertebrate vector in the absence of a vertebrate host is also unlikely.", [["vertebrate host", "OBSERVATION", 56, 71], ["is also unlikely", "UNCERTAINTY", 72, 88]]], ["Cimicid bugs (the Cimicidae, or bed and bat bugs) are the only known vectors of T. dionisii and also transmit several other bat trypanosome species (Gardner and Molyneux, 1988b, Hamilton et al., 2007).", [["bed", "ORGANISM_SUBDIVISION", 32, 35], ["T. dionisii", "ORGANISM", 80, 91], ["T. dionisii", "SPECIES", 80, 91], ["T. dionisii", "SPECIES", 80, 91], ["Cimicid bugs", "TREATMENT", 0, 12], ["the Cimicidae, or bed and bat bugs", "TREATMENT", 14, 48], ["T. dionisii", "PROBLEM", 80, 91]]], ["Cimicid bugs are unable to fly; some species are associated with bat roosts where they associate with bats mostly during feeding, and then leave for substantial periods of time (Reinhardt and Siva-Jothy, 2007).", [["Cimicid bugs", "PROBLEM", 0, 12], ["some species", "PROBLEM", 32, 44]]], ["Movement by an arthropod vector on bird hosts is possible, as some cimicid species can feed on both birds and bats (Reinhardt and Siva-Jothy, 2007), but this is an unlikely scenario as a bug would need to feed on an infected bat in one continent, transfer to a bird, migrate and then transfer to and infect a bat in the second continent.", [["a bug", "PROBLEM", 185, 190], ["infected", "OBSERVATION", 216, 224]]], ["Additionally, the infection could not be maintained in generations of bugs feeding exclusively on birds, since birds are not known hosts of bat trypanosomes.", [["infection", "DISEASE", 18, 27], ["birds", "ORGANISM", 98, 103], ["birds", "ORGANISM", 111, 116], ["bat trypanosomes", "ORGANISM", 140, 156], ["the infection", "PROBLEM", 14, 27], ["infection", "OBSERVATION", 18, 27]]], ["The vectorial capacity of the other bug family that is parasitic on bats, Polyctenidae (polictenids, or \u201cbat bugs\u201d), is unknown, but could not move in the absence of a bat host.", [["vectorial capacity", "OBSERVATION", 4, 22], ["parasitic", "OBSERVATION", 55, 64]]], ["These wingless bugs live exclusively and permanently on bat hosts and are found on certain microchiropteran bats in tropical and subtropical regions of both the Old and New Worlds; of these, each of the two bug subfamilies is exclusive to one or other region, with no overlap between the Old and New Worlds.", [["tropical", "ANATOMY_MODIFIER", 116, 124], ["subtropical", "ANATOMY_MODIFIER", 129, 140]]], ["Moreover, while polictenid bugs can be transmitted experimentally between bats (Dick et al., 2009), bat\u2013bird transmission has not been reported.DiscussionThis raises the question of whether movement(s) of the infected bat(s) occurred naturally or was facilitated by humans.", [["polictenid bugs", "ORGANISM", 16, 31], ["bat", "ORGANISM", 218, 221], ["humans", "ORGANISM", 266, 272], ["humans", "SPECIES", 266, 272], ["humans", "SPECIES", 266, 272], ["the infected bat", "PROBLEM", 205, 221], ["infected", "OBSERVATION", 209, 217]]], ["Constantine (2003) cited several reports of bats which had been inadvertently transported by humans, for example, by bats roosting in airplanes or ships.", [["bats", "ORGANISM", 44, 48], ["humans", "ORGANISM", 93, 99], ["humans", "SPECIES", 93, 99], ["humans", "SPECIES", 93, 99]]], ["Presumably, most human-assisted transportations go unreported and these are likely to have occurred with increasing frequency since the 1800s, when ships increased significantly in size and speed, together with increased volumes of trade.", [["human", "ORGANISM", 17, 22], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22], ["increased volumes of trade", "PROBLEM", 211, 237], ["increased", "OBSERVATION_MODIFIER", 154, 163], ["significantly", "OBSERVATION_MODIFIER", 164, 177], ["size", "OBSERVATION_MODIFIER", 181, 185]]], ["In support of this idea, trypanosome infections were found in Eptesicus and Myotis in this study; there are reports of long-distance translocations of members of these genera that were mediated by humans, likely because these bats occasionally roost in ships (Constantine, 2003).", [["trypanosome infections", "DISEASE", 25, 47], ["trypanosome", "ORGANISM", 25, 36], ["humans", "ORGANISM", 197, 203], ["bats", "ORGANISM", 226, 230], ["humans", "SPECIES", 197, 203], ["humans", "SPECIES", 197, 203], ["trypanosome infections", "PROBLEM", 25, 47], ["this study", "TEST", 86, 96], ["trypanosome", "OBSERVATION_MODIFIER", 25, 36], ["infections", "OBSERVATION", 37, 47]]], ["However it seems that two separate introductions would have been required to produce the two distinct T. dionisii B genotypes we have identified within the UK.", [["T. dionisii B", "ORGANISM", 102, 115], ["UK", "GENE_OR_GENE_PRODUCT", 156, 158], ["T. dionisii", "SPECIES", 102, 113], ["T. dionisii", "SPECIES", 102, 113], ["the two distinct T. dionisii B genotypes", "PROBLEM", 85, 125]]], ["The gGAPDH genes of these strains differed by 4 bp, and there is even greater divergence between some of the South American T. dionisii strains.", [["gGAPDH", "GENE_OR_GENE_PRODUCT", 4, 10], ["T. dionisii strains", "ORGANISM", 124, 143], ["gGAPDH genes", "DNA", 4, 16], ["T. dionisii", "SPECIES", 124, 135], ["T. dionisii", "SPECIES", 124, 135], ["these strains", "PROBLEM", 20, 33], ["bp", "TEST", 48, 50], ["greater", "OBSERVATION_MODIFIER", 70, 77]]], ["While it is difficult to date how recently this divergence occurred, it seems unlikely that such divergence could have occurred since any human-mediated introduction of their bat hosts.", [["human", "ORGANISM", 138, 143], ["bat hosts", "ORGANISM", 175, 184], ["human", "SPECIES", 138, 143], ["human", "SPECIES", 138, 143], ["seems unlikely", "UNCERTAINTY", 72, 86]]], ["Trypanosoma vivax was introduced into Latin America in cattle imported from Africa, possibly in the late 19th century (Jones and Davila, 2001), yet gGAPDH sequences of South American and West African T. vivax are identical (Adams et al., 2010).", [["Trypanosoma vivax", "DISEASE", 0, 17], ["T. vivax", "DISEASE", 200, 208], ["Trypanosoma vivax", "ORGANISM", 0, 17], ["cattle", "ORGANISM", 55, 61], ["gGAPDH", "GENE_OR_GENE_PRODUCT", 148, 154], ["T. vivax", "ORGANISM", 200, 208], ["gGAPDH sequences", "DNA", 148, 164], ["Trypanosoma vivax", "SPECIES", 0, 17], ["cattle", "SPECIES", 55, 61], ["T. vivax", "SPECIES", 200, 208], ["Trypanosoma vivax", "SPECIES", 0, 17], ["cattle", "SPECIES", 55, 61], ["T. vivax", "SPECIES", 200, 208], ["Trypanosoma vivax", "TREATMENT", 0, 17]]], ["Thus, natural movement of bats seems a more likely explanation, as this would provide sufficient time for either T. dionisii divergence within the Old or New Worlds and/or multiple introductions to occur.", [["T. dionisii", "ORGANISM", 113, 124], ["T. dionisii", "SPECIES", 113, 124], ["T. dionisii", "SPECIES", 113, 124], ["movement", "OBSERVATION_MODIFIER", 14, 22]]], ["However, more evidence is required to definitively resolve this issue.DiscussionWhile the precise route of parasite movement cannot be inferred based on the current evidence, one possible route for movement of bats between the Old and New Worlds is between Alaska and Siberia, particularly across the Bering Land Bridge during a period of low sea level.", [["movement of bats", "PROBLEM", 198, 214], ["low sea", "OBSERVATION_MODIFIER", 339, 346]]], ["Bats are known to occur throughout much of Alaska, some close to the Arctic circle (MacDonald and Cook, 2009).", [["Bats", "CELL", 0, 4]]], ["Phylogenetic evidence supports a Palaearctic origin of the New World Myotis (Stadelmann et al., 2007), suggesting this as a possible route, while within the New Word the relatively small sea barrier prior to closure of the Isthmus of Central America (2\u20133 MYA) is unlikely to have represented a major barrier to bat movement (Stadelmann et al., 2007).DiscussionMore broadly, the T. cruzi clade includes several other species/lineages found in bats and also trypanosomes found in terrestrial mammals from Australia, the New World and Africa.", [["T. cruzi", "ORGANISM", 378, 386], ["T. cruzi", "SPECIES", 378, 386], ["T. cruzi", "SPECIES", 378, 386], ["small sea barrier", "TREATMENT", 181, 198], ["closure", "TREATMENT", 208, 215], ["the T. cruzi clade", "PROBLEM", 374, 392], ["several other species/lineages", "PROBLEM", 402, 432], ["Palaearctic origin", "OBSERVATION_MODIFIER", 33, 51], ["New", "OBSERVATION_MODIFIER", 59, 62], ["relatively", "OBSERVATION_MODIFIER", 170, 180], ["small", "OBSERVATION_MODIFIER", 181, 186], ["closure", "OBSERVATION", 208, 215], ["Isthmus", "ANATOMY_MODIFIER", 223, 230], ["Central", "ANATOMY_MODIFIER", 234, 241], ["America", "ANATOMY_MODIFIER", 242, 249], ["terrestrial mammals", "OBSERVATION", 478, 497], ["New", "OBSERVATION_MODIFIER", 518, 521]]], ["Our results suggest that bats can disperse trypanosome genotypes across substantial geographical barriers, a mechanism previously proposed to explain the widespread distribution of the T. cruzi clade (Stevens et al., 1999, Hamilton et al., 2009).DiscussionIn conclusion, the distribution of trypanosome strains in this study implies relatively recent bat movements that are not possible to infer from the direct examination of bat phylogenies.", [["bats", "ORGANISM", 25, 29], ["T. cruzi", "ORGANISM", 185, 193], ["T. cruzi", "SPECIES", 185, 193], ["T. cruzi", "SPECIES", 185, 193], ["trypanosome strains", "PROBLEM", 291, 310], ["this study", "TEST", 314, 324], ["the direct examination", "TEST", 401, 423], ["widespread", "OBSERVATION_MODIFIER", 154, 164], ["distribution", "OBSERVATION_MODIFIER", 165, 177], ["cruzi clade", "OBSERVATION", 188, 199], ["trypanosome strains", "OBSERVATION", 291, 310]]], ["Given the importance of bats as hosts of zoonoses highly pathogenic to humans, understanding the historical patterns of parasite/host movements can provide useful insights into the contemporary distributions and potential spread of pathogens such as rabies and coronaviruses.", [["zoonoses", "DISEASE", 41, 49], ["rabies and coronaviruses", "DISEASE", 250, 274], ["humans", "ORGANISM", 71, 77], ["rabies", "ORGANISM", 250, 256], ["coronaviruses", "ORGANISM", 261, 274], ["humans", "SPECIES", 71, 77], ["humans", "SPECIES", 71, 77], ["rabies", "SPECIES", 250, 256], ["parasite/host movements", "TREATMENT", 120, 143], ["pathogens", "PROBLEM", 232, 241], ["coronaviruses", "PROBLEM", 261, 274]]]], "f628fb6b96f782c8f269a24b65c30d8ad3fb2efc": [["This viral infection spread very rapidly across the china and multiplied in number in a very short time and migrated to other country by person migration.", [["viral infection", "DISEASE", 5, 20], ["person", "SPECIES", 137, 143], ["This viral infection", "PROBLEM", 0, 20], ["viral", "OBSERVATION_MODIFIER", 5, 10], ["infection", "OBSERVATION", 11, 20]]], ["The WHO (World Health Organization) director general declared on January 30, 2020 that corona virus outbreak, health safety and emergency are recommended under the international health regulations [2] .", [["corona virus outbreak", "PROBLEM", 87, 108]]], ["On February 2, 2020 the China NHC (National Health Commission) reported about 304 deaths in a total of 14,488 cases in china and from other country total 146 cases confirmed with death number 1.", [["NHC", "DISEASE", 30, 33], ["deaths", "DISEASE", 82, 88], ["death", "DISEASE", 179, 184]]], ["This viral diseases is still continues throughout the world and today so many country are effected from that so proper attention towards this are needed and is important to discover and design therapeutic agents for this infection either form natural or from synthetic source.", [["viral diseases", "DISEASE", 5, 19], ["infection", "DISEASE", 221, 230], ["This viral diseases", "PROBLEM", 0, 19], ["therapeutic agents", "TREATMENT", 193, 211], ["this infection", "PROBLEM", 216, 230], ["viral diseases", "OBSERVATION", 5, 19]]], ["High risk and isolation should be preferred social interaction hand shaking must be stop and proper attention should be given at first positive stage.", [["hand", "ANATOMY", 63, 67], ["hand", "ORGANISM_SUBDIVISION", 63, 67], ["High risk and isolation", "PROBLEM", 0, 23]]], ["There are still no such effective antiviral drug or any vaccines are available for the corona virus infection because any specific treatment and drug designing required a lot of time however traditional Chinese medication is might available in 2003 outbreak of contagious disease severe acute respiratory syndrome (SARS) [3] .", [["corona virus infection", "DISEASE", 87, 109], ["contagious disease", "DISEASE", 261, 279], ["acute respiratory syndrome", "DISEASE", 287, 313], ["SARS", "DISEASE", 315, 319], ["corona virus", "ORGANISM", 87, 99], ["corona virus", "SPECIES", 87, 99], ["antiviral drug", "TREATMENT", 34, 48], ["any vaccines", "TREATMENT", 52, 64], ["the corona virus infection", "PROBLEM", 83, 109], ["traditional Chinese medication", "TREATMENT", 191, 221], ["contagious disease severe acute respiratory syndrome", "PROBLEM", 261, 313], ["contagious disease", "OBSERVATION", 261, 279], ["severe", "OBSERVATION_MODIFIER", 280, 286], ["acute", "OBSERVATION_MODIFIER", 287, 292], ["respiratory syndrome", "OBSERVATION", 293, 313]]]], "PMC7531320": [["Intensivmedizin ::: DefinitionenDies ist die Versorgung schwerst bis lebensbedrohlich erkrankter Patienten in speziellen Einrichtungen, den Intensivstationen, mit einem \u00fcber das sonstige Ma\u00df weit hinausgehenden medizinischen und pflegerischen Aufwand.", [["Intensivmedizin", "CHEMICAL", 0, 15], ["Intensivmedizin", "CHEMICAL", 0, 15], ["Intensivmedizin", "SIMPLE_CHEMICAL", 0, 15]]], ["Sie setzt sich zusammen aus Intensiv\u00fcberwachung, Intensivtherapie und Intensivpflege.Intensiv\u00fcberwachung ::: DefinitionenEine weit \u00fcber das \u00fcbliche Ma\u00df hinausgehende klinische Beobachtung und apparative \u00dcberwachung von Patienten.Intensivtherapie ::: DefinitionenHiermit bezeichnet man die mit erh\u00f6htem Aufwand betriebene Intensiv\u00fcberwachung und Behandlung von schwer erkrankten Patienten, meist mit St\u00f6rungen der Atmung, der Herz-Kreislauf-Funktion, des Stoffwechsels, des zentralen Nervensystems, des Wasser-Elektrolyt- und S\u00e4ure-Basen-Gleichgewichts, der Nierenfunktion oder der Temperaturregulation, wobei diese St\u00f6rungen h\u00e4ufig mit einer vitalen Bedrohung des Patienten verbunden sind oder zu einer Bedrohung werden k\u00f6nnen.Intensivpflege ::: DefinitionenSie kennzeichnet die spezifische Pflege des Intensivpatienten im Gegensatz zur allgemeinen Krankenpflege.An\u00e4sthesiologisch-operative (chirurgische) Intensivstation ::: Gemischte Intensivstationen ::: Verschiedene IntensivstationenAuf dieser Station werden v. a. postoperative Patienten verschiedener chirurgischer Disziplinen sowie schwere Traumen oder Polytraumen behandelt, weiterhin Patienten nach Reanimation, Vergiftung, Tetanus, Eklampsie, Verbrennungen und Langzeitbeatmete.An\u00e4sthesiologisch-operative (chirurgische) Intensivstation ::: Gemischte Intensivstationen ::: Verschiedene IntensivstationenGeleitet werden diese Stationen von An\u00e4sthesiologen oder Chirurgen in enger Kooperation mit den beteiligten chirurgischen Fachdisziplinen.Internistische Intensivstation ::: Gemischte Intensivstationen ::: Verschiedene IntensivstationenHier werden mit konservativen Methoden v. a.", [["man", "SPECIES", 281, 284], ["DefinitionenHiermit bezeichnet man die mit erh\u00f6htem Aufwand betriebene Intensiv\u00fcberwachung und Behandlung von schwer erkrankten Patienten, meist mit St\u00f6rungen der Atmung, der Herz-Kreislauf-Funktion, des Stoffwechsels, des zentralen Nervensystems, des Wasser-Elektrolyt- und S\u00e4ure-Basen-Gleichgewichts, der Nierenfunktion oder der Temperaturregulation, wobei diese St\u00f6rungen h\u00e4ufig mit einer vitalen Bedrohung des Patienten verbunden sind oder zu einer Bedrohung werden k\u00f6nnen", "SPECIES", 250, 726], ["des zentralen Nervensystems", "TREATMENT", 469, 496], ["Tetanus", "TREATMENT", 1184, 1191], ["Verschiedene IntensivstationenGeleitet", "TREATMENT", 1334, 1372]]], ["Patienten mit Herz-Kreislauf-Erkrankungen, akutem Nierenversagen, schweren Stoffwechselst\u00f6rungen, endokrinen Krisen, dekompensierter chronisch-obstruktiver Lungenerkrankung, Vergiftungen und schweren Thromboembolien behandelt.Interdisziplin\u00e4re Intensivstation ::: Gemischte Intensivstationen ::: Verschiedene IntensivstationenHier werden operative und nichtoperative, einschlie\u00dflich internistischer, Patienten behandelt.Neurochirurgische Intensivstation ::: Fachspezifische Intensivstationen ::: Verschiedene IntensivstationenEs werden Patienten mit akutem Sch\u00e4del-Hirn-Trauma und Patienten nach neurochirurgischen Eingriffen (v. a. intrakraniellen) intensivmedizinisch versorgt (10.1007/978-3-662-50444-4_61).Herzchirurgische Intensivstation ::: Fachspezifische Intensivstationen ::: Verschiedene IntensivstationenHier erfolgt die postoperative Betreuung herzchirurgischer Patienten mit dem Schwerpunkt der Intensivtherapie von St\u00f6rungen der Herz-Kreislauf-Funktion, daneben von entsprechenden postoperativen Komplikationen, wie respiratorische Insuffizienz, Nierenversagen usw.", [["Verschiedene IntensivstationenEs werden Patienten mit akutem Sch\u00e4del-Hirn-Trauma und Patienten nach neurochirurgischen Eingriffen (v. a. intrakraniellen) intensivmedizinisch versorgt (10.1007/978-3-662-50444-4_61", "SPECIES", 496, 708], ["Verschiedene IntensivstationenHier erfolgt die postoperative Betreuung herzchirurgischer Patienten mit dem Schwerpunkt der Intensivtherapie von St\u00f6rungen der Herz-Kreislauf-Funktion, daneben von entsprechenden postoperativen Komplikationen, wie respiratorische Insuffizienz", "SPECIES", 785, 1058], ["Kreislauf", "TEST", 19, 28], ["Erkrankungen", "TEST", 29, 41], ["Trauma", "PROBLEM", 570, 576]]], ["Die Betreuung anderer Kinder kann zumeist auf interdisziplin\u00e4ren Intensivstationen erfolgen (10.1007/978-3-662-50444-4_64).Neurologische Intensivstation ::: Fachspezifische Intensivstationen ::: Verschiedene IntensivstationenBehandelt verschiedenartige Erkrankungen des zentralen Nervensystems und der Muskulatur, die mit einer vitalen Bedrohung des Patienten einhergehen (10.1007/978-3-662-50444-4_61).Intensiv-Krei\u00dfsaal ::: Fachspezifische Intensivstationen ::: Verschiedene IntensivstationenHier erfolgt die \u00dcberwachung von Patientinnen mit Risikoschwangerschaft w\u00e4hrend der Geburtsperiode mit Registrierung der Wehent\u00e4tigkeit, \u00dcberwachung der fetalen Herzaktion und des S\u00e4ure-Basen-Haushalts sowie der Blutgase, au\u00dferdem die \u00dcberwachung der maternalen Herz-Kreislauf-Funktion.", [["Die Betreuung anderer Kinder kann zumeist auf interdisziplin\u00e4ren Intensivstationen erfolgen (10.1007/978-3-662-50444-4_64", "SPECIES", 0, 121], ["Verschiedene IntensivstationenBehandelt verschiedenartige Erkrankungen des zentralen Nervensystems und der Muskulatur, die mit einer vitalen Bedrohung des Patienten einhergehen (10.1007/978-3-662-50444-4_61", "SPECIES", 195, 401], ["Verschiedene IntensivstationenHier erfolgt die \u00dcberwachung von Patientinnen mit Risikoschwangerschaft w\u00e4hrend der Geburtsperiode mit Registrierung der Wehent\u00e4tigkeit, \u00dcberwachung der fetalen Herzaktion und des S\u00e4ure-Basen-Haushalts sowie der Blutgase, au\u00dferdem die \u00dcberwachung der maternalen Herz-Kreislauf-Funktion", "SPECIES", 464, 779], ["Verschiedene", "PROBLEM", 195, 207], ["Erkrankungen des zentralen", "TREATMENT", 253, 279]]], ["Die zentrale Aufgabe besteht darin, Myokardisch\u00e4mien und Herzrhythmusst\u00f6rungen zu verhindern oder zu behandeln.", [["Die zentrale Aufgabe besteht darin, Myokardisch\u00e4mien und Herzrhythmusst\u00f6rungen zu verhindern oder zu behandeln", "SPECIES", 0, 110]]], ["Meist ist die Verbrennungseinheit in eine gemischte Intensivstation integriert (10.1007/978-3-662-50444-4_70).Transplantationseinheit ::: Organ- oder erkrankungsspezifische Intensivstationen ::: Verschiedene IntensivstationenHier erfolgt die kurzfristige Nachbehandlung von Patienten mit Organtransplantaten.", [["Organtransplantaten", "CHEMICAL", 288, 307], ["Meist ist die Verbrennungseinheit in eine gemischte Intensivstation integriert (10.1007/978-3-662-50444-4_70", "SPECIES", 0, 108]]], ["Die Notwendigkeit einer speziellen Einheit ergibt sich aus der besonderen Infektionsgef\u00e4hrdung dieser Patienten (10.1007/978-3-662-50444-4_63).Vergiftungseinheit ::: Organ- oder erkrankungsspezifische Intensivstationen ::: Verschiedene IntensivstationenDie Entgiftungsstation befasst sich mit der Behandlung exogener Vergiftungen (10.1007/978-3-662-50444-4_69).", [["Die Notwendigkeit einer speziellen Einheit ergibt sich aus der besonderen Infektionsgef\u00e4hrdung dieser Patienten (10.1007/978-3-662-50444-4_63", "SPECIES", 0, 141], ["Verschiedene IntensivstationenDie Entgiftungsstation befasst sich mit der Behandlung exogener Vergiftungen (10.1007/978-3-662-50444-4_69", "SPECIES", 223, 359]]], ["Das Behandlungsrepertoire unterscheidet sich nicht von dem einer gemischten Intensivstation.Dialyseeinheit ::: Organ- oder erkrankungsspezifische Intensivstationen ::: Verschiedene IntensivstationenHier werden in erster Linie Patienten mit chronischer Niereninsuffizienz behandelt, w\u00e4hrend bei akutem Nierenversagen die Dialyse h\u00e4ufig auf der Intensivstation erfolgt, in die der Patient wegen seiner Grunderkrankung aufgenommen worden ist.Postoperative \u00dcberwachungsstation ::: Aufwachraum ::: Postoperative Einheiten ::: Verschiedene IntensivstationenAuf dieser Station werden Patienten nach lange dauernden bzw. ausgedehnten Eingriffen oder St\u00f6rungen des postoperativen Verlaufs intensiv \u00fcberwacht und \u2013 bei Bedarf \u2013 behandelt.Intermediate Care Unit (IMC) oder High Dependency Unit (HDU) ::: Verschiedene IntensivstationenDie Behandlungsstufe der IMC oder HDU liegt zwischen Intensivtherapie und Normal-/Minimalpflege.", [["ausgedehnten Eingriffen oder St\u00f6rungen des postoperativen Verlaufs intensiv \u00fcberwacht und \u2013 bei Bedarf \u2013 behandelt", "SPECIES", 613, 727], ["Verschiedene IntensivstationenDie Behandlungsstufe der IMC oder HDU liegt zwischen Intensivtherapie und Normal-/Minimalpflege", "SPECIES", 793, 918]]], ["Invasive und nichtinvasive Beatmung, kontinuierliche extrakorporale Verfahren und erweitertes Monitoring (z.", [["Invasive und nichtinvasive Beatmung", "TREATMENT", 0, 35]]], ["B. Pulmonaliskatheter) sollten daher auf der IMC nicht durchgef\u00fchrt werden.Intermediate Care Unit (IMC) oder High Dependency Unit (HDU) ::: Verschiedene IntensivstationenDer Pflegeschl\u00fcssel wird f\u00fcr IMCs mit 1 : 4 bis 1 : 6 angegeben, d. h., 1 Pflegefachkraft versorgt 4\u20136 Patienten pro Schicht.", [["1 : 4 bis 1 : 6 angegeben", "CHEMICAL", 208, 233]]], ["Die Station sollte 7 Tage in der Woche betrieben werden.Lage ::: Struktur von IntensivstationenGemischte Intensivstationen sollten in unmittelbarer N\u00e4he von Operationstrakt, Notfallaufnahme und Diagnostikabteilung gelegen sein.Gr\u00f6\u00dfe und Aufbau ::: Struktur von IntensivstationenDie Anzahl erforderlicher Intensivbetten eines Krankenhauses wird mit 5% der Gesamtbettenzahl angegeben.", [["Struktur von IntensivstationenDie Anzahl erforderlicher Intensivbetten eines Krankenhauses wird mit 5% der Gesamtbettenzahl angegeben", "SPECIES", 248, 381], ["Struktur von IntensivstationenDie Anzahl erforderlicher", "TREATMENT", 248, 303]]], ["Einzelne Intensivstationen sollten von \u00fcberschaubarer Gr\u00f6\u00dfe sein: die untere Grenze sollte bei 4\u20136, die obere bei 12 Betten liegen.", [["Einzelne Intensivstationen sollten von \u00fcberschaubarer Gr\u00f6\u00dfe sein: die untere Grenze sollte bei 4\u20136, die obere bei 12 Betten liegen", "SPECIES", 0, 130], ["Einzelne", "TREATMENT", 0, 8]]], ["Baulich bestehen Intensivstationen aus einer Patientenzone und einer Funktionszone mit Betriebs-, Schleusen- und Zentralr\u00e4umen.", [["Baulich bestehen Intensivstationen aus einer Patientenzone und einer Funktionszone mit Betriebs-, Schleusen- und Zentralr\u00e4umen", "SPECIES", 0, 126], ["Betriebs", "TEST", 87, 95]]], ["Der einzelne Bettplatz sollte eine Gr\u00f6\u00dfe von 25 m2 aufweisen.", [["Der einzelne Bettplatz sollte eine Gr\u00f6\u00dfe von 25 m2 aufweisen", "SPECIES", 0, 60], ["Der einzelne Bettplatz", "TREATMENT", 0, 22]]], ["Die Versorgung der Patienten erfolgt in offenen Pl\u00e4tzen oder in Einzelboxen.Gr\u00f6\u00dfe und Aufbau ::: Struktur von IntensivstationenOffene Pl\u00e4tze mit mehreren Patienten bieten bessere \u00dcberwachungsm\u00f6glichkeiten und k\u00fcrzere Wege, haben jedoch den Nachteil eines h\u00f6heren L\u00e4rmpegels, gr\u00f6\u00dferer Gefahr der Kreuzinfektionen und des Mangels an Intimsph\u00e4re f\u00fcr den Patienten.Gr\u00f6\u00dfe und Aufbau ::: Struktur von IntensivstationenEinzelboxen bieten gr\u00f6\u00dferen Schutz vor Kreuzinfektionen, eine ausreichende Intimsph\u00e4re und niedrigen L\u00e4rmpegel, jedoch sind die Wege l\u00e4nger und die \u00dcberwachungsm\u00f6glichkeiten schlechter.Akutlabor ::: Struktur von IntensivstationenBeim Intensivpatienten m\u00fcssen h\u00e4ufig bestimmte Laborwerte sofort bzw. ohne wesentliche Verz\u00f6gerung bestimmt werden.", [["Einzelboxen", "CHEMICAL", 64, 75], ["Struktur von IntensivstationenOffene Pl\u00e4tze mit mehreren Patienten bieten bessere \u00dcberwachungsm\u00f6glichkeiten und k\u00fcrzere Wege, haben jedoch den Nachteil eines h\u00f6heren L\u00e4rmpegels, gr\u00f6\u00dferer Gefahr der Kreuzinfektionen und des Mangels an Intimsph\u00e4re f\u00fcr den Patienten", "SPECIES", 97, 360], ["Struktur von IntensivstationenEinzelboxen bieten gr\u00f6\u00dferen Schutz vor Kreuzinfektionen, eine ausreichende Intimsph\u00e4re und niedrigen L\u00e4rmpegel, jedoch sind die Wege l\u00e4nger und die \u00dcberwachungsm\u00f6glichkeiten schlechter", "SPECIES", 382, 596], ["m\u00fcssen h\u00e4ufig bestimmte Laborwerte sofort bzw", "SPECIES", 664, 709], ["Einzelboxen", "TREATMENT", 64, 75], ["Struktur", "TEST", 382, 390], ["Einzelboxen", "TREATMENT", 412, 423]]], ["Hierf\u00fcr sollte m\u00f6glichst ein in die Intensivstation integriertes Labor zur Verf\u00fcgung stehen, in dem rund um die Uhr entsprechende Untersuchungen durchgef\u00fchrt werden k\u00f6nnen.", [["Labor", "PROBLEM", 65, 70]]], ["Das Leistungsangebot des Labors sollte folgende Parameter umfassen:Grundleistungen wie H\u00e4moglobin, H\u00e4matokrit, Elektrolyte, Blutzucker, Serum- und Urinosmolarit\u00e4t, Urinstatus,Blutgasanalyse und S\u00e4ure-Basen-Parameter,Laktat,Standardgerinnungsanalysen.", [["Grundleistungen", "TEST", 67, 82], ["H\u00e4moglobin", "TEST", 87, 97], ["H\u00e4matokrit", "TEST", 99, 109], ["Elektrolyte", "TEST", 111, 122], ["Blutzucker", "TEST", 124, 134], ["Serum", "TEST", 136, 141], ["Urinosmolarit\u00e4t", "TEST", 147, 162], ["Urinstatus", "TEST", 164, 174], ["Blutgasanalyse", "TEST", 175, 189], ["Laktat", "TREATMENT", 216, 222], ["Standardgerinnungsanalysen", "TREATMENT", 223, 249]]]]}